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[Diagnostic Test Accuracy Review]
Dermoscopy, with and without visual inspection, for
diagnosing melanoma in adults
Jacqueline Dinnes1 , Jonathan J Deeks1, Naomi Chuchu1, Lavinia Ferrante di Ruffano1, Rubeta N Matin2, David R Thomson3 , Kai
Yuen Wong4 , Roger Benjamin Aldridge5, Rachel Abbott6 , Monica Fawzy7 , Susan E Bayliss1, Matthew J Grainge8 , Yemisi Takwoingi1 ,
Clare Davenport1, Kathie Godfrey9, Fiona MWalter10, Hywel C Williams11, Cochrane Skin Cancer Diagnostic Test Accuracy Group
1
1Institute of AppliedHealth Research,University of Birmingham, Birmingham, UK. 2Department of Dermatology, ChurchillHospital,
Oxford, UK. 3Department of Plastic Surgery, St George’s Hospital, London, UK. 4Department of Plastic and Reconstructive Surgery,
Oxford University Hospitals NHS Foundation Trust, Oxford, UK. 5Department of Plastic Surgery, NHS Lothian/University of
Edinburgh, Edinburgh, UK. 6Welsh Institute of Dermatology, University Hospital of Wales, Cardiff, UK. 7Department of Plastic
and Reconstructive Surgery, Norfolk and Norwich University Hospital NHS Trust, Norwich, UK. 8Division of Epidemiology and
Public Health, School of Medicine, Nottingham, UK. 9c/o Cochrane Skin Group, The University of Nottingham, Nottingham, UK.
10Public Health & Primary Care, University of Cambridge, Cambridge, UK. 11Centre of Evidence Based Dermatology, University of
Nottingham, Nottingham, UK
Contact address: Jacqueline Dinnes, Institute of Applied Health Research, University of Birmingham, Birmingham, B15 2TT, UK.
j.dinnes@bham.ac.uk.
Editorial group: Cochrane Skin Group.
Publication status and date: New, published in Issue 12, 2018.
Citation: Dinnes J, Deeks JJ, Chuchu N, Ferrante di Ruffano L, Matin RN, Thomson DR, Wong KY, Aldridge RB, Abbott R, Fawzy
M, Bayliss SE, Grainge MJ, Takwoingi Y, Davenport C, Godfrey K, Walter FM, Williams HC, Cochrane Skin Cancer Diagnostic Test
Accuracy Group. Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults. Cochrane Database of Systematic
Reviews 2018, Issue 12. Art. No.: CD011902. DOI: 10.1002/14651858.CD011902.pub2.
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Melanoma has one of the fastest rising incidence rates of any cancer. It accounts for a small percentage of skin cancer cases but is
responsible for the majority of skin cancer deaths. Although history-taking and visual inspection of a suspicious lesion by a clinician are
usually the first in a series of ‘tests’ to diagnose skin cancer, dermoscopy has become an important tool to assist diagnosis by specialist
clinicians and is increasingly used in primary care settings. Dermoscopy is a magnification technique using visible light that allows more
detailed examination of the skin compared to examination by the naked eye alone. Establishing the additive value of dermoscopy over
and above visual inspection alone across a range of observers and settings is critical to understanding its contribution for the diagnosis of
melanoma and to future understanding of the potential role of the growing number of other high-resolution image analysis techniques.
Objectives
To determine the diagnostic accuracy of dermoscopy alone, or when added to visual inspection of a skin lesion, for the detection of
cutaneous invasive melanoma and atypical intraepidermal melanocytic variants in adults. We separated studies according to whether
the diagnosis was recorded face-to-face (in-person), or based on remote (image-based), assessment.
Search methods
We undertook a comprehensive search of the following databases from inception up to August 2016: CENTRAL;MEDLINE; Embase;
CINAHL; CPCI; Zetoc; Science Citation Index; US National Institutes of Health Ongoing Trials Register; NIHR Clinical Research
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Network Portfolio Database; and the World Health Organization International Clinical Trials Registry Platform. We studied reference
lists and published systematic review articles.
Selection criteria
Studies of any design that evaluated dermoscopy in adults with lesions suspicious for melanoma, compared with a reference standard
of either histological confirmation or clinical follow-up. Data on the accuracy of visual inspection, to allow comparisons of tests, was
included only if reported in the included studies of dermoscopy.
Data collection and analysis
Two review authors independently extracted all data using a standardised data extraction and quality assessment form (based on
QUADAS-2). We contacted authors of included studies where information related to the target condition or diagnostic threshold
were missing. We estimated accuracy using hierarchical summary receiver operating characteristic (SROC),methods. Analysis of studies
allowing direct comparison between tests was undertaken. To facilitate interpretation of results, we computed values of sensitivity at the
point on the SROC curve with 80% fixed specificity and values of specificity with 80% fixed sensitivity. We investigated the impact of
in-person test interpretation; use of a purposely developed algorithm to assist diagnosis; observer expertise; and dermoscopy training.
Main results
We included a total of 104 study publications reporting on 103 study cohorts with 42,788 lesions (including 5700 cases), providing
354 datasets for dermoscopy. The risk of bias was mainly low for the index test and reference standard domains and mainly high or
unclear for participant selection and participant flow. Concerns regarding the applicability of study findings were largely scored as ‘high’
concern in three of four domains assessed. Selective participant recruitment, lack of reproducibility of diagnostic thresholds and lack
of detail on observer expertise were particularly problematic.
The accuracy of dermoscopy for the detection of invasive melanoma or atypical intraepidermal melanocytic variants was reported in 86
datasets; 26 for evaluations conducted in person (dermoscopy added to visual inspection), and 60 for image-based evaluations (diagnosis
based on interpretation of dermoscopic images). Analyses of studies by prior testing revealed no obvious effect on accuracy; analyses
were hampered by the lack of studies in primary care, lack of relevant information and the restricted inclusion of lesions selected for
biopsy or excision. Accuracy was higher for in-person diagnosis compared to image-based evaluations (relative diagnostic odds ratio
(RDOR) 4.6, 95% confidence interval (CI) 2.4 to 9.0; P < 0.001).
We compared accuracy for (a), in-person evaluations of dermoscopy (26 evaluations; 23,169 lesions and 1664 melanomas),versus visual
inspection alone (13 evaluations; 6740 lesions and 459melanomas), and for (b), image-based evaluations of dermoscopy (60 evaluations;
13,475 lesions and 2851 melanomas),versus image-based visual inspection (11 evaluations; 1740 lesions and 305 melanomas). For
both comparisons, meta-analysis found dermoscopy to be more accurate than visual inspection alone, with RDORs of (a), 4.7 (95%
CI 3.0 to 7.5; P < 0.001), and (b), 5.6 (95% CI 3.7 to 8.5; P < 0.001). For a), the predicted difference in sensitivity at a fixed specificity
of 80% was 16% (95% CI 8% to 23%; 92% for dermoscopy + visual inspection versus 76% for visual inspection), and predicted
difference in specificity at a fixed sensitivity of 80% was 20% (95% CI 7% to 33%; 95% for dermoscopy + visual inspection versus
75% for visual inspection). For b) the predicted differences in sensitivity was 34% (95% CI 24% to 46%; 81% for dermoscopy versus
47% for visual inspection), at a fixed specificity of 80%, and predicted difference in specificity was 40% (95% CI 27% to 57%; 82%
for dermoscopy versus 42% for visual inspection), at a fixed sensitivity of 80%.
Using the median prevalence of disease in each set of studies ((a), 12% for in-person and (b), 24% for image-based), for a hypothetical
population of 1000 lesions, an increase in sensitivity of (a), 16% (in-person), and (b), 34% (image-based), from using dermoscopy
at a fixed specificity of 80% equates to a reduction in the number of melanomas missed of (a), 19 and (b), 81 with (a), 176 and (b),
152 false positive results. An increase in specificity of (a), 20% (in-person), and (b), 40% (image-based), at a fixed sensitivity of 80%
equates to a reduction in the number of unnecessary excisions from using dermoscopy of (a), 176 and (b), 304 with (a), 24 and (b), 48
melanomas missed.
The use of a named or published algorithm to assist dermoscopy interpretation (as opposed to no reported algorithm or reported use
of pattern analysis), had no significant impact on accuracy either for in-person (RDOR 1.4, 95% CI 0.34 to 5.6; P = 0.17), or image-
based (RDOR 1.4, 95% CI 0.60 to 3.3; P = 0.22), evaluations. This result was supported by subgroup analysis according to algorithm
used. We observed higher accuracy for observers reported as having high experience and for those classed as ‘expert consultants’ in
comparison to those considered to have less experience in dermoscopy, particularly for image-based evaluations. Evidence for the effect
of dermoscopy training on test accuracy was very limited but suggested associated improvements in sensitivity.
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Authors’ conclusions
Despite the observed limitations in the evidence base, dermoscopy is a valuable tool to support the visual inspection of a suspicious skin
lesion for the detection of melanoma and atypical intraepidermal melanocytic variants, particularly in referred populations and in the
hands of experienced users. Data to support its use in primary care are limited, however, it may assist in triaging suspicious lesions for
urgent referral when employed by suitably trained clinicians. Formal algorithms may be of most use for dermoscopy training purposes
and for less expert observers, however reliable data comparing approaches using dermoscopy in person are lacking.
P L A I N L A N G U A G E S U M M A R Y
How accurate is dermoscopy compared to visual inspection of the skin for diagnosing skin cancer (melanoma) in adults?
What is the aim of the review?
The aim of this Cochrane Review was to find out the accuracy of dermoscopy for the diagnosis of melanoma in comparison to visual
inspection of the skin with the naked eye. The Review also investigated whether diagnostic accuracy using dermoscopy on a patient
in person differed to the accuracy of diagnosis using dermoscopic images of the skin. Researchers in Cochrane included 104 studies to
answer this question.
Why is improving the diagnosis of melanoma important?
Melanoma is one of the most dangerous forms of skin cancer. Not recognising a melanoma when it is present (a false-negative test
result), delays surgery to remove it, risking cancer spreading to other organs in the body, and possibly death. Diagnosing a skin lesion
(a mole or area of skin with an unusual appearance in comparison with the surrounding skin) as a melanoma when it is not (a false-
positive result), may result in unnecessary surgery, further investigations and patient anxiety. Visual inspection of suspicious skin lesions
by a clinician using the naked eye is usually the first of a series of ‘tests’ to diagnose melanoma. Magnification techniques can be used by
skin cancer specialists to allow a more detailed examination of suspicious skin lesions than can be achieved using the naked eye alone.
What was studied in the review?
A dermatoscope is a handheld device using visible light (such as from incandescent or LED bulbs), that can be used as part of the
clinical examination of suspicious skin lesions. Dermoscopy has become an important tool to assist diagnosis by specialist clinicians
and is also increasingly used in primary care settings. Knowing the diagnostic accuracy of dermoscopy added to visual inspection alone
is important to understanding who it should be used by and in which healthcare settings.
Researchers sought to find out the diagnostic accuracy of dermoscopy of suspicious skin lesions on a patient in person and using
dermoscopic images compared to visual inspection alone. Researchers also sought to find out whether diagnostic accuracy was improved
by use of a dermoscopy checklist or by an increase in level of clinical expertise.
What are the main results of the review?
The review included 104 studies reporting data for people with lesions suspected of melanoma. The main results for the diagnosis
of melanoma (including very early melanomas), are based on 86 of the studies, 26 of which provide information on the accuracy of
dermoscopy added to in-person visual inspection of a skin lesion and 60 provide information based on examination of dermoscopic
images without the patient being present.
The 26 in-person studies provide the most relevant data for the use of dermoscopy in practice and their results are summarised here.
A total of 23,169 suspicious skin lesions were included in the 26 studies and 13 of them also provided information on the accuracy of
visual inspection of a lesion without the use of dermoscopy. The results suggest that dermoscopy is more accurate than visual inspection
on its own, both for identifying melanoma correctly and excluding things that are not melanoma.
The studies used different ways of deciding whether a skin lesion was a melanoma or not, which means that we cannot be exactly sure
about how much better dermoscopy is compared to visual inspection alone. Instead we can give an illustrative example of the expected
effect of the increase in accuracy using a group of 1000 lesions, of which 120 (12%), are melanoma. In order to see how much better
dermoscopy is in identifying melanoma correctly when compared to just looking at the skin, we have to assume that both lead to the
same number of lesions being falsely diagnosed as melanoma (we assumed that 176 of the 880 lesions without melanoma would have an
incorrect diagnosis of melanoma). In this fixed situation, adding dermoscopy to visual inspection would correctly identify an extra 19
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melanomas (110 compared with 91), that would have been missed by just looking at the skin alone. In other words, more melanomas
would be correctly identified.
In order to see how much better dermoscopy is in deciding if a skin lesion is not a melanoma when compared to just looking at the
skin, we have to assume that both lead to the same number of melanomas being correctly diagnosed (in this case we assumed that 96
out of the 120 melanomas would be correctly diagnosed). In this situation, adding in dermoscopy to visual inspection would reduce
the number of lesions being wrongly diagnosed as being melanoma by 176 (a reduction from 220 in the visual inspection group to 44
lesions in the dermoscopy group). In other words, more lesions that were not melanoma would be correctly identified and fewer people
would end up being sent for surgery.
Value of visual inspection checklists and effect of observer expertise
There was no evidence that use of a checklist to help dermoscopy interpretation changed diagnostic accuracy. Accuracy was better (with
fewer missed melanomas and fewer people having unnecessary surgery), when the diagnosis was made by people with more clinical
expertise and training.
How reliable are the results of the studies of this review?
In the majority of included studies, the diagnosis of melanoma was made by lesion biopsy and the absence of melanoma was confirmed
by biopsy or by follow-up over time to make sure the skin lesion remained negative for melanoma, both of which are likely to have
been a reliable method for deciding whether patients really had melanoma*. In a few studies, the absence of melanoma was made by
expert diagnosis, which is unlikely to have been a reliable method for deciding whether patients really had melanoma. Poor reporting
of study conduct made assessment of the reliability of studies difficult. Selective participant recruitment and lack of detail regarding
the threshold for deciding on a positive test result were particularly problematic.
Who do the results of this review apply to?
Sixty-six studies were undertaken in Europe (77%), with the remainder undertaken in North America (6 studies), Asia (4), Oceania (4),
or were multicentre (7). Mean age ranged from 30 to 58 years (reported in 26 studies). The percentage of individuals with melanoma
ranged between 1% and 41% for dermoscopy in-person studies (median 12%), and between 3% and 61% in studies using dermoscopy
images (median 24%). Almost all of the studies were carried out in referral settings rather than in primary care. In the majority of
studies the lesions were unlikely to be representative of the range of those seen in practice, for example only including skin lesions of
a certain size or with a specific appearance. In addition variation in the expertise of clinicians performing visual inspection and the
definition used for a positive dermoscopy test result across studies makes it unclear as to how dermoscopy should be carried out and by
people with different levels of clinical expertise in order to achieve the accuracy observed in studies.
What are the implications of this review?
When used by specialists, dermoscopy is better at diagnosing melanoma compared to inspection of a suspicious skin lesion using
the naked eye alone. Dermoscopy is more accurate when interpreted with the patient present rather than using dermoscopy images.
Dermoscopy might help general practitioners to correctly identify people with suspicious lesions who need to be seen by a specialist.
Checklists to help interpret dermoscopy might improve the accuracy of people with less expertise and training. Further, well-reported
studies assessing the diagnostic accuracy of dermoscopy when used in primary care and to identify the best way of delivering dermoscopy
training are needed.
How up-to-date is this review?
The review authors searched for and used studies published up to August 2016.
*In these studies biopsy, clinical follow-up or specialist clinician diagnosis were the reference standards (means of establishing the final
diagnosis).
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Question What is the diagnostic accuracy of dermoscopy, in comparison to visual inspection, for the detection of cutaneous invasive melanoma and atypical
intraepidermal melanocytic variantsin adults?
Population Adults with lesions suspicious for melanoma, including:
• those with lim ited prior test ing (present ing in primary, community or private dermatology sett ings), and
• referred populat ions (present ing in secondary care or specialist skin cancer clinics).
Index test Dermoscopy with or without the use of any established algorithms or checklist to aid diagnosis, including:
• in-person evaluat ions (face-to-face diagnosis), and
• image-based evaluat ions (diagnosis based on assessment of a clinical image).
Comparator test Visual inspect ion
Target condition Cutaneous invasive melanoma and atypical intraepidermal melanocyt ic variants
Reference stan-
dard
Histology with or without follow-up to conf irm absence of malignancy in benign-appearing lesions
Action If accurate, posit ive results ensure melanoma lesions are not missed but are appropriately excised (or referred), and those with negat ive results can be
safely reassured and discharged
Number of studies Total lesions Total melanomas
Quantity of evi-
dence
104 42,788 5700
Limitations
Risk of bias
(in-person; im-
age-based)
Potent ial risk for part icipant select ion f rom use of case-control type design (19 image-based), inappropriate exclusion criteria (8; 25), or lack of detail (17;
27). All dermoscopy interpretat ion was blinded to reference standard diagnosis. Dermoscopy thresholds were clearly pre-specif ied (25; 50). Low risk for
reference standard (29; 63); high risk f rom use of expert diagnosis or > 20% of benign lesions with no histology (5; 11). Blinding of reference standard to
clinical diagnosis reported only in one image-based evaluat ion. High risk for part icipant f low (15; 26), due to dif ferent ial verif icat ion (6; 15), and exclusions
following recruitment (10; 16). Tim ing of tests was not mentioned in 23 (18)
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Applicability of
evidence to ques-
tion
(in-person; im-
age-based)
Part icipants restricted to those with melanocyt ic lesions only (10; 35), or other narrowly def ined groups (5 image-based), or to those with histopathology
results (29; 57), and included mult iple lesions per part icipant (8 in-person). High concern for dermoscopy (16; 57), with no descript ion of diagnost ic
thresholds (8; 25), or report ing of average or consensus diagnoses (9; 35). Dermoscopic image interpretat ion blinded to clinical images (51 image-based).
Lit t le information given concerning the expert ise of the histopathologist (28; 50)
Findings
We included 104 study publicat ions (providing data for 103 cohorts of lesions). We separated a priori 83 publicat ions providing 86 datasets for evaluat ion of the primary target
condit ion into in-person (n = 26), and image-based (n = 60), evaluat ions. Subsequent analysis conf irmed dif ferences in accuracy according to the dif ferent approaches to
diagnosis (P < 0.0001). Analyses of studies by degree of prior test ing revealed no obvious ef fect on accuracy; the study publicat ions provided insuf f icient relevant information,
and the majority of studies were apparent ly conducted in referred populat ions, which hampered our analyses. The f indings presented are based on results for all studies
regardless of posit ion on the clinical pathway. Sensit ivit ies at f ixed specif icit ies and specif icit ies at f ixed sensit ivit ies are given for illustrat ive purposes only and should not
be taken as indicat ive of actual test performance
Test In-person visual inspection alone versus visual inspection plus dermoscopy: any algorithm or threshold
Data analysed Visual inspect ion 13 datasets; 6740 lesions; 459 cases
Dermoscopy 26 datasets; 23,169 lesions; 1664 cases
Resultsa Sensitivity (95% CI) % Fixed specificity Fixed sensitivity Specificity (95% CI) %
Visual inspect ion 76% (66 to 85) 80% 80% 75% (57 to 87)
Dermoscopy 92% (87 to 95) 95% (90 to 98)
Numbers applied to a hypothetical cohort of 1000 lesionsb
TP FN FP TN TP FN FP TN
At a prevalence of
5%
VI: 38
D: 46
8
VI: 12
D: 4
8
190 760 40 10 VI: 238
D: 47
191
VI: 713
D: 904
191
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At a prevalence of
12%
VI: 91
D: 110
19
VI: 29
D: 10
19
176 704 96 24 VI: 220
D: 44
176
VI: 660
D: 836
176
At a prevalence of
21%
VI: 160
D: 193
33
VI: 50
D: 17
33
158 632 168 42 VI: 198
D: 40
158
VI: 5935
D: 750
158
Test: Image-based visual inspection alone versus visual inspection plus dermoscopy: any algorithm or threshold
Data analysed Visual inspect ion 11 datasets; 1740 lesions; 305 cases
Dermoscopy 60 datasets; 13475 lesions; 2851 cases
Results Sensitivity (95% CI) % Fixed specificity Fixed sensitivity Specificity (95% CI) %
Visual inspect ion 47% (34 to 59) 80% 80% 42% (28 to 58)
Dermoscopy 81% (76 to 86) 82% (75 to 87)
Numbers applied to a hypothetical cohort of 1000 lesionsc
TP FN FP TN TP FN FP TN
At a prevalence of
18%
VI: 85
D: 146
61
VI: 95
D: 34
61
164 656 144 36 VI: 476
D: 148
328
VI: 344
D: 672
328
At a prevalence of
24%
VI: 113
D: 194
81
VI: 127
D: 46
81
152 608 192 48 VI: 441
D: 137
304
VI: 319
D: 623
304
At a prevalence of
39%
VI: 183
D: 316
133
VI: 207
D: 74
133
122 488 312 78 VI: 354
D: 110
244
VI: 256
D: 500
244
Test Results according to algorithm used to assist dermoscopy interpretation
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Datasets Lesions; cases Sensitivity
(95% CIs) %
Specificity
(95% CI) %
Numbers in a cohort of 1000 lesionsd
TP FN FP TN
In-person At median prevalence of 12%
No algorithm 8 4704; 849 88%
(75 to 95)
87%
(80 to 92)
106 14 114 766
Pattern analysis 6 4307; 296 92%
(87 to 95)
92%
(68 to 98)
110 10 70 810
ABCD at > 5.45 (or
likely)
5 1438; 160 81%
(62 to 92)
92%
(82 to 97)
97 235 70 810
Image-based At median prevalence of 24%
No algorithm 24 4498; 941 76%
(70 to 82)
79%
(71 to 85)
182 58 61 699
Pattern analysis 20 4621; 989 83%
(76 to 88)
87%
(80 to 92)
199 41 99 661
ABCD at > 5.45 7 2471; 406 81%
(60 to 92)
81%
(69 to 89)
194 46 144 616
7PCL at ≥ 3 11 3408; 798 80%
(63 to 91)
67%
(51 to 80)
192 48 251 509
3PCL 7 1505; 363 74%
(61 to 85)
60%
(42 to 76)
178 62 304 456
3PCL: three-point checklist ; 7PCL: seven-point checklist ; ABCD(E): asymmetry, border, colour, dif f erent ial structures (enlargement); CI: conf idence interval; D: dermoscopy;
FN: f alse-negat ive; FP: f alse-posit ive; TN: t rue-negat ive; TP: t rue-posit ive; VI: visual inspect ion
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aNumbers for a hypothet ical cohort of 1000 lesions are presented for two illustrat ive examples of points on the SROC
curves: f irst ly for the sensit ivit ies of tests at f ixed specif icit ies of 80%; and secondly for the specif icit ies of tests at f ixed
sensit ivit ies of 80%.
bNumbers est imated at 25th, 50th (median), and 75%percent iles of invasive melanoma or atypical intraepidermal melanocyt ic
variants prevalence observed across 26 datasets report ing in-person evaluat ions of dermoscopy added to visual inspect ion.
cNumbers est imated at 25th, 50th (median), and 75%percent iles of invasive melanoma or atypical intraepidermal melanocyt ic
variants prevalence observed across 60 datasets report ing diagnosis using dermoscopic images
dNumbers est imated at median prevalence (50th percent ile), of invasive melanoma or atypical intraepidermal melanocyt ic
variants observed across 26 datasets report ing in-person evaluat ions of dermoscopy added to visual inspect ion and then for
60 datasets report ing diagnosis using dermoscopic images
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
This review is one of a series of Cochrane Diagnostic Test Accu-
racy (DTA) Reviews on the diagnosis and staging of melanoma
and keratinocyte skin cancers conducted for the National Insti-
tute for Health Research (NIHR) Cochrane Systematic Reviews
Programme. Appendix 1 shows the content and structure of the
programme.
Target condition being diagnosed
Melanoma is one of the most aggressive forms of skin cancer,
with the potential to metastasise to other parts of the body via
the lymphatic system and blood stream. It accounts for a small
percentage of skin cancer cases but is responsible for up to 75%
of skin cancer deaths (Boring 1994; Cancer Research UK 2017a).
Melanoma arises from uncontrolled proliferation of melanocytes -
the epidermal cells that produce pigment ormelanin. It most com-
monly arises in the skin but can occur in any organ that contains
melanocytes, including mucosal surfaces, the back of the eye, and
lining around the spinal cord and brain. Cutaneous melanoma
refers to a skin lesion with malignant melanocytes present in the
dermis, and includes superficial spreading, nodular, acral lentig-
inous, and lentigo maligna melanoma variants (see Figure 1).
Melanoma ’in situ’ refers to malignant melanocytes that are con-
tained within the epidermis and have not yet invaded the der-
mis, but are at risk of progression to melanoma if left untreated.
Lentigomaligna, a subtype ofmelanoma in situ in chronically sun-
damaged skin, denotes another form of proliferation of abnormal
melanocytes. Lentigo maligna can progress to invasive melanoma
if its growth breaches the dermo-epidermal junction during a ver-
tical growth phase (when it becomes known as ’lentigo maligna
melanoma’), however its rate of malignant transformation is both
lower and slower than for melanoma in situ (Kasprzak 2015).
Melanoma in situ and lentigo maligna are both atypical intraepi-
dermal melanocytic variants.
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Figure 1. Sample photographs of superficial spreading melanoma (left) and nodular melanoma (right).
Copyright © 2010 Dr Rubeta Matin: reproduced with permission.
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The incidence of melanoma rose to over 200,000 newly diagnosed
cases worldwide in 2012 (Erdmann 2013; Ferlay 2015), with an
estimated 55,000 deaths (Ferlay 2015). The highest incidence is
observed in Australia with 13,134 new cases of melanoma of the
skin in 2014 (ACIM 2017), and in New Zealand with 2341 reg-
istered cases in 2010 (HPA and MelNet NZ 2014). For 2014 in
the USA, the predicted incidence was 73,870 per annum and the
predicted number of deaths 9940 (Siegel 2015). The highest rates
in Europe are seen in north-western Europe and the Scandina-
vian countries, with highest incidence reported in Switzerland of
25.8 per 100,000 in 2012. Rates in England have tripled from 4.6
and 6.0 per 100,000 in men and women, respectively, in 1990, to
18.6 and 19.6 per 100,000 in 2012 (EUCAN 2012). Indeed in
the UK, melanoma has one of the fastest rising incidence rates of
any cancer, and has the biggest projected increase in incidence be-
tween 2007 and 2030 (Mistry 2011). In the decade leading up to
2013, age-standardised incidence increased by 46%, with 14,500
new cases in 2013 and 2459 deaths in 2014 (Cancer Research UK
2017b). While overall incidence rates are higher in women than
in men, the rate of incidence in the latter is increasing faster than
in women (Arnold 2014).
The rising incidence in melanoma is thought to be primarily re-
lated to an increase in recreational sun exposure and use of tanning
beds, and an increasingly ageing population with higher lifetime
ultraviolet (UV), exposure, in conjunction with possible earlier
detection (Belbasis 2016; Linos 2009). Putative risk factors are
reviewed in detail elsewhere (Belbasis 2016), but can be broadly
divided into host or environmental factors. Host factors include
fair skin and light hair or eye colour; older age (Geller 2002); male
sex (Geller 2002); previous skin cancer history (Tucker 1985);
predisposing skin lesions, for example, high melanocytic naevus
counts (Gandini 2005), clinically atypical naevi (Gandini 2005),
or large congenital naevi (Swerdlow 1995); genetically inherited
skin disorders, such as xeroderma pigmentosum (Lehmann 2011),
and a family history of melanoma (Gandini 2005). Environmental
factors include recreational and occupational exposure to sunlight,
both cumulative and episodic burning (Armstrong 2017; Gandini
2005); artificial tanning (Boniol 2012); and immunosuppression,
for example, in organ transplant recipients or HIV-positive indi-
viduals (DePry 2011). Lower socioeconomic class may be associ-
ated with delayed presentation and thus more advanced disease at
diagnosis (Reyes-Ortiz 2006).
A database of over 40,000 US patients from 1998 onwards, which
assisted the development of the 8th American Joint Commit-
tee on Cancer (AJCC) Staging System indicated a five-year sur-
vival of 99% for very early stage melanoma, dropping to any-
thing between 32% and 93% in stage III disease depending on
tumour thickness, the presence of ulceration and number of in-
volved nodes (Gershenwald 2017). Before the advent of targeted
and immunotherapies, disseminated melanoma (to distant sites/
visceral organs), was associated with median survival of six to nine
months, one-year survival rate of 25%, and three-year survival of
15% (Balch 2009; Korn 2008).
Between 1975 and 2010, five-year relative survival for melanoma
(i.e. not including deaths from other causes), in the USA increased
from80% to 94%,with survival for localised, regional, and distant
disease estimated at 99%, 70%, and 18%, respectively in 2010
(Cho 2014). However, mortality rates showed little change, at 2.1
per 100,000 deaths in 1975 and 2.7 per 100,000 in 2010 (Cho
2014). Increasing incidence in localised disease over the same pe-
riod (from 5.7 to 21 per 100,000), suggests that much of the
observed improvement in survival may be due to earlier detec-
tion and heightened vigilance (Cho 2014). New targeted therapies
for advanced (stage IV), melanoma (e.g. BRAF inhibitors), have
improved survival, and immunotherapies are evolving such that
long-term survival is being documented (Pasquali 2018; Rozeman
2017). No new data regarding the survival prospects for patients
with stage IV disease were analysed for the AJCC 8 staging guide-
lines due to lack of contemporary data (Gershenwald 2017).
Treatment of melanoma
For primary melanoma, the mainstay of definitive treatment is
early detection and excision of the lesion, to remove both the
tumour and any malignant cells that might have spread into the
surrounding skin (Garbe 2016; Marsden 2010; NICE 2015a;
SIGN 2017; Sladden 2009). Recommended surgical margins vary
according to tumour thickness (Garbe 2016), and stage of disease
at presentation (NICE 2015a).
Index test(s)
For the purposes of our series of reviews, we consider each compo-
nent of the diagnostic process, including visual inspection or clini-
cal examination, a diagnostic or index ‘test’, the accuracy of which
can be established in comparison with a reference standard of di-
agnosis, either alone or in combination with other available tech-
nologies that may assist the diagnostic process. In this review, al-
though dermoscopy is the primary focus, two index tests are in fact
under consideration, namely visual inspection and dermoscopy,
both of which can be undertaken in person (face-to-face with the
patient), or as an image-based examination (remote from the pa-
tient using images). As dermoscopy is added to visual inspection
of a skin lesion when it is undertaken in person, we effectively
have three index tests: visual inspection alone (in person or using
images), visual inspection + dermoscopy (in-person dermoscopy),
and dermoscopy alone (image-based dermoscopy).
As visual inspection of a lesion is always undertaken first in a
face-to-face patient consultation, in this section we first consider
visual inspection alone before going on to describe the addition of
dermoscopy.
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Visual inspection
Clinical history-taking to identify risk factors and visual inspection
of the lesion, surrounding skin and comparison with other lesions
on the rest of the body, is fundamental to the diagnosis of skin
cancer. In the UK, clinical examination is typically done at two
decision points - first in the general practice (GP) surgery where a
decision is made to refer or not to refer, and then a second time by
a dermatologist or other secondary care clinician where a decision
is made to biopsy or not.
Visual inspection of a lesion relies on both non-analytical and ana-
lytical pattern recognition strategies (Elstein 2002; Norman 1989;
Norman 2009). Non-analytical pattern recognition formulates an
initial hypothesis hidden from the conscious view of the diagnos-
tician, while analytical pattern recognition uses more explicit rules
based on conscious analytical reasoning (Norman 2009). The bal-
ance between non-analytical and analytical reasoning varies be-
tween clinicians, according to factors such as constitutional rea-
soning style preference, experience and familiarity with the diag-
nostic question. Various attempts have been made to formalise
the ’mental rules’ involved in analytical pattern recognition for
melanoma, ranging from setting out criteria that should be consid-
ered (e.g. ‘pattern analysis’; Friedman 1985; Sober 1979), to for-
mal scoring systems with explicit numerical thresholds (MacKie
1985; MacKie 1990). These variants on visual inspection strate-
gies, and their comparative accuracy, are reviewed in detail in a
separate systematic review in this series (Dinnes 2018a). We have
included in this review data on the accuracy of visual inspection
only where both visual inspection and dermoscopy were evaluated
in the same lesions in order to robustly estimate the comparative
accuracy of adding dermoscopy to visual inspection compared to
visual inspection alone, so that the benefit of dermoscopy can be
quantified.
Visual inspection of a digital photograph (or ‘macroscopic’ image),
of a suspicious skin lesion can also be undertaken as part of a teled-
ermatology consultation, whereby photographs, dermoscopic im-
ages, or both are taken by non-specialist clinicians and forwarded
to a dermatologist to obtain a specialist opinion (Chuchu 2018a).
Images can also be encompassed in a store-and-forward smart-
phone application, whereby a photograph of a concerning lesion
is taken by the smartphone user and forwarded for an assessment
of skin cancer risk by a specialist clinician (Chuchu 2018b). Im-
ages are often accompanied by a summary of the medical history
and demographic information as part of a consultation package
(Ndegwa 2010). According to UK guidelines, both clinical and
dermoscopic images must be sent for ‘full dermatology’, that is, as
a replacement for a face-to-face consultation, whereas for ‘triage
teledermatology’ dermoscopic images should be sent where facil-
ities permit (BAD 2013).
Dermoscopy
Dermoscopy (also referred to as dermatoscopy or epiluminescence
microscopy or ELM), has become a widely used tool for the spe-
cialist clinician and is increasingly being used in primary care set-
tings. It uses a hand-held microscope and incident light (with or
without oil immersion), to reveal subsurface images of the skin
at increased magnification of x 10 to x 100 (Kittler 2011). Used
alongside clinical examination, dermoscopy has been shown in
some studies to increase the sensitivity of clinical diagnosis of
melanoma from around 60% to as much as 90% (Bono 2006;
Carli 2002a; Kittler 1999; Stanganelli 2000), with much smaller
effects in others (Benelli 1999; Bono 2002a).
The visual nature of dermoscopic interpretation means that, when
used on an in-person basis, dermoscopy is essentially added to
visual inspection of a skin lesion, and similar non-analytical and
analytical pattern recognition strategies are also employed to reach
a diagnosis. Pattern analysis (Pehamberger 1993; Steiner 1987a),
is thought to be the most specific and reliable technique to aid
dermoscopy interpretation when used by specialists (Maley 2014);
however, dermoscopic histological correlations have been estab-
lished and diagnostic algorithms developed based on colour, as-
pect, pigmentation pattern, and skin vessels. One of the first for-
mal scoring systems was the ABCD rule for dermoscopy (Nachbar
1994; Stolz 1994a), which includes 21 different features to be
considered and scored (two based on asymmetry of the lesion,
eight on lesion border, six related to lesion colour and five to dif-
ferential structures), and has reported sensitivity ranging between
84% and 93% (Nachbar 1994; Stolz 1994a). Subsequently pub-
lished algorithms attempt to simplify assessment without miss-
ing melanomas, for example, the Menzies tool (Menzies 1996),
the seven-point dermoscopy checklist (Annessi 2007; Argenziano
1998; Argenziano 2001; Gereli 2010, amongst others), and the
three-point checklist (Gereli 2010). However, dermoscopy can
fail to diagnose atypical or early or featureless melanomas (Skvara
2005). These and other identified algorithms are described in de-
tail in Appendix 2.
In modern practice, dermoscopic images are almost always ob-
tained for skin lesions that are recommended for excision and
are also obtained for lesions that have not yet met the diagnostic
threshold for excision but are to be monitored over time in case
of any further suspicious changes. Dermoscopic images are also a
key component of teledermatology consultations, usually accom-
panied by digital photographs and other pertinent information
(Chuchu 2018a), as discussed above.
The accuracy of dermoscopy has been suggested to vary with ex-
aminer experience (Kittler 2011), and results when used by un-
trained or less experienced examiners are potentially no better
than clinical inspection alone (Binder 1997; Kittler 2002). Train-
ing in dermoscopy use can vary from a single one-hour lecture
(Benvenuto-Andrade 2006), to an intensive course lasting a week
or more (De Giorgi 2011), often supplemented with web-based
learning or using textbooks or CD-ROMs (Carli 2003a; Menzies
2009; Tan 2009). The most effective means of training health
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professionals in dermoscopy remains to be established. Evidence
from Australia suggests that it takes time to train non-expert clin-
icians in the use of dermoscopy, and dropout rates from training
programmes may be up to 40% (Menzies 2009).
Clinical pathway
The diagnosis of melanoma can take place in primary, secondary,
and tertiary care settings by both generalist and specialist health-
care providers. In the UK, people with concerns about a new or
changing lesion will usually present first to their GP or less com-
monly, directly to a specialist in secondary care, which could in-
clude a dermatologist, plastic surgeon, general surgeon or other
specialist surgeon (such as an ear, nose, and throat (ENT) spe-
cialist or maxillofacial surgeon), or ophthalmologist (Figure 2).
Current UK guidelines recommend that all suspicious pigmented
lesions presenting in primary care should be assessed by taking a
clinical history and visual inspection using the weighted seven-
point checklist (MacKie 1990); lesions suspected to be melanoma
should be referred for appropriate specialist assessment within two
weeks (Chao 2013; Marsden 2010; NICE 2015a). There are cur-
rently no recommendations promoting the use of dermoscopy in
primary care in the UK, although the 2015 NICE suspected can-
cer recognition and referral guidelines state that people should
be referred “using a suspected cancer pathway referral (for an ap-
pointment within 2 weeks), if dermoscopy suggests melanoma of
the skin” (NICE 2015a). Studies from France (Chappuis 2016),
and the Netherlands (Ahmadi 2017), suggest that around 8% of
GPs use dermoscopy, compared to as many as 40% of GPs in Aus-
tralia reported to use a dermoscope in their routine practice (Youl
2007a).
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Figure 2. Current clinical pathway for people with skin lesions.
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Theoretically, teledermatology consultations may aid appropriate
triage of lesions into urgent referral; non-urgent secondary care
referral (e.g. for suspected basal cell carcinoma); or where available,
referral to an intermediate care setting, such as clinics run by GPs
with a special interest in dermatology. The distinction between
setting and examiner qualifications and experience is important, as
specialist clinicians might work in primary care settings (e.g. in the
UK, GPs with a special interest in dermatology and skin surgery
who have undergone appropriate training), and generalists might
practice in secondary care settings (e.g. plastic surgeons who do
not specialise in skin cancer). The level of skill and experience in
skin cancer diagnosis will vary for both generalist and specialist
care providers and will also have an impact on test accuracy.
Following referral, a specialist clinician will also use history-tak-
ing and visual inspection of the lesion (in comparison with other
lesions on the skin), usually in conjunction with dermoscopic ex-
amination, to inform a clinical decision. If melanoma is suspected,
then urgent excision biopsy is recommended; for suspected cu-
taneous squamous cell carcinoma (cSCC), urgent excision with
predetermined surgical margins. Other lesions such as basal cell
carcinoma (BCC), suspected dysplastic naevi or pre-malignant le-
sions such as lentigo maligna may also be referred for a diagnostic
biopsy, followed by appropriate treatment, further surveillance or
reassurance and discharge.
Prior test(s)
Although smartphone applications and community-based teled-
ermatology services can increasingly be directly accessed by people
who have concerns about a skin lesion, visual inspection of a sus-
picious lesion by a clinician is usually the first in a series of tests to
diagnose skin cancer. In the UK this usually takes place in primary
care setting, however in some countries people with suspicious
lesions can present directly to a specialist setting (NICE 2015b).
Dermoscopy is likely to be added to visual inspection of a lesion
in secondary care and referral settings, however, it is increasingly
used in primary care, particularly in countries such as Australia
(Youl 2007a).
Consideration of the degree of prior testing that study participants
have undergone is key to interpretation of test accuracy indices, as
these are known to vary according to the disease spectrum (or case-
mix), of included participants (Lachs 1992;Moons 1997; Leeflang
2013; Usher-Smith 2016). Spectrum effects are often observed
when tests that are developed further down the referral pathway
have lower sensitivity and higher specificity when applied in set-
tings with participants with limited prior testing (Usher-Smith
2016). Studies of individuals with suspicious lesions at the initial
clinical presentation stage (’test naïve’), are likely to have a wider
range of differential diagnoses and include a higher proportion of
people with benign diagnoses compared with studies of partici-
pants who have been referred for a specialist opinion on the basis
of visual inspection (with or without dermoscopy), by a generalist
practitioner. Furthermore, studies in more specialist settings may
focus on equivocal or difficult-to-diagnose lesions rather than le-
sions with a more general level of clinical suspicion. However this
direction of effect is not consistent across tests and diseases, the
mechanisms in action often being more complex than prevalence
alone and can be difficult to identify (Leeflang 2013). A simple
categorisation of studies according to primary, secondary or spe-
cialist setting may not always adequately reflect this difference in
disease spectrum.
Role of index test(s)
Although visual inspection and history-taking are key to diagnos-
ing skin cancer and are always undertaken as part of a clinical ex-
amination, dermoscopy has become an important tool to assist di-
agnosis by specialist clinicians and is increasingly used in primary
care settings. For the majority of generalist practitioners, the pri-
mary goal is to identify people with benign lesions and appropri-
ately reassure them, thereby minimising the proportion of people
who are referred unnecessarily, while still identifying those lesions
that require referral and expert assessment. For the specialist, the
aim is not only to identify those in need of urgent excision due
to invasive cancer, but also to identify high-risk lesions with con-
siderable potential to progress to invasive disease, such as those
with severe dysplasia or in situ disease, such as lentigo maligna, for
example.
When diagnosing potentially life-threatening conditions such as
melanoma, the consequences of falsely reassuring a person that
they do not have skin cancer can be serious and potentially fatal, as
the resulting delay to diagnosis means that the window for success-
ful early treatmentmay bemissed. Tominimise such false-negative
diagnoses, a good diagnostic test will demonstrate high sensitivity
and a high negative predictive value (NPV), where very few of
those with a negative test result will actually have a melanoma.
False-positive test results from a test with poor specificity will result
in the removal of many benign lesions. Unneccessary surgery is
arguably less of an error thanmissing a potentially fatal melanoma,
but is costly: false-positive diagnoses not only cause unnecessary
scarring from the biopsy or excision procedure, but also increase
patient anxiety whilst they await the definite histology results and
increase healthcare costs as the number needed to remove to yield
one melanoma diagnosis increases.
The additive value of dermoscopy over and above visual inspec-
tion alone is likely to vary with differences in setting, prior testing
and selection of participants, and observer qualifications, experi-
ence and training. Furthermore dermoscopic images of lesions are
increasingly taken by non-expert clinicians or by non-clinicians,
sometimes using mobile phone applications, and are forwarded
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to specialist clinics or to commercial organisations for interpre-
tation, sometimes accompanied by a clinical image of the lesion
with varying amounts of patient information (such as age, gender,
and location of the lesion). With skin cancer rates continuing to
rise, the increasing availability of dermoscopy for generalist use,
and with a growing number of other high-resolution image-anal-
ysis techniques, particularly for specialist use, it is important to
understand the relative accuracy and appropriate place of available
tests in the diagnostic pathway (whether as replacements for der-
moscopy, or as add-on diagnostic tools).
Although this review examines the accuracy of image-based der-
moscopy interpretation, studies conducted specifically in a teled-
ermatology context are the subject of a separate systematic review
(Chuchu 2018a). Similarly, studies of mobile phone applications,
where the intended users are members of the general public rather
than clinicians are the subject of another review (Chuchu 2018b).
Alternative test(s)
As part of our series of systematic reviews, we have reviewed
a number of other tests that may have a role in the diagnosis
of melanoma in a specialist setting, including reflectance con-
focal microscopy (RCM) (Dinnes 2018b), optical coherence to-
mography (OCT) (Ferrante di Ruffano 2018a), and computer-
aided diagnosis (CAD) techniques applied to various types of im-
ages, including those generated by dermoscopy, diffuse reflectance
spectrophotometry (DRS) and electrical impedance spectroscopy
(EIS) (Ferrante di Ruffano 2018b), and high-frequency ultra-
sound (Dinnes 2018c). Other tests reviewed include telederma-
tology (Chuchu 2018a), and mobile phone applications (Chuchu
2018b). Evidence permitting, we plan to compare the accuracy
of available tests in an overview review, exploiting within-study
comparisons of tests and allowing the analysis and comparison
of commonly used diagnostic strategies where tests may be used
singly or in combination.
We also considered and excluded a number of tests from this re-
view, such as tests used for monitoring people (e.g. total body pho-
tography of those with large numbers of typical or atypical naevi).
We also did not assess histopathological confirmation following
lesion excision because it is the established reference standard for
melanoma diagnosis and one of the standards against which the
index tests are evaluated in these reviews.
Rationale
This series of reviews of diagnostic tests used to assist clinical di-
agnosis in either clinical practice or in a research setting, aims to
identify the most accurate approaches to diagnosis and provide
clinical and policy decision-makers with the highest possible stan-
dard of evidence on which to base diagnostic and treatment deci-
sions. With increasing rates of melanoma and a trend to adopt the
use of dermoscopy and other high-resolution image analysis in pri-
mary care, the anxiety around missing early cases needs to be bal-
anced against the risk of over referrals, to avoid sending too many
people with benign lesions for a specialist opinion. It is question-
able whether all skin cancers identified by sophisticated techniques
contribute to morbidity andmortality or whether newer technolo-
gies run the risk of increasing false-positive diagnoses. The full
impact of use of these technologies cannot be understood without
an understanding of the accuracy of more established techniques
such as dermoscopy, in comparison to visual inspection. It is also
possible that widespread use of dermoscopy in primary care with
inadequate training could result in harm frommissed melanomas,
particularly if used as a replacement for traditional history-tak-
ing and clinical examination of the entire skin. Many branches of
medicine have noted the danger of such “gizmo idolatry” amongst
doctors (Leff 2008). The trend towards remote interpretation of
clinical images (whether macroscopic or dermoscopic images of
lesions), and the use of remote technologies that do not involve
clinicians without substantive evidence could further disrupt clin-
ical pathways and healthcare payments as they may attract custom
from the worried well, leaving an ever decreasing pool of qualified
doctors to pick up any resulting problems.
There are a number of available systematic reviews in the field.
Some are limited by now out-of-date search periods, for exam-
ple searches in Rajpara 2009 were carried out up to 2007, and
in Vestergaard 2008 up to 2008. Others are focused on specific
clinical questions, for example, selected healthcare professionals
(Corbo 2012 including only direct comparisons of the accuracy of
primary care physicians versus dermatologists, and Loescher 2011
reviewing the skin cancer detection skills of advanced practice
nurses), or settings (Herschorn 2012 including direct comparisons
of visual inspection versus dermoscopy in primary care). More re-
cently, Harrington and colleagues (Harrington 2017), published
a systematic review of clinical prediction rules (or published al-
gorithms), to assist the diagnosis of melanoma (both for clinical
examination and for dermoscopy), and included studies published
up to May 2015. This review did not consider whether diagnoses
were made based on images or were conducted in person, nor did
it consider variations in the definition of the target condition, and
furthermore it did not compare diagnosis with and without the
use of an algorithm.
The critical question about the accuracy of dermoscopy in addition
to visual inspection and the impact of examiner, prior patient
testing, underlying risk status and the use of images for diagnosis
needs to be answered before the potential contribution of other
diagnostic tests can be set in context and appropriately placed in
the diagnostic pathway.
This review follows a generic protocol that covers the full series of
Cochrane DTA Reviews for the diagnosis of melanoma (Dinnes
2015a). The Background and Methods sections of this review
therefore use some text that was originally published in the pro-
tocol (Dinnes 2015a), and text that overlaps some of our other
reviews (Dinnes 2018a; Dinnes 2018b). Appendix 3 provides a
glossary of terms used.
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O B J E C T I V E S
To determine the diagnostic accuracy of dermoscopy alone, or
when added to visual inspection of a skin lesion, for the detec-
tion of cutaneous invasive melanoma and atypical intraepidermal
melanocytic variants in adults.
Accuracy was estimated separately, according to the prior testing
undergone by study participants, comparing those with limited
prior testing with those referred for further evaluation of a suspi-
cious lesion.We originally aimed to estimate the effect on accuracy
of diagnosis based on a face-to-face (in-person), encounter versus
a remote (image-based), assessment as a secondary objective, how-
ever given the considerable difference in nature of an in-person
consultation compared to the viewing of an image, we estimated
accuracy separately for each approach to diagnosis. We therefore
aimed to compare tests in the following way:
To estimate incremental accuracy for the diagnosis of invasive
melanoma and atypical intraepidermal melanocytic variants in
adults, a), from dermoscopy added to in-person visual inspection
of a skin lesion, or b), from dermoscopic image-based assessment
in comparison to visual inspection of a clinical photograph.
Secondary objectives
For the identificationof cutaneous invasivemelanoma and atypical
intraepidermal melanocytic variants:
• to compare the accuracy of dermoscopy to visual inspection
alone, where both tests have been evaluated in the same studies
(direct test comparisons);
• to determine the diagnostic accuracy of individual
algorithms used to assist dermoscopy;
• to determine the effect of observer experience on diagnostic
accuracy;
• to determine the effect of dermoscopy training on
diagnostic accuracy
For the alternative definitions of the target condition:
• to determine the diagnostic accuracy of dermoscopy alone,
or added to visual inspection of a skin lesion, for the detection of
invasive melanoma only in adults, and to estimate incremental
accuracy a), from dermoscopy added to in-person visual
inspection of a skin lesion, or b), from dermoscopic image-based
assessment in comparison to visual inspection of a clinical
photograph;
• to determine the diagnostic accuracy of dermoscopy alone,
or added to visual inspection of a skin lesion, for the detection of
any skin cancer or skin lesion with a high risk of progression to
melanoma in adults, and to estimate incremental accuracy a),
from dermoscopy added to in-person visual inspection of a skin
lesion, or b), from dermoscopic image-based assessment in
comparison to visual inspection of a clinical photograph.
Investigation of sources of heterogeneity
We set out to address a range of potential sources of heterogeneity
for investigation across our series of reviews, as outlined in our
generic protocol (Dinnes 2015a), and described in Appendix 4,
however our ability to investigate these was necessarily limited by
the available data on each individual test reviewed.
The sources of heterogeneity that we investigated for dermoscopy
were:
• prior testing: comparing those at initial presentation versus
referred patients
• in-person versus image-based evaluations
• type of reference standard: histology alone versus histology
+ clinical follow-up or other reference standard
• use of a diagnostic algorithm: no algorithm reported versus
any named algorithm used
• lesion type: pigmented versus melanocytic lesions
• number of observers making the diagnosis: single observer
versus consensus of two or more
• disease prevalence: 0% to 5%; 5% to 10%, 10% to 20%,
more than 20%
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included test accuracy studies that allowed comparison of the
result of the index test with that of a reference standard, including
the following:
• studies where all participants received a single index test
and a reference standard;
• studies where all participants received more than one index
test(s) and reference standard;
• studies where participants were allocated (by any method),
to receive different index tests or combinations of index tests and
all received a reference standard (between-person comparative
studies (BPC));
• studies that recruited series of participants unselected by
true disease status (referred to as case series for the purposes of
this review);
• diagnostic case-control studies that separately recruited
diseased and non-diseased groups (see Rutjes 2005);
• both prospective and retrospective studies; and
• studies where previously acquired clinical or dermoscopic
images were retrieved and prospectively interpreted for study
purposes.
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We excluded studies from which we could not extract 2x2 contin-
gency data or if they included fewer than five melanoma cases or
fewer than five benign lesions. The size threshold of five is arbi-
trary. However such small studies are unlikely to add precision to
estimate of accuracy.
Studies available only as conference abstracts were excluded; how-
ever, attempts were made to identify full papers for potentially
relevant conference abstracts (Searching other resources).
Participants
We included studies in adults with pigmented skin lesions or le-
sions suspicious for melanoma or those at high risk of developing
melanoma, including those with a family history or previous his-
tory of melanoma skin cancer, atypical or dysplastic naevus syn-
drome, or genetic cancer syndromes.
We excluded studies that recruited only participants with malig-
nant diagnoses and studies that compared test results in partici-
pants with malignancy compared with test results based on ’nor-
mal’ skin as controls, due to the inherent bias in such comparisons
(Rutjes 2006).
We excluded studies conducted in children or that clearly reported
inclusion of more than 50% of participants aged 16 and under.
Index tests
Studies reporting accuracy data for dermoscopy, with diagnosis
made either in person (face-to-face diagnosis), or image-based (di-
agnosis based on dermoscopic images, remotely from the study
participant), were eligible for inclusion. We included all estab-
lished algorithms or checklists to assist diagnosis.
We included studies developing new algorithms or methods of
diagnosis (i.e. derivation studies), if they:
• used a separate independent ’test set’ of participants or
images to evaluate the new approach; or
• investigated lesion characteristics that had previously been
suggested as associated with melanoma and the study reported
accuracy based on the presence or absence of specific
combinations of characteristics.
We excluded studies if they:
• used a statistical model to produce a data-driven equation,
or algorithm based on multiple diagnostic features, with no
separate test set;
• used cross-validation approaches such as ’leave-one-out’
cross-validation (Efron 1983);
• evaluated the accuracy of the presence or absence of
individual lesion characteristics or morphological features, with
no overall diagnosis of malignancy;
• reported accuracy data for ‘clinical diagnosis’ with no clear
description as to whether the reported data related to visual
inspection alone or included dermoscopy in all study
participants;
• were based on the experience of a skin cancer-specific clinic,
where dermoscopy may or may not have been used on an
individual participant basis.
Although primary care clinicians can have a specialist interest in
skin cancer, for the purposes of this review we considered primary
care physicians as generalist practitioners and dermatologists as
specialists. Within each group, we extracted any reporting of spe-
cial interest or accreditation in skin cancer.
Target conditions
We defined the primary target condition as the detection of:
• any form of invasive cutaneous melanoma, or atypical
intraepidermal melanocytic variants (i.e. including melanoma in
situ, or lentigo maligna, which has a risk of progression to
invasive melanoma).
We considered two additional definitions of the target condition
in secondary analyses, namely the detection of:
• any form of invasive cutaneous melanoma alone;
• any skin lesion requiring excision. This latter definition
includes other forms of skin cancer, such as basal cell carcinoma
(BCC) and cutaneous squamous cell carcinoma (cSCC), as well
as melanoma in situ, lentigo maligna, and lesions with severe
melanocytic dysplasia.
The diagnosis of the keratinocyte skin cancers, basal cell carci-
noma, and squamous cell carcinoma as primary target conditions
using visual inspection and/or dermoscopy are the subject of a
separate review (Dinnes 2018d).
Reference standards
The ideal reference standard is histopathological diagnosis in all eli-
gible lesions. A qualified pathologist or dermatopathologist should
perform histopathology. Ideally, reporting should be standardised,
detailing a minimum dataset to include the histopathological fea-
tures of melanoma to determine the American Joint Committee
on Cancer (AJCC) Staging System (e.g. Slater 2014). We did not
apply this as a necessary inclusion criterion, but extracted any per-
tinent information.
Partial verification (applying the reference test only to a subset of
those undergoing the index test), was of concern given that lesion
excision or biopsy are unlikely to be carried out for all benign-ap-
pearing lesions within a representative population sample. There-
fore to reflect what happens in reality, we accepted clinical follow-
up of benign-appearing lesions as an eligible reference standard,
whilst recognising the risk of differential verification bias (as mis-
classification rates of histopathology and follow-up will differ).
Additional eligible reference standards included cancer registry
follow-up and ’expert opinion’ with no histology or clinical fol-
low-up. Cancer registry follow-up is considered less desirable than
active clinical follow-up, as follow-up is not carried out within
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the control of the study investigators. Furthermore, if participant-
based analyses as opposed to lesion-based analyses are presented,
it may be difficult to determine whether the detection of a ma-
lignant lesion during follow-up is the same lesion that originally
tested negative on the index test.
All of the above were considered eligible reference standards with
the following caveats:
• all study participants with a final diagnosis of the target
disorder must have had a histological diagnosis, either
subsequent to the application of the index test or after a period
of clinical follow-up; and
• at least 50% of all participants with benign lesions must
have had either a histological diagnosis or clinical follow-up to
confirm benignity.
Search methods for identification of studies
Electronic searches
The Information Specialist (SB) carried out a comprehensive
search for published and unpublished studies. A single large liter-
ature search was conducted to cover all topics in the programme
grant (see Appendix 1 for a summary of reviews included in the
programme grant). This allowed for the screening of search results
for potentially relevant papers for all reviews at the same time.
A search combining disease related terms with terms related to
the test names, using both text words and subject headings was
formulated. The search strategy was designed to capture studies
evaluating tests for the diagnosis or staging of skin cancer. As the
majority of records were related to the searches for tests for stag-
ing of disease, a filter using terms related to cancer staging and
to accuracy indices was applied to the staging test search, to try
to eliminate irrelevant studies, for example, those using imaging
tests to assess treatment effectiveness. A sample of 300 records that
would be missed by applying this filter was screened and the filter
adjusted to include potentially relevant studies. When piloted on
MEDLINE, inclusion of the filter for the staging tests reduced the
overall numbers by around 6000. The final search strategy, incor-
porating the filter, was subsequently applied to all bibliographic
databases as listed below (Appendix 5). The final search result was
cross-checked against the list of studies included in five systematic
reviews; our search identified all but one of the studies, and this
study was not indexed onMEDLINE. The Information Specialist
(SB) devised the search strategy, with input from the Information
Specialist from Cochrane Skin. No additional limits were used.
We searched the following bibliographic databases to 29 August
2016 for relevant published studies:
• MEDLINE via OVID (from 1946);
• MEDLINE In-Process & Other Non-Indexed Citations via
OVID; and
• Embase via OVID (from 1980).
We searched the following bibliographic databases to 30 August
2016 for relevant published studies:
• the Cochrane Central Register of Controlled Trials
(CENTRAL; 2016, Issue 7), in the Cochrane Library;
• the Cochrane Database of Systematic Reviews (CDSR;
2016, Issue 8), in the Cochrane Library;
• Cochrane Database of Abstracts of Reviews of Effects
(DARE; 2015, Issue 2);
• CRD HTA (Health Technology Assessment), database
2016, Issue 3; and
• CINAHL (Cumulative Index to Nursing and Allied Health
Literature via EBSCO from 1960).
We searched the followingdatabases for relevant unpublished stud-
ies using a strategy based on the MEDLINE search:
• CPCI (Conference Proceedings Citation Index), via Web of
Science™ (from 1990; searched 28 August 2016); and
• SCI Science Citation Index Expanded™ via Web of
Science™ (from 1900, using the ’Proceedings and Meetings
Abstracts’ Limit function; searched 29 August 2016).
We searched the following trials registers using the search terms
’melanoma’, ’squamous cell’, ’basal cell’ and ’skin cancer’ combined
with ’diagnosis’:
• Zetoc (from 1993; searched 28 August 2016).
• The US National Institutes of Health Ongoing Trials
Register (www.clinicaltrials.gov); searched 29 August 2016.
• NIHR Clinical Research Network Portfolio Database (
www.nihr.ac.uk/research-and-impact/nihr-clinical-research-
network-portfolio/); searched 29 August 2016.
• The World Health Organization International Clinical
Trials Registry Platform ( apps.who.int/trialsearch/); searched 29
August 2016.
We aimed to identify all relevant studies regardless of language
or publication status (published, unpublished, in press, or in
progress). We applied no date limits.
Searching other resources
We screened relevant systematic reviews identified by the searches
for their included primary studies, and included anymissed by our
searches.We checked the reference lists of all included papers, and
subject experts within the author team reviewed the final list of
included studies. No electronic citation searching was conducted.
Data collection and analysis
Selection of studies
At least one review author (JDi or NC), screened titles and ab-
stracts, with any queries discussed and resolved by consensus. A
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pilot screen of 539MEDLINE references showed good agreement
(89% with a kappa of 0.77), between screeners. We included at
initial screening primary test accuracy studies and test accuracy
reviews (for scanning of reference lists), of any test used to investi-
gate suspectedmelanoma, BCC, or cSCC. Both a clinical reviewer
(from one of a team of 12 clinician reviewers), and a methodolo-
gist reviewer (JDi orNC), applied inclusion criteria independently
to all full-text articles (Appendix 6). We resolved disagreements
by consensus or by consulting a third party (JDe, CD, HW, and
RM). We contacted authors of eligible studies when insufficient
data were presented to allow for the construction of 2x2 contin-
gency tables.
Data extraction and management
One clinical (as detailed above), and one methodologist reviewer
(JDi, NC or LFR), independently extracted data concerning de-
tails of the study design, participants, index test(s) or test combi-
nations and criteria for index test positivity, reference standards,
and data required to populate a 2x2 diagnostic contingency ta-
ble for each index test using a piloted data extraction form. We
extracted data at all available index test thresholds. We resolved
disagreements by consensus or by involving a third party (JDe,
CD, HW, and RM).
Where information related to final lesion diagnoses or diagnostic
thresholds were missing, we contacted authors of included studies.
In particular, invasive cSCC (included as disease-positive for one
of our secondary objectives), is not always differentiated from ’in
situ’ variants such as Bowens disease (which we did not consider as
disease-positive for any of our definitions of the target condition).
We contacted authors of conference abstracts published from2013
to 2015 to ask whether full data were available. If no full paper
was identified, we marked conference abstracts as ’pending’ and
will revisit them in a future review update.
Dealing with multiple publications and companion papers
Where we identified multiple reports of a primary study, we max-
imised yield of information by collating all available data. Where
there were inconsistencies in reporting or overlapping study pop-
ulations, we contacted study authors for clarification in the first
instance. If this contact with study authors was unsuccessful, we
used the most complete and up-to-date data source where possi-
ble.
Assessment of methodological quality
We assessed risk of bias and applicability of included studies using
the QUADAS-2 checklist (Whiting 2011), tailored to the review
topic (see Appendix 7). We piloted the modified QUADAS-2
tool on a small number of included full-text articles. One clinical
(as detailed above), and one methodologist reviewer (JDi, NC or
LFR), independently assessed quality for the remaining studies;
we resolved any disagreement by consensus or by involving a third
party where necessary (JDe, CD, HW, and RM).
Statistical analysis and data synthesis
We planned separate analyses according to the point that study
participants had reached in the clinical pathway (numbered from
1 to 7 in Figure 3), the clarity with which the pathway could
be determined (clear or unclear), and the evaluation of in-person
versus image-based diagnosis.
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Figure 3. Clinical pathway
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Our unit of analysis was the lesion rather than the participant. This
is because firstly, in skin cancer initial treatment is directed to the
lesion rather than systemically (thus it is important to be able to
correctly identify cancerous lesions for each person), and secondly,
it is the most common way in which the primary studies reported
data. Although there is a theoretical possibility of correlations of
test errors when the same people contribute data for multiple le-
sions, most studies included very few people with multiple lesions
and any potential impact on findings was likely to be very small,
particularly in comparison with other concerns regarding risk of
bias and applicability. For each analysis, we included only one
dataset per study to avoid multiple counting of lesions. Where an
individual study assessed multiple algorithms, we selected datasets
on the following preferential basis:
• ‘no algorithm’ reported; data presented for clinician’s overall
diagnosis or management decision;
• pattern analysis or pattern recognition;
• ABCD algorithm (or derivatives of );
• seven-point checklist (7PCL; also referred to as Glasgow/
Mackie checklist);
• Menzies algorithm;
• three-point checklist (3PCL).
For each index test, algorithm or checklist under consideration,
we plotted estimates of sensitivity and specificity on coupled for-
est plots and in receiver operating characteristic (ROC) space. For
tests where commonly used thresholds were reported we estimated
summary operating points (summary sensitivities and specifici-
ties), with 95% confidence and prediction regions using the bi-
variate hierarchical model (Chu 2006; Reitsma 2005). Where in-
adequate data were available for the model to converge, we sim-
plified it, first by assuming no correlation between estimates of
sensitivity and specificity and secondly by setting estimates of near
zero variance terms to zero (Takwoingi 2015). Where all studies
reported 100% sensitivity (or 100% specificity), we summed the
number with disease (or no disease), across studies and used it to
compute a binomial exact 95% confidence interval. Where miss-
ing or indeterminate results were reported, study authors usually
did not provide sufficient details to allow us to include these data
in our analyses. Where study authors reported missing or indeter-
minate results in more detail, these results were excluded by us for
consistency.
We included data on the accuracy of visual inspection, to al-
low comparisons of tests, only if reported in the studies of der-
moscopy, due to the known substantial unexplained heterogeneity
in all studies of the accuracy of visual inspection (Dinnes 2018a).
We made comparisons between visual inspection results with der-
moscopy data from all dermoscopy studies, and then only using
dermoscopy data from studies that also reported visual inspection
data for the same participants, to enable a robust direct compari-
son (Takwoingi 2013).
Wemade comparisons between tests by comparing summaryROC
curves using the hierarchical summary receiver-operator curves
(HSROC)model (Rutter 2001), rather than by estimating average
operating points, as this approach allows incorporation of data at
different thresholds and from different algorithms or checklists.
We used a HSROC model that assumed a constant SROC shape
between tests and subgroups (allowing for asymmetry in shape),
and modelled differences in threshold and accuracy by addition of
covariates. We assessed the significance of the differences between
tests by the likelihood ratio test (LR test), assessing differences
in both accuracy and threshold. We fitted simpler models when
convergence was not achieved due to small numbers of studies,
first assuming symmetric SROC curves (setting the shape term to
zero), and then setting random effects variance estimates to zero.
We have presented estimates of accuracy from HSROC models as
diagnostic odds ratios (estimated where the SROC curve crosses
the sensitivity=specificity line), with 95% confidence intervals.
We have presented differences between tests and subgroups from
HSROC analyses as relative diagnostic odds ratios with 95% con-
fidence intervals. To facilitate interpretation in terms of rates of
false-positive and false-negative diagnoses, we computed values
of sensitivity at the point on the SROC curve with 80% speci-
ficity and of specificity at the point on the SROC curve with 80%
sensitivity, choosing these 80% values because they lie within the
estimates for the majority of analyses. These results should only
be considered as illustrative examples of possible sensitivities (and
specificities), and differences in sensitivities (and specificities), that
could be expected.We computed confidence intervals for these es-
timates of sensitivity and specificity assuming normal distribution
of sampling error on logit scales; and computed confidence inter-
vals for differences in sensitivity and specificity assuming normal
distributions of sampling error on untransformed scales.
For computation of likely numbers of true-positive, false-positive,
false-negative and true-negative findings in the ’Summary of find-
ings’ tables, we applied these indicative values to lower, median
and upper quartiles of the prevalence observed in the study groups.
We fitted bivariate models using the ’xtmelogit’ command in
STATA 15 and HSROC models using the ’NLMIXED’ proce-
dure in the SAS statistical software package (SAS 2012), and the
metadas macro (Takwoingi 2010).
Investigations of heterogeneity
We also investigated heterogeneity, and made comparisons be-
tween algorithms and according to observer experience and quali-
fications by comparing summary ROC curves using the HSROC
model (Rutter 2001), with additional covariates for differences in
threshold and accuracy as used for comparing tests. We omitted
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small subgroups from models where parameter estimates could
not be obtained due to convergence problems.
Sensitivity analyses
We planned sensitivity analyses, restricting analyses to studies
where:
• the same study evaluated both dermoscopy (added to visual
inspection), and visual inspection alone (direct test comparisons
as discussed above);
• partial verification was avoided (restricting to studies
including follow-up of benign lesions);
• for studies using follow-up of benign-appearing lesions, the
interval between the index test and the reference standard was at
least three months;
• for direct test comparisons, the period of application
between the index tests was within one month;
• concerns around applicability for participant selection were
low;
• there was low risk of bias for the index test;
• there was low risk of bias for the reference standard.
Assessment of reporting bias
Because of uncertainty about the determinants of publication bias
for diagnostic accuracy studies and the inadequacy of tests for de-
tecting funnel plot asymmetry (Deeks 2005), we did not perform
tests to detect publication bias.
R E S U L T S
Results of the search
We identified and screened a total of 34,517 unique references for
inclusion.Of these, we reviewed1051 full-text papers for eligibility
for any one of the suite of reviews of tests to assist in the diagnosis of
melanomaor keratinocyte skin cancer.Of the 1051 full-text papers
assessed, we excluded 848 from all the reviews in our series (see
Figure 4, PRISMA flow diagram of search and eligibility results;
Moher 2009).
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Figure 4. PRISMA flow diagram.
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Of the 340 studies tagged as potentially eligible for this review
of dermoscopy, we included 104 publications. Exclusions were
mainly due to the inability to construct a 2x2 contingency table
based on the data presented (n = 43); the use of ineligible index
tests (n = 19) (for example, reporting of data for ‘clinical diagnosis’
or for serial use of the index test in a follow-up context); assess-
ment of individual lesion characteristics (n = 28); or derivation
type studies, developing new algorithms or checklists without a
separate training and test set of lesions (n = 31). Other reasons for
exclusion included not meeting our requirements for an eligible
reference standard (n = 15), ineligible study populations (n = 21),
(for example, recruiting only malignant or only benign lesions),
inadequate sample size (n = 22), ineligible definition of the target
condition (n = 18), or with test interpretation by medical students
or laypersons (n = 3). A list of the 236 publications excluded from
this review with reasons for exclusion is provided inCharacteristics
of excluded studies, with a list of all studies excluded from the
full series of reviews available as a separate PDF (please contact
skin.cochrane.org for a copy of the pdf ).
We contacted the authors of 17 publications for further data to
allow study inclusion in the review and received responses from
four authors with regard to seven publications. Two authors pro-
vided additional data but these were insufficient to allow inclu-
sion of the studies (Cabrijan 2008; Warshaw 2009a; Warshaw
2009b; Warshaw 2010), one replied indicating that dermoscopy
was not necessarily used in all study participants (Youl 2007a; Youl
2007b), and one replied but was unable to access the data needed
(Fabbrocini 2008). We contacted the authors of a further 20 in-
cluded studies for further details of study methods and received
responses in regard to 10 studies, eight providing further informa-
tion regarding the diagnostic thresholds used (Blum 2003a; Blum
2004a; Bono 2006; Bourne 2012; Carrera 2016; Durdu 2011;
Kittler 1999; Stanganelli 2000), one providing full anonymised
study data (Rosendahl 2011), and one unable to provide the in-
formation requested, although the study could still be included
(Menzies 2009).
Of the 104 included study publications, two provide data for two
separate cohorts of lesions: Guitera et al reports data for one co-
hort of lesions recruited in Modena, Italy (denoted Guitera 2009a
(Modena)), and one cohort recruited in Sydney (denoted Guitera
2009b (Sydney)); Haenssle 2010 reports data for one cohort of le-
sions examined on participants’ first visit (denotedHaenssle 2010a
(FV)), and one cohort of lesions identified during participant fol-
low-up (denoted Haenssle 2010b (FU)). Four different publica-
tions report data on one further cohort; we included data from
one publication (Blum 2004b), in the primary analyses, with data
fromBlum 2003a, Blum 2003b and Blum 2004a providing results
for different algorithms or thresholds for the same set of lesions.
The total number of cohorts of lesions described in the 104 study
publications is therefore 103 (104 + 2 minus 3). The 104 study
publications provided a total of 354 dermoscopy datasets (each
publication often providing more than one 2x2 contingency table
according to the use of different algorithms, different test thresh-
olds or different observers), for 42,788 lesions and 5700malignan-
cies. The total number of study participants with suspicious lesions
cannot be estimated due to lack of reporting in study publications
(reported in only 44 studies with 9591 participants). A third of
study publications (n = 31; 30%), also reported accuracy data for
diagnosis using visual inspection; these provided 61 datasets for
9025 lesions and 959 malignancies. A systematic review of the
accuracy of visual inspection per se is reported in Dinnes 2018a.
A further 29 of the 104 included study publications reported data
for tests other than dermoscopy or visual inspection including:
teledermatology (n = 3), reflectance confocal microscopy (RCM),
(n = 7), exfoliative cytology (n = 1), and computer-assisted diag-
nosis (CAD) techniques (n = 18).
Methodological quality of included studies
We have summarised the overall methodological quality of all in-
cluded studies (regardless of target condition), according to in-
person or image-based approaches to dermoscopy or to visual in-
spection. Figure 5 shows a total of 35 in-person evaluations, with
results per study presented in Figure 6; and Figure 7 shows a to-
tal of 74 image-based evaluations of dermoscopy, with results per
study presented in Figure 8. The total number of entries in Figure
6 and Figure 8 sums to 109 (35 + 74), instead of 103 (as per the
number of included cohorts), for the following reasons: a), three
publications (Carli 2002a; Dummer 1993; Unlu 2014), reported
both in-person and image-based data and therefore appear in both
the in-person and image-based plots (making 106 entries), and b),
one cohort was reported on in four papers (Blum 2003a; Blum
2003b; Blum 2004a; Blum 2004b), which all contributed data to
the review analyses and were therefore quality assessed four times
(making 109 entries).
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Figure 5. Risk of bias and applicability concerns graph for in-person evaluations: review authors’ judgements
about each domain presented as percentages across included studies
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Figure 6. Risk of bias and applicability concerns for in-person evaluations summary: review authors’
judgements about each domain for each included study
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Figure 7. Risk of bias and applicability concerns graph for image-based evaluations: review authors’
judgements about each domain presented as percentages across included studies
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Figure 8. Risk of bias and applicability concerns for image-based evaluations summary: review authors’
judgements about each domain for each included study
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In-person evaluations
We judged risk of bias to be low for the majority of studies in only
two of five quality domains that we assessed (dermoscopy index
test, reference standard); the majority of studies were at high or
unclear risk of bias for the remaining three domains (participant
selection, visual inspection index test flow and timing; Figure 5).
We scored applicability of study findings as of high or unclear
concern in all four domains that we assessed (participant selection,
dermoscopy and visual inspection index tests, reference standards).
For participant selection, we judged 11 studies (31%), at low risk
of bias (Carli 1994; Dreiseitl 2009; Duff 2001; Grimaldi 2009;
Langley 2007; Menzies 2009; Morales Callaghan 2008; Nachbar
1994; Soyer 2004; Stanganelli 2000; Unlu 2014); and we con-
sidered eight (23%), at high risk (Figure 6), due to exclusion
of lesions by size (Bono 2002b; Bono 2006; Kittler 1999), or
type (Ahnlide 2016; Cristofolini 1994; Guitera 2009a (Modena);
Haenssle 2010a (FV); Haenssle 2010b (FU)). The study by
Haenssle and colleagues excluded participants showing melanoma
development on pre-existing pigmented lesions during the 12
months after the analysed time frame. Twelve studies (34%), did
not report the method of participant selection and 15 (43%), did
not clearly describe exclusions from the study. We considered al-
most all cohorts (91%; n = 32), at high concern for applicability
of participants. In the majority of cases (n = 30), this was due to
restricted study populations, such as inclusion of onlymelanocytic
lesions (n = 10), or inclusion of lesions selected for excision based
on the clinical or dermoscopic diagnosis (n = 28). We judged
only four cohorts (11%), to have included a representative pa-
tient population (Dreiseitl 2009; Grimaldi 2009; Menzies 2009;
Stanganelli 2000). Eight cohorts (23%), also included multiple
lesions per participant (Durdu 2011; Gokdemir 2011; Grimaldi
2009; Haenssle 2010b (FU); Haenssle 2010a (FV); Kittler 1999;
Morales Callaghan 2008; Stanganelli 2000), and 12 others (34%),
did not clearly report number of included participants.
For the index test domain, there are 33 evaluations of in-per-
son dermoscopy and 16 evaluations of in-person visual inspection
(Figure 5). For dermoscopy, we considered 24 evaluations (73%),
at low risk of bias (Ahnlide 2016; Argenziano 2006; Ascierto
2010; Bauer 2000; Benelli 1999; Bono 2002a; Bono 2002b;
Bono 2006; Broganelli 2005; Carli 1994; Carli 2002a; Coras
2003; Cristofolini 1994; Durdu 2011; Feldmann 1998; Grimaldi
2009; Guitera 2009a (Modena); Haenssle 2010a (FV); Haenssle
2010b (FU); Langley 2007; Menzies 2009; Morales Callaghan
2008; Stanganelli 2000; Viglizzo 2004), and we judged two eval-
uations (6%), at high risk (Kittler 1999; Nachbar 1994); seven
studies (21%), did not provide sufficient information to allow
us to make a full ’Risk of bias’ judgement. We judged all stud-
ies to have made the diagnosis blinded to the reference stan-
dard result, given that this is always undertaken prior to histol-
ogy; 25 (76%), also clearly reported pre-specification of the diag-
nostic threshold, 20 using named algorithms or pattern analysis
(Ahnlide 2016; Argenziano 2006; Ascierto 2010; Benelli 1999;
Bono 2006; Broganelli 2005; Carli 1994; Carli 2002a; Coras
2003; Cristofolini 1994; Durdu 2011; Feldmann 1998; Grimaldi
2009; Guitera 2009a (Modena); Haenssle 2010a (FV); Haenssle
2010b (FU); Langley 2007;Morales Callaghan 2008; Soyer 1995;
Stanganelli 2000), and five (15%), describing the process bywhich
they reached their diagnosis (Bauer 2000; Bono 2002a; Bono
2002b; Menzies 2009; Viglizzo 2004). Two studies (6%), de-
veloped new algorithms (Nachbar 1994), or evaluated multiple
thresholds for test positivity (Kittler 1999).
We considered that all 16 visual inspection evaluations also made
the diagnosis blinded to the reference standard result. One (6%),
was at high risk of bias due to evaluation of several different
ABCDE algorithm thresholds (Benelli 1999), and we judged nine
studies (56%), unclear as to the diagnostic thresholds used.
We recordedhigh concern for the applicability of the index tests for
16 in-person evaluations of dermoscopy (48%; Figure 5), primarily
due to a lack of description of the diagnostic thresholds used (n =
8), but also as a result of presentationof average (Argenziano 2006),
or consensus diagnoses (Bauer 2000; Benelli 1999; Carli 1994;
Carli 2002a;Haenssle 2010b (FU);Haenssle 2010a (FV);Morales
Callaghan 2008), as opposed to the diagnosis of a single observer.
Six studies (18%), did not provide sufficient information to allow
us to judge the clinical applicability of the dermoscopy diagnosis,
and we could not fully judge observer expertise in dermoscopy in
five evaluations.
We recorded high concern for the applicability of the index tests
for 14 of the 16 (88%), visual inspection evaluations Argenziano
2006; Benelli 1999; Bono 2002a; Bono 2002b; Bono 2006; Carli
2002a; Dummer 1993; Grimaldi 2009; Krahn 1998; Menzies
2009; Morales Callaghan 2008; Soyer 1995; Unlu 2014; Viglizzo
2004), due to the threshold for diagnosis not being detailed in 12
studies (75%), reporting of average (Argenziano 2006), or con-
sensus diagnoses (Benelli 1999; Carli 2002a; Morales Callaghan
2008), or diagnosis by non-expert observers (Grimaldi 2009;
Menzies 2009).
Of the 35 included in-person evaluations, we judged 29 (83%),
at low risk of bias for the reference standard due to the use
of an acceptable reference standard (Ahnlide 2016; Argenziano
2006; Ascierto 2010; Bauer 2000; Benelli 1999; Bono 2002a;
Bono 2002b; Bono 2006; Broganelli 2005; Carli 1994; Carli
2002a;Coras 2003;Cristofolini 1994;Duff 2001;Dummer 1993;
Durdu 2011; Feldmann 1998; Gokdemir 2011; Guitera 2009a
(Modena); Kittler 1999; Krahn 1998; Langley 2007; Morales
Callaghan 2008; Nachbar 1994; Piccolo 2000; Soyer 1995; Soyer
2004; Unlu 2014; Viglizzo 2004; Figure 5). Five (14%), did not
meet our criteria for an acceptable reference standard, with more
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than 20% of the benign lesions undergoing follow-up rather than
excision (Grimaldi 2009; Haenssle 2010b (FU); Haenssle 2010a
(FV); Menzies 2009; Stanganelli 2000), and we judged one study
at unclear risk of bias due to lack of reporting of the number of
participants with a histological reference standard and number
with follow-up (Dreiseitl 2009). Blinding of the reference stan-
dard to the index test (in this case the pathology referral diagno-
sis), was recorded but did not contribute to the overall risk of bias
for this domain. Menzies 2009 did not implement any blinding
of the reference standard, and 34 studies (97%), did not describe
blinding. The applicability of the reference standard was of low
concern in seven evaluations (20%; Argenziano 2006; Duff 2001;
Feldmann 1998; Krahn 1998; Langley 2007;Nachbar 1994;Unlu
2014), high in one (Menzies 2009), and unclear for 27 (77%). In
Menzies 2009, high concern was due to the use of expert opin-
ion for classifying the final diagnosis of some lesions. Only seven
studies reported histopathology interpretation by an experienced
histopathologist or by a dermatopathologist (Argenziano 2006;
Duff 2001; Feldmann 1998; Krahn 1998; Langley 2007; Nachbar
1994; Unlu 2014).
In terms of flow and timing, we judged 15 of the 35 cohorts at
high risk of bias (43%), (Ahnlide 2016; Argenziano 2006; Coras
2003; Dreiseitl 2009; Dummer 1993; Durdu 2011; Feldmann
1998; Grimaldi 2009; Guitera 2009a (Modena); Haenssle 2010a
(FV); Haenssle 2010b (FU); Kittler 1999; Langley 2007; Menzies
2009; Stanganelli 2000), six (17%), at low risk (Ascierto 2010;
Bauer 2000; Benelli 1999; Carli 1994; Morales Callaghan 2008;
Soyer 2004), and 13 (37%), did not provide enough information
on which to judge this domain (Figure 5). Of those at high risk,
six evaluations did not use the same reference standard for all
participants (differential verification), (Dreiseitl 2009; Grimaldi
2009;Haenssle 2010a (FV);Haenssle 2010b (FU);Menzies 2009;
Stanganelli 2000), and 10 did not include all participants in the
analysis (Ahnlide 2016; Argenziano 2006; Coras 2003; Dreiseitl
2009; Dummer 1993; Feldmann 1998; Guitera 2009a (Modena);
Kittler 1999; Langley 2007; Menzies 2009). A further 23 (66%)
cohorts were unclear on the interval between the application of
the index test and excision for histology, with only 12 (34%),
reporting consecutive diagnosis and excision or biopsy (Ahnlide
2016; Ascierto 2010; Benelli 1999; Carli 1994; Durdu 2011;
Feldmann 1998; Guitera 2009a (Modena); Haenssle 2010a (FV);
Haenssle 2010b (FU); Langley 2007; Morales Callaghan 2008;
Soyer 2004).
Image-based evaluations
Across the 74 image-based dermoscopy evaluations, we judged
risk of bias to be high or unclear in all domains apart from the
dermoscopy index test domain (Figure 7; Figure 8). We scored
applicability of study findings as being of high concern in almost
all studies for three out of four domains that we assessed. Only the
reference standard domain raised few concerns about applicability.
For participant selection, we judged 38 of the 74 evaluations
(51%), at high risk of bias (Arevalo 2008; Argenziano 2011;
Benelli 2000a; Binder 1994; Blum 2003b; Blum 2004a; Carli
2003b; Carrera 2016; di Meo 2016; Feci 2015; Ferrari 2015;
Friedman 2008; Gereli 2010; Guitera 2009b (Sydney); Hauschild
2014; Kittler 2001; Malvehy 2014; Menzies 2005;Menzies 2008;
Menzies 2013; Piccolo 2014; Pizzichetta 2002; Pizzichetta 2004;
Pupelli 2013; Rosendahl 2011; Rubegni 2012; Sboner 2004;
Seidenari 1998; Skvara 2005; Stanganelli 1998a; Stanganelli 1999;
Stolz 1994a; Tan 2009; Tenenhaus 2010; Troyanova 2003; Wells
2012; Westerhoff 2000; Winkelmann 2016), and 27 (36%), did
not provide sufficient information to judge this domain (Figure
7). Nineteen evaluations (26%), implemented a case-control type
design with separate sampling of melanoma and non-melanoma
lesions, and 25 (34%), excluded lesions on the basis of size or
thickness (n = 6); type of lesion (n = 8); lesion site (n = 3); equivocal
pathology (n = 4); or inadequate image quality (n = 8). Twenty-
nine evaluations (39%), did not report the method of partici-
pant selection and 31 (42%), did not clearly describe exclusions
from the study. We considered all evaluation cohorts at high con-
cern for applicability of participants. In the majority of cases, this
was due to restricted study populations such as inclusion of only
melanocytic (n = 35), amelanotic (n = 2), nodular (n = 1), regress-
ing (n = 1), or acral (n = 1), lesions, or inclusion of lesions se-
lected for excision based on the clinical or dermoscopic diagnosis
(n = 57). Nineteen evaluations clearly reported including similar
numbers of participants and lesions, seven reported inclusion of
multiple lesions per participant and 48 did not report the number
of participants.
For the index test domain, there are 74 evaluations of image-
based dermoscopy and 15 evaluations of visual inspection of
clinical images (Figure 7). For dermoscopy, we considered 50
evaluations (68%), at low risk of bias (Annessi 2007; Arevalo
2008; Argenziano 1998; Argenziano 2011; Benelli 2000a; Benelli
2001; Binder 1994; Binder 1995; Binder 1999; Blum 2004a;
Blum 2004b; Bourne 2012; Carli 2002a; Carli 2003a; Carli
2003b; Carrera 2016; Dal Pozzo 1999; di Meo 2016; Dolianitis
2005; Dummer 1993; Feci 2015; Ferrari 2015; Friedman 2008;
Gereli 2010; Guitera 2009b (Sydney); Kreusch 1992; Lorentzen
1999a; Lorentzen 2000; Lorentzen 2008;Malvehy 2014;Menzies
1996; Menzies 2008; Menzies 2013; Nilles 1994; Pagnanelli
2003; Piccolo 2014; Pizzichetta 2002; Pizzichetta 2004; Pupelli
2013; Rao 1997; Rosendahl 2011; Rubegni 2012; Rubegni 2016;
Seidenari 2005; Skvara 2005; Stanganelli 2015; Stolz 1994a; Tan
2009; Unlu 2014; Zalaudek 2006), and we judged two evalua-
tions high risk, both appearing to report new algorithms or le-
sion scoring based on their own study data (Blum 2003a; Blum
2003b). Twenty-two evaluations (30%), did not provide sufficient
information to allow to make a full ’Risk of bias’ judgement. We
judged all studies to have made the diagnosis blinded to the ref-
erence standard result; 50 (68%), also clearly reported pre-speci-
fication of the diagnostic threshold (40 using named algorithms
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or pattern analysis, four reporting new algorithms developed us-
ing training and test sets (Dal Pozzo 1999; Menzies 1996; Nilles
1994; Stolz 1994a), and six providing an indication as to how the
diagnosis was to be reached (Binder 1995; Carli 2003b; Carrera
2016; Friedman 2008; Lorentzen 1999a; Malvehy 2014)).
We considered that all 15 image-based visual inspection evalua-
tions also made the diagnosis blinded to the reference standard
result. We considered three at low risk of bias due to the use of
named algorithms with pre-specified thresholds (Benelli 2000a;
Benelli 2001; Rao 1997), and two (Pizzichetta 2004; Rosendahl
2011), provided some prior indication as to how the diagnosis was
to be reached in the study. We judged the remaining 10 unclear
as to pre-specification of the diagnostic thresholds used.
We recordedhigh concern for the applicability of the index tests for
67 (91%), image-based evaluations of dermoscopy (Alarcon 2014;
Annessi 2007; Arevalo 2008; Argenziano 1998; Argenziano 2011;
Benelli 2000a; Benelli 2001; Binder 1994; Binder 1995; Binder
1999; Blum 2003a; Blum 2003b; Blum 2004a; Bourne 2012;
Carli 2002a;Carli 2002b;Carli 2003a;Carli 2003b;Carrera 2016;
Dal Pozzo 1999; di Meo 2016; Dolianitis 2005; Feci 2015; Ferrari
2015; Ferris 2015; Friedman 2008; Gereli 2010; Gilmore 2010;
Glud 2009; Guitera 2009b (Sydney); Hauschild 2014; Kittler
1998; Kittler 2001; Kreusch 1992; Lorentzen 1999a; Lorentzen
2000; Lorentzen 2008; Malvehy 2014; Menzies 1996; Menzies
2005; Menzies 2008; Menzies 2013; Nilles 1994; Pagnanelli
2003; Piccolo 2002a; Piccolo 2014; Pizzichetta 2002; Rigel 2012;
Rubegni 2012; Rubegni 2016; Sboner 2004; Seidenari 1998;
Seidenari 2005; Seidenari 2007; Skvara 2005; Stanganelli 1998a;
Stanganelli 1999; Stanganelli 2005; Stanganelli 2015; Stolz 1994a;
Tan 2009; Troyanova 2003; Unlu 2014; Wells 2012; Westerhoff
2000; Winkelmann 2016), primarily due to blinded interpreta-
tion of dermoscopic images without reference to a macro pho-
tograph or other patient information (n = 51), or the presenta-
tion of average or consensus diagnoses as opposed to for a sin-
gle observer (n = 35). Twenty-five evaluations did not provide
sufficient detail regarding the diagnostic threshold used, and we
judged four to have reported data for non-expert observers. The
seven evaluations that we judged as having unclear concern for
the applicability of dermoscopy reported data for single observers,
and provided the clinical image of the lesion alongside the der-
moscopic image (Blum 2004b; Lorentzen 2000; Pizzichetta 2004;
Pupelli 2013; Rao 1997; Rosendahl 2011; Tenenhaus 2010). All
exceptTenenhaus 2010 also detailed the diagnostic thresholds used
and four clearly described image interpretation by an expert ob-
server (Blum2004b; Lorentzen 2000;Rosendahl 2011;Tenenhaus
2010). See Figure 7.
We recorded high concern for the applicability of the index tests
for all 15 visual inspection evaluations due to the image-based na-
ture of test interpretation; only three of these clearly reported diag-
nosis by a single observer (Pizzichetta 2004; Rao 1997; Rosendahl
2011), the remaining 12 reported average (n = 10), or consensus (n
= 2), diagnoses. Thirteen evaluations also did not detail the thresh-
old for diagnosis (all apart from Benelli 2000a and Benelli 2001).
Eight evaluations clearly described diagnosis by expert observers
(Benelli 2001; Carli 2002b; Carli 2003b; Lorentzen 1999a; Rao
1997; Rosendahl 2011; Stanganelli 2005; Troyanova 2003).
Of the 74 included image-based evaluations, we judged 63 (85%),
at low risk of bias for the reference standard due to the use of
an acceptable reference standard (Alarcon 2014; Annessi 2007;
Arevalo 2008; Argenziano 1998; Benelli 2000a; Benelli 2001;
Binder 1994; Binder 1995; Binder 1999; Blum 2003a; Blum
2003b; Blum 2004a; Carli 2002a; Carli 2002b; Carli 2003a;
Carli 2003b; Dal Pozzo 1999; di Meo 2016; Dummer 1993; Feci
2015; Ferrari 2015; Ferris 2015; Friedman 2008; Gereli 2010;
Gilmore 2010; Glud 2009; Guitera 2009b (Sydney); Hauschild
2014; Kittler 1998; Lorentzen 1999a; Lorentzen 2000; Lorentzen
2008; Malvehy 2014; Menzies 1996; Nilles 1994; Pagnanelli
2003; Piccolo 2002a; Piccolo 2014; Pizzichetta 2002; Pizzichetta
2004; Pupelli 2013; Rao 1997; Rigel 2012; Rosendahl 2011;
Rubegni 2012; Rubegni 2016; Sboner 2004; Seidenari 1998;
Seidenari 2005; Seidenari 2007; Skvara 2005; Stanganelli 1998a;
Stanganelli 1999; Stanganelli 2005; Stanganelli 2015; Stolz 1994a;
Tan 2009; Troyanova 2003; Unlu 2014; Wells 2012; Westerhoff
2000; Winkelmann 2016; Zalaudek 2006). Seven evaluations
were at high risk of bias, having more than 20% of the benign
lesions undergoing follow-up rather than excision (Argenziano
2011; Blum 2004b; Kittler 2001; Menzies 2005), or including
some lesions with expert diagnosis only and no follow-up (Bourne
2012; Dolianitis 2005; Menzies 2005; Tenenhaus 2010), or both.
We recorded blinding of the reference standard to the index test
(in this case the pathology referral diagnosis), but this did not con-
tribute to the overall risk of bias for this domain. Only one study
implemented blinding of the reference standard to the original
clinical diagnosis (Friedman 2008), and the remaining studies did
NR it. See Figure 7.
The applicability of the reference standard was of low concern
in 20 evaluations (27%), all of which reported histopathology
interpretation by an experienced histopathologist or by a der-
matopathologist (Alarcon 2014; Annessi 2007; Carli 2003b; di
Meo 2016; Ferrari 2015; Ferris 2015; Friedman 2008; Gilmore
2010; Glud 2009; Hauschild 2014; Lorentzen 2000; Malvehy
2014; Piccolo 2002a; Pupelli 2013; Rao 1997; Rubegni 2012;
Rubegni 2016; Stanganelli 2015; Unlu 2014; Wells 2012), was
of high concern in four (5%), due to the use of expert opinion
for classifying the final diagnosis of some lesions (Bourne 2012;
Dolianitis 2005;Menzies 2005; Tenenhaus 2010), and unclear for
50 (68%). In terms of flow and timing, we judged 26 (35%), co-
horts at high risk of bias (Alarcon 2014; Arevalo 2008; Argenziano
2011; Blum 2004b; Bourne 2012; Carrera 2016; di Meo 2016;
Dolianitis 2005; Dummer 1993; Feci 2015; Ferrari 2015; Guitera
2009b (Sydney); Kittler 2001; Kreusch 1992; Lorentzen 1999a;
Lorentzen 2008; Malvehy 2014; Menzies 2005; Menzies 2008;
Menzies 2013; Pizzichetta 2004; Rosendahl 2011; Stanganelli
2005; Tenenhaus 2010; Westerhoff 2000; Zalaudek 2006), 16
33Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(22%), at low risk (Annessi 2007; Binder 1995; Binder 1999;
Blum2003a; Blum2003b; Blum2004a; Carli 2002b; Ferris 2015;
Glud 2009; Hauschild 2014; Lorentzen 2000; Pizzichetta 2002;
Rao 1997; Skvara 2005; Stanganelli 2015; Wells 2012), and 32
(43%), did not provide enough information on which to judge
this domain (Figure 7). Of those at high risk, 15 evaluations did
not use the same reference standard for all participants (differential
verification), and 16 did not include all participants in the analysis.
Eighteen cohorts (24%), were unclear on the interval between the
application of the index test and lesion excision with only eight
(11%), considered to report consecutive diagnosis and excision or
biopsy.
Findings
Unless otherwise stated, we undertook all analyses using HSROC
models.
1. Target condition: invasive melanoma and atypical
intraepidermal melanocytic variants
Eighty-three study publications reported accuracy data for der-
moscopy for the detection of primary target condition, inva-
sive melanoma and atypical intraepidermal melanocytic variants.
Two study publications each reported data for two different sets
of lesions (Guitera 2009a (Modena); Guitera 2009b (Sydney);
Haenssle 2010a (FV);Haenssle 2010b (FU)); and one study (Carli
2002a), provided one dataset for in-person dermoscopy and one
for image-based interpretationof dermoscopic images.We selected
a total of 86 datasets for the primary analyses; 26 for evaluations
conducted in person and 60 for image-based evaluations. Twenty-
four of the 83 study publications provided direct comparisons of
dermoscopy with visual inspection alone (i.e. data for both tests
reported for the same study population). Eleven studies compared
in-person visual inspection with in-person visual inspection + der-
moscopy; 11 studies compared diagnosis based on clinical images
with diagnosis based on dermoscopic images of the same lesions;
and two studies compared in-person visual inspection with image-
based dermoscopy.
Analyses by clinical pathway and in-person versus image-
based design
We have provided summary details of the in-person and image-
based studies in Appendix 8 and Appendix 9 and have presented
results for the primary analyses inTable 1 andTable 2, with hetero-
geneity investigations presented in Table 3. Forest plots of study
data for each analysis are in Figure 9 and Figure 10; summary es-
timates for in-person comparisons are in Figure 11 and Figure 12,
and for image-based comparisons in Figure 13 and Figure 14.
Figure 9. In-person evaluations of the accuracy of dermoscopy added to visual inspection grouped by
pathway categorisation for detecting invasive melanoma or atypical intraepidermal melanocytic variants
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Figure 10. Image-based evaluations of the accuracy of dermoscopy grouped by pathway categorisation for
detecting for detecting invasive melanoma or atypical intraepidermal melanocytic variants
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Figure 11. Comparison of the accuracy of visual inspection with visual inspection (VI) + dermoscopy for
detection of invasive melanoma or atypical intraepidermal melanocytic variants from in-person studies
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Figure 12. Paired comparisons of the accuracy of visual inspection with visual inspection (VI) + dermoscopy
for detection of invasive melanoma or atypical intraepidermal melanocytic variants from in-person studies
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Figure 13. Comparison of the accuracy of visual inspection with dermoscopy for detection of invasive
melanoma or atypical intraepidermal melanocytic variants from image-based studies
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Figure 14. Paired comparison of the accuracy of visual inspection versus dermoscopy for detection of
invasive melanoma or atypical intraepidermal melanocytic variants from paired image-based studies
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We noted clear differences in accuracy between studies under-
taken in person and those that evaluated images, with the accu-
racy of diagnosis using dermoscopic images and visual inspection
of photographs being significantly lower in image-based studies.
For dermoscopy, the diagnostic odds ratio for in-person diagnosis
was more than four times that of image-based diagnosis (RDOR
4.6, 95% CI 2.40 to 9.0; P < 0.001; Table 3; Figure 15). The
high magnitude and importance of this observed difference drove
our decision to undertake all analyses separately for in-person and
image-based analyses as a primary objective of the review.
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Figure 15. Comparison of the accuracy of dermoscopy for detection of invasive melanoma or atypical
intraepidermal melanocytic variants between in-person (visual inspection + dermoscopy) and image-based
(dermoscopy) studies
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Of the 26 evaluations conducted on an in-person basis, 11 con-
tained enough information to describe where on the clinical path-
way they had assessed their participants (coded as ‘clear’ on path-
way), and we considered that 15 did not provide sufficient infor-
mation to allow us to identify the pathway (coded ‘unclear’ on
pathway). We coded pathway positions between 1 (test-naïve par-
ticipants), and 7 (participants identified as high risk for developing
melanoma with lesions undergoing follow-up surveillance). See
Figure 3 for a diagram of the clinical pathway. For the 60 image-
based evaluations, we coded 11 as clear on the pathway and 49
as unclear. Across both sets of studies, we considered only 5% (4
of 86 studies), to have included participants who were presenting
for a first structured clinical assessment of a suspicious lesion, the
remaining datasets came from studies in participants referred for
specialist assessment.
Although there were significant differences between studies under-
taken at different points on the pathway, for both in-person (Table
1a; Figure 9), and image-based approaches (Table 1b; Figure 10),
there was no clear trend in the estimates of accuracy of dermoscopy
according to the degree of prior testing of study participants (as
represented by study position on the pathway). Accuracy did ap-
pear to be lowest (in terms of DORs), in studies with limited
prior testing of the participants (Bourne 2012; Grimaldi 2009;
Menzies 2009; Rosendahl 2011), and in those with lesions un-
dergoing follow-up (Haenssle 2010b (FU); Kittler 2001; Skvara
2005; Stanganelli 2015), however, the data were too scarce to draw
any firm conclusions. We did not give any further analytical con-
sideration to classification of evaluations by position on the clini-
cal pathway.
Dermoscopy added to visual inspection of a skin lesion (in-
person evaluations)
Of the 26 in-person evaluations of dermoscopy (Appendix 8 and
Figure 9), 11 compared visual inspection alone to visual inspec-
tion + dermoscopy, including two that compared both tests to a
CAD-based test (Bono 2002a), and one that reported data for a
teledermatology consultation (Grimaldi 2009), and 15 presented
data only for dermoscopy in addition to visual inspection (with
no data for visual inspection alone), including four that compared
in-person dermoscopy to the accuracy of other tests, including
RCM (Langley 2007; Guitera 2009a (Modena)), exfoliative cy-
tology (Durdu 2011), and CAD (Bauer 2000). Two studies com-
pared the accuracy of different dermoscopy algorithms (Kittler
1999; Menzies 2009).
Two evaluations were conducted in limited prior testing popula-
tions (Grimaldi 2009; Menzies 2009). Of those in referred popu-
lations, we considered two to have been conducted in participants
with equivocal lesions (Carli 1994; Soyer 1995), and one in par-
ticipants at high risk for developingmelanoma with lesions under-
going surveillance (Haenssle 2010b (FU)). The latter study also
reported data separately for the same participants at their first visit
for lesion assessment (Haenssle 2010a (FV)). Seventeen evalua-
tions were prospective case series, five were retrospective (Ahnlide
2016; Bono 2006; Carli 2002a;Duff 2001; Stanganelli 2000), and
four did not clearly report the design (Bauer 2000; Carli 1994;
Gokdemir 2011; Soyer 1995). One study included all melanomas
observed across the recruitment period but only a random sam-
ple of 50% of observed benign naevi (Guitera 2009a (Modena)).
Eighteen evaluations included only pigmented lesions and eight
restricted inclusion to lesions considered to be melanocytic in na-
ture. Eighteen of the 26 evaluations (69%), clearly reported in-
cluding in situ melanomas as disease-positive, the remaining eight
describing only ’melanomas’ not broken down by invasive or in
situ (Broganelli 2005; Cristofolini 1994; Durdu 2011; Gokdemir
2011; Grimaldi 2009; Morales Callaghan 2008; Nachbar 1994;
Stanganelli 2000). The prevalence of invasive melanoma and atyp-
ical intraepidermal melanocytic variants ranged from less than 1%
(Haenssle 2010a (FV)), to 41% (Guitera 2009a (Modena); Soyer
1995); median 12% (IQR 5, 21%).
Twenty-four evaluations (89%), clearly reported that they had
conducted diagnosis on an in-person basis and we assumed in-
person diagnosis in three studies that did not clearly report the use
of images or face-to-face diagnosis (Broganelli 2005; Gokdemir
2011; Stanganelli 2000). Diagnosis was recorded by primary care
physicians in two studies (7%), (Grimaldi 2009; Menzies 2009),
by dermatology residents (trainees), under the supervision of a se-
nior dermatologist (Haenssle 2010b (FU); Haenssle 2010a (FV)),
or by a mixed group of dermatology residents and consultants
(Ahnlide 2016), in three (11%), by dermatologists or presumed-
to-be dermatologists (based on author’s institutions), in 17 (63%),
by plastic surgeons (Duff 2001), or oncologists (Bono 2002a;
Bono 2002b; Bono 2006), in four (15%), or was NR (4%),
(Feldmann 1998). Where reported (n = 22), the number of ob-
servers ranged from 1 to 63 (median 2, IQR 1.25 to 4). Thirteen
evaluations (48%), reported test accuracy for a single observer,
eight (30%), for a consensus of two or three observers, and we
couldnot derive this information for the remaining six evaluations.
Eight evaluations (30%), did not report any formal algorithm to
assist diagnosis and nine (33%), reported using pattern analysis.
The remaining evaluations used formal algorithms to assist diag-
nosis: the ABCD algorithm (n = 5), the seven-point checklist (n =
3), the Menzies criteria (n = 1), and seven features for melanoma
(n = 1). See Appendix 2 for details of the algorithms used.
Across the 27 evaluations the sensitivity of dermoscopy ranged
from 53% to 100% and specificity from 28% to 100% (Figure
9). The low specificities of 28% (Guitera 2009a (Modena), and
56% (Carli 1994), appeared as outliers, all other studies having
specificities of 69% or above. Guitera 2009a (Modena) included
42Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
a relatively high proportion of Spitz naevi in the disease-negative
group than might be expected in routine clinical practice (19%),
while Carli 1994 primarily aimed to distinguish atypical from
typical melanocytic lesions and reported accuracy for the decision
to excise a lesion as opposed to accurate diagnosis of melanoma.
We pooled results across algorithms and thresholds as a summary
ROC curve (23,487 lesions and 1737 melanomas; Figure 11). Es-
timates of accuracy obtained from the curve suggest that the speci-
ficity of dermoscopy would be 95% (95% CI 90% to 98%), at a
fixed threshold of 80% sensitivity, and sensitivity would be 92%
(95% CI 87% to 95%), at a fixed threshold of 80% specificity
(Table 2).We chose these 80%fixed values as they lie within the es-
timates for the majority of analyses and should only be considered
as illustrative examples of the values that might be achieved based
on the observed data (see Statistical analysis and data synthesis).
Incremental accuracy from dermoscopy added to in-person
visual inspection alone
Of the 13 available in-person evaluations of visual inspection,
11 were reported in these in-person dermoscopy studies and two
(Dummer 1993; Unlu 2014), compared in-person visual inspec-
tion to image-based dermoscopy (see results for image-based der-
moscopy below). Of the 13 evaluations, 77% (n = 10), reported
using no algorithm to assist visual inspection diagnosis and three
used the ABCD (Stanganelli 2000), or ABCDE algorithm (Benelli
1999; Cristofolini 1994).
Sensitivities for visual inspection ranged from38%to100%; speci-
ficities ranged from 45% to 99% (Appendix 10; Figure 11). We
compared the accuracy of visual inspection with the accuracy of
dermoscopy estimated from (a), all 26dermoscopy studies (23,169
lesions and 1664 melanomas), and all 13 in-person visual inspec-
tion studies (6740 lesions and 459 melanomas; Figure 11), and
(b), estimated from direct comparisons in the subset of 11 stud-
ies that evaluated both visual inspection and dermoscopy on an
in-person basis (5854 lesions and 412 melanomas; Figure 12). In
both comparisons the accuracy of dermoscopy in addition to vi-
sual inspection exceeded that of visual inspection alone (Table 2).
In (a), the diagnostic odds ratio (DOR), for dermoscopy was 4.7
(95% CI 3.0 to 7.5; P < 0.001), times that of visual inspection
alone, in (b), it was 4.8 (95% CI 2.8 to 8.1; P < 0.001), times that
of visual inspection alone. These effects correspond to predicted
differences in specificity of (a), 20% (95% CI 7% to 33%), (based
on specificity with dermoscopy of 95% vs 75% for visual inspec-
tion), and (b), 21% (95% CI 2% to 39%), (based on specificity
with dermoscopy of 96% vs 75% for visual inspection), at a fixed
sensitivity of 80% (Table 2), and predicted differences in sensitiv-
ity of (a), 16% (95% CI 8% to 23%), (based on sensitivity with
dermoscopy of 92% vs 76% for visual inspection), and (b), 15%
(95% CI 7% to 23%), (based on sensitivity with dermoscopy of
92% vs 77% for visual inspection,), at a fixed specificity of 80%
(Table 2).
Dermoscopic images (image-based evaluations)
Of the 60 image-based evaluations of dermoscopy (Appendix 9
and Figure 10), 30 presented data only for dermoscopy, 14 com-
pared diagnosis based on clinical images to diagnosis based on
dermoscopic images, 19 compared dermoscopy to the accuracy of
other tests including RCM- (Alarcon 2014; Ferrari 2015; Guitera
2009b (Sydney); Pupelli 2013; Stanganelli 2015), and CAD-
based tests (Binder 1994; Blum 2004b; Ferris 2015; Friedman
2008;Glud2009;Hauschild 2014;Malvehy 2014;Menzies 2005;
Piccolo 2002a; Piccolo 2014; Rigel 2012; Stanganelli 2005; Wells
2012;Winkelmann 2016). Studies that evaluated dermoscopy im-
ages rather than using real-time in-person dermoscopy tended to
have been undertaken for reasons of efficiency and not as evalua-
tions of a remote-imaging service, for example, 18 (30%), evalua-
tions compared the accuracy of different dermoscopy algorithms
and 13 (22%), compared the accuracy of different observers (see
Table 4, Analysis by observer experience).
Two evaluations recruited participants from limited prior test-
ing populations (Bourne 2012; Rosendahl 2011). Of those in re-
ferred populations, we considered that nine had been conducted
in participants with equivocal lesions (Alarcon 2014; Annessi
2007; Carli 2003b; Dummer 1993; Ferrari 2015; Kittler 1998;
Pupelli 2013; Rubegni 2012; Stolz 1994a), and three in partic-
ipants with lesions undergoing follow-up (Kittler 2001; Skvara
2005; Stanganelli 2015). Seven (12%), evaluations were prospec-
tive case series, 33 (55%), were retrospective case series, 17 (28%),
used a case-control type design and in two (3%), the design was
not clearly reported. All studies prospectively re-interpreted previ-
ously acquired dermoscopic images for the purposes of the study.
The majority of studies recruited either pigmented (26; 43%),
or melanocytic (30; 50%), lesions, including one restricted to
melanocytic acral lesions only (Rubegni 2012). Two studies (3%),
recruited any lesion selected for excision (Malvehy 2014; Zalaudek
2006), and two (3%), included only amelanotic (Pizzichetta
2004), or amelanotic or hypomelanotic (Menzies 2008), lesions.
Forty-four of the 60 evaluations (73%), clearly reported includ-
ing in situ melanomas as disease-positive, the remaining 16 de-
scribing only ’melanomas’ not broken down by invasive or in situ
(Binder 1994; Binder 1995; Ferrari 2015; Gilmore 2010; Kittler
1998;Malvehy 2014; Pagnanelli 2003; Piccolo 2002a; Pizzichetta
2002; Rigel 2012; Rubegni 2016; Seidenari 1998; Seidenari 2005;
Stanganelli 1998a; Stanganelli 2005; Unlu 2014). The prevalence
of disease ranged from3%(Dummer 1993), to 61%(Stolz 1994a),
(median 24%, IQR 18% to 39%). Prevalence was generally higher
in case-control type studies (median 37%, IQR 25% to 50%),
compared to other designs (median 23%, IQR 18% to 33%).
Diagnosis was recorded by dermatologists or assessors presumed to
be dermatologists in 80% of studies (n = 48), by dermatology resi-
dents in one (Carli 2003a), and by observers with mixed qualifica-
tions in 17% (n = 10), including one where all observers were pri-
mary care-based (three GPS and a clinical nurse in Bourne 2012).
Observer qualifications were NR in one study (Stolz 1994a).
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Where reported (n = 56), the number of observers ranged from 1
to 179 (median 3, IQR 2 to 8). Twenty-five evaluations (42%),
reported test accuracy for a single observer, nine (15%), for a con-
sensus of two or three observers, one study for a consensus of at
least 50% of all observers (Carrera 2016), and 19 (32%), for the
median or average across observers. We could not derive this infor-
mation for the remaining six evaluations. Half of all evaluations (n
= 30), blinded dermoscopic image interpretation; a further third
of evaluations (n = 20), provided the associated clinical (n = 17),
RCM (n = 2), or baseline dermoscopy image (n = 1), to assist di-
agnosis. Four evaluations provided information on lesion site, or
patient age or gender and the remaining six did not describe the
provision of additional information. Twenty-three studies (38%),
did not report any formal algorithm to assist diagnosis, and 19
(32%), reported using pattern analysis. The remaining 18 studies
used formal algorithms to assist diagnosis: the ABCD algorithm (n
= 6), the seven-point checklist (n = 3), or a revised version thereof
(n = 1), the three-point checklist (n = 3), the Menzies criteria (n
= 1), and seven features for melanoma (n = 3), or the observers’
own choice of algorithm (n = 1; Appendix 9).
Across the 60 image-based dermoscopy evaluations, the sensitivity
ranged from 22% to 100% and specificity from 31% to 99%. We
pooled results across algorithms and thresholds as a summaryROC
curve (13,475 lesions and 2851 melanomas; Figure 13). Estimates
of accuracy obtained from the curve suggest that the specificity
of dermoscopy would be 82% (95% CI 75% to 87%), at a fixed
threshold of 80% sensitivity and sensitivity would be 81% (95%
CI 76% to 86%), at a fixed threshold of 80% specificity (Table 2).
Incremental accuracy of dermoscopic image-based diagnosis
compared to visual inspection of images
Of the 11 visual inspection evaluations based on interpretation
of clinical images, nine (82%), reported using no algorithm to
assist image interpretation, and two used the ABCD algorithm
(Benelli 2000a; Benelli 2001). Seven studies reported blinded in-
terpretation of the clinical image with no further patient or lesion
information provided, one study allowed observers to view both
the clinical and dermoscopic image simultaneously (Pizzichetta
2004), and three did not clearly describe blinding between the
clinical and dermoscopic images (Benelli 2000a; Stanganelli 2005;
Winkelmann 2016).
Sensitivities for image-based visual inspection ranged from 21%
to 80%; specificities ranged from 53% to 97% (Figure 13). We
compared the accuracy of visual inspection with the accuracy of
dermoscopy estimated from (a), all 60dermoscopy studies (13,475
lesions and 2851 melanomas), and the 11 image-based visual in-
spection studies (1740 lesions and 305 melanomas), (Figure 13),
and estimated from direct comparisons in (b), the subset of 11
studies that evaluated both clinical and dermoscopic images (1740
lesions and 305 melanomas; Figure 14). In both comparisons, the
accuracy of dermoscopy exceeded that of visual inspection alone
(Table 2). In (a), the diagnostic odds ratio (DOR), for dermoscopy
was 5.6 (95% CI 3.7 to 8.5; P < 0.001), times that of visual in-
spection alone, in (b), it was 5.3 (95% CI 3.5 to 8.0; P < 0.001),
times that of visual inspection alone. These effects correspond to
predicted differences in specificity of (a), 40% (95% CI 27% to
57%), (based on specificity with dermoscopy of 82% vs 42% for
visual inspection), and (b), 34% (95%CI 15% to 53%), (based on
specificity with dermoscopy of 83% vs 48% for visual inspection),
at a fixed sensitivity of 80% (Table 2), and predicted differences
in sensitivity of (a), 34% (95% CI 24% to 46%), based on sensi-
tivity with dermoscopy of 81% vs 47% for visual inspection and
(b), 36% (95% CI 20% to 52%), based on sensitivity with der-
moscopy of 83% vs 47% for visual inspection at a fixed specificity
of 80% (Table 2).
Secondary analyses for the detection of invasive melanoma
and melanocytic intra-epidermal variants
Covariate investigations
Table 3 and Table 5 report the results of the heterogeneity investi-
gations. Given the large difference in accuracy for in-person evalu-
ations compared to those based on the assessment of dermoscopic
images, we elected to undertake all subsequent covariate investiga-
tions for in-person (Table 3), and image-based (Table 5), studies
separately. In four of the covariate investigations (apart from that
by disease prevalence), we dropped subgroups with small numbers
of studies to allow a comparison between the two larger subgroups.
In-person evaluations
Further analysis of the 26 in-person evaluations found no clearly
significant relationships between accuracy and the five covariates
that we considered. We noted some evidence of differences for
choice of reference standard and disease prevalence (Table 3).
• Choice of reference standard: observed accuracy was lower
in studies that relied on a histological reference standard (n =
18), as opposed to those (n = 7), that included follow-up of some
benign lesions although the difference was not statistically
significant (RDOR 0.27, 95% CI 0.06 to 1.22; P = 0.23).
Theoretically, the inclusion of a follow-up reference standard: has
the potential to lower sensitivity (as any melanomas missed on
the index clinic visit that are identified on follow-up would be
considered as false negatives), and increase specificity (as lesions
considered benign and not recommended for excision on the
index clinic visit and that do not show any changes on follow-up
will increase the number of true-negative results). The data
observed did demonstrate the anticipated effect on specificity
(with specificities at 80% sensitivity increasing from 94% in
histology-only studies to 99% in histology or follow-up
evaluations), however the effect on sensitivity at 80% fixed
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specificities was the opposite to that anticipated (sensitivity was
6% higher in the histology or follow-up group compared to
histology alone). Three of the six in-person evaluations using
histology or follow-up as a reference standard reported
sensitivities of over 95% (Duff 2001; Dreiseitl 2009; Grimaldi
2009). Of the nine false-negative cases in Duff 2001, eight
melanomas were identified during follow-up (between 5 to 41
months after the initial diagnosis), however with high overall
prevalence of disease, sensitivity remained high at 98%. Dreiseitl
2009 and Grimaldi 2009 did not report any melanomas picked
up during follow-up (at 1 year and 6 months’ follow-up,
respectively). The perfect sensitivity in Grimaldi 2009 is likely
due to lesions classified as positive if they were ‘suspicious for
melanoma’ as opposed to being a likely or definite melanoma.
For Dreiseitl 2009 the high sensitivity is likely explained by
diagnosis by an expert clinician, and with more than six lesions
examined per patient assisting diagnosis.
• Disease prevalence: observed accuracy was somewhat
higher where disease prevalence of melanoma was 5% or less
(RDOR 5.4, 95% CI 0.80 to 36.6), and where prevalence was
greater than 20% (RDOR 5.0; 95% CI 0.78 to 32.4), compared
to those with disease prevalence between 5% and 10%
(likelihood ratio (LR) test for differences between groups: P =
0.008). No obvious explanation for these results could be derived
from the study characteristics (Table 3).
• Other investigations: the RDOR for use of no algorithm
to aid diagnosis compared to a named algorithm was 1.4 (95%
CI 0.34 to 5.6; P = 0.17), for a single observer compared to a
consensus of two or more observers was 1.0 (95% CI 0.18 to
5.8; P = 0.30), and for evaluations including only melanocytic
lesions compared to any pigmented lesion was 0.48 (95% CI
0.12 to 2.0; P = 0.60), (Table 3).
Image-based evaluations
For the 60 image-based evaluations, we noted no clearly significant
relationships between accuracy and the five covariates. The choice
of reference standard showed an effect in the opposite direction
to that observed for the in-person evaluation (Table 5). Observed
accuracy was higher in studies that relied on a histological refer-
ence standard (n = 48), as opposed to those (n = 8), that included
follow-up of some benign lesions (RDOR 2.8; 95% CI 0.92 to
8.9; P = 0.19). At a fixed specificity of 80%, observed sensitivity
in studies using a follow-up reference standard was lower (65%),
compared to those using histology alone (84%), as might be ex-
pected, however at a fixed sensitivity of 80%, specificities in stud-
ies that included follow-up of some benign lesions was also lower
(64%), compared to those using histology alone (84%). This ef-
fect is likely due to a combination of reasons that cannot be de-
rived from the data due to heterogeneity in participants, tests and
observers.
• Disease prevalence: disease prevalence was higher in
image-based studies than in in-person studies and a different
grouping for prevalence was used. Observed accuracy appeared
highest where disease prevalence of melanoma was 20% or less
(RDOR 30.7, 95% CI 1.51 to 6.24), compared to prevalence
more than 20% to 30% and higher.
• Other investigations: for the other characteristics
investigated, we observed similar results to those obtained for in-
person evaluations for use of a named algorithm, the effect from
restriction to melanocytic lesions only was in the opposite
direction although non-significant (P = 0.16), and we observed
results to a greater order of magnitude for diagnosis by a single
observer compared to a consensus of two or more observers.
1.1.1. Analyses by algorithms used to assist dermoscopy
Appendix 2 has details of the algorithms used to assist diagnosis
and Table 6 shows results by algorithm used (or not used), for each
of the target conditions under consideration in this review. We
undertook all analyses in this section using the bivariate normal
model.
In-person evaluations of dermoscopy added to visual
inspection
The 26 in-person evaluations of dermoscopy added to visual in-
spection of a lesion provide a total of 39 datasets using different
algorithms or diagnostic thresholds for the detection of invasive
melanoma or atypical intraepidermal melanocytic variants. Eight
of the datasets did not report the use of any algorithm to assist di-
agnosis, eight reported data for pattern analysis, and the remaining
23 datasets used one or more of seven different formally developed
algorithms (Table 6a).
We estimated a pooled sensitivity of 88% (95% CI 75% to 95%),
and specificity of 87% (95% CI 80% to 92%), for observer diag-
nosis without the use of a formal algorithm (n = 8 datasets; 4707
lesions, 849 melanomas). The approach to diagnosis was not well
described; however, most studies in this dataset reported accuracy
for the clinician’s correct diagnosis of melanoma rather than the
decision to biopsy or excise a lesion (Appendix 8). Pooled results
for studies using pattern analysis were similar but with narrower
confidence intervals for sensitivity (sensitivity 92%, 95% CI 87%
to 95%; specificity 92%, 95% CI 68% to 98%; 6 datasets with
4307 lesions and 296 melanomas).
Of the more formal algorithms for melanoma diagnosis, we could
pool results for only two. Five datasets (1438 lesions and 160
melanomas), using the ABCD algorithm at a threshold of above
5.45 produced a sensitivity of 81% (95% CI 62% to 92%),
and specificity of 92% (95% CI 82% to 97%). Two evaluations
(11,137 lesions and 127 melanomas), reported data for the seven-
point checklist (7PCL), at a threshold of 3 or above, giving a sensi-
tivity of 67% (95%CI 46% to 83%), and specificity of 96% (95%
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CI 88% to 99%). The latter result is based on a single study publi-
cation, which reports results for 8449 lesions detected on a partic-
ipant’s first clinic visit (Haenssle 2010a (FV)), and separately for
2373 lesions examined during follow-up (Haenssle 2010b (FU)).
The ABCDE algorithm, seven features for melanoma (7FFM),
and the Menzies criteria were each assessed in a single study on
an in-person basis; results were generally similar to those observed
above (Table 6a).
Image-based evaluations of dermoscopic images
The 60 evaluations of dermoscopic images provide a total of 113
datasets using different algorithms or diagnostic thresholds for
the detection of invasive melanoma or atypical intraepidermal
melanocytic variants. Twenty-eight of the datasets did not report
the use of any algorithm to assist diagnosis (4 studies reporting data
at two thresholds), 22 report data for pattern analysis (2 studies
reporting data at two thresholds), and the remaining 63 datasets
used one or more of 14 different formally developed algorithms
(Table 6a).
For observer diagnosis without the use of a formal algorithm, di-
agnostic thresholds (i.e. the clinical decision that was recorded by
the clinician concerned), were poorly reported; however, we at-
tempted to differentiate between those studies reporting the ob-
server’s correct diagnosis of melanoma from those reporting the
decision to excise a lesion. Pooling all data regardless of threshold
(24 datasets; 4498 lesions and 941 melanomas), gave a sensitivity
of 76% (95% CI 70% to 82%), and specificity of 79% (95% CI
71% to 85%). Restricting the analysis to the 18 datasets report-
ing data for observers correctly diagnosing melanoma (4118 le-
sions; 795 melanomas), gave a sensitivity of 77% (95% CI 69% to
83%), and specificity of 84% (95% CI 76% to 89%). For the 10
datasets that reported data for the decision to excise a lesion (831
lesions; 263 melanomas), sensitivity was similar at 79% (95% CI
69% to 86%), but specificity reduced to 55% (95% CI 50% to
61%). Pooled results for 20 evaluations (4621 lesions and 989
melanomas), reporting use of pattern analysis resulted in higher
sensitivity (83%, 95% CI 76% to 88%), and specificity (87%,
95% CI 80% to 92%), compared to the no-algorithm-reported
studies but results were both lower in comparison to the in-person
evaluations.
Sufficient data were available to allow pooling for seven differ-
ent formal algorithms to assist diagnosis (Table 6a); all summary
estimates showed either lower sensitivity or lower specificity, or
both, in comparison to either the no-algorithm or pattern-anal-
ysis datasets. The ABCD checklist at a threshold of above 5.45
(7 datasets; 2471 lesions and 406 melanomas), had a sensitivity
of 81% (95% CI 60% to 92%), and specificity of 81% (95% CI
69% to 89%). At the lower threshold of above 4.75 for diagnosis
of melanoma, sensitivity remained at 81% (95%CI 67% to 90%),
with narrower confidence intervals with a lower specificity of 72%
(95% CI 93% to 80%), (10 datasets; 4242 lesions and 816 cases).
Eleven datasets evaluated the 7PCL at a threshold of 3 or above
(3408 lesions and 798 melanomas), pooled sensitivity was 80%
(95% CI 63% to 91%), and specificity 67% (95% CI 51% to
80%). Four evaluations that did not report the threshold used with
the 7PCL demonstrated lower sensitivity (72%, 95% CI 56% to
84%), but higher specificity (79%, 95% CI 61% to 90%).
Four datasets, with 2200 lesions and 340 melanomas assessed the
7FFM tool. Sensitivity was 89% (95% CI 76% to 96%), with
specificity 84% (95% CI 78% to 89%). Four datasets evaluated
the Menzies criteria using the method described in the original
Menzies 1996 paper, pooled sensitivity was 78% (95% CI 38% to
96%), and specificity 63% (95% CI 39% to 81%), (1856 lesions
and 317 melanomas).
We pooled seven evaluations of the 3PCL at a threshold of 2 or
above (1505 lesions and 363 melanomas), summary sensitivity
was 74% (95% CI 61% to 85%), and specificity 60% (95% CI
42% to 76%). Sixteen additional datasets reporting data for other
algorithms or at different thresholds are reported in Table 6a, how-
ever study numbers are too small to describe results in any detail.
1.1.2. Analyses by observer experience and qualifications
Table 4 and Table 7 report results for the effect of observer experi-
ence and qualifications. Observer experience was generally poorly
described in the study reports (see Appendix 8 and Appendix 9);
however, we attempted broad classifications by expertise in der-
moscopy and reported qualificationswith the ‘consultant’ category
in the latter analysis separated into ‘Expert consultant’ (for any
study describing observers as expert or experienced), and ‘Consul-
tant’ where experience or expertise was not otherwise reported (for
example, for those that described observers as dermatologists). We
have described results separately for in-person (Figure 16; Figure
17), and image-based evaluations (Figure 18; Figure 19).
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Figure 16. Comparison of the accuracy of visual inspection + dermoscopy for detection of invasive
melanoma or atypical intraepidermal melanocytic variants from in-person studies according to reported
observer experience
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Figure 17. Comparison of the accuracy of dermoscopy for detection of invasive melanoma or atypical
intraepidermal melanocytic variants from image-based studies according to observer experience
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Figure 18. Comparison of the accuracy of visual inspection + dermoscopy for detection of invasive
melanoma or atypical intraepidermal melanocytic variants from in-person studies according to observer
qualifications (summary receiver operating characteristic (ROC) curves were not estimable from the model
for ’resident/registrar’ and ’mixed (secondary care-based)’ experience groups)
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Figure 19. Comparison of the accuracy of dermoscopy for detection of invasive melanoma or atypical
intraepidermal melanocytic variants from image-based studies according to observer qualification.
(Hierarchical summary receiver operating characteristic (HSROC) curves could not be estimated for ’mixed
(secondary care-based)’ and ’physician assistant’ groups)
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The in-person evaluations classified the majority of observers as
having high dermoscopy experience (n = 14), or as experience NR
(n = 10). Two studies reported data for GPs provided with some
dermoscopy training for the purposes of the study (Grimaldi 2009;
Menzies 2009). We found no statistically significant differences
between groups (Table 4), although we noted that the poorest
performance was in the GP training group.
The 60 image-based evaluations provided 77 datasets according to
observer experience; 13 evaluations providing data for more than
one observer (Argenziano 1998; Benelli 2001; Binder 1995; Ferris
2015; Hauschild 2014; Menzies 2005; Pagnanelli 2003; Piccolo
2002a; Piccolo 2014; Seidenari 1998; Seidenari 2005; Stanganelli
1999; Tan 2009). The LR test for differences between groups
was statistically significant (P < 0.001). Using the high-experi-
ence group as the reference (34 datasets; 8933 lesions and 1956
melanomas), the RDOR for the observers where experience was
NR (11 datasets; 2777 lesions and 465 melanomas), was 2.0 (95%
CI 0.8 to 4.9), while the RDORs for the lower experience groups
all suggested lower accuracy (Table 4; Figure 17). The RDORs
for each group in comparison to the high-experience group were:
moderate experience 0.64 (95% CI 0.37 to 1.1; 5 datasets, 678
lesions and 193 melanomas); low experience 0.30 (95% CI 0.15
to 0.58; 6 datasets; 448 lesions and 123 melanomas); ‘mixed’ ex-
perience 0.25 (95% CI 0.07 to 0.81; 5 datasets, 473 lesions and
117 melanomas); and for the ’trained’ group 0.15 (95% CI 0.25
to 1.02; 11 datasets, 1087 lesions and 240 melanomas).
We observed similar trends when we subgrouped evaluations ac-
cording to reported observer qualifications, however data for clin-
icians other than consultant or ‘consultant experts’ were relatively
sparse, especially for the in-person evaluations where no statisti-
cally significant differences between groups was determined (Table
7; Figure 18). For the image-based evaluations accuracy was high-
est for the ‘Expert consultant’ group (DOR 19.4, 95% CI 13.1
to 28.8; 33 datasets, 8664 lesions and 1854 melanomas; Figure
19). RDORs in comparison to the ‘expert’ group were 0.61 (95%
CI 0.40 to 0.92), for observers described as ‘dermatologists’ (25
datasets; 4589 lesions and 955 melanomas), 0.31 (95%CI 0.14 to
0.71 for registrar (trainee), or resident-level observers (5 datasets;
927 lesions and 138 observers), and 0.10 (95% CI 0.04 to 0.25),
for the GP group (3 datasets; 288 lesions and 55 melanomas).
Results for the GP group may simply be attributed to small sam-
ple sizes; however, we observed the lowest sensitivity for detection
of melanoma (22%), for Bourne 2012, in which seven of nine
malignancies were melanomas in situ or lentigo maligna, and we
observed the lowest specificity (44%), for Piccolo 2014, which in-
cluded a relatively high percentage of Spitz naevi (14% of the dis-
ease-negative group), whichmay have beenmore difficult to differ-
entiate from melanomas. Both studies also implemented blinded
dermoscopy image interpretation whereas the third study in this
group (Menzies 2005), also provided the clinical image and infor-
mation on patient history to the interpreting clinicians.
1.1.3. Results of sensitivity analyses
In our generic protocol we planned a number of sensitivity anal-
yses. We discussed one of these, restricting comparisons between
dermoscopy and visual inspection alone to studies where the same
study evaluated both tests (direct comparisons), alongside themain
test comparisons above (Table 2). For completeness, we have in-
cluded the results of these in Table 8 (in-person evaluations), and
Table 9 (image-based evaluations), along with the results of all
other sensitivity analyses.
In-person evaluations
Analyses restricting studies to those avoiding partial verification
(including only those that allowed histology or follow-up), in-
creased the relative benefit from adding dermoscopy to visual in-
spection from an RDOR of 4.7 (95% CI 3.0 to 7.5), to 14.4
(95% CI 4.4 to 47.6), however study numbers were small and the
increase in sensitivity at 80% specificity and in specificity at 80%
sensitivity remained similar (Table 8). We observed limited differ-
ences for the analyses restricting studies to those with low risk of
bias for the index test or low risk of bias for the reference stan-
dard. An additional post hoc analysis restricting studies to those
with low risk of bias for flow and timing resulted in small study
numbers and did not appear to have a large impact on accuracy.
Planned analyses restricting to studies with at least a three-month
interval between the index test and the reference standard, and
where concerns around applicability for participant selection were
low, were not possible due to lack of studies.
Image-based evaluations
There were small study numbers for visual inspection in compar-
ison to the numbers for dermoscopy, so it was more difficult to
interpret sensitivity analyses for image-based evaluations in terms
of the differences between diagnosis using dermoscopic images
versus visual inspection of images, for example, for restriction to
those that allowed histology or follow-up as a reference standard
(7 datasets for dermoscopy compared to 0 for visual inspection),
for low risk of bias for the index test (40 for dermoscopy versus 3
for visual inspection), and for low risk of bias for flow and timing
(11 datasets for dermoscopy versus 1 for visual inspection; Table
9). Restriction to studies with low risk of bias for the reference
standard made very little difference to the accuracy of either test
or to the RDOR for dermoscopy versus visual inspection.
Again, due to lack of studies, we could not carry out planned
analyses restricting to studies with at least a three-month interval
between the index test and the reference standard, and where con-
cerns around applicability for participant selection were low.
An additional post hoc sensitivity analysis restricting studies to
those that did not use a case-control design increased the accuracy
of visual inspection of images from a DOR of 3.2 (95% CI 1.9 to
5.4), to DOR 7.2 (95% CI 3.5 to 14.8), for the seven remaining
datasets, and increased the DOR for diagnosis using dermoscopic
images from 17.8 (95%CI 12.3 to 25.7) for all 60 datasets to 24.3
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(95% CI 15.2 to 39.0) for the remaining 37 datasets; the RDOR
between tests reduced from 5.6 (95% CI 3.7 to 8.5), to 3.4 (95%
CI 1.8 to 6.4) (Table 9). From the sensitivities and specificities
estimated from SROC curves, this fall in RDOR appears to be
primarily related to an increase in accuracy for diagnosis based
on visual inspection of images rather than a fall in accuracy for
dermoscopic examination, due to the exclusion of case-control
studies. The direction of this finding is contrary to the standard
expectation that case-control studies overestimate test accuracy
compared to other designs (Rutjes 2006).
2. Target condition: invasive melanoma only
In this section we present the results for studies of dermoscopy
for the identification of invasive melanoma, according to the ap-
proach taken for diagnosis: in-person or image-based evaluations.
Summary characteristics of studies are presented in Appendix 11,
with forest plots of study data in Appendix 12 and results of meta-
analyses in Table 10, and Figure 20 and Figure 21.
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Figure 20. Comparison of the accuracy of visual inspection with visual inspection (VI) + dermoscopy for
detection of invasive melanoma from in-person studies
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Figure 21. Comparison of the accuracy of visual inspection with dermoscopy for detection of invasive
melanoma from image-based studies
Dermoscopy added to visual inspection of a skin lesion (in-
person evaluations)
Six studies evaluated the accuracy of in-person dermoscopy for the
detection of invasive melanoma only, one of which also reported
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data for the primary target condition (Feldmann 1998), and two of
which presented data for visual inspection (Krahn 1998; Viglizzo
2004). All studies were case series based in secondary care or spe-
cialist units apart from Coras 2003, which was based in a private
dermatology clinic. All the studies recruited participants with pig-
mented lesions, Viglizzo 2004 restricting to melanocytic lesions
only. Four studies did not report using any formal algorithm to
assist dermoscopy diagnosis (Coras 2003; Krahn 1998; Piccolo
2000; Viglizzo 2004); Feldmann 1998 used the ABCD checklist
and Ascierto 2010 used a modified version of the Kenet risk strat-
ification approach (referenced to Ascierto 1998). The prevalence
of melanoma ranged from 5% (Feldmann 1998), to 49% (Krahn
1998). All studies used a histological reference standard.
The sensitivity of in-person dermoscopy ranged from 64% to
100% and specificities ranged from 93% to 98% (Appendix 12).
In meta-analysis the DOR was 129 (95% CI 19.2 to 870; 789
lesions and 115 melanomas). The specificity of in-person der-
moscopy at 80% fixed sensitivity was 97% (95%CI 94% to 98%),
and sensitivity at 80%fixed specificity was also 97% (95%CI 46%
to 100%; Table 10). Again, these sensitivities and specificities at
fixed values should be taken as illustrative of the data observed.
In Feldmann 1998, the sensitivity for the detection of inva-
sive melanoma alone was 11% higher compared to sensitiv-
ity for the detection of invasive melanoma or atypical intraepi-
dermal melanocytic variants (64% vs 53%), because the 5 in-
cluded melanoma in situ lesions were all classified as negative for
melanoma on dermoscopy and were classed as true-negative re-
sults for the detection of invasive melanoma alone.
Incremental accuracy from dermoscopy added to in-person
visual inspection alone
The two studies providing direct comparisons of visual inspection
alone and visual inspection + dermoscopy reported using no algo-
rithm to assist visual inspection diagnosis (Krahn 1998; Viglizzo
2004). Based on reported authors’ institutions, we assumed that
observers in both studies were dermatologists.
Sensitivities for visual inspection were 79% (Krahn 1998), and
67% (Viglizzo 2004); specificities were 78%and 95%, respectively
(Appendix 12). We compared the accuracy of visual inspection
with the accuracy of dermoscopy estimated from (a), all six der-
moscopy studies (789 lesions and 115 melanomas), and both in-
person visual inspection studies (147 lesions and 51 melanomas),
and estimated from (b), direct comparisons in the subset of two
studies that evaluated both visual inspection and dermoscopy on
an in-person basis (147 lesions and 51 melanomas). In both com-
parisons the accuracy of dermoscopy added to visual inspection
exceeded that of visual inspection alone (Table 10). In (a), the
DOR for dermoscopy was 6.2 (95% CI 1.5 to 26.6; P = 0.015),
times that of visual inspection alone, in (b), it was 11.3 (95% CI
1.4 to 689.8; P = 0.015), times that of visual inspection alone.
These effects correspond to predicted differences in specificity of
(a), 13% (95% CI -1% to 27%), based on sensitivity with der-
moscopy of 97% vs 84% for visual inspection and (b), 24% (95%
CI -21% to 69%), based on sensitivity with dermoscopy of 99%
vs 75% for visual inspection at a fixed sensitivity of 80% (Table
10); and predicted differences in sensitivity of (a), 13% (95% CI
-0% to 27%), based on specificity with dermoscopy of 97% vs
84% for visual inspection and (b), 15% (95% CI 2% to 29%),
based on specificity with dermoscopy of 94% vs 78% for visual
inspection at a fixed specificity of 80% (Table 10).
Dermoscopic images (image-based evaluations)
Thirteen datasets reported the accuracy of image-based der-
moscopy for the detection of invasive melanoma, none of which
reported data for the primary target condition. Eight evaluations
included series of lesions observed in secondary care or specialist
clinic settings (prevalence 10% to 36%). The remaining five eval-
uations used a case-control type design, with separate sampling
of melanoma and benign lesion images. Prevalence ranged from
27% to 65%. Studies used the ABCD checklist (Lorentzen 2000;
Menzies 2013), the Menzies algorithm (Arevalo 2008; Menzies
1996; Westerhoff 2000), or their own algorithm (Kreusch 1992;
Nilles 1994), to assist dermoscopic diagnosis. Six evaluations did
not report using any algorithm to assist diagnosis.
Five evaluations presented only the dermoscopic image with
no further patient information (Arevalo 2008; Lorentzen 2008;
Menzies 1996; Nilles 1994; Troyanova 2003), five presented ob-
servers with a concurrent clinical image of the lesion (Hauschild
2014; Lorentzen 1999a; Lorentzen 2000; Rao 1997; Westerhoff
2000); two provided only lesion site (Kreusch 1992), or site, age
and gender (Friedman 2008), and one did not describe any further
information (Menzies 2013). Images were interpreted by derma-
tologists or assumed-to-be dermatologists in 10 studies, by derma-
tologists or melanoma fellows in Rao 1997, by GPs in Westerhoff
2000 and by mixed secondary care clinicians in Friedman 2008.
Sensitivities ranged from 48% to 100%, specificities ranged from
49% to 97% (Appendix 12). In meta-analysis the DOR was 27.5
(95% CI 12.2 to 61.7; 5618 lesions and 1092 melanoma cases).
Specificity at 80% fixed sensitivity was 87% (95% CI 75% to
94%), and sensitivity at 80% fixed specificity was 88% (95% CI
75% to 94%), (Table 10).
Incremental accuracy of dermoscopic image-based diagnosis
compared to visual inspection of images
The four studies providing direct comparisons of diagnosis based
on clinical images and diagnosis based on dermoscopic images
reported using no algorithm to assist visual inspection diagnosis
(Lorentzen 1999a; Troyanova 2003; Westerhoff 2000), or use of
the ABCD algorithm (Rao 1997). Observers were dermatologists
(Lorentzen 1999a; Troyanova 2003), a melanoma fellow (Rao
1997), or GPs (Westerhoff 2000).
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Sensitivities for visual inspection ranged from 62% to 86%; and
specificities from 54% to 89%, respectively (Appendix 12). We
compared the accuracy of visual inspection with the accuracy of
dermoscopy estimated from (a), all 13 dermoscopy studies (5618
lesions and 1092 melanomas), and the four visual inspection stud-
ies (454 lesions and 145 melanomas), and estimated from direct
comparisons in (b), with the subset of four studies that evaluated
both visual inspection and dermoscopy on an image-based basis
(454 lesions and 145 melanomas). In both comparisons the accu-
racy of diagnosis based on dermoscopic images exceeded that based
on clinical images (Table 10). In (a), the DOR for dermoscopy
was 2.5 (95% CI 1.2 to 5.1; P = 0.032), times that of visual in-
spection alone, in (b), it was 3.4 (95% CI 1.0 to 11.1; P = 0.049),
times that of visual inspection alone. These effects correspond to
predicted differences in specificity of (a), 13% (95% CI -1% to
28%), based on sensitivity with dermoscopy of 87% vs 74% for
visual inspection and (b), 44% (95%CI -20% to 100%), based on
sensitivity with dermoscopy of 89% vs 45% for visual inspection
at a fixed sensitivity of 80% and predicted differences in sensitivity
of (a), 15% (95% CI -1% to 30%), based on specificity with der-
moscopy of 88% vs 72% for visual inspection and (b), 11% (95%
CI 1% to 22%), based on specificity with dermoscopy of 83% vs
72% for visual inspection at a fixed specificity of 80% (Table 10).
3. Target condition: any skin lesion requiring excision
In this section we present the results for studies of visual inspec-
tion for the identification of any skin lesion requiring excision,
according to the approach taken for diagnosis: in-person or im-
age-based evaluations. For each study we could only extract data
for the detection of any skin cancer. We have presented summary
characteristics of studies in Appendix 13, with forest plots of study
data in Figure 22 and Figure 23, and results of meta-analyses in
Table 11. Heterogeneity was too high and data too sparse to allow
us to make formal statistical comparisons between tests, thus the
analysis focuses on describing the observed accuracy. Only meta-
analytical models assuming underlying symmetric SROC curves
could be fitted to these data.
Figure 22. Forest plot of tests. 9 Visual inspection - in-person (any skin cancer), 10 VI+dermoscopy - in-
person (any skin cancer)
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Figure 23. Forest plot of tests. 11 Visual inspection - image-based (any skin cancer), 12 dermoscopy alone -
image-based (any skin cancer)
Dermoscopy added to visual inspection of a skin lesion (in-
person evaluations)
Four datasets evaluated the accuracy of in-person dermoscopy for
the detection of any skin lesion requiring excision (Argenziano
2006; Durdu 2011; Soyer 2004; Stanganelli 2000), one of which
also reported data for the primary outcome (Durdu 2011), and
two reported data for visual inspection alone (Argenziano 2006;
Stanganelli 2000). Studies were based in primary care, with di-
agnosis by GPs (Argenziano 2006), or secondary care or special-
ist referral clinics, with diagnosis by dermatologists. The preva-
lence of skin cancer ranged from 3% in Stanganelli 2000 to
51% in Argenziano 2006. Studies used the ABCD algorithm
(Durdu 2011), the 3PCL (Argenziano 2006), pattern analysis
(Stanganelli 2000), or no algorithm (Soyer 2004), to assist diagno-
sis. Stanganelli 2000 supplemented a histological reference stan-
dard with clinical follow-up, and the others reported data com-
pared to histology alone.
Sensitivities ranged from 85% to 98%; specificities ranged from
26% to 100% (Figure 22). In meta-analysis the DOR was 232
(95% CI 16.0 to 3354; 3880 lesions and 260 skin cancer cases)
(Table 11). We could not make any formal comparison with in-
person visual inspection due to heterogeneity and sparsity of data;
however, the DOR for the two studies reporting data for visual
inspection alone (3457 lesions and 151 skin cancers), was 15.0
(95%CI 0.18 to 1225; Argenziano 2006; Stanganelli 2000), com-
pared to 88.1 (95% CI 1.1 to 7338), for in-person dermoscopy
in these same two studies (3449 lesions and 137 skin cancers; the
total number of lesions andmelanomas differs because Argenziano
2006 was a between-person comparison study with a different
number of lesions randomised to each arm). Sensitivities at 80%
fixed specificity and specificities at 80% fixed sensitivity were both
17% higher using dermoscopy (both 96% with dermoscopy com-
pared to 79% for visual inspection alone), due to the use of sym-
metric ROC curves for these analyses.
We observed the lowest sensitivity and specificity for dermoscopy
in Argenziano 2006, however we could only include 2x2 data for
the GP diagnosis using the 3PCL for the 77 lesions selected for ex-
cision by an expert dermatologist, as the remaining 1126 for which
GP diagnosis was recorded did not have an adequate reference
standard for inclusion in our review. In Durdu 2011 specificity
estimates were not affected by the wider definition of the target
condition; however, sensitivity increased from 80% for detection
of melanoma or atypical intraepidermal melanocytic variants to
98% for detection of any lesion requiring excision, as all 34 BCCs
were correctly identified.
Dermoscopic images (image-based evaluations)
Five datasets reported the accuracy of image-based visual inspec-
tion for the detection of any skin lesion requiring excision (Carli
2002b; Lorentzen 2008; Rosendahl 2011; Stanganelli 1998a;
Zalaudek 2006), all of which also reported data for the pri-
mary target condition or for the detection of invasive melanoma
alone (Lorentzen 2008), and three of which reported data for
diagnosis based on clinical images (Carli 2002b; Rosendahl
2011; Stanganelli 1998a). Studies selected images from secondary
care clinics or specialist units (Carli 2002b; Lorentzen 2008;
Stanganelli 1998a; Zalaudek 2006), or from a primary care prac-
tice (Rosendahl 2011). The prevalence of lesions suitable for ex-
cision ranged from 22% (Rosendahl 2011), to 47% (Stanganelli
1998a); the latter selecting images for use in a dermoscopy train-
ing study. Diagnosis was based on the 3PCL (Zalaudek 2006),
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pattern analysis (Rosendahl 2011), or no formal algorithm. Data
were presented for a single dermatologist (Rosendahl 2011), for
a consensus of two dermatologists (Carli 2002b), for the average
across 20 dermatologists (Stanganelli 1998a), or 150 dermatol-
ogists (Zalaudek 2006), or was not clearly reported (Lorentzen
2008).Observers were also providedwith the clinical image for the
same lesion (Rosendahl 2011; Stanganelli 1998a), with lesion site,
and patient age and gender (Zalaudek 2006), or with no further
clinical information to assist diagnosis (Carli 2002b; Lorentzen
2008).
Sensitivities ranged from 78% to 100%; specificities ranged from
72% to 96% (Figure 23). In meta-analysis the DOR was 37.5
(95% CI 8.8 to 161; 815 lesions and 217 skin cancer cases). We
could not make any formal comparison with diagnosis based on
clinical images due to heterogeneity and sparsity of data, however
the DOR for the three studies reporting image-based visual in-
spection (547 lesions and 138 skin cancers), was 12.1 (95%CI 5.4
to 26.7; Carli 2002b; Rosendahl 2011; Stanganelli 1998a), com-
pared to 18.4 (95% CI 8.1 to 41.7), for image-based dermoscopy
in these same three studies. Sensitivities at 80% fixed specificity
and specificities at 80% fixed sensitivity were 7% higher using
dermoscopy (both 82% with dermoscopy compared to 75% for
visual inspection of clinical images).
The wider definition of the target condition to include any skin
lesion requiring excision led to increased sensitivities and lower
specificities in three studies due to classification of BCCs as true
positives rather than false negatives (Carli 2002b; Rosendahl 2011;
Stanganelli 1998a). We also extracted data from Rosendahl 2011
and Stanganelli 1998a for the correct diagnosis of any malignancy
rather than correct diagnosis of each individual type of skin cancer,
which led to considerable increased in sensitivity in both studies.
4. Evaluations of dermoscopy training
Six studies evaluated observer accuracy using dermoscopy before
and after a dermoscopy training intervention. Two studies re-
ported data for detection of invasive melanoma alone (Troyanova
2003; Westerhoff 2000), and four reported data for the detection
of invasive melanoma and atypical intraepidermal melanocytic
variants (Pagnanelli 2003; Piccolo 2014; Stanganelli 1999; Tan
2009). A further 14 studies reported the delivery of some form
of dermoscopy training, either prior to the study commencing
(Kittler 1998; Seidenari 2007), or within the context of the study
itself (Argenziano 1998; Argenziano 2006; Binder 1999; Carli
2003a; Dolianitis 2005; Grimaldi 2009; Kittler 1998; Menzies
2008;Menzies 2009; Seidenari 2007; Stanganelli 1998a; Zalaudek
2006). Six of the latter group of studies compared the accuracy of
diagnosis based on visual inspection alone (pre-dermoscopy train-
ing), to visual inspection and dermoscopy (post-dermoscopy train-
ing); we have incorporated these data into the visual inspection
versus dermoscopy comparisons reported above.
We have shown details of the training interventions provided in
the six eligible studies in Appendix 14 and reported results of the
analyses in Table 12 and Figure 24. All studies were image-based
evaluations.
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Figure 24. Forest plot of tests. Accuracy of dermoscopy before and after dermoscopy training (MM and
invasive melanoma or atypical intraepidermal melanocytic variants)
For the detection of invasive melanoma or atypical intraepider-
mal melanocytic variants, all four evaluations (Pagnanelli 2003;
Piccolo 2014; Stanganelli 1999; Tan 2009), demonstrated an in-
crease in the average sensitivity of dermoscopy of between 13%
and 15% (pre-training sensitivity ranged from 36% to 80% and
post-training from 73% to 93%). We observed no change in av-
erage specificity following dermoscopy training for three studies,
and specificity fell from 70% pre-training to 44% post-training in
Piccolo 2014. The pooled analysis showed no impact on accuracy
from dermoscopy training (RDOR 1.4, 95% CI 0.38 to 5.3).
Three of the four studies reported the training of dermatologists (n
= 83 in Stanganelli 2000), or of a mixed group of dermatologists,
registrars or residents (n = 16 in Pagnanelli 2003; n = 6 in Tan
2009). Pagnanelli 2003 also included three medical students in
their group of “16 trainees”. These three studies provided web-
based interactive training (Pagnanelli 2003; Tan 2009), with an
expectation of a time commitment of one hour per day for two
weeks (Pagnanelli 2003), or with a dermatoscope provided for use
in clinical practice for 10 months between tests (Tan 2009), or
in-person dermoscopy training workshops (Stanganelli 1999). In
Piccolo 2014 however, the ‘trainee’ was a singleGPwhoundertook
similar online training using an interactive atlas of dermoscopy,
which may explain the outlying result for specificity.
For the detection of invasive melanoma, both evaluations demon-
strated an increase in the average sensitivity of dermoscopy in the
order of 16% to 18% following dermoscopy training (from 76%
to 92% in Troyanova 2003’s study of 32 dermatologists and from
58% to 76% inWesterhoff 2000’s study of 74 GPs), with minimal
impact on specificity (84% before and after training in Troyanova
2003 and 56% before and 58% after training inWesterhoff 2000).
The pooled analysis showed a non-statistically significant increase
in accuracy after training of 3.2 times that before training (95%
CI 0.94 to 10.6, P = 0.05; 150 lesions and 75 cases). As well as
the differences in clinician qualifications, the content and dura-
tion of the training programmes also varied. Troyanova 2003 pro-
vided six hours of in-person teaching daily for two consecutive
days; the test using clinical and dermoscopic images of 50 lesions
was undertaken at the beginning and at the end of the course. In
Westerhoff 2000, GPs were provided with a pictorial atlas outlin-
ing the Menzies approach to dermoscopic diagnosis and given a
one-hour presentation on themethod; the pre- and post-tests were
undertaken at the leisure of the individual GPs.
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D I S C U S S I O N
Summary of main results
The included studies evaluated dermoscopy to assist the diagnosis
ofmelanoma in a range of study populations, on an in-person basis
added to visual inspection of a skin lesion and using dermoscopic
images, and bothwith andwithout the use of published algorithms
to assist diagnosis. We observed wide variations in both sensitivity
and specificity for dermoscopy use for all definitions of the target
condition. In terms of methodological quality, many studies were
at high or unclear risk of bias for participant selection and for
timing of diagnosis in relation to reference standard diagnosis, but
were at low risk of bias for the index test and reference standard.
Concern around the applicability of studies was almost universally
high due to restricted inclusion of lesions (for example inclusion of
onlymelanocytic lesions or of lesions selected for excision based on
the clinical or dermoscopic diagnosis), and lack of reproducibility
of diagnostic thresholds. Poor reporting in the primary studies
hindered attempts to analyse studies according to their position
on the clinical pathway and to fully assess sources of heterogeneity
and methodological quality.
In this review we have estimated the incremental accuracy of der-
moscopy in comparison to visual inspection using summary ROC
curves rather than by estimating average sensitivity and specificity
operating points. We have reported points from the fitted SROC
curves (the sensitivity at 80% specificity, and the specificity at
80% sensitivity), however these are for illustrative purposes and
should not be quoted as the actual performance of dermoscopy.
Whilst it may not be possible to estimate the absolute accuracy of
dermoscopy, nor to make any clear recommendations to ensure
that dermoscopy is used in such a way as to maximise sensitivity,
we can make a strong comparison between dermoscopy and vi-
sual inspection alone despite the limitations and heterogeneity of
included studies, particularly from the studies that make within-
patient comparisons between diagnostic strategies of visual inspec-
tion alone, and visual inspection supplemented by dermoscopy.
We have also presented results separately for in-person and image-
based studies, as we observed clear differences in their findings. We
chose to emphasise the in-person findings over the image-based
studies as these are more applicable to typical practice.
Thus, whilst we cannot answer the overall question of how accu-
rate dermoscopy is, we are able to assess the incremental gain in
accuracy of using dermoscopy, and identify some characteristics
that increase or decrease its accuracy.
Five main findings can be drawn from our review:
1) On average, the addition of dermoscopy to in-person visual
inspection of a lesion increases both sensitivity and specificity by
a considerable margin.
Approximately one third of eligible studies presented data for in-
person dermoscopy (26 of 86), for the primary target condition
of invasive melanoma or atypical intraepidermal melanocytic vari-
ants. Studies included a range of study populations and used a
number of different algorithms to assist interpretation, such that
we observed considerable heterogeneity in both sensitivity and
specificity for both visual inspection alone and for visual inspec-
tion + dermoscopy. The Summary of findings presents key results
and translates summary estimates to a hypothetical cohort of 1000
lesions.
Sensitivity: at a fixed specificity of 80%, the use of dermoscopy
increased the sensitivity of in-person visual inspection by 16%,
from 76% to 92%. Assuming melanoma or atypical intraepider-
mal melanocytic variant prevalences of 5%, 12% and 21%, a test
sensitivity of 92% with the added use of dermoscopy would re-
duce the number of melanomas missed in comparison to using
visual inspection alone by 8, 19 and 33 (resulting in 4, 10 and 17
melanomas missed). An assumed test specificity of 80% (for both
visual inspection and visual inspection + dermoscopy), would re-
sult in 190, 176 and 158 false-positive test results (or unnecessary
excisions).
Specificity: at a fixed sensitivity of 80%, the use of dermoscopy
increased the specificity of in-person visual inspection by 20%,
from 75% to 95%. Applying these results to a cohort of 1000 le-
sions at the same three prevalences of disease, both tests wouldmiss
between 10 and 42 melanomas, with the addition of dermoscopy
reducing false positives (or reducing the number of excisions that
would be performed), by 191, 176 and 158 per 1000 (compared
with 238, 220 and 198 unnecessary excisions with visual inspec-
tion alone).
We noted very similar findings between the analysis of all stud-
ies, and the analyses restricted to studies that made within-person
comparisons of strategies of visual inspection alone and visual in-
spection aided by dermoscopy. The same difference was evident
for our secondary analyses for the detection of invasive melanoma
alone and for the detection of any skin lesion requiring excision.
2) In-person dermoscopy is substantially more accurate than im-
age-based assessments
Much of the available evidence for the diagnostic accuracy of der-
moscopy is based on the interpretation of dermoscopic images (60
of 86), as opposed to ‘real time’ diagnosis, face-to-face with the
patient concerned. Formal comparison of test accuracy found in-
person dermoscopy to be substantially more accurate compared
to diagnosis based on dermoscopic images (RDOR 4.6, 95% CI
2.4 to 9.0; P < 0.001). Although there may be a number of con-
tributing factors, including differences in study populations, dif-
ferent algorithms to assist test interpretation and differences in
observer experience, it is likely that, as for visual inspection of a
clinical image (Dinnes 2018a), remote test interpretation cannot
approximate a physical, face-to-face patient to clinician interac-
tion. In particular, total body skin examination is likely to have a
significant impact on the decision to excise a lesion suspected to be
melanoma (Argenziano 2012; Aldridge 2013; Grob 1998). Across
the 60 image-based evaluations, half (30 of 60), were blinded to all
other patient information and only 17 (28%), provided observers
with the clinical image of the same lesion to assist test interpreta-
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tion.
Nevertheless, given the increasing trend towards remote test in-
terpretation (or teledermatology), it is important to try to under-
stand the potential impact from image-based assessments. From
the data observed, at a fixed specificity of 80%, diagnosis based on
dermoscopic images was 34% more sensitive than diagnosis based
on clinical images alone (an increase from 47% to 81% sensitiv-
ity). Assuming melanoma or atypical intraepidermal melanocytic
variant prevalences of 18%, 24% and 39%, these results translate
to 164, 152 and 122 false-positive test results, with 34, 46 and
74 melanomas missed (false negatives), using dermoscopic images
(a reduction of 61, 81 and 133 compared to diagnosis based on
clinical images alone). At a fixed sensitivity of 80%, test specificity
for diagnosis based on dermoscopic images would be 40% higher
compared to that based on clinical images (specificity of 82% com-
pared to 42%). Applying these results to a cohort of 1000 lesions
wouldmiss between 36 and 78melanomas, with 148, 137 and 110
false-positive results based on dermoscopic image interpretation
(a reduction of 328, 304 and 244 in comparison to the evaluation
of clinical images alone).
A post hoc analysis restricting study inclusion to those that did
not use a case-control design appeared to increase the accuracy
of image-based visual inspection and, to a lesser extent, the accu-
racy of diagnosis based on dermoscopic images. Nevertheless the
observed accuracy of in-person dermoscopy was still greater than
that using dermoscopic images. It is also important to note that
none of the included image-based dermoscopy evaluations pur-
ported to be an evaluation of teledermatology. Such evaluations
are included in a separate systematic review of teledermatology for
the diagnosis of skin cancer (Chuchu 2018a). Although the results
for image-based dermoscopy from this review have some bearing
on the accuracy that might be achieved by the remote assessment
of dermoscopic images, we suggest that future studies should not
be undertaken that evaluate dermoscopic images to approximate
to in-person evaluation. We have retained the image-based studies
in the review as they do enable comparisons of different aspects of
dermoscopic diagnosis (see below), but they could potentially be
excluded from future reviews.
3) We could determine no effect from prior testing of participants
or study position on the clinical pathway, and there is insufficient
evidence to assess the accuracy of dermoscopy in a primary care
setting.
Less than half of in-person evaluations (42%; 11 of 26), and only
18% of image-based evaluations (11 of 60), contributing to analy-
ses for the primary target condition contained enough information
to describe the position of participants on the clinical pathway.
This figure is lower than for our review of visual inspection for the
detection of melanoma, where two-thirds of in-person evaluations
were clearly positioned on the clinical pathway (Dinnes 2018a).
Themajority of evaluations of dermoscopy however appear to have
been conducted in referral settings, with only four eligible studies
conducted in primary care populations; two in-person evaluations
and two image-based, thus our planned comparison between ini-
tial presentation versus referred patients is underpowered. Within
the referred population studies there was some (largely non-sig-
nificant), indication of higher accuracy in equivocal lesions and
lower accuracy in studies of patients with lesions undergoing fol-
low-up, particularly in image-based studies. The classification of
study populations was dependent on the terminology used by the
study authors and the groupings may not fully reflect differences
between study populations.
4) There is no clear evidence that accuracy is improved by the use
of any named or published algorithm to assist diagnosis.
The use of a named or published algorithm to assist dermoscopy
interpretation (as opposed to no reported algorithm or reported
use of pattern analysis), had no significant impact on accuracy ei-
ther for in-person (RDOR 1.4, 95% CI 0.34 to 5.6; P = 0.17), or
image-based (RDOR 1.4, 95% CI 0.60 to 3.3; P = 0.22), evalua-
tions. This result was supported by subgroup analysis according to
algorithm used. Although the vast majority of data comparing al-
gorithms came from image-based evaluations there is no reason to
suggest that the relative accuracy of different approaches to diag-
nosis would vary according to whether the evaluation was image-
based as opposed to in person, even if in absolute terms accuracy
was higher for the latter group of studies.
In this instance, we were able to pool data separately according to
algorithm and threshold used, therefore we used the bivariate nor-
malmodel rather than the summaryROCapproach. For in-person
evaluations most of the data related to no algorithm (8 datasets),
to pattern analysis (6 datasets), or to the ABCD approach at a
threshold of above 5.45 (5 datasets). Test sensitivities and specifici-
ties were broadly similar for no algorithm (88% (95% CI 75% to
95%), and 87% (95% CI 80% to 92%)), and for pattern analysis
(92% (95% CI 87% to 95%), and 92% (95% CI 68% to 98%));
use of the ABCD algorithm produced similar specificity (92%,
95%CI 82% to 97%), but lower sensitivity (81%, 95%CI 62% to
92%), although confidence intervals were wide and overlapping.
At themedian prevalence ofmelanoma of 12%observed across the
in-person evaluations, the number of melanomas missed per 1000
lesions tested ranged between 10 and 23 with false-positive results
of 70 to 114 (Summary of findings). For image-based evaluations,
test sensitivities and specificities were again broadly similar for no
algorithm (76% (95% CI 70% to 82%), and 79% (95% CI 71%
to 85%)), and for pattern analysis (83% (95% CI 76% to 88%),
and 87% 95% CI 80% to 92%)). The formal algorithms with the
most data included ABCD at above 5.45 (7 datasets), the seven-
point checklist at 3 or above (11 datasets), and the three-point
checklist (7 datasets). Sensitivities were broadly similar with over-
lapping confidence intervals (ranging from 74% to 81%), with
generally lower specificities but again with overlapping confidence
intervals (summary estimates ranging from 60% to 81%). At the
median prevalence of melanoma of 24% observed across the im-
age-based evaluations, the number of melanomas missed per 1000
lesions tested ranged between 41 and 62 with false-positive re-
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sults of 61 for no algorithm to 304 for the three-point checklist
(Summary of findings).
The lack of reporting of diagnostic thresholds in the studies that
did not use algorithms to assist diagnosis (’no algorithm’ studies),
means that we have not been able to clearly compare accuracy for
the diagnosis of melanoma in comparison to a clinician’s decision
to excise a skin lesion; the latter perhaps being more clinically rel-
evant in practice. Data from image-based studies appear to show
similar sensitivity for correct diagnosis of melanoma and for the
decision to excise a lesion but considerably lower specificity for
the decision to excise a lesion, when the target condition was de-
fined as melanoma or atypical intraepidermal melanocytic vari-
ants. For the target condition of any skin cancer or lesion with a
high risk of progression tomelanoma, sensitivities and specificities
were both over 90% in three of the four studies reporting data
for dermoscopy added to in-person visual inspection, suggesting
that clinicians may be better at identifying skin lesions that re-
quire some intervention than at correctly identifying melanomas,
however the data are too limited to allow us to draw strong con-
clusions.
5) Observer expertise and training in dermoscopy improves diag-
nostic accuracy
Observer experience and expertise in using dermoscopy to assess
pigmented lesions is likely to have an impact on test accuracy,
however this information was often not provided in great detail,
particularly for the in-person evaluations. We made broad classi-
fications of reported experience in dermoscopy and by observer
qualifications which, on the whole, led to statistically significantly
higher accuracy for observers reported as having high experience
and for those classed as ‘expert consultants’ in comparison to those
considered to have less experience in dermoscopy. Much of the
evidence for the effect of observer expertise was again provided
by image-based dermoscopy interpretations as opposed to those
conducted in person, however similar patterns were observed for
both sets of studies. Only two in-person and three image-based
studies evaluated dermoscopy in the hands of GPs; these showed
lower accuracy (RDOR 0.21 (95%CI 0.01 to 3.12), for in-person
and RDOR 0.09 (95%CI 0.04 to 0.24), for image-based studies),
than expert consultants.
Six studies assessed the effect of dermoscopy training on test ac-
curacy in a limited number of participants. Despite differences in
the type and length of training interventions, all of the six eligi-
ble evaluations resulted in increased sensitivity following training
with limited effects on specificity in five of the six studies.
Strengths and weaknesses of the review
The strengths of this review include an in-depth and comprehen-
sive electronic literature search, systematic reviewmethods includ-
ing double extraction of papers by both clinicians and method-
ologists, and contact with study authors to allow study inclusion
or clarify data. We adopted a clear analysis structure focusing on
estimating incremental gains in accuracy.We undertook a detailed
and replicable analysis of methodologic quality.
For our main analyses however, we estimated summary ROC
curves rather than average sensitivity and specificity operating
points. We took this approach to facilitate pooling across the het-
erogeneous mixture of thresholds and scoring systems, however it
does mean that quoted sensitivities and specificities are at best il-
lustrative and do not reflect the actual performance of dermoscopy.
As a result, although we can assess the incremental gain from der-
moscopy added to visual inspection, we cannot make any clear
recommendations regarding how dermoscopy should be used in
order to ensure that melanomas are not missed.
In comparison to other available systematic reviews, our review ex-
tends the time period searched for eligible studies, and includes all
eligible studies regardless of availability of a direct comparisonwith
visual inspection alone (Vestergaard 2008), requirement for an al-
gorithm or ‘clinical prediction rule’ (Harrington 2017), or focus
on specific healthcare professionals or study settings (Corbo 2012;
Herschorn 2012; Loescher 2011). Our review of a single large lit-
erature search and concurrent systematic review of a number of
other tests for the diagnosis of melanoma has led to the identifi-
cation of additional dermoscopy datasets and inclusion of a much
greater of number of studies (i.e. 104 compared to 23 in Rajpara
2009; nine in Vestergaard 2008; and 43 in Harrington 2017). We
also explicitly considered whether diagnoses were made based on
dermoscopic images or were conducted in person and considered
variations in the definition of the target condition. Most impor-
tantly perhaps, our review considers the accuracy of dermoscopy
both in comparison to visual inspection and for diagnosis with
and without the use of a formal algorithm. As for considerations of
the accuracy of visual inspection of a lesion per se (Dinnes 2018a),
unless the accuracy of diagnostic decisions made without the use
of a formal algorithm can be established, the added contribution
of such algorithms cannot be fully understood.
Our stringent application of review inclusion criteria meant that
we excluded some studies included in previous reviews. For ex-
ample, those reporting accuracy data for ‘clinical diagnosis’, where
dermoscopy may or may not have been used to assist diagnosis,
were not included. Of the nine studies included in the Vestergaard
2008 review, we excluded two due to the inclusion of fewer than
five melanomas (Carli 2003c; Carli 2004a), and of the 23 in
Rajpara 2009 we excluded one due lack of clarity on the 2x2 con-
tingency table (Ascierto 2000). We also excluded seven of the 43
studies included in the Harrington review due to lack of clear data
to construct a 2x2 contingency table (Argenziano 2003), or re-
porting of data in brief letter format (Blum 2004c; Strumia 2003),
the serial use of the algorithm in the context of lesion follow-up
(Buhl 2012), the derivation aspect to the study (Henning 2008;
MacKie 2002), or diagnosis by laypersons (Luttrell 2012).
The main concerns for the review are a result of the poor re-
porting of primary studies, in particular limiting assessment of
methodological quality, and limiting both the assessment of stud-
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ies by prior testing of participants and by observer expertise in der-
moscopy. Our review of visual inspection alone for the diagnosis
of melanoma identified a general trade-off between sensitivity and
specificity along the clinical pathway, with higher sensitivity and
lower specificity in limited prior testing studies compared to those
in referred populations (Dinnes 2018a). The lack of data from
limited prior testing populations in this review and the lack of
detailed information on the prior testing of participants included
in referred populations meant that we could not derive any clear
patterns in sensitivity or specificity.We did identify some evidence
of higher accuracy by more specialist or experienced observers,
however, better study descriptions of observers would assist such
investigations.
Applicability of findings to the review question
There are clear concerns regarding the clinical applicability of stud-
ies included in this review. Approximately three-quarters of studies
only provided data from evaluations of dermoscopic images (with
or without data from visual inspection of clinical photographs),
such that resulting accuracy estimates cannot be extrapolated to
in-person assessments of skin lesions. Furthermore, almost all in-
person evaluations of dermoscopy used in conjunction with visual
inspection had high concerns for the applicability of the included
population and half had high concern for the applicability of the
test. The restriction of including only excised lesions and the small
number of studies conducted in a limited prior testing population
mean that our results cannot be extrapolated to a primary care
population.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Due to methodological limitations of the included studies and
heterogeneity in study methods and results, we cannot explicitly
estimate the sensitivity and specificity of dermoscopy, either with
or without visual inspection, however, we can conclude that the
incremental benefit of dermoscopy over and above visual inspec-
tion alone is consistent and considerable. Dermoscopy is there-
fore a valuable tool to support visual inspection of a suspicious
skin lesion for the detection of melanoma and atypical intraepi-
dermal melanocytic variants, particularly in referred populations
and in the hands of experienced users. Data to support its use in
a primary care population are limited; however, it is likely to be
of some benefit for triaging suspicious lesions for urgent referral
when employed by suitably trained clinicians. Overall, the use of
formal algorithms to assist diagnosis does not appear to improve
accuracy, however, neither is there sufficient evidence to suggest
that the ‘no algorithm’ approach should be preferred in all settings.
Formal algorithms may be more useful for dermoscopy training
purposes and for less expert observers, however reliable data from
in-person evaluations of dermoscopy are lacking.
Implications for research
Given the vast volume of research that has been funded to evaluate
dermoscopy, further research into the added value of established
dermoscopy algorithms per se is unlikely to be warranted. Further
evaluation of dermoscopy use in the primary care setting and to
identify the optimal approach to dermoscopy training may be war-
ranted, however. Such evaluations should be conducted on an in-
person basis with prospective recruitment of consecutive series of
participants and with systematic follow-up of non-excised lesions
to avoid over-reliance on a histological reference standard. A clear
identification of the level of training and experience required to
achieve good results is required. Any future research study needs
to be clear about the diagnostic pathway followed by study partic-
ipants prior to study enrolment, and should conform to the up-
dated Standards for Reporting of Diagnostic Accuracy (STARD)
guideline (Bossuyt 2015).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ahnlide 2016
Study characteristics
Patient sampling Study design: case series
Data collection: retrospective
Period of data collection: 7 March 2013-28 April 2014
Country: Sweden
Patient characteristics and set-
ting
Inclusion criteria: excised melanocytic skin lesions with recorded dermoscopy ABCD score and
clinician’s preliminary diagnosis
Setting: secondary (general dermatology)
Prior testing: clinical and/or dermatoscopic suspicion
Setting for prior testing: secondary (general dermatology)
Exclusion criteria: previously biopsied lesions andwide excisions not included; other exclusion prior
to enrolment included: invalid report or missing data (n = 34); visiting residents’ data (n = 66); non-
melanocytic on histology or benign melanocytic lesions with special patterns (e.g. papillomatous,
congenital naevi and mucosal lesions) (n = 658)
Sample size (participants): NR
Sample size (lesions): number eligible: 1135/number included: 309
Participant characteristics: NR
Lesion characteristics: NR
Index tests Dermoscopy: no algorithm (clinician’s preliminary diagnosis); ABCD
Method of diagnosis: in-person diagnosis
Prior test data: clinical examination and/or case notes
Diagnostic threshold: ABCD > 4.75 or > 5.45 (calculated automatically based on clinician scoring
presence/absence of ABCD criteria into computerised patient file)
Preliminary preoperative diagnosis was based on physical examination and dermoscopic assessment
(including application of ABCD algorithm)
Diagnosis based on: single observer (n = 13)
Observer qualifications: dermatology residents (n = 6; “residents were encouraged to consult the
specialists in difficult cases”); dermatologists (n = 7)
Experience in practice: not described
Experience with dermoscopy: NR per observer, but assumed High given training described; de-
scribe use of dermoscopy and ABCD at department for > 10 years; reports “repeated joint feed-
back sessions evaluating the preoperative dermoscopy photographs of excised lesions, enrolment in
dermoscopy courses for both residents and senior consultants and daily continuous education in
dermoscopy for residents.”
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone; histopathological diagnosis was recorded postop-
eratively in the patient file by a nurse
Disease-positive: 46; disease-negative: 263
Target condition (final diagnoses)
Melanoma (invasive): 23; melanoma (in situ): 23
Benign naevus: 263
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Ahnlide 2016 (Continued)
Flow and timing Excluded participants: missing scoring (n = 57); wrongly scored due to pre-op non-melanocytic
diagnosis (n = 5); lesions with preliminary diagnosis of lentigo maligna or SN (n = 5); ambiguous
histology (n = 1)
Time interval to reference test:NR - but likely consecutively as dermoscopywas used preoperatively
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
High High
DOMAIN 2: Index Test Dermoscopy - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
No
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Ahnlide 2016 (Continued)
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
89Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Ahnlide 2016 (Continued)
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Yes
High
Alarcon 2014
Study characteristics
Patient sampling Study design: case series
Data collection: prospective; dermoscopic images assessed remotely from the patient
Period of data collection: 1 June 2011-30 May 2012; 1 year
Country: Spain
Patient characteristics and set-
ting
Inclusion criteria: dermoscopically equivocal pigmented lesions, assumed to be melanocytic, seen
at Melanoma Unit
Setting: specialist unit (skin cancer/PLC), Melanoma Unit of the Hospital Clinic of Barcelona
Prior testing: dermatoscopic suspicion in all cases
Setting for prior testing: specialist unit (skin cancer/PLC)
Exclusion criteria: non-melanocytic appearance
Sample size (participants): number eligible: unclear/number included: 264
Sample size (lesions): number eligible: 343/number included: 264
Participant characteristics: median age (years): 54.7 (8-89 years); 51.5% male
Lesion characteristics: Fitzpatrick phototype: I-II, 42%; III-IV, 50%; lesion site: head/neck: 73;
27.7%; trunk: 135; 51.1%; limbs: 49; 18.6%; describe if other 7; 7% (acral). Lesion thickness: ≤
1 mm: 86 of 92 melanoma
Index tests Dermoscopy: no algorithm
Method of diagnosis: dermoscopic images
Prior test data: clinical examination and/or case notes - lesion site and age provided + RCM images.
Dermoscopy and RCM interpretation appear to have been conducted by same observer with no
indication of blinding
Diagnostic threshold: NR; no details
Diagnosis based on: single observer (n = 3)
Observer qualifications: dermatologist. All the images were interpreted independently by 1/3
dermatologists with expertise in RCM
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Experience in practice: not described
Experience with dermoscopy: assumed High experience; 3 dermatologists with expertise in RCM
Any other detail: all of the lesions were imaged with a digital camera (Canon PowerShot G10;
Canon, Tokyo, Japan) and a high-resolution dermatoscope dermatoscope (DermLite Photo; 3Gen
LLC, Dana Point, CA, USA)
Target condition and reference
standard(s)
Reference standard: histological diagnosis + follow-up
Histology (n = 264); follow-up (n = 79); selection for excision based on RCM diagnosis otherwise
all would have been excised
Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 92; BCC: 12
Benign naevus: 107; 53 SK and AK
Flow and timing Excluded participants: none reported
Time interval for reference: appears consecutive; “Data regarding age, sex, anatomical location,
melanoma risk factors and dermoscopic diagnosis were collected before the RCM examination and
histopathological analyses were performed”
Time interval between index test(s): not specified but appears consecutive application of der-
moscopy and RCM
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
Low High
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DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
Yes
92Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Alarcon 2014 (Continued)
matopathologist?
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
Annessi 2007
Study characteristics
Patient sampling Study design: case series
Data collection: NR
Period of data collection: December 2004-June 2006
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: consecutive atypical macular melanocytic lesions; all > 5 mm in diameter, with
a flat or barely elevated surface and at least 3 of the following features: (a) asymmetry, (b) irregular
margins, (c) ill-defined borders, and (d) colour variegation
Setting: specialist unit (skin cancer/PLC)
Prior testing: clinical suspicion of malignancy without dermatoscopic suspicion
Setting for prior testing: specialist unit (skin cancer/PLC)
Exclusion criteria: none reported
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Sample size (participants): number included: 195
Sample size (lesions): number included: 198
Participant characteristics: mean age: 43 years; male: (106 men) 54%
Lesion characteristics: all ≤ 1 mm thickness; mean 0.3 mm; all > 5 mm diameter
Index tests Dermoscopy: pattern analysis; 7PCL; ABCD
Method of diagnosis: dermoscopic images
Prior test data: unclear; clinical and ELM digital images taken but unclear what was actually
presented to observers
Diagnostic threshold: reported only for ABCD; melanocytic lesions with ABCD scores 4.76-5.45
(suspect lesions) were considered test-positive
Diagnosis based on: consensus (n = 2)
Observer qualifications: described as “ELM-experienced dermatologists”
Experience in practice: high experience or ’expert’
Experience with dermoscopy: high experience /‘expert’ users
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone; conducted in dermatopathology laboratory
Disease-positive: 96; disease-negative: 102
Target condition (final diagnoses)
Melanoma (invasive): 72; melanoma (in situ): 24
Benign naevi: 102 - described as Clark’s melanocytic naevi (68 junctional and 34 compound)
Flow and timing Excluded participants: none described
Time interval to reference test: appears consecutive; “After ELMassessment, all lesionswere excised
and processed for routine histopathologic examination”
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
No
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Did the study avoid including
participants with multiple le-
sions?
Yes
Low High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Unclear
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
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Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
Unclear
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Low
Arevalo 2008
Study characteristics
Patient sampling Study design: case series
Data collection: retrospective image selection/prospective interpretation
Period of data collection: no time period given just states lesions evaluated since 1991
Country: Australia
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Patient characteristics and set-
ting
Inclusion criteria: melanocytic lesions imaged at the SydneyMelanomaUnit with a histopathologic
diagnosis or that remained unchanged following short-term (4.5-5 months) digital monitoring
(diagnosed as benign)
Setting: specialist unit (skin cancer/PLC)
Prior testing: selected for excision (no further detail); changes on digital monitoring
Setting for prior testing: NR
Exclusion criteria: lentigo maligna and lentigo malignant melanoma
Sample size (participants): NR
Sample size (lesions): number eligible: 3367 melanocytic lesions/number included: 3367
Participant characteristics: NR
Lesion characteristics NR
Index tests Dermoscopy:Menzies criteria
Method of diagnosis: dermoscopic images
Prior test data: no further information used
Diagnostic threshold: lesion must have none of the 2 negative features of symmetry of pattern
or single colour, and must have ≥ 1 of the following 9 positive features of melanoma; blue-white
veil, pseudopods, radial streaming, peripheral black dots or globules, multiple brown dots, multiple
blue-grey dots, scar-like depigmentation, broadened network and multiple colours
Diagnosis based on: unclear; appears to be consensus (n = 2); all lesions scored independently by
2 observers blinded to the diagnosis, with referral to a 3rd observer if there was a disagreement
Observer qualifications: NR; likely dermatologists
Experience in practice: not described
Experience with dermoscopy: not described
Any other detail: the images were obtained using a dermoscopic camera (Dermaphot; Heine Ltd)
or a digital imaging device (Solarscan)
Target condition and reference
standard(s)
Reference standard: histological diagnosis + follow-up
Further details: not described in detail; only included lesions with histopathology or those that
remained unchanged following short-term (2.5-4.5 months)
Target condition (final diagnoses)
Melanoma (invasive): 341
’Benign’ diagnoses: 3026
Flow and timing Excluded participants: poor-quality index test image as exclusion criterion
Time interval to reference test: NR
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
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Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
High High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Low High
DOMAIN 3: Reference Standard
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Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
No
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
No
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
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Study characteristics
Patient sampling Study design: unclear
Data collection: retrospective image selection/prospective interpretation
Period of data collection: NR
Country: Italy
Test set derived: 342 lesions were randomly divided into a training set of 57 CMs and 139 MN
and a test set of 60 CMs and 86 MN
Patient characteristics and set-
ting
Inclusion criteria: atypical melanocytic skin lesions with dermoscopic images that had undergone
biopsy due to clinician suspicion
Setting: NR
Prior testing: dermatoscopic suspicion in all cases
Setting for prior testing: secondary (general dermatology)
Exclusion criteria: none reported
Sample size (participants): NR
Sample size (lesions): number eligible: 342/number included: 342
Participant characteristics: NR
Lesion characteristics: lesion thickness ≤ 1 mm: 28%; 68 CMs < 0.76 mm; 49 CMs > 0.75 mm
Index tests Dermoscopy: pattern analysis (not described but classified by clinical reviewer); 7PCL (derived and
evaluated in this study); ABCD
Method of diagnosis: dermoscopic images; in vivo photography as x10 magnification with special
photography equipment after being covered in immersion oil
Prior test data: no further information used; “In a blind study”- implies no information beyond
the dermoscopic images available
Diagnostic threshold: pattern analysis - ’overall ELM diagnosis; ’ABCD - Score > 4.75; 7PCL -
Score of 3 or more
Diagnosis based on: single (n = 2; less experienced observers) and Consensus (2 observers) (n = 3;
ELM-experienced observers)
Observer qualifications: dermatologist
Experience in practice: not described.
Experience with dermoscopy: high experience - 3 ELM-experienced; moderate/trained - less ex-
perienced dermatologists (who underwent “short formal ELM training of 9 hours”)
Any other detail: Training set used to derive 7PCL. Initially two models were developed. One using
multivariate analysis to create a formula for calculating the probability of each lesion belonging
to the group of melanomas but was deemed too complex for clinical use. The second model used
the odds ratios (ORs) from the multivariate analysis to create a simpler diagnostic method based
on identification of major and minor ELM criteria. A score of 2 was given to the 3 criteria with
ORs> 5 (major criteria) and a score of 1 was given to the 4 criteria with OR< 5 (minor criteria)
; a total score of 3 or more set to identify melanoma. Major criteria included atypical pigment
network (presence of an irregular and prominent pigment network), grey-blue areas and atypical
vascular pattern. Minor criteria: streaks, blotches, irregular dots and globules, and regression pattern
(presence of white areas or peppering)
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone (not further described)
Disease-positive: 117; disease-negative: 225
Target condition (final diagnoses)
Melanoma (invasive): 99; melanoma (in situ): 18
’Benign’ diagnoses: 114 atypical naevi; 111 common naevi
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Flow and timing Excluded participants: none reported
Time interval to reference test: NR
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Unclear
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Unclear High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Unclear
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Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
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If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Yes
Unclear
Argenziano 2006
Study characteristics
Patient sampling Study design: RCT allocating primary care physicians to use either VI alone or VI + dermoscopy
(only excised lesions can be included for each arm)
Data collection: prospective
Period of data collection: May 2003-September 2004
Country: Italy and Spain
Patient characteristics and set-
ting
Inclusion criteria: patients asking for screening or exhibiting ≥ 1 skin tumours as seen during
routine physical examination (patient-finding screening) were considered for inclusion; those un-
dergoing excision were included in this review (i.e. those deemed sufficiently suspicious by the ex-
pert evaluation). PCPs were invited to participate in the trial; only those who attended the training
sessions and who then screened patients and referred them to the PLCs were randomised
Setting: primary
Prior testing: no prior testing
Setting for prior testing: N/A
Exclusion criteria: NR
Sample size (participants): number eligible: 3271 patients screened; 1325 participants allocated
to ’Naked Eye’ observation and 1197 participants allocated to dermoscopy observation; number
included: 162 received histology after expert evaluation at the PLC
Sample size (lesions): 85 in VI arm and 77 in dermoscopy arm underwent excision
Participant characteristics: based on full sample: mean age 40, range 2-90 (VI group)/41, range
3-94 (dermoscopy group). Male: 498 (38%) VI group/451 (38%) dermoscopy
Lesion characteristics NR
Index tests VI: ABCD (control arm of RCT)
Method of diagnosis: in-person diagnosis
Prior test data: N/A in-person diagnosis
Diagnostic threshold: qualitative NR; described in Intro as: simple morphologic features sum-
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marised by the asymmetry, border irregularity, colour variegation, and diameter 5 mm (ABCD)
Diagnosis based on: average (n = 37)
Observer qualifications: primary care physicians
Experience in practice: not described
Experience with dermoscopy: not described
Other detail: pre-randomisation all participating PCPs underwent training in ABCD rule for
clinical diagnosis and 3PCL for dermoscopy (see below)
Dermoscopy: 3-point rule (intervention arm of RCT)
Method of diagnosis: in-person diagnosis
Prior test data: N/A in-person diagnosis
Diagnostic threshold: ≥ 2 characteristics present (algorithm is based on the recognition of only
3 individual features: dermoscopic asymmetry (in colour and/or structure, not in shape), atypical
network (pigmented network with thick lines and irregular distribution), and blue-white structures
(presence of any blue and/or white colour within the lesion). Each PCP in both groups examined
the individual lesions and scored the patient outcome, as banal or suggestive of skin cancer
Diagnosis based on: average (n = 36)
Observer qualifications: primary care physicians
Experience in practice: not described
Experience with dermoscopy: not described
Dermoscopy training: all PCPs received training (2 hour session) on the clinical ABCD rule for
diagnosis of melanoma, basic recognition of non-melanoma skin cancers including BCC and SCC
+ a 2 hour session describing the dermoscopy 3PCL
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
All lesions considered suggestive of skin cancer at the PLC were excised and subsequently diagnosed
histopathologically. Equivocal lesions by histopathologic examination were reviewed by a second
independent pathologist and a final diagnosis made.
Disease-positive: 92 malignant tumours; disease-negative: 70 benign tumours
Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 12; BCC: 66; cSCC: 14
Sebhorrheic keratosis: 13; melanocytic naevi = 51; other: 6
Flow and timing Excluded participants: only those participants who were considered to have lesions suggestive of
skin cancer had histology and were included. All the rest had expert diagnosis (not included in the
final 2x2 data extracted)
Time interval to reference test: NR
Time interval between index test(s): N/A (RCT)
Comparative RCT examining effect of making dermoscopy available to primary care practitioners
Blinding between tests: randomised comparison
Time interval between index test(s): N/A tests used in different participants
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
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Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Unclear High
DOMAIN 2: Index Test Visual Inspection - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Low High
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DOMAIN 2: Index Test Dermoscopy - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
Yes
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matopathologist?
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
DOMAIN 5: Comparative
Was each index test result in-
terpreted without knowledge of
the results of other index tests
or testing strategies?
Yes
Was the interval between ap-
plication of the index tests less
than one month?
Yes
Were all tests applied and inter-
preted in a clinically applicable
manner?
Yes
Low Low
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Study characteristics
Patient sampling Study design: case-control
Data collection: retrospective
Period of data collection: 2006-2008
Country: Naples, Italy
Patient characteristics and set-
ting
Inclusion criteria: randomly sampled 100 melanomas and 100 excised melanocytic naevi from a
digital collection of lesions screened 2006-2008 at the Department of Dermatology of the Second
University of Naples; also randomly sampled 100melanocytic naevi that showed no relevant changes
to warrant excision during the follow-up period from a larger database of monitored naevi
Setting: secondary (general dermatology)
Prior testing: retrospective study of a random sample of dermoscopic images collected in depart-
mental database. 100/349 excised melanomas 100/1512 excised naevi
Setting for prior testing: NR
Exclusion criteria: excluded non-melanocytic lesions, lesions on certain anatomical sites (facial,
acral, mucosal and nail lesions), lesions > 15 mm, and lesions with conflicting histopathological
features
Sample size (participants): NR
Sample size (lesions): number included: 300
Participant characteristics: NR
Lesion characteristics: NR
Index tests Dermoscopy: pattern analysis; 7PCL; revised 7PCL
Method of diagnosis: dermoscopic images
Prior test data: no further information used; “No additional information was provided, to avoid
the possible bias that clinical information may give to the assessment on morphological criteria.”
Diagnostic threshold: pattern analysis - classify as naevus/melanoma/or lesion to be excised. 7PCL
- individual criteria scored. Original 7-point-score ≥ 3 merits excision (based on 3 major criteria
with 2 points each (atypical network, blue-white veil and atypical vascular pattern) and 4 minor
criteria with 1 point each (irregular dots/globules, irregular streaks, irregular blotches and regression
structures). Revised 7PCL: score ≥ 1 merits excision (each criterion is given a score of 1 point)
Diagnosis based on: average; (n = 8)
Observer qualifications: dermatologist
Experience in practice: high; “Experienced dermatologists”
Experience with dermoscopy: high; dermatologists specifically trained in dermoscopy
Target condition and reference
standard(s)
Reference standard: histological diagnosis + follow-up; 200/300 had histology. 100/300 were naevi
that had been followed up 1-3 years (median 22 months; range 1-3 years)
Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 100; not clear if in situ included
Excised naevi included: 57 Clark naevi, 28 SN, 10 small congenital naevi and 5 blue naevi
The remaining 100 monitored lesions were reported as 74 reticular naevi and 26 globular naevi
Flow and timing Excluded participants: none reported
Time interval to reference test: unknown
Comparative
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Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
High High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Unclear
Was the test applied and inter-
preted in a clinically applicable
manner?
No
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Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
High Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
Yes
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of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
High
Ascierto 2010
Study characteristics
Patient sampling Study design: case series
Data collection: prospective
Period of data collection: NR (states in a period of 1 year)
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: clinically relevant cutaneous pigmented lesions, undergoing dermoscopy and
excision; only melanocytic lesions meeting ≥ 2 clinical ABCDE criteria underwent dermoscopy
Setting: specialist unit (skin cancer/PLC)
Prior testing: clinical examination with ABCDE
Setting for prior testing: specialist unit (skin cancer/PLC)
Exclusion criteria: none reported
Sample size (participants): number eligible: 54/number included: 54
Sample size (lesions): NR
Participant characteristics: median age 41 (19-73 years); 19 men
Lesion characteristics NR
Index tests Dermoscopy: risk stratification (modified Kenet 1994)
Method of diagnosis: in-person diagnosis; all participants underwent total body skin examination
Prior test data: clinical examination and/or case notes
Diagnostic threshold: very high risk; lesion with a pigment network and any of the classical ELM
features specific for melanoma (pseudopods, radial streaming, blue-grey veil, atypical vessel, etc.).
High risk: lesion with a pigment network and subtle new ELM features that may suggest melanoma
but often are also seen in atypical naevi
Diagnosis based on: unclear, assumed single observer per participant (n = 3)
Observer qualifications: dermatologist
Experience in practice: high; “evaluations made by expert dermatologists (at least 3 years of expe-
rience)”
Experience with dermoscopy: assumed high
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone (not further described)
Disease-positive: 12 MM; disease-negative: 42
Target condition (final diagnoses)
Melanoma (invasive) 12
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’Benign’ diagnoses: 42
Flow and timing Exclusions: none reported
Time interval to reference test: “Before surgery, all patients were investigated by clinical and
epiluminescence microscopy (ELM) screenings”
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
Unclear High
DOMAIN 2: Index Test Dermoscopy - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
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out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
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If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Low
Bauer 2000
Study characteristics
Patient sampling Study design: case series
Data collection: NR. Appears retrospective
Period of data collection: January 1996-February 1997
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: PSLs examined and excised during a campaign for the early diagnosis of cuta-
neous melanoma (CM)
Setting: secondary (general dermatology); from authors’ institution
Prior testing: NR ”campaign for the early diagnosis of cutaneous melanoma (CM)“
Setting for prior testing: NR
Exclusion criteria: none reported
Sample size (participants): number included: 311
Sample size (lesions): number included: 315
Participant characteristics: NR
Lesion characteristics: thickness: 14 < 0.75 mm, 10 0.75-1.5 mm, and 6 > 1.5 mm (n = 42
melanoma)
Index tests Dermoscopy: no algorithm; possibly based on pattern analysis
Method of diagnosis: in-person diagnosis
Prior test data: clinical examination based on ABCD
Diagnostic threshold: presence of malignancy; ELM parameters considered included irregular and
multi component pigmentary network pattern, peripheral dark network patches, sharp network
margin, pseudopods, radial streaming, blue-grey areas, pigment dots (blotches, black dots, brown
globules), black dots at periphery, whitish veil, depigmentation and hypopigmented areas, erythema,
telangiectasia, comedo-like openings, milia-like cysts, red-blue areas
Diagnosis based on: consensus (3 observers) ”diagnosis was made by consensus amongst the der-
matologists (Stanganelli 2005) ... when they disagreed a fourth dermatologist, an expert in the
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diagnosis of PSLs, was consulted.“; n = 4
Observer qualifications: dermatologist
Experience in practice: not described
Experience with dermoscopy: assumed high - all dermatologists were ”trained in the recognition
of PSLs during a training course on the clinical diagnosis of naevi and melanomas“; with referral of
disagreements to PSL expert
Also evaluates a CAD-based test not included in this review
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone (not further described)
Disease-positive: 42; disease-negative: 273
Target condition (final diagnoses)
Melanoma (invasive): 30; melanoma (in situ): 12
Severe dysplasia: 25 ’atypical’ dysplastic; benign naevus: 212; 36 nonmelanocytic
Flow and timing Particpant exclusions: none reported
Index test to reference standard interval: after diagnosis, ”all lesions were then excised and exam-
ined histologically
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
Unclear High
DOMAIN 2: Index Test Dermoscopy - in-person
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Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
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Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Low
Benelli 1999
Study characteristics
Patient sampling Study design: case series
Data collection: prospective
Period of data collection: 1 September 1997-30 September 1998
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: all PSLs observed and excised at the Dermatologic Surgery Department
Setting: Dermatologic Surgery Department
Prior testing: selected for excision (no further detail)
Setting for prior testing: Dermatologic Surgery Department
Exclusion criteria: none reported
Sample size (participants): NR
Sample size (lesions): number included: 401
Participant characteristics: NR
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Lesion characteristics: thickness 42, < 0.75 mm thick; 80, 0.76 to 1.5 mm thick; 4, 1.5 to 4 mm
thick (mean 0.60 mm, median 0.55 mm. max 1.9 mm, min 0.10 mm, SD 0.45)
Index tests VI: ABCDE
Method of diagnosis: in-person diagnosis
Prior test data: N/A in-person diagnosis
Diagnostic threshold: data given for accuracy of each potential score (1-5); score estimation de-
scribed in detail
Diagnosis based on: consensus (2 observers) n = 2
Observer qualifications: dermatologist
Experience in practice: not described
Experience with dermoscopy: not described
Dermoscopy 7FFM
Method of diagnosis: in-person diagnosis
Prior test data: clinical and dermoscopic evaluations made in person by 2 dermatologists prior to
excision. Decision to excise the lesions was taken prior to this by 3 different dermatologists
Diagnostic threshold: 2x2 available for 77FM on its own, and for 77FM + each of 5 clinical
features, and also for 77FM + each of 5 clinical scores (1-5); score estimation described in detail
Test observers as described for VI (above)
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Disease-positive: 60 (15%) lesions; disease-negative: 340 (non-melanoma) + 1 BCC
Target condition (final diagnoses)
Melanoma (invasive): 54 (13.5%); melanoma (in situ): 6 (1.5%); BCC: 1 (0.4%)
Sebhorrheic keratosis: 1 (0.4%); melanocytic naevi: 316; epithelioid and/or spindle cell naevi: 18
(4.5%); LS: 5 (1.2%)
Flow and timing Excluded participants: NR
Time interval to reference test: same day
Comparative Blinding between tests: clinical and dermoscopic evaluations made in person by 2 dermatologists
prior to excision
Time interval between index test(s): same day
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
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Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Unclear High
DOMAIN 2: Index Test Visual Inspection - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
High High
DOMAIN 2: Index Test Dermoscopy - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
Yes
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dard?
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
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Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Low
DOMAIN 5: Comparative
Was each index test result in-
terpreted without knowledge of
the results of other index tests
or testing strategies?
No
Was the interval between ap-
plication of the index tests less
than one month?
Yes
Were all tests applied and inter-
preted in a clinically applicable
manner?
No
Low High
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Study characteristics
Patient sampling Study design: case-control
Data collection: retrospective image selection/prospective interpretation
Period of data collection: January 1993-December 1998 (melanomas); September 1997-Septem-
ber 1999 (melanocytic naevi)
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: all small (≤ 6 mm)melanomas and melanocytic naevi consecutively excised over
2 different time periods
Setting: secondary (general dermatology)
Prior testing: NR; all excised
Setting for prior testing: NR
Exclusion criteria: size > 6 mm
Sample size (participants): NR
Sample size (lesions): 600
Participant characteristics: mean age 44 years (range 20-79)
Lesion characteristics: NR
Index tests VI: ABCDE
Method of diagnosis: image-based
Prior test data: unclear whether dermoscopic image also shown at same time
Diagnostic threshold: ≥ 2 characteristics present
Diagnosis based on: consensus of 3 (evaluated by 3 different observers; in case of disagreement,
the majority view prevailed)
Observer qualifications: dermatologist (assumed from authors’ institution)
Experience in practice: NR
Experience with dermoscopy: NR
Dermoscopy: 7FFM
Method of diagnosis: image-based
Prior test data: unclear whether clinical image also shown at same time
Diagnostic threshold: ≥ 2
Test observers: as described for VI (above)
Target condition and reference
standard(s)
Reference standard: histology alone; no further details
Target condition (final diagnoses)
Melanoma (invasive or in situ) 76 (8/468 melanomas in full sample were in situ; NR for ≤ 6 mm
group)
Benign naevi 524
Flow and timing Excluded participants: none reported
Time interval to reference test: NR
Comparative Blinding between tests: unclear whether images shown at same time
Time interval between index test(s): image capture not described
Notes -
Methodological quality
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Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
High High
DOMAIN 2: Index Test Visual inspection - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
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Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Low High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
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Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
DOMAIN 5: Comparative
Was each index test result in-
terpreted without knowledge of
the results of other index tests
or testing strategies?
Unclear
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Was the interval between ap-
plication of the index tests less
than one month?
Unclear
Were all tests applied and inter-
preted in a clinically applicable
manner?
Unclear
Benelli 2001
Study characteristics
Patient sampling Study design: case series
Data collection: retrospective image selection/prospective interpretation
Period of data collection: NR - only dates of training course and agreement study given (April-
May 1999)
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: slides of pigmented skin tumours were selected for evaluation during a training
course on dermoscopy. Lesions not located on head, palms or soles histological slide available
Setting: training images; authors’ institution. Institute of Dermatologic Sciences, University of
Milan
Prior testing: slides of pigmented skin tumours were selected for evaluation during a training course
on dermoscopy
Setting for prior testing: unspecified
Exclusion criteria: none reported
Sample size (participants): NR
Sample size (lesions): number included: 49 (paper reports 50 but only 49 accounted for in text)
Participant characteristics: none reported
Lesion characteristics: none reported
Index tests VI: ABCDE
Method of diagnosis: clinical photographs
Prior test data: no further information used
Diagnostic threshold: ABCDE Score ≥ 2; presence of 2 criteria; ABCDE Score ≥ 3; presence of
3 criteria. All criteria described in full
Diagnosis based on: single (n = 1); average (n = 65; attending 1/3 courses in dermoscopy held to
inform dermatologists about a new dermatoscopic diagnostic method (7FFM))
Observer qualifications: dermatologists
Experience in practice: expert author; not described for participating dermatologists
Experience with dermoscopy: expert author; prior experience not described for participating der-
matologists; all underwent dermoscopy training for study purposes
Dermoscopy: 7FFM
Method of diagnosis: dermoscopic images
Prior test data: no further information used although clinicians had evaluated clinical images for
the same 50 lesions earlier the same day
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Diagnostic threshold: malignant if 7FFM Score≥ 2; i.e. presence of 1 major feature or concurrent
presence of 2 minor features. All criteria described in full
Test observers: as described for VI (above)
Dermoscopy training: 3 one-day dermatoscopy courses held to inform dermatologists about au-
thors’ own new dermoscopy algorithm (7FFM). Each course lasted 6 hours. Morning session par-
ticipants executed pre-test interpretation of clinical images using ABCDE. Then principles of der-
matoscopy were presented during the course and as post-test, participants evaluated 50 dermoscopic
slides of same lesions using 7FFM
Length of training 1 day (6 hours)
Post-training experience: < 6months
Training format: in-person teaching
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Disease-positive: 12/49 melanomas (paper reports 50 but only 49 accounted for in text)
Target condition (final diagnoses)
Melanoma (invasive): 10; melanoma (in situ): 2; BCC: 2 pigmented BCC
3 seborrhoeic keratoses, 2 pigmented BCC, 1 blue naevus, 2 angiokeratoma, 5 SN, 5 junctional
naevi, 9 compound naevi, 10 naevi undergoing regression
Flow and timing Excluded participants: none reported
Time interval to reference test: unclear
Comparative Blinding between tests: clinical images interpreted in the morning and dermoscopic images in the
afternoon
Time interval between index test(s): image capture NR
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
Unclear
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sions?
Unclear High
DOMAIN 2: Index Test Visual inspection - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
Unclear
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out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
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If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
DOMAIN 5: Comparative
Was each index test result in-
terpreted without knowledge of
the results of other index tests
or testing strategies?
Yes
Was the interval between ap-
plication of the index tests less
than one month?
Unclear
Were all tests applied and inter-
preted in a clinically applicable
manner?
No
Unclear High
Binder 1994
Study characteristics
Patient sampling Study design: case-control
Data collection: retrospective image selection/prospective interpretation
Period of data collection: NR
Country: Austria
Test set derived: from a sample of 200 PSL, 2 databases were randomly created for learning and
testing purposes. The database was also provided with the histological diagnosis
Patient characteristics and set-
ting
Inclusion criteria: images of PSLs randomly selected from a PSL image database
Setting: secondary (general dermatology)
Prior testing: selected for excision (no further detail)
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Setting for prior testing: NR
Exclusion criteria: none reported
Sample size (participants): NR
Sample size (lesions): NR
Participant characteristics: NR
Lesion characteristics: NR
Index tests Dermoscopy: (modified) pattern analysis
Method of diagnosis: dermoscopic images
Prior test data: no further information used; no additional clinical information was provided
Diagnostic threshold: observer correct diagnosis of melanoma; presence/absence of 8 ELM criteria
were judged (pigment network, brown globules, radial streaming, pseudopods, black dots, margin
regularity, pigmentation, depigmentation) and individual diagnosis made
Diagnosis based on: consensus (2 observers); n = 3. Images were examined independently by each
observer; presence/absence of each ELM criterion decided by agreement of at least 2/3 observers
Observer qualifications: dermatologist
Experience in practice: high experience or ’Expert’
Experience with dermoscopy: high experience - described as “ELM experienced dermatologists”
Any other detail: the images were obtained by photographing the PSL on 24 x 36 mm colour slide
film, with oil immersion, using a Wild binocular stereomicroscope M 650 (Wild Heerbrugg AG,
Switzerland) at a final magnification of x16 using flashlight illumination
Also evaluates a CAD-based test not included in this review.
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone (no further details)
Disease-positive: 40; disease-negative: 60
Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 40
Benign naevus: 60
Flow and timing Excluded participants: none reported
Time interval to reference test: NR
Time interval between index test(s): NR
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
No
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Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
High High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
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Binder 1994 (Continued)
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
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Study characteristics
Patient sampling Study design: case series
Data collection: retrospective image selection/prospective interpretation
Period of data collection: NR
Country: Austria
Patient characteristics and set-
ting
Inclusion criteria: PSLs with available dermoscopy images, both with and without oil immersion,
and histological confirmation of diagnosis
Setting: secondary (general dermatology)
Prior testing: selected for excision (no further detail)
Setting for prior testing: NR
Exclusion criteria: none reported
Sample size (participants): NR
Sample size (lesions): number included: 240
Participant characteristics: NR
Lesion characteristics: median thickness 0.7 mm, IQR 0.48-0.76 mm; all < 1 cm diameter
Index tests Dermoscopy: no algorithm
Method of diagnosis: dermoscopic images of lesions with and without oil immersion (results
with oil immersion used for primary analysis); images randomly presented to prevent consecutive
presentation of slides for the same lesion. Each image was shown for 20 seconds with a 20-minute
break after 240 slides
Prior test data: no further information presented
Diagnostic threshold: correct diagnosis of melanoma. For each PSL image only one diagnosis was
allowed (MM or not MM)
Diagnosis based on: average (n = 19); 6 ELM experts and 13 randomly picked dermatologist
’nonexperts’
Observer qualifications: dermatologist
Experience in practice: high - all certified dermatologists, experienced in clinical diagnosis
Experience with dermoscopy:mixed. ’Nonexperts’ had no formal ELM training; ‘expert’ users had
been working scientifically in the development of ELM for at least 3 years
Any other detail: images were obtained by photographing the PSLs on 24 x 36-mm colour-slide
filmwith ELM and without oil immersion (surface microscopy ISM) using a binocular stereomicro-
scope (M 650, Wild AG, Heerbrugg, Switzerland) at a final magnification of x 16 using flashlight
illumination
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone (not further described)
Disease-positive: 57; disease-negative: 183
Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 57; BCC: 8
Severe dysplasia: 42; other ’Benign’ : 133
Flow and timing Reference interval: appears consecutive; “After photographing, all lesions were excised”
Excluded participants: none reported
Comparative
Notes -
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Binder 1995 (Continued)
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Unclear High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Yes
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
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Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
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If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Low
Binder 1999
Study characteristics
Patient sampling Study design: case series
Data collection: retrospective image selection/prospective interpretation
Period of data collection: NR
Country: Austria
Patient characteristics and set-
ting
Inclusion criteria: randomly selected, histologically proven PSLs with digital dermoscopy images
Setting: secondary (general dermatology)
Prior testing: NR
Setting for prior testing: NR
Exclusion criteria: none reported
Sample size (participants): NR
Sample size (lesions): number included: 250
Participant characteristics: NR
Lesion characteristics: thickness; 7 (17%) of the 41 melanomas were in situ lesions, 24 (59%) <
0.75 mm, and 10 (24%) ranged from 0.76-1.8 mm; lesion size: all ≤ 8 mm diameter
Index tests Dermoscopy: ABCD; pattern analysis/no algorithm
Method of diagnosis: dermoscopic images
Prior test data: no further information used. Computer presented images in random order
Diagnostic threshold: ABCD classification (score > 5.45, > 4.75); sensitivity and specificity also
estimated at Q* (point where sensitivity=specificity)
Subjective diagnosis (based on certainty of melanoma between 1 and 5) also recorded using pattern
analysis (experts) or subjective rating (1st-year residents)
Diagnosis based on: average (n = 17)
Observer qualifications: dermatology residents = 5; dermatologist (board-certified) = 12
Experience in practice: mixed. 1st-year residents (n = 5); practicing board-certified dermatologists
with experience ranging from 4-15 years (n = 8), and 4 board-certified recognised as experts mainly
working at PSL units (n = 4)
Experience with dermoscopy: mixed experience “Ten of the 17 raters (58.8%) reported on previous
usage of the ABCD score, at least for testing purposes of the method.”
Dermoscopy training: written materials “Before testing all readers were instructed how to apply
the ABCD criteria according to the literature published”
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Disease-positive: 41 (16.4%) lesions; disease-negative: 209 (83.3%) lesions
Target condition (final diagnoses)
137Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Binder 1999 (Continued)
Melanoma (invasive): 34 lesions; melanoma (in situ): 7 lesions
Benign naevus: 96 nevocellular naevi of the compound type, 62 junctional type, 24 dermal type,
13 SN; 14 lentigines
Flow and timing Participant exclusions: none reported
Index to reference interval: consecutive; “After photography all lesions were excised”
Time interval between algorithms: same time; image-based
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Unclear High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
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Binder 1999 (Continued)
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Unclear
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
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Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Yes
Low
Blum 2003a
Study characteristics
Patient sampling Study design: case series
Data collection: retrospective image selection/prospective interpretation
Period of data collection: November 1998-March 2000; lesions overlap with Blum 2004b; data
only included in algorithm comparison and not in primary analysis
Country: Germany
Test set derived: study developed a simplified version of ABCD algorithm; described full data set
“randomly divided into 2 groups (N0 and N1)” but new algorithm development was based on full
dataset
Patient characteristics and set-
ting
Inclusion criteria: melanocytic skin lesions to be excised because of clinically and/or dermoscopi-
cally clear or suspicious malignancy, or by the wish of the patient after clear benign diagnosis
Setting: secondary (general dermatology)
Prior testing: clinical and/or dermatoscopic suspicion; patient request for evaluation/excision
Setting for prior testing: NR
Exclusion criteria: consecutive images of 1 lesion and external recorded images were not included.
Images from all parts of the bodies were taken except of subungual and mucosal sites
Sample size (participants): 269
Sample size (lesions): 269
Participant characteristics: male: (45/84)
Lesion characteristics: median Breslow thickness 0.96 mm (SD 0.70 mm) for all melanomas
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Blum 2003a (Continued)
Index tests Dermoscopy modified ABCD (with and without ’E’ for evolution); denoted by study authors as
ABC-point list; + 7FFM; 7PCL; Menzies criteria; original ABCD not included due to lesion overlap
with Blum 2004b
Method of diagnosis: dermoscopic images
Prior test data: unclear; study described image acquisition and storage but did not describe image
interpretation
Diagnostic threshold:NR for established algorithms “performed according to the criteria given in
literature”
For ABC-point list: ≥ 4 points. A - asymmetry of the outer shape in at least 1 axis (+1) (as per
(Stolz; Nachbar); (A) - asymmetry of the differential structures inside the lesion in at least 1 axis
(+1) (new item); B - abrupt cutoff of network at the border of the lesion in at least 1 quarter of the
circumference (+1); C - ≥ 3 colours (+1); D - ≥ 3 differential structures (+1); E - evolution/change
noticed by the patient during the last 3 months (+1); no or uncertain information +0; no change
in the last 3 months (-1)
Diagnosis based on: unclear (n = NR)
Observer qualifications: NR; likely dermatologists
Experience in practice: not described
Experience with dermoscopy: not described
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Target condition (final diagnoses)
Melanoma (invasive): 71; melanoma (in situ): 9; lentigo maligna 4
’Benign’ diagnoses: 185
Flow and timing Excluded participants: none reported
Time interval to reference test: appears consecutive; consent given “for the recording and the
following operation under local anaesthesia”
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
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Blum 2003a (Continued)
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
Low High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Yes
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
High High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
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Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
Low
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Blum 2003b
Study characteristics
Patient sampling Study design: case series
Data collection: retrospective image selection/prospective interpretation
Period of data collection: September 1998-December 1999; lesions overlap with Blum 2004b;
data only included in algorithm comparison and not in primary analysis
Country: Germany
Patient characteristics and set-
ting
Inclusion criteria: all lesions of patients with multiple atypical naevi excised due to suspicious
clinical and/or dermoscopic features were included
Setting: specialist unit (skin cancer/PLC)
Prior testing: clinical and/or dermatoscopic suspicion
Setting for prior testing: specialist unit (skin cancer/PLC)
Exclusion criteria: lesions located on soles, palms, subungual and mucosal sites were excluded
Sample size (participants): number included: 205
Sample size (lesions): number eligible: 254/number included: 254
Participant characteristics: median age: 39.2 (1.6-86.4 years); male: 97 (47.3%)
Lesion characteristics: NR
Index tests Dermoscopy: new algorithm (based on criteria of Hofmann-Wellenhof 2001)
Method of diagnosis: dermoscopic images
Prior test data: unclear; looks like blinded test interpretation
Diagnostic threshold: lesions were classified into six different types according to morphological
criteria of the new classification of atypical naevi (Clark naevi): reticular, globular and homogeneous
or combinations of two of these types (Hofmann-Wellenhof 2001). If reticular, globular and homo-
geneous structures were found in one melanocytic lesion, this lesion was classified as a 3-structure
type
Diagnosis based on: consensus (2 observers); n = 2
Observer qualifications: NR; likely dermatologists, “All images were viewed by two investigators”
Experience in practice: not described
Experience with dermoscopy: not described
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Disease-positive: 75 MM; disease-negative: 179
Target condition (final diagnoses)
Melanoma (invasive): 63; melanoma (in situ): 12
Benign naevus: recurrent naevus 6; SN or Reed naevus 6; congenital naevus 4; blue naevus 3; naevus
without dysplasia 64; dysplastic naevus 96
Flow and timing Excluded participants: none reported
Time interval between index and reference: assumed consecutive, “All patients gave written
informed consent for the digital documentation and the following operation under local anaesthesia”
Comparative
Notes -
Methodological quality
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Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
No
High High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
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Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
High High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
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If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Yes
Low
Blum 2004a
Study characteristics
Patient sampling Study design: case series
Data collection: retrospective
Period of data collection: September 1998 to March 1999; lesions overlap with Blum 2004b; data
only included in algorithm comparison and not in primary analysis
Country: Germany
Patient characteristics and set-
ting
Inclusion criteria: PSLs excised due to suspicious clinical and/or dermoscopic features
Setting: pigmented lesion clinic
Prior testing: clinical and/or dermatoscopic suspicion
Setting for prior testing: specialist unit (skin cancer/PLC)
Exclusion criteria: “Consecutive (repeat) images of one lesion were not included”; malignant
epithelial tumours (BCC, SCC) were excluded
Sample size (participants): number eligible: 157/number included: 157
Sample size (lesions): number eligible: 162/number included: 157
Participant characteristics: median age: 38.9 years (2 to 87 years); 45.2% male
Lesion characteristics no change in the past 3 months was reported by 87 (55.4%) patients,
followed by an observed change in 39 (24.8%) patients and no clear clinical history was given by
31 (19.7%) patients.Lesion site: Face/Ears: 9 (5.7%); trunk: 102 (65%); limbs: 38(24.2%); Acral
6(3.8%), mucosal sites 2(1.2%); lesion thickness ≤ 1 mm: 23 CMs (2 in-situ, 29 invasive) median
Breslow thickness 0.86 mm (standard deviation 0.54 mm; range 0.30-40 mm)
Index tests Dermoscopy: pattern analysis
Method of diagnosis: dermoscopic images
Prior test data: Images interpreted with and without clinical information (clinical history, age, sex
of the patients and location of the tumour)
Diagnostic threshold: diagnosis of suspect CMmade when the level of suspicion was ’roughly 50%
or more’. “ Clinical history was scored as positive ”when any morphological change was recognized
by the patient in the past 3 months. Morphological changes included change in size, colour or shape
or any sign of ulceration or spontaneous bleeding. Possible dermoscopic classifications were benign
naevi, atypical naevi, cutaneous melanoma and other benign epithelial tumours (e.g. SK, angioma)
“
Diagnosis based on: single observer (n=3)
Observer qualifications: not described; likely dermatologists
Experience in practice: not described
Experience with dermoscopy: high/Moderate/Low ”Three investigators ... with different experi-
ences in dermoscopy: excellent (A), average (B) and beginner (C).“
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Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Target condition (final diagnoses)
Melanoma (invasive): 29; melanoma (in situ): 2
Benign naevus: 53; 59 dysplastic naevi; 13 ’epithelial benign tumours’
Flow and timing Excluded participants: consecutive images of one lesion were not included - assumed to be repeated
images of same lesion; 162 images originally with 5 excluded to give a total study number of 157
lesion
Index to reference interval: assumed consecutive; ”“All patients gave their written consent for the
digital documentation and the following operation under local anaesthesia”
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
High High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
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If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Unclear
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
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Blum 2004a (Continued)
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Low
Blum 2004b
Study characteristics
Patient sampling Study design: case series
Data collection: prospective; dermoscopic images assessed remotely from the patient
Period of data collection: 11 November 1998-2 March 2000
Country: Germany
Test set derived: for validation of a new CAD procedure the complete collection (837 melanocytic
lesions) was divided into 2 equal random subgroups n1 (training set) and n2 (test set)
Patient characteristics and set-
ting
Inclusion criteria: melanocytic skin lesions imaged prospectively at the PLC of the Department of
Dermatology, University of Tuebingen, Germany
Setting: specialist unit (skin cancer/PLC)
Prior testing: NR
Setting for prior testing: specialist unit (skin cancer/PLC)
Exclusion criteria: images from mucous membrane areas were excluded
Sample size (participants): NR
Sample size (lesions): number eligible: 837/number included: 837
Participant characteristics: NR
Lesion characteristics: median Breslow thickness for all melanomas 0.78 mm (range 0.10-3.50)
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Index tests Dermoscopy: 7FFM; 7PCL; ABCD; Menzies criteria
Method of diagnosis: dermoscopic images
Prior test data: not clearly reported; results using new CAD algorithm were, “compared with
established dermoscopic classification rules applied to the same image material as the diagnostic
computer algorithm.”
Diagnostic threshold:NR; original algorithms cited, “established dermoscopic classification rules”;
authored confirmed published standard thresholds of the mentioned algorithms were used
Diagnosis based on: single observer; n= 1
Observer qualifications: dermatologist
Experience in practice: not described
Experience with dermoscopy: not described, assumed high; “lesions were prospectively classified
as benign or malignant melanocytic lesions by the principal investigator (A.B.)”
Target condition and reference
standard(s)
Reference standard: histological diagnosis + follow-up
Disease-positive: 84; disease-negative: 185
Clinical follow-up + histology of suspicious lesions: unexcised lesions were analysed indepen-
dently by 2 of the investigators 2-3 times in 6 months on the basis of dermoscopic criteria. These
lesions were classified as benign without any suspicion of malignancy by dermoscopic criteria, and
follow-up records for at least 6 months showed no evidence of malignancy; n = 568
Target condition (final diagnoses)
Melanoma (invasive): 71; melanoma (in situ): 9; lentigo maligna 4
’Benign’ diagnoses: 766
Flow and timing Excluded participants: none reported
Time interval to reference test: appears consecutive; “After obtaining informed written patient
consent, 269 melanocytic skin lesions were excised under local anaesthesia and the diagnosis was
established by histopathology”
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
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Blum 2004b (Continued)
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Low High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Unclear
Was the test applied and inter-
preted in a clinically applicable
manner?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
Unclear
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interpreted without knowledge
of the results of the index tests?
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
High Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
Yes
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
High
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Study characteristics
Patient sampling Study design: case series
Data collection: prospective
Period of data collection: June 1998-March 2000
Country: Italy
Test set derived: a training set was separately derived using data obtained from 237 previously
studied lesions (Farina 2000)
Patient characteristics and set-
ting
Inclusion criteria: cutaneous pigmented lesions with clinical and/or dermatoscopic features that
suggested a more or less important suspicion for CM
Setting: specialist unit (skin cancer/PLC)
Prior testing: clinical and/or dermatoscopic suspicion
Setting for prior testing: specialist unit (skin cancer/PLC)
Exclusion criteria: location/site of lesion - awkwardly situated lesions e.g. interdigital space, ears,
nose or eyelids. Lesions on scalp excluded due to hair interference with reflectance; lesion size obvious
large, thick melanomas
Sample size (participants): number included: 298
Sample size (lesions): number included: 313
Participant characteristics: mean age: 40 years (10-86 years); male: 122; 41%
Lesion characteristics: lesion site: head/neck 3%; trunk 61%; limbs 36%; thickness≤ 1 mm 70%
(46/66); for 55 invasive MM: median thickness 0.64 mm, range 0.17-3.24 mm. Median diameter:
11 mm (3-31 mm)
Index tests VI: no algorithm (training in the unit is based on ABCD but subjective experience of the clinician
used for diagnosis)
Method of diagnosis: in-person diagnosis
Prior test data: N/A in-person diagnosis
Diagnostic threshold: clinical diagnostic criteria based on subjective experience; emphasise lesion
colour over dimensions. Diagnosis of suspect CM made when the level of suspicion was “roughly
50% or more”. ABCD criteria have been the basis of training at the unit, but is not implemented
in diagnosis; preferred emphasis on colour rather than dimensional character
Diagnosis based on: single observer; (n = 1)
Observer qualifications: surgical oncologists
Experience in practice: high experience or ‘Expert’; > 5 years
Experience with dermoscopy: assumed high experience; > 5 years
Dermoscopy: no algorithm
Method of diagnosis: in-person diagnosis
Prior test data: clinical examination and/or case notes
Diagnostic threshold: presence of at least one of the following criterion: radial streaming, pseu-
dopods, grey-blue veil, regression and erythema, whitish veil, black dots at the periphery (if network
present), thick irregular network or milky-red background with red dots
Test observers as described for VI (above)
Dermatoscopy performed by a hand-held monocular microscope equipped with an achromatic lens
permitting a magnification of x10 (Heine Delta 10)
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Target condition (final diagnoses)
Melanoma (invasive): 55; melanoma (in situ): 11; BCC: 6
’Benign’ diagnoses: 241;151 compound naevus, 24 junctional naevus, 12 dermal naevus, 12 LS, 10
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dysplastic naevus, 8 spindle-cell naevus, 8 SK, 5 blue naevus, 3 SN, 8 other
Flow and timing Excluded participants: NR
Interval between index and reference: NR
Comparative Blinding between tests: same clinician undertook both diagnoses (in-person)
Time interval between index test(s): appears consecutive but not fully clear
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
Unclear High
DOMAIN 2: Index Test Visual Inspection - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
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out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Unclear High
DOMAIN 2: Index Test Dermoscopy - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low Low
DOMAIN 3: Reference Standard
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Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
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DOMAIN 5: Comparative
Was each index test result in-
terpreted without knowledge of
the results of other index tests
or testing strategies?
No
Was the interval between ap-
plication of the index tests less
than one month?
Yes
Were all tests applied and inter-
preted in a clinically applicable
manner?
No
Low High
Bono 2002b
Study characteristics
Patient sampling Study design: case series
Data collection: prospective
Period of data collection: December 2000-Aug 2001
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: consecutive cutaneous pigmented lesions that were ≤ 6 mm in diameter and
required surgical biopsy for diagnosis based on clinical or dermoscopic suspicion of CMM
Setting: specialist unit (skin cancer/PLC)
Prior testing: clinical and/or dermatoscopic suspicion
Setting for prior testing: NR
Exclusion criteria: lesion size > 6 mm; non-pigmented
Sample size (participants): number eligible: 349/number included: 157
Sample size (lesions): number eligible: 375/number included: 161
Participant characteristics: mean age 38 years (14-82); male: 61 (39%)
Lesion characteristics: site: head/neck 14 (9%); trunk 88 (55%); limbs 59 (36%); lesion size:
median: 5 mm (1 mm-6 mm)
Index tests VI: no algorithm ABCD criteria have been the basis of training at the unit, but is not implemented
in diagnosis; preferred emphasis on colour rather than dimensional character
Method of diagnosis: in-person diagnosis
Prior test data: N/A, in-person diagnosis
Diagnostic threshold: a diagnosis of suspect CM is made when the level of suspicion is roughly ≥
50%; lesions at a lower index of suspicion were considered benign for the purposes of this study.
ABCD criteria have been the basis of training at the unit, but is not implemented in diagnosis;
preferred emphasis on colour rather than dimensional character
Diagnosis based on: single observer diagnostic criteria based on the subjective experience of the
single clinician examining the pigmented lesion (n = 2)
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Observer qualifications: surgical oncologists
Experience in practice: high experience or ‘Expert’; described as “expert in the recognition of
pigmented lesions”
Experience with dermoscopy: high experience/‘Expert’ users
Other detail: diagnostic criteria were based on the subjective experience of the single clinician
examining the pigmented lesion, although the ABCD criteria have been the basis of training at the
unit, they did not consider the ABCD mnemonic an essential formula for diagnosis of CM. They
did not take into consideration the dimensional character and attributed great importance to the
colour of a given lesion
Dermoscopy: no algorithm
Method of diagnosis: in-person diagnosis
Prior test data: clinical examination and/or case notes in-person; dermoscopy performed by the
same 2 clinicians who firstly made and registered the clinical diagnosis
Diagnostic threshold: dermatoscopic criteria for diagnosis of malignancy were radial streaming,
pseudopods, grey-blue veil, regression and erythema,whiteish veil, black dots at periphery (if network
present), thick irregular network, or milky-red background with red dots. A lesion was suspected
for CM when positive for at least one criterion
Test observers as described for VI (above)
Any other detail: this technique was performed by a hand-held monocular microscope equipped
with an achromatic lens permitting a magnification of 10x (Heine Delta 10)
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Disease-positive: 13 CM; disease-negative: 148
Target condition (final diagnoses)
Melanoma (invasive): 10; melanoma (in situ): 3; BCC: 2(1.2%)
Mild/moderate dysplasia: 26 (16.1%); SK: 4 (5%); benign naevus: compound naevus 57 (35.4%),
junctional naevus 38 (23.6%), spindle-cell naevus 6 (3.7%), SN 5 (3.1%), blue naevus 2 (1.2%),
other 6 (3.7%), LS 2 (1.2%)
Flow and timing Excluded participants: none reported
Time interval to reference test: NR
Comparative Blinding between tests: dermoscopy performed by the same 2 clinicians who firstly made and
registered the clinical diagnosis
Time interval between index test(s): appears consecutive
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
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Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
High High
DOMAIN 2: Index Test Visual Inspection - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Unclear High
DOMAIN 2: Index Test Dermoscopy - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
Yes
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dard?
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
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Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
DOMAIN 5: Comparative
Was each index test result in-
terpreted without knowledge of
the results of other index tests
or testing strategies?
No
Was the interval between ap-
plication of the index tests less
than one month?
Yes
Were all tests applied and inter-
preted in a clinically applicable
manner?
Yes
Low Low
162Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bono 2006
Study characteristics
Patient sampling Study design: case series
Data collection: retrospective
Period of data collection: January 2003-December 2004
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: consecutive patientswith PSLswith amaximumdiameter of≤ 3mmundergoing
excision. The decision for diagnostic excision was based on clinical and/or dermoscopic features
suggesting a more or less important suspicion for CM
Setting: specialist unit (skin cancer/PLC) Melanoma and Sarcoma Unit; Istituto Nazionale Tumori
of Milan
Prior testing: clinical and/or dermatoscopic suspicion
Setting for prior testing: specialist unit (skin cancer/PLC)
Exclusion criteria: - lesion size > 3 mm
Sample size (participants): number eligible: 204/number included: 204
Sample size (lesions): number eligible: 206/number included: 206
Participant characteristics: median age: 40 (6-74); male: 71 (35%)
Lesion characteristics: head/neck 8 (4%); trunk 84 (41%); limbs 114 (55%). Median size: 2 mm
(1-3 mm)
Index tests VI: no algorithm
Method of diagnosis: in-person diagnosis
Prior test data: N/A in-person diagnosis
Diagnostic threshold: a diagnosis of suspicious CM is made when the level of suspicion is roughly
≥ 50%; lesions at a lower index of suspicion were considered not CM; ABCD criteria have been
the basis of training at the unit, but is not implemented in diagnosis; preferred emphasis on colour
rather than dimensional character
Diagnosis based on: single observer; n = 1
Observer qualifications: NR (assumed oncologist as per Bono 2002a and Bono 2002b); “single
clinician examining the pigmented lesion”
Experience in practice: not described
Experience with dermoscopy: not described
Dermoscopy:Menzies criteria
Method of diagnosis: in-person diagnosis
Prior test data: clinical examination and/or case notes
Diagnostic threshold: dermoscopic criteria for diagnosis of malignancy were those ofMenzies 1996
and Menzies 2003
Test observers as described for VI (above)
A hand-held monocular microscope equipped with an achromatic lens permitting a magnification
of 10x (Heine Delta 20 microscope; Heine Ltd, Herrsching, Germany)
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Details: the slides were evaluated according to widely accepted criteria for the histopathological
diagnosis of the various pigmented lesions.
Disease-positive: 23; disease-negative: 183
Target condition (final diagnoses)
Melanoma (invasive): 19 (9.2%); melanoma (in situ): 4 (0%)
Mild/moderate dysplasia: dysplastic naevus 10 (4.9%); junctional naevus 76 (36.9%); compound
naevus 50 (24.3%); dermal naevus 12 (5.8%); blue naevus 11 (5.3%); Reed naevus 7 (3.4%); SN
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3 (1.5%); halo naevus 3 (1.5%); LS 7 (3.4%); other 4 (1.9%)
Flow and timing Excluded participants: none
Time interval to reference test: NR
Comparative Blinding between tests: Single observer performed both tests
Time interval between index test(s): NR
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
High High
DOMAIN 2: Index Test Visual Inspection - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
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the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Low High
DOMAIN 2: Index Test Dermoscopy - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Low Unclear
DOMAIN 3: Reference Standard
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Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
No
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
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DOMAIN 5: Comparative
Was each index test result in-
terpreted without knowledge of
the results of other index tests
or testing strategies?
No
Was the interval between ap-
plication of the index tests less
than one month?
Yes
Were all tests applied and inter-
preted in a clinically applicable
manner?
Yes
Low Low
Bourne 2012
Study characteristics
Patient sampling Study design: case series
Data collection: retrospective image selection/prospective interpretation
Period of data collection: June 1-July 6 2009
Country: Australia
Patient characteristics and set-
ting
Inclusion criteria: all skin lesions consecutively excised at a skin cancer practice to exclude skin
cancer and common lesions assessed as clearly benign and not biopsied were included
Setting: private; “a dedicated skin cancer practice in Brisbane, Australia”
Prior testing: clinical and/or dermatoscopic suspicion. Prior testing to assemble the test set occurs
in secondary care by an experienced skin cancer doctor, then the images are tested on primary care
professionals
Setting for prior testing: specialist unit (skin cancer/PLC)
Exclusion criteria: clinically obvious BCCs, which could be easily diagnosed without dermoscopy
were not included in the collection set
Sample size (participants): number eligible: 46/number included: 46
Sample size (lesions): number eligible: 50/number included: 50
Participant characteristics: mean age: 58y (30-60y); male: 22
Lesion characteristics: face = 8; neck = 1; chest = 3; back = 21; shoulder = 2; arm = 3; thigh = 4;
leg = 7; foot plantar = 1
Index tests VI: no algorithm
Method of diagnosis: clinical photographs
Prior test data: no further information used; image assessments were done on 4 occasions, each
time using a different diagnostic approach
Diagnostic threshold:NR clinicians provided with Excel answer sheets for each method listing the
various criteria used in that algorithm but no algorithm was cited for VI
Diagnosis based on: average (n = 4)
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Observer qualifications: 3 GPs and 1 clinical nurse
Experience in practice: mixed; described as varying levels of dermatoscopic experience
Experience with dermoscopy: mixed; described as varying levels of dermatoscopic experience
Dermoscopy 3-point rule; Menzies criteria
Method of diagnosis: dermoscopic images
Prior test data: no further information used; image assessments were done on 4 occasions, each
time using a different diagnostic approach
Diagnostic threshold: NR in paper; author communications states that standard thresholds were
used, ≥ 2 for the 3PCL and Menzies method as described in original paper
Test observers as described for VI (above)
Target condition and reference
standard(s)
Reference standard: histological diagnosis + other
Histopathological examination (n = 46); expert diagnosis as benign (n = 3); digital follow-up (n =
1)
Target condition (final diagnoses)
Melanoma (invasive): 1; melanoma (in situ): 7; BCC: 6; lentigo maligna 1
Sebhorrheic keratosis: 5;
’Benign’ diagnoses: banal naevus 10, blue naevus 1, naevus and SK/solar lentigo collision 3, solar
lentigo 4, LP or LK 4, DF 1, psoriasis 1, solar keratosis 2, intraepidermal carcinoma 3, regressed
keratoacanthoma 1
Flow and timing Excluded participants: as 2 of the methods (Menzies and 3PCL) related to only pigmented lesions,
the 5 non-pigmented specimens in the set of 50 were excluded from the contingency tables for these
methods
Time interval to reference test: “all skin lesions consecutively excised to exclude skin cancer were
recorded”
Comparative Blinding between tests: image assessments on 4 different occasions different algorithms
Time interval between index test(s): same day; images acquired at time of face-to-face consultation
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
No
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Did the study avoid including
participants with multiple le-
sions?
Yes
Low High
DOMAIN 2: Index Test Visual inspection - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Unclear High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
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For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Unclear
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
No
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
High High
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
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Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
No
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
Unclear
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Yes
High
DOMAIN 5: Comparative
Was each index test result in-
terpreted without knowledge of
the results of other index tests
or testing strategies?
Yes
Was the interval between ap-
plication of the index tests less
than one month?
Yes
Were all tests applied and inter-
preted in a clinically applicable
manner?
No
Low High
Broganelli 2005
Study characteristics
Patient sampling Study design: case series
Data collection: prospective
Period of data collection: 1998-2002
Country: Italy
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Patient characteristics and set-
ting
Inclusion criteria: PSLs excised atDept ofDermatology; all lesions considered suspicious on clinical
parameters (on at least one of ABCDE parameters apart from diameter) underwent dermoscopy;
2x2 for melanocytic only included
Setting: secondary (general dermatology)
Prior testing: clinical suspicion only; decision to excise “follows the dermoscopic diagnosis”
Setting for prior testing: specialist unit (skin cancer/PLC)
Exclusion criteria: none reported
Sample size (participants): NR
Sample size (lesions): number included: 638 melanocytic lesions
Participant characteristics: age range: between 2 months and 90 years
Lesion characteristics NR
Index tests Dermoscopy; 7PCL
Method of diagnosis: unclear. Study describes “day-to-day” office activity, but ELM interpretation
referred to as evaluating “recorded images” to split into melanocytic and non-melanocytic lesions.
“Melanocytic lesions were investigated on the basis of a pattern analysis and those that revealed
altered dermoscopic parameters were distinguished between minor and major criteria”
Prior test data: unclear what additional information was available
Diagnostic threshold: > 1 alteration in minor criteria or ≥ 1 major char present; not further
described. Based on data in Argenziano 1998, this is akin to a score of ≥ 2 as major criteria score 2
points and minor ones score 1 each
Diagnosis based on: unclear appears to be in clinic diagnoses n = NR
Observer qualifications: NR likely dermatologists
Experience in practice: not described
Experience with dermoscopy: not described
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Details: “lesions were fixed with formaline and included in paraffin
for histological examination. For some of them serial sections were made”
Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 108
’Benign’ diagnoses: non-melanomas = 530
Flow and timing Excluded participants: none reported
Time interval to reference test: NR
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
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Broganelli 2005 (Continued)
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Unclear High
DOMAIN 2: Index Test Dermoscopy - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Low Unclear
DOMAIN 3: Reference Standard
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Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
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Carli 1994
Study characteristics
Patient sampling Study design: case series
Data collection: unclear
Period of data collection: November 1993-May 1994
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: clinically suspicious melanocytic lesions undergoing excision for diagnostic pur-
poses
Setting: secondary (general dermatology)
Prior testing: clinical suspicion of malignancy based on: recent lesion changes or presence of at
least two of: diameter > 6 mm, asymmetric, irregular feathery edges, uneven or “very” dark colour,
“increased or disappearance of skin outline”
Setting for prior testing: secondary (general dermatology)
Exclusion criteria: clinically obvious melanomas excluded
Sample size (participants): number included: 67
Sample size (lesions): number included: 67
Participant characteristics: mean age 36 years; median age 33; all > 20 years; male: 31%
Lesion characteristics: none reported
Index tests Dermoscopy: pattern analysis; criteria derived from a number of other studies (citations include
Steiner 1993, Pehamberger 1987, Steiner 1987, Nachbar 1994, Bahmer 1990, Kenet 1993, Stolz
1989, Soyer 1987, Dal Pozzo 1994)
Method of diagnosis: in-person diagnosis
Prior test data: clinical examination
Diagnostic threshold: a pigment network that was irregular, accentuated, wide-meshed, with dis-
tinct borders, + at least one of the following parameters: inhomogeneous depigmentation present at
the periphery; presence of unevenly distributed black dots; uneven brown globules, with irregular
distribution; presence of radial streaks; presence of pseudopods; the presence of grey-blue veil
Diagnosis based on: consensus (2 observers); n = 2
Observer qualifications: NR; likely dermatologist
Experience in practice: high; described as “two experienced observers”
Experience with dermoscopy: high; as above
Target condition and reference
standard(s)
Reference standard: histology (not further described)
Disease-positive: 5; disease-negative: 63
Target condition (final diagnoses)
Melanoma (invasive): 3; melanoma (in situ): 2
’Benign’ diagnoses: atypical melanocytic hyperplasia 2; naevi with architectural atypia 14; naevi
with ‘cyto’-architectural atypia 7; no atypia 40
Flow and timing Participant exclusions: none reported
Time interval to reference test: ELM performed at the time of excision of the lesion
Comparative
Notes -
Methodological quality
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Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
Low High
DOMAIN 2: Index Test Dermoscopy - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
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Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
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If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Low
Carli 2002a
Study characteristics
Patient sampling Study design: case series
Data collection: prospective for clinical examination and in-vivo dermoscopy; retrospective image
selection/prospective interpretation for ex-vivo dermoscopic evaluation
Period of data collection: June 1997-December 1998
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: clinically equivocal and suspicious PSLs subjected to excisional biopsy at the
Institute of Dermatology
Setting: secondary (not further specified)
Prior testing: clinical and/or dermatoscopic suspicion
Setting for prior testing: secondary
Exclusion criteria: none reported
Sample size (participants): NR
Sample size (lesions): 256
Participant characteristics: none reported
Lesion characteristics: of the cutaneousmelanomas, 14 (25.9%)were in situmelanoma (Clark level
I), 18 (33.3%) were invasive with < 0.75 mm thickness, 19 (35.3%) were of intermediate thickness
(0.76-1.50 mm) and 3 (5.5%) were > 1.5 mm. The median thickness of invasive melanomas was
0.94 mm ± 0.5 (SD) (range 0.2-6)
Index tests VI: no algorithm
Method of diagnosis: in-person diagnosis
Prior test data: unclear
Diagnostic threshold: NR
Diagnosis based on: consensus (2 observers); final clinical diagnosis was based on agreement
between the 2 observers. In case of disagreement, the opinion of a 3rd observer was considered to
be the judge for the diagnosis
Observer qualifications: dermatologist
Experience in practice: high experience or ‘Expert’; described as “dermatologists with extensive
experience in both clinical and dermoscopic diagnosis of pigmented skin lesions”
Experience with dermoscopy: high experience /‘Expert’ users
Dermoscopy: pattern analysis
Method of diagnosis: in-person diagnosis and image-based diagnosis. Clinical examination and in
vivo dermoscopy were performed before excision by 2 trained dermatologists and diagnosis reached.
Dermoscopic images were re-analysed by the same 2 observers at the end of the inclusion period
(December 1998), blind to the previous clinical and histological diagnoses
178Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
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Prior test data: N/A for in-person; for image-based: slides of dermoscopic images were evaluated
using a viewer that made it impossible to analyse the clinical features of the lesion; both observers
had access to clinical information, including the age of the participant, the site of the lesion, the
history of change over time as reported by the participant at the time of in vivo examination
Diagnostic threshold: dermoscopic diagnosis was based on the ELM pattern analysis criteria,
using the same diagnostic categories used for clinical diagnosis; characteristics investigated included
pigment network, pigmentation, hypopigmentation, brown globules, black dots, pseudopods, radial
streaming, grey-blue veil, atypical vascular pattern
Test observers as described for VI (above)
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Target condition (final diagnoses)
Melanoma (invasive): 40; melanoma (in situ): 14
BCC: 5
Sebhorrheic keratosis: 4;
Benign naevus: 90 common melanocytic naevi; 78 melanocytic naevi; 9 blue naevi; 16 SN/ Reed
naevi
Flow and timing Excluded participants: none reported
Time interval to reference test: NR
Comparative Blinding between tests: In-person clinical examination and dermoscopy
Time interval between index test(s): the interval between in vivo dermoscopy and re-evaluation
of dermoscopic images was reported as 1 year
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
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Unclear High
DOMAIN 2: Index Test Visual Inspection - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Unclear High
DOMAIN 2: Index Test Dermoscopy - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
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Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low Low
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
DOMAIN 3: Reference Standard
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Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
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DOMAIN 5: Comparative
Was each index test result in-
terpreted without knowledge of
the results of other index tests
or testing strategies?
No
Was the interval between ap-
plication of the index tests less
than one month?
Yes
Were all tests applied and inter-
preted in a clinically applicable
manner?
No
Low High
Carli 2002b
Study characteristics
Patient sampling Study design: case series
Data collection: NR
Period of data collection: NR
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: clinically suspicious or equivocal PSLs undergoing excision for diagnostic pur-
poses; only lesions with a diameter of ≤ 14 mm were included
Setting: secondary (general dermatology)
Prior testing: clinical suspicion of malignancy without dermatoscopic suspicion
Setting for prior testing: secondary (general dermatology)
Exclusion criteria: none reported
Sample size (participants): number included: NR
Sample size (lesions): number included: 57
Participant characteristics: none reported
Lesion characteristics: thickness ≤ 1 mm: 11 cases (5 in situ 6 invasive); All ≤ 14 mm diameter
Index tests VI: no algorithm
Method of diagnosis: clinical photographs; fixed focus distance of 10 cm; images observed using
a viewer in 2 separate diagnostic sessions
Prior test data: no further information used; contact (dermoscopic) images viewed first and then
distant images (clinical), without knowing the classification of the contact image of the individual
lesions
Diagnostic threshold: NR
Diagnosis based on: consensus (2 observers); n = 2
Observer qualifications: dermatologist
Experience in practice: high experience or ‘Expert’; states, “with experience in the field of PSL”
Experience with dermoscopy: high experience /‘Expert’ users; “experienced in the field of PSLs”
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Other detail: used an auto focus micro Nikkon 60 lens objective mounted on a Nikon f50 camera,
with a fixed focus distance of 10 cm
Dermoscopy: no algorithm
Method of diagnosis: dermoscopic images
Prior test data: no further information used; contact (dermoscopic) images viewed first and then
distant images (clinical), without knowing the classification of the contact image of the individual
lesions
Diagnostic threshold: NR
Test observers as described for VI (above)
Any other detail: Dermaphot device placed directly on the lesion without previous application
of oil; only lesions with a diameter of ≤ 14 mm were included in the study. The image has an
automatic, original magnification of x 10
Target condition and reference
standard(s)
Reference standard: histology (not further described)
Disease-positive: 21; disease-negative: 36
Target condition (final diagnoses)
Melanoma (invasive): 6; melanoma (in situ): 5; BCC: 10
’Benign’ diagnoses: 36
Flow and timing Excluded participants: no exclusions reported
Time interval to reference test: photographic procedures performed consecutively prior to surgery
Comparative Blinding between tests: described as blinded
Time interval between index test(s): photographic procedures performed consecutively prior to
surgery
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
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Did the study avoid including
participants with multiple le-
sions?
Unclear
Unclear High
DOMAIN 2: Index Test Visual inspection - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Unclear High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
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For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
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Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Low
DOMAIN 5: Comparative
Was each index test result in-
terpreted without knowledge of
the results of other index tests
or testing strategies?
Yes
Was the interval between ap-
plication of the index tests less
than one month?
Yes
Were all tests applied and inter-
preted in a clinically applicable
manner?
No
Low High
Carli 2003a
Study characteristics
Patient sampling Study design: case series
Data collection: retrospective image selection/prospective interpretation
Period of data collection: NR
Country: Italy (from authors’ institution)
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Patient characteristics and set-
ting
Inclusion criteria: melanocytic lesions < 14 mm in diameter, excised because they were clinically
suspicious or equivocal
Setting: secondary (general dermatology)
Prior testing: clinical and/or dermatoscopic suspicion
Setting for prior testing: specialist unit (skin cancer/PLC)
Exclusion criteria: non-melanocytic lesions
Sample size (participants): NR
Sample size (lesions): number included: 200
Participant characteristics: none reported
Lesion characteristics: all < 14 mm in diameter
Index tests Dermoscopy: pattern analysis; 7PCL; ABCD
Method of diagnosis: dermoscopic images
Prior test data: no further information used; “Dermoscopic images were examined using a viewer”
Diagnostic threshold: for ABCD>5.45; for the 7PCL≥ 3; pattern analysis: threshold not described
Diagnosis based on: single observer (n = 5); average also presented
Observer qualifications: dermatology residents working out of the PLC: 3 working predominantly
in the inpatient units and in mycology laboratories, 1 working in dermato-allergology and 1 in the
general outpatient units of the dermatology clinic
Experience in practice: low experience or recently qualified
Experience with dermoscopy: low experience/novice users - considered as ’Trained’; all had under-
gone training in dermoscopy; 1 had previously taken part in a study on dermoscopy based both on
pattern analysis and on the ABCD rule while the others had had no previous experience in practical
dermoscopy during work in other fields of dermatology
Dermoscopy training: length of training 8-h formal lessons + interactive CD of dermoscopy
Post-training experience: 4-h practice at pigmented lesion clinic
Training format: in-person teaching; CD-ROM tutorial
Any other detail: images taken at x10 magnification using a Dermaphot (Heine Optotechnik,
Germany) mounted on a Nikon F50 camera
Target condition and reference
standard(s)
Reference standard: histology (not further described)
Disease-positive: 44; disease-negative: 156
Target condition (final diagnoses)
Melanoma (invasive): 30; melanoma (in situ): 14
Benign naevus: 156
Flow and timing Participant exclusions: none reported
Reference interval NR
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
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Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Unclear High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Unclear
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
No
Low High
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DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Yes
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Unclear
Carli 2003b
Study characteristics
Patient sampling Study design: case series
Data collection: retrospective image selection/prospective interpretation
Period of data collection: 1999-2001
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: clinically difficult to diagnose or equivocalmelanocytic lesions randomly selected
from image database; all melanomas < 1 mm thickness
Setting: secondary (general dermatology)
Prior testing: clinical suspicion of malignancy without dermatoscopic suspicion
Setting for prior testing: secondary (general dermatology)
Exclusion criteria: ≥ 1 mm thick melanomas, non-melanocytic lesions, easy to diagnose, dermo-
scopically peculiar lesions (e.g. blue naevi or SN)
Sample size (participants): NR
Sample size (lesions): number included: 200
Participant characteristics: none reported
Lesion characteristics ≤ 1 mm thickness: 64; median thickness 0.3 mm, 25th-75th centile 0.00-
0.58 mm; mean diameter 7.4 (SD 79) mm; median: 7 mm (2-16 mm)
Any other detail: same lesions appear to be reported in De Giorgi 2011 but with a different set of
8 observers (De Giorgi 2011 excluded from review on this basis)
Index tests VI: no algorithm
Method of diagnosis: clinical photographs
Prior test data: no further information used
Diagnostic threshold: NR
Diagnosis based on: average; n = 8
Observer qualifications: dermatology registrar; 2 final-year residents. Dermatologist 6
Experience in practice: mixed experience, 2 senior experts, 4 practicing dermatologists, 2 last-year
resident dermatologists. Both latter groups formally trained in dermoscopy
Experience with dermoscopy: classified as ’high’ due to expertise/training in dermoscopy use
Other detail: clinical photos using Nikon F40 with macro lens at 15 cm
Dermoscopy: no algorithm (own choice)
Method of diagnosis: clinical photographs and dermoscopic images
Prior test data: unclear
Diagnostic threshold: NR. All observers familiar with pattern analysis, ABCD and 7PCL, each
was free to choose method of choice
Test observers as described for VI (above)
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Disease-positive: 64; disease-negative: 136
Target condition (final diagnoses)
Melanoma (invasive): 40; melanoma (in situ): 24
Other: 136 melanocytic naevi
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Flow and timing Excluded participants: no exclusions reported
Time interval to reference test: interval not described
Comparative Blinding between tests: clinical diagnosis made and then clinical and dermoscopic images viewed
together
Time interval between index test(s): images obtained at time of excision
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
High High
DOMAIN 2: Index Test Visual inspection - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
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the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Unclear High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
DOMAIN 3: Reference Standard
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Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
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DOMAIN 5: Comparative
Was each index test result in-
terpreted without knowledge of
the results of other index tests
or testing strategies?
No
Was the interval between ap-
plication of the index tests less
than one month?
Yes
Were all tests applied and inter-
preted in a clinically applicable
manner?
No
Low High
Carrera 2016
Study characteristics
Patient sampling Study design: case-control
Data collection: retrospective image selection/prospective interpretation. Each PLC provided up
to 50 lesions with a 1:3 ratio of melanomas to naevi. Each contributor randomly selected either
polarised or non-polarised images based on 1:1 randomisation. Following exclusions, lesions were
randomised into 12 image sets containing 39 (n = 8) or 40 (n = 7) unique lesions and 5 non-unique
lesion images (2 melanoma, 3 benign) that were repeated in all sets
Period of data collection: NR
Country:multicentre (images contributed from PLCs in Australia, Austria, Germany, Italy, Spain,
Switzerland, and the USA)
Patient characteristics and set-
ting
Inclusion criteria: images of melanocytic lesions including melanomas with an unequivocal
histopathologic diagnosis, and histopathologically verified naevi or naevi demonstrating stability
under sequential dermoscopic imaging over time
Setting: specialist unit (skin cancer/PLC) 12 PLCs
Prior testing: selected for excision (no further detail)
Setting for prior testing: specialist unit (skin cancer/PLC)
Exclusion criteria: acral, mucosal, or facial sites excluded; non-melanocytic appearance; lesions
with equivocal (final) diagnosis after review of the pathology report or sequential imaging
Sample size (participants): number eligible: NR; number included: NR
Sample size (lesions): number eligible: 580 lesion images were contributed; number included: 477
(103 excluded on review by Memorial Sloan Kettering Cancer Center investigators)
Participant characteristics: none reported
Lesion characteristics: none reported
Index tests Dermoscopy 3-point rule; 7PCL; ABCD; Menzies criteria; chaos and clues
Method of diagnosis: dermoscopic images
Prior test data: clinical image, evaluators examined the close-up clinical image of each lesion before
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viewing the dermoscopic image; image contributors also asked to provide information on anatomical
location, patient age and sex, and imaging modality (polarised vs non-polarised) but unclear whether
this information was provided to observers or not
Diagnostic threshold: observers asked to evaluate “a comprehensive list” of dermoscopic structures
abstracted from various algorithms; overlapping criteria were merged into 1 criterion. Criteria were
grouped into (1) global pattern, (2) pattern organization, (3) symmetry of contour, (4) symmetry of
pattern, (5) architectural disorder, (6) abruptness of lesion border, (7) colours, and (8) melanocytic
structures, including network and vascular structures. Algorithm performance was retrospectively
assessed based on the following thresholds: 7PCL ≥ 3; CASH ≥ 6; Menzies NR; ABCD > 4.75;
3PCL NR; chaos and clues NR. For NR thresholds, author communications state “We assessed all
of the algorithms. There isn’t a threshold for these algorithms, there are just published rules of usage
that determine the benign/malignant classification of the lesion”
Diagnosis based on: consensus (≥ 50%); when ≥ 50% of the observers identified a dermoscopic
feature for a given study lesion, the attribute was considered present; n = 130 (240 participants
registered via the IDS website for the study; 103 completed all available images in their data sets
and 130 evaluated ≥ 20 lesions)
Observer qualifications: GP 24; dermatology registrar 25; dermatologist 73; 1 medical student
and 7 ’other’
Experience in practice: mixed; mean 12 (SD 8.7) years of dermatology experience
Experience with dermoscopy: mixed; 122 (93.8%) reported being comfortable using dermoscopy,
and 121 (93.1%) were regular users of dermoscopy
Dermoscopy training: algorithm tutorials were created and posted by dermoscopic experts through
the IDS website; review of these was encouraged but not mandatory
Target condition and reference
standard(s)
Reference standard: histological diagnosis + follow-up
Histology: all melanomas (n = 119) and a proportion of benign lesions (n = NR)
Clinical follow-up + histology of suspicious lesions: sequential dermoscopic imaging over time; not
further detailed; length of follow-up NR; naevi required to be either histopathologically verified or
to have demonstrated stability under sequential dermoscopic imaging over time
Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 119
Benign naevus: melanocytic naevus: 358
Flow and timing Excluded participants: poor quality index test image as exclusion criterion
Time interval to reference test: NR
Time interval between index test(s): in-person; sequential
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
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Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
High High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Yes
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Low High
DOMAIN 3: Reference Standard
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Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
No
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
Unclear
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Yes
High
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Coras 2003
Study characteristics
Patient sampling Study design: case series
Data collection: prospective
Period of data collection: 16-month period. Date NR
Country: Germany
Patient characteristics and set-
ting
Inclusion criteria: PSLs undergoing excision due to diagnosis of melanoma or atypical naevus, to
rule out melanoma or at the participant’s request. Paper states, ”Each of the three participating der-
matologists in private practice sent their digital images via email attachment including anonymized
identification to the department of dermatology. (Face-to-face diagnosis)
Setting: secondary (general dermatology) (teledermatoscopy diagnosis); private care; face-to-face
diagnosis
Prior testing: NR
Setting for prior testing: NR
Exclusion criteria: none reported
Sample size (participants): NR
Sample size (lesions): number eligible: 90; number included: 45
Participant characteristics: none reported
Lesion characteristics: none reported
Index tests In-person assessment (for those comparing face-to-face vs histology)
Method of diagnosis: participating dermatologists with experience in dermatoscopy established
a clinical diagnosis based on pattern analysis after personal consultation with the patient in their
private practice clinics
Prior test data: NR
Diagnostic threshold: NR
Diagnosis based on: single
Number of examiners: 3
Observer qualifications: dermatologist (experts with great experience in dermoscopy)
Experience in practice: high
Experience with index test: high
Teledermatology
Acquisition and transmission of images: each of the participating dermatologists acquired digital
images after face-to-face consultation, and sent them via an email attachment with corresponding
participant data and medical history
Nature of images used: clinical photographs and dermoscopic images
Any additional patient information provided: clinical examination and/or case notes
Observer qualifications (remote diagnosis): physician experienced in dermatoscopy
Diagnosis based on: single observer
Method of diagnosis: a physician evaluated the images and made a diagnosis based on the images
and history of the participant
Other detail: the participating dermatologists used the same technical equipment for the acquisition
of digital images
Target condition and reference
standard(s)
Reference standard: histology
Details: the histological diagnosis of majority of cases was performed at the Department of Der-
matology Regensburg
45 participants; disease-positive: 16; disease-negative: 29
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Target condition (final diagnoses)
Melanoma (invasive): 16; ’Benign’ diagnoses: 29
Flow and timing Excluded participants: reported that many images were of poor quality (10) and that only 45
biopsies were done 50 participants who did not have histology excluded
Time interval to reference test: unclear
Time interval between index test(s): most likely days (email transmission of images for remote
assessment)
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Unclear High
DOMAIN 2: Index Test Dermoscopy - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
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For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
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Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
Cristofolini 1994
Study characteristics
Patient sampling Study design: case series
Data collection: prospective
Period of data collection: October 1990-June 1991
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: patients with pigmented lesions presenting during a campaign for the early
diagnosis of cutaneous melanoma at the Dermatology Department in Trento
Setting: secondary (general dermatology)
Prior testing: NR
Setting for prior testing: NR
Exclusion criteria: lesions that were not taken into consideration included benign lesions, naevi
of Unna and Miescher types and naevi that showed no inclusion criteria at the ABCDE clinical
examination
Sample size (participants): number eligible: 700 people; number included: NR
Sample size (lesions): number eligible: 220; number included: 220
Participant characteristics: none reported
Lesion characteristics: none reported
Index tests VI: ABCDE
Method of diagnosis: in-person diagnosis
Prior test data: N/A in-person diagnosis
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Diagnostic threshold: lesions showing ≥ 2 of the ABCDE criteria all of which were shown the
same diagnostic importance, were considered positive
Diagnosis based on: unclear; n = 4
Observer qualifications: dermatologist
Experience in practice: high experience or ‘Expert’; all trained in the recognition of pigmented
lesions during a training course about the clinical diagnosis of naevi and melanomas; all working in
a department where the early diagnosis of melanoma had been dealt with for > 10 years
Experience with dermoscopy: high experience /‘Expert’ users
Other detail: ABCDE criteria are (asymmetry in shape, border irregular and notched, colour
mottled-haphazard display, dimension > 6 mm, evolution changes in pigmentation)
Dermoscopy: pattern analysis
Method of diagnosis: in-person diagnosis
Prior test data: clinical evaluation directly followed by dermoscopy
Diagnostic threshold: lesion positive for at least 1 criterion: irregular and multicomponent pig-
mentary network pattern, peripheral dark network patches, sharp network margins, pseudopods (if
network present), radial streaming (if network present), black dots at periphery (if network present)
, blue-grey areas (if network present) and whitish veil (milky way, if network present)
Observers: as described above
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 33
Mild/moderate dysplasia: 23 dysplastic naevi; SK: 4; benign naevus: 158 common naevus
Other: 2 thrombosed angiomas
Flow and timing Excluded participants: no exclusions reported
Time interval to reference test: not described
Time interval between index tests: clinical evaluation directly followed by dermoscopy
Comparative Blinding between tests: clinical evaluation directly followed by dermoscopy
Time interval between index test(s): same day
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
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Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
High High
DOMAIN 2: Index Test Visual Inspection - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low Unclear
DOMAIN 2: Index Test Dermoscopy - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
204Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cristofolini 1994 (Continued)
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Low Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
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Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
DOMAIN 5: Comparative
Was each index test result in-
terpreted without knowledge of
the results of other index tests
or testing strategies?
No
Was the interval between ap-
plication of the index tests less
than one month?
Yes
Were all tests applied and inter-
preted in a clinically applicable
manner?
Unclear
Low Unclear
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Dal Pozzo 1999
Study characteristics
Patient sampling Study design: case series
Data collection: prospective; dermoscopic images assessed remotely from the patient
Period of data collection: January 1992-June 1997
Country: Italy
Test set derived: “Training set” 218 pigmented lesions classified as: 45 melanomas (19 of which in
situ), 38 epithelioid and/or spindle cell naevi; 45 melanocytic naevi; 45 mainly dermal melanocytic
naevi. “Test set”; 713 PSLs-melanocytic in nature consecutively observed
Patient characteristics and set-
ting
Inclusion criteria: PSLs observed clinically and dermoscopically at the Institute of Dermatology
Sciences University of Milan; all excised
Setting: secondary (general dermatology)
Prior testing: NR
Setting for prior testing: NR
Exclusion criteria: none reported
Sample size (participants): NR
Sample size (lesions): number eligible: test set - 713 PSLs; number included: 713
Participant characteristics: NR
Lesion characteristics: NR
Index tests Dermoscopy 7FFM (own new algorithm)
Method of diagnosis: dermoscopic images
Prior test data: no further information used
Diagnostic threshold: the lesions where the sum of the features gave a score ≥ 2 were diagnosed
as being malignant
Diagnosis based on: consensus (3 observers); n = 3
Observer qualifications: NR; appears to be the 3 co-authors; likely expert dermatologists
Experience in practice: not described
Experience with dermoscopy: not described
Any other detail: training set of 218 pigmented lesions used to develop new algorithm. All dermo-
scopic features recorded. Statistical significance of each feature assessed using Chi2 test and Fischer’s
exact test. Final features chosen according to reproducibility by different observers and relationships
with histopathological criteria predictive of malignancy. Final algorithm: to diagnose melanoma
the presence of one major feature or the concurrent presence of two minor features is regarded as
sufficient. “We attributed a score of 2 to themajor features and a score 1 to the minor features: major
features are regression erythema, radial streaming, grey-blue veil, irregularly distributed pseudopods;
minor features are unhomogeneity, irregular pigment network, sharp margin.”
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Disease-positive: 168; disease-negative: 545
Target condition (final diagnoses)
Melanoma (invasive): 139; melanoma (in situ): 29; BCC: 1
Sebhorrheic keratosis: 3;
Benign naevus: junctional melanocytic naevi = 92; mainly junctional compound melanocytic naevi
= 37; compound melanocytic naevi = 224; congenital melanocytic naevi = 20; melanocytic naevi
showing regression and inflammatory infiltrate = 102; combined melanocytic naevi = 8
Epithelioid and/or spindle cell naevi = 53; LS = 3; black reticulated solar lentigo = 1; melanoacan-
thoma = 1
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Flow and timing Excluded participants: none reported
Time interval to reference test: none reported
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Unclear High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
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Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
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If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
di Meo 2016
Study characteristics
Patient sampling Study design: case series
Data collection: retrospective image selection/prospective interpretation
Period of data collection: February-December 2014
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: melanocytic skin lesions that underwent excision
Setting: secondary (general dermatology)
Prior testing: selected for excision (no further detail)
Setting for prior testing: secondary (general dermatology)
Exclusion criteria: acral and mucosal lesions; dysplastic naevi excluded; disagreement between
evaluators on tumour histological classification - lesions that did not meet at least 2 consents were
excluded; poor-quality index test image (considered under flow and timing)
Sample size (participants): number included: 125
Sample size (lesions): number included: 125
Participant characteristics: mean age: men 44.6 years; women 50.0 years; male: 61; 58%
Lesion characteristics: thickness ≤ 1 mm: all 32 melanomas
Index tests Dermoscopy 3PCL; scored 3-point ’4-point checklist’ (authors’ own scoring); CASH algorithm
Method of diagnosis: dermoscopic images
Prior test data: no further information used
Diagnostic threshold: 3PCL ≥ 2 criteria present; CASH score > 7; 4-point checklist > 2
Diagnosis based on: unclear; lesions were “randomly assessed by two independent dermatologists”
not clear if average or consensus; n = 2
Observer qualifications: dermatologist
Experience in practice: high
Experience with dermoscopy: high; dermatologists with > 7 years of experience in dermoscopy
Any other detail:
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The 3PCL criteria: asymmetry in colour and/or structures in 1/2 axes, pigmented network with
thickened lines and irregular distribution, and any blue and/or white structure within the lesion
CASH algorithm has 4 criteria: colour, architectural disorder, symmetry and homo/heterogeneity.
Scoring described in detail
4-point checklist; doubled all 3 criteria of the 3PCL and chose the one conferring more sensitivity,
specificity and accuracy (symmetry parameter doubled)
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
All lesions were excised and independently analysed by 2 dermatopathologists. The diagnosis of
dysplastic naevus was based on the histopathological diagnostic criteria set by the World Health
Organization Melanoma Programme (Clemente 1991). It was considered as a benign lesion
Disease-positive: 32; disease-negative: 93
Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 32
Mild/moderate dysplasia: 50; benign naevus: 43
Flow and timing Excluded participants: dysplastic naevi (n = 50) excluded from 2x2; poor-quality index test images
- exclusion criterion
Interval between index and reference standard: not clearly described
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
High High
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DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Unclear
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
Yes
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matopathologist?
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Yes
High
Dolianitis 2005
Study characteristics
Patient sampling Study design: case series
Data collection: retrospective image selection/prospective interpretation
Period of data collection: July 2001-June 2002
Country: Australia
Patient characteristics and set-
ting
Inclusion criteria: dermoscopy training study using a CD with 5 test sets of images, each with 40
images of melanocytic skin lesions. Only good-quality macroscopic and dermoscopic images were
included
Setting: specialist unit; Victorian Melanoma Service, Department of Dermatology, University of
Melbourne
Prior testing: unclear
Setting for prior testing: NR
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Exclusion criteria: non-melanocytic lesions; poor-quality index test image. Only good-quality
macroscopic and dermoscopic images were included, where the whole lesion was visible, including
the entire periphery (considered under flow/timing)
Sample size (participants): NR
Sample size (lesions): number eligible: 40; number included: 40
Participant characteristics: none reported
Lesion characteristics: ≤ 1 mm thickness: 14 invasive melanomas; median 0.50 mm
Index tests VI: no algorithm
Method of diagnosis: clinical photographs alone
Prior test data: no further information used
Other test data: dermoscopic images presented to observer subsequent to diagnosis using clinical
images alone
Diagnostic threshold: NR
Diagnosis based on: average; 61 participants (invited to participate in a study comparing dermo-
scopic algorithms; advertised at several medical meetings and on a website for primary care physi-
cians)
Observer qualifications: 10 dermatologists, 16 dermatology trainees, 35 GPs
Experience in practice: mixed. Participant (volunteers) ”had a range of experience levels with
assessment of skin lesions [outlined in detail in the paper] .. and a significant number were novices
in dermoscopy”. Paper reports 82% of participants responded that they assessed at least 2-4 PSL
per week
Experience in dermoscopy: mixed (as above); some educational material provided
Dermoscopy: pattern analysis; 7PCL; ABCD; Menzies criteria
Method of diagnosis: dermoscopic images
Prior test data: no further information used. Macroscopic image not shown
Diagnostic threshold: ABCD rule; lesions scoring > 4.75 (i.e. lesions “of concern” were considered
test-positive along with those considered to be melanomas, scoring > 5.45); thresholds NR for the
other algorithms (original studies referenced)
Test observers as described for VI (above)
Dermoscopy training: participants were given explanatory written material as well as 3 CDs. 2
CDs contained educational material on dermoscopy,1 from the American Academy of Dermatology
and the other from the website dermoscopy.org. Participants were advised to work through all the
educational material prior to assessing the test set of images
Length of training: not clear
Post-training experience: < 6 months
Training format: online/written materials/CD-ROM tutorial
Target condition and reference
standard(s)
Reference standard: histological diagnosis + other (1 lesion described as having no biopsy per-
formed). Histology not further described
Disease-positive: 20; disease-negative: 19
Expert diagnosis: 1
Target condition (final diagnoses)
Melanoma (invasive): 18; lentigo maligna 2
Benign naevus: 7 dysplactic naevi; 3 SN; 3 junctional naevi; 2 compound naevi; 4 other (ink-spot
lentigo, blue naevus, solar lentigo, ephelis)
Flow and timing Excluded participants: none reported
Time interval to reference test: NR
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Time interval between index test(s): NR
Comparative Blinding between tests: dermoscopic images presented to observer subsequent to diagnosis using
clinical images alone
Time interval between index test(s): image acquisition NR
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Unclear High
DOMAIN 2: Index Test Visual inspection - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
215Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Dolianitis 2005 (Continued)
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Unclear High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Unclear
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Low High
DOMAIN 3: Reference Standard
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Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
No
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
High High
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
Unclear
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
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DOMAIN 5: Comparative
Was each index test result in-
terpreted without knowledge of
the results of other index tests
or testing strategies?
Yes
Was the interval between ap-
plication of the index tests less
than one month?
Unclear
Were all tests applied and inter-
preted in a clinically applicable
manner?
No
Unclear High
Dreiseitl 2009
Study characteristics
Patient sampling Study design: case series
Data collection: prospective
Period of data collection: test set: February-November 2004
Country: Austria
Test set derived: study focuses on test set but gives detail of separate study in which classifier was
trained
Patient characteristics and set-
ting
Inclusion criteria: patients presenting at PSL clinic
Setting: specialist unit (skin cancer/PLC) The PSL unit of the Department of Dermatology at the
Medical University of Vienna serves as a secondary and tertiary referral centre
Prior testing: NR
Setting for prior testing: specialist unit (skin cancer/PLC)
Exclusion criteria: none reported
Sample size (participants):number eligible: 511; number included: 458with complete information
Sample size (lesions): number eligible: 3827; number included: 3021; however data reported on
a per-participant basis
Participant characteristics: none reported
Lesion characteristics: none reported
Index tests Dermoscopy: no algorithm
Method of diagnosis: in-person diagnosis; physicians were instructed to perform an independent
routine examination on the study participants
Prior test data: clinical examination and/or case notes
Diagnostic threshold: NR; decision to excise to rule out melanoma histopathologically
Diagnosis based on: single observer (n = 1)
Observer qualifications: dermatologist; data reported for 6 additional less experienced observers
using MoleMax II system (reported in CAD review)
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Experience in practice: high experience; “Expert dermatologist”
Experience with dermoscopy: high experience
Target condition and reference
standard(s)
Reference standard: histological diagnosis + follow-up
Histology (excision); number patient/lesions: NR
Clinical follow-up + histology of suspicious lesions Length of follow-up: 6 months; number partic-
ipants: NR
Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 27 participants; 31 lesions
’Benign’ diagnoses: 431 participants; 2990 lesions
Flow and timing Excluded participants: 806 lesions (53 participants) with inadequate follow-up
Index test to reference standard interval:
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
Yes
Did the study avoid including
participants with multiple le-
sions?
Yes
Low Low
DOMAIN 2: Index Test Dermoscopy - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
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If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Unclear Unclear
DOMAIN 4: Flow and Timing
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Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
No
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
Yes
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
Duff 2001
Study characteristics
Patient sampling Study design: case series
Data collection: retrospective
Period of data collection: January 1993-December 1998
Country: UK
Patient characteristics and set-
ting
Inclusion criteria: excised lesions recorded on PLC database with data supplemented with hospital
patient administration system and pathology database
Setting: rapid-access PLC at Frenchay Hospital
Prior testing: selected for excision (no further detail)
Setting for prior testing: specialist unit (skin cancer/PLC)
Exclusion criteria: none reported
Sample size (participants): number eligible: 9968 attended clinic during time period; number
included: NR
Sample size (lesions): number included: 2372 (1256 undertaken immediately)
Participant characteristics: male: 40% (n = 950)
Lesion characteristics: mean thickness of melanomas reported graphically per annum (all estimates
are approximate): 1993, 1.44 mm; 1994, 0.82 mm; 1995, 1.22 mm; 1996, 1.40 mm; 1997, 1.35;
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1998, 0.90 mm
Index tests Dermoscopy; no algorithm
Method of diagnosis: in-person diagnosis
Prior test data: clinical examination and/or case notes
Diagnostic threshold: NR; diagnosis of melanoma
Diagnosis based on: single observer (n = 2 as reported in Kirkpatrick 1995)
Observer qualifications: plastic surgeons
Experience in practice: NR
Experience with dermoscopy: not described; “A consultant examines all lesions with a dermato-
scope.”
Target condition and reference
standard(s)
Reference standard: histology alone; histopathologist with special interest in melanoproliferative
lesions
Disease-positive: 586; disease-negative: 1786
Target condition (final diagnoses)
Melanoma (invasive): 400; melanoma (in situ): 186 (128 in situ 58 LMs)
BCC: 316; cSCC: 97
Atypical/dysplastic 195; “other” 14; ’Benign’: 1164
Flow and timing Participant exclusions: none reported
Index test to reference standard interval: not all lesions were excised immediately (2372 excisions
were undertaken, of which 1256 were done immediately
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
No
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Did the study avoid including
participants with multiple le-
sions?
Unclear
Low High
DOMAIN 2: Index Test Dermoscopy - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
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Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
Dummer 1993
Study characteristics
Patient sampling Study design: case series
Data collection: prospective; dermoscopic images assessed remotely from the patient
Period of data collection: 12 month period (year/dates NR)
Country: Germany
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Patient characteristics and set-
ting
Inclusion criteria: patients with skin lesions difficult to diagnose clinically
Setting: secondary
Prior testing: clinical suspicion of malignancy without dermatoscopic suspicion
Setting for prior testing: specialist unit (skin cancer/PLC) a type of specialist care- dermatology
based clinic
Exclusion criteria: patients who had excisions performed in individual practices or where there was
no histology or cases that were so obvious they didn’t need to have further investigation (clearly
benign)
Sample size (participants): NR
Sample size (lesions): number eligible: 824; number included: 771
Participant characteristics: none reported
Lesion characteristics: none reported
Index tests VI: no algorithm
Method of diagnosis: in person
Prior test data: in person
Other test data: dermoscopic images viewed separately
Diagnostic threshold: NR
Diagnosis based on: single observer; (n = 2 or 3)
Observer qualifications: unclear; clinician based in dermatology clinic (assumed dermatologist)
Experience in practice: unclear
Experience with index test: unclear
Dermoscopy: pattern analysis
Method of diagnosis: dermoscopic images
Prior test data: unclear
Diagnostic threshold: NR
Observers: as described above
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Disease-positive: 23 MM; disease-negative: 748 benign
Target condition (final diagnoses)
Invasive melanoma: 23
Benign naevus 706; SK 4; benign non-melanocytic naevus 32
Flow and timing Excluded participants: 53non-melanocytic lesions not included in the final analysis (nomelanomas
present in this group)
Time interval to reference test: NR
Time interval between index test(s): NR
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
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Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Unclear High
DOMAIN 2: Index Test Visual Inspection - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Unclear High
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DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Low Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
No
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
Unclear
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matopathologist?
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
Durdu 2011
Study characteristics
Patient sampling Study design: case series
Data collection: prospective
Period of data collection: January 2006-January 2009
Country: Turkey
Patient characteristics and set-
ting
Inclusion criteria: PSLs that could not be diagnosed with only dermatologic physical examination
Setting: secondary (general dermatology)
Prior testing: clinical examination and dermoscopy
Setting for prior testing: secondary (general dermatology)
Exclusion criteria: none reported
Sample size (participants): number included: 176
Sample size (lesions): number included: 200
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Participant characteristics: mean age: 48 years (4-85 years). male: 64; 36.4%
Lesion characteristics:9%nodulo-ulcerative, 56%papular, 17%macular, 10%nodular, 8%plaque
Index tests Dermoscopy: ABCD
Method of diagnosis: in-person diagnosis
Prior test data: clinical examination
Diagnostic threshold: 2-step process: step 1 melanocytic and non-melanocytic were differentiated
(Braun 2005; Zalaudek 2008); step 2 ABCD applied to melanocytic lesions only (threshold > 5.45)
Diagnosis based on: single observer; n = 2; 1 for dermoscopy diagnosis and 1 for Tzanck smear
Observer qualifications: dermatologist
Experience in practice: not described
Experience with dermoscopy: not described
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone (excisional biopsies (n = 166) or punch biopsy (n
= 34)
Details: “Biopsy specimens were stained with hematoxylin and eosin. Immunohistochemical (anti-
S-100 and human melanoma black [HMB]-45) and histochemical (Fontana-Masson) stains were
also applied, if necessary”; interpretation by a “pathologist”
Disease-positive: 46; disease-negative: 154
Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 10; BCC: 34; 1 pigmented mammary Paget disease; 1
pigmented metastatic mammary carcinoma
Sebhorrheic keratosis: 24; benign melanocytic naevus: 100; DF 12; warts 16; 1 dirt; 1 hereditary
hemorrhagic telangiectasia
Flow and timing Participant exclusions: none reported
Time interval to reference test: appears consecutive. Following dermoscopic examination and
cytology “either a punch or an excisional biopsy specimen was taken from the lesions and was
examined histopathologically”
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
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Are the included patients and
chosen study setting appropri-
ate?
Yes
Did the study avoid including
participants with multiple le-
sions?
No
Unclear High
DOMAIN 2: Index Test Dermoscopy - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Low Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
Unclear
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interpreted without knowledge
of the results of the index tests?
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
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Feci 2015
Study characteristics
Patient sampling Study design: RCT of the effect of ambient stressors and time constraints on decision making;
PSL images were randomised to control group, ambient stress group and time stress* group (*result
included in main analysis)
Data collection: retrospective image selection/prospective interpretation
Period of data collection: January-December 2013
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: PSLs suspicious for melanoma and with histopathological diagnoses
Setting: secondary (general dermatology)
Prior testing: clinical and/or dermatoscopic suspicion of melanoma or atypical
Setting for prior testing: secondary (general dermatology)
Exclusion criteria: not clearly reported however only melanomas and atypical naevi included
Sample size (participants): number included: appears to be 1 lesion per participant - “consecutive
PSL removed from different patients”
Sample size (lesions): number included: 321; 102 in time stress group
Participant characteristics: none reported
Lesion characteristics: mean thickness 0.28 mm, range - in situ to 1.88 mm
Index tests Dermoscopy: pattern analysis
Method of diagnosis: dermoscopic images
Prior test data: no further information used; “dermatologists” knew neither the aim of the study
nor the number of naevi and melanomas within each sample group
Diagnostic threshold: NR
Diagnosis based on: unclear; appears to be single (and different) observer per arm of the trial (n =
3). The time stress group “simulated clinical decision making by arbitrarily allowing a time of 10s
for the evaluation of each PSL” using Microsoft PowerPoint slide show
Observer qualifications: dermatologist
Experience in practice: high experience
Experience with dermoscopy: high experience; described as “expert dermatologists” “with at least
10 years’ experience in dermoscopy”
Any other detail: dermoscopic image acquisition was performed using DermLite ® II pro (3Gen;
DermLite, San Juan Capistrano,Calif., USA) connected to a Cyber-shot 7.2megapixel camera (Sony
Inc., Tokyo, Japan)
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Details: diagnosis was based on AJCC guidelines (Balch 2001) and always made by the same
pathologist
Disease-positive: 102 (34 per arm); disease-negative: 219 (73 per arm)
Target condition (final diagnoses)
Melanoma (invasive): 69 (33 per arm); melanoma (in situ): 33 (11 per arm)
Benign naevus: benign melanocytic naevi 219
Flow and timing Excluded participants: appear to have excluded on image quality “Among 686 PSL dermoscopic
images acquired during the study period, 321 were suitable for our study”
Time interval to reference test: NR
Comparative
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Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
High High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
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Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
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of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
Feldmann 1998
Study characteristics
Patient sampling Study design: case series
Data collection: prospective
Period of data collection: NR
Country: Austria
Patient characteristics and set-
ting
Inclusion criteria: melanocytic lesions examined by dermatoscopy prior to excision
Setting: secondary (general dermatology)
Prior testing: NR; “selection for excision was not exclusively based on the dermatoscopic findings
but also according to the wishes of the patients.”
Setting for prior testing: NR
Exclusion criteria: none reported
Sample size (participants): NR
Sample size (lesions): number included: 500
Participant characteristics: none reported
Lesion characteristics: mean Breslow thickness 0.49 mm, range 0.12-1.38 mm
Index tests Dermoscopy: ABCD
Method of diagnosis: in-person diagnosis
Prior test data: clinical examination
Diagnostic threshold: > 5.45 (Nachbar 1994); from study results > 4.2
Diagnosis based on: unclear; n = unclear
Observer qualifications: NR
Experience in practice: not described
Experience with dermoscopy: not described
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Details: histology was performed with at least 3 incisions (naevi), and serial sections through the
entire lesion (melanomas). The assessment was based on the generally accepted criteria for dysplasia
and malignancy (1, 4). In the case of diagnostic uncertainties, the Austrian reference center for
histopathological diagnostics carried out a second assessment
Disease-positive: 30 MM; disease-negative: 470
Target condition (final diagnoses)
Melanoma (invasive): 25; melanoma (in situ): 5
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Mild/moderate dysplasia: 190; benign naevus: 272; 7 lentigines 1 lentigo naevi
Flow and timing Excluded participants: results not presented for 8 lesions
Time interval to reference test: appears consecutive; dermoscopy described as used “prior to ...
excision and histology)”
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Unclear High
DOMAIN 2: Index Test Dermoscopy - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
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out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Low Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
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If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
Unclear
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
Ferrari 2015
Study characteristics
Patient sampling Study design: case series
Data collection: retrospective image selection/prospective interpretation
Period of data collection: 2010
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: melanocytic lesions with equivocal clinical and/or dermoscopic features that
underwent excision and had a complete set of dermoscopy and RCM images with histopathology
report. Only dermoscopically featureless (scoring 0-2 on 7PCL) or equivocal lesions (those scoring
3-4 on dermoscopy 7PCL) were included in RCM evaluation
Setting: secondary (general dermatology)
Prior testing: clinical and/or dermatoscopic suspicion
Setting for prior testing: secondary (general dermatology)
Exclusion criteria: incomplete histopathology report; 90 “positive-clear cut” lesions (scoring ≥ 5
on 7PCL) were excluded from RCM evaluation
Poor-quality index test image, “Only lesions with high quality dermoscopic images, a complete
set of confocal images and histopathology report available were included in the study”; considered
under flow and timing
Sample size (participants): number included: NR
Sample size (lesions): number eligible: 322; number included: 322 for dermoscopy; 232 for RCM
Participant characteristics: none reported
Lesion characteristics: overall mean thickness 1.05 +/- 16 mm, range 0-10 mm (70 melanomas)
; those scoring 0-2 on 7PCL: mean 0.18 +/- 0.42 mm; range 0-0.94 mm) (6 melanomas). Those
scoring 3-4 on 7PCL: mean 0.36 +/-0.42, range 0-1.4 mm (17 melanomas)
Index tests Dermoscopy: 7PCL
Method of diagnosis: dermoscopic images
Prior test data: RCM and dermoscopy images interpreted by same observer; no indication of
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randomisation or interpretation in isolation
Diagnostic threshold: “featureless” lesions for score ranging between 0-2, “positive-borderline”
lesions for score between 3-4 and “positive- clear cut” lesions for score from 5-10
Diagnosis based on: single observer (n = 1)
Observer qualifications: dermatologist
Experience in practice: not described
Experience with dermoscopy: assumed to be high, described as “dermatologist trained in der-
moscopy and RCM”
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Details: histopathology was performed by a board-certified pathologist
Disease-positive: 70; disease-negative: 252
Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 70
’Benign’ naevi: 252 (including 15 SN)
Flow and timing Excluded participants: “Only lesions with high quality dermoscopic images, a complete set of
confocal images and histopathology report available were included in the study”
Time interval to reference test: images taken ’before excision’, “Before excision, all lesions were
recorded by means of digital
dermoscopy and RCM”
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
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High High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
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Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
Ferris 2015
Study characteristics
Patient sampling Study design: unclear. Some dermoscopic images were collected prospectively and some were
obtained from collection of existing images; selection process not described
Data collection: retrospective image selection/prospective interpretation
Period of data collection: NR
Country: USA
Test set derived: study developed a newCADclassifier using training/test set of images; plus a ’reader
study’* conducted to compare accuracy with dermatologist interpretation of images (*reported here)
. Some dermoscopic images used to train the classifier were obtained from publicly available or
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purchased image libraries, these were not included in the reader study or used to test the performance
of the classifier. The image set was randomly divided into 2 by diagnosis, with half used for training
and half used for testing, with the exception that all high-grade dysplastic naevi were exclusively
assigned to the training set to increase the representation of dermoscopic features that could be
present in melanoma. Results were extracted only for the test set
Patient characteristics and set-
ting
Inclusion criteria: dermoscopic images of skin lesions excised on the basis of clinical suspicion
of malignancy, with available histologic diagnoses. Reader study included one melanoma that was
misclassified as benign by the new CAD classifier + random sample of images determined to be of
suitable quality for display on a computer screen
Setting: secondary (general dermatology)
Prior testing: clinical suspicion (no further detail)
Setting for prior testing: secondary (general dermatology)
Exclusion criteria: high-grade dysplastic naevi were not included in the test set or reader study
Sample size (participants): number eligible: NR; number included: NR
Sample size (lesions): number eligible: 473 (includes 273 randomised to training set and 27 non-
biopsied lesions); number included: CAD test set 173 lesions; dermoscopy- 65 lesions
Participant characteristics: none reported
Lesion characteristics: test set: mean lesion thickness 0.76 mm, median 0.5 mm, range 0.2-98
mm); reader study: mean 0.93 mm, median 0.74 mm, range 0.2-98 mm
Index tests Dermoscopy: no algorithm
Method of diagnosis: dermoscopic images
Prior test data: no further information used
Diagnostic threshold: NR
Diagnosis based on: average (n = 30); 35 invited to participate.
Observer qualifications: 2 board-certified dermatologists, 10 dermatology residents, and 8 physi-
cian assistants currently practicing dermatology
Experience in practice: mixed
Experience with dermoscopy: mixed; all observers self-reported some training and experience with
the use of dermoscopy. Among board-certified dermatologists, 67% reported using dermoscopy
“always/almost always” or “very frequently.”, compared to 90% of the dermatology residents and
75% of the physician assistants
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Details: all lesions were biopsied based on clinical suspicion of malignancy. All histologic diagnoses
were rendered by at least 1 board-certifieddermatopathologist andwere used as the reference standard
for diagnosis
Disease-positive: dermoscopy 25 MM; CAD 39 MM/disease-negative: dermoscopy 40 MM; CAD
134 MM
Target condition (final diagnoses)
For reader study only:
Invasive melanomas 15; melanoma in situ 10
Low-grade dysplastic naevi 16, benign naevi 14 , blue naevi 2, lentigines 4 , SK 4
Flow and timing Excluded participants: none reported
Time interval to reference test: “Dermoscopic images of skin lesions were collected before biopsy”
Comparative
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Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Unclear
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Unclear High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
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Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
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of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Low
Friedman 2008
Study characteristics
Patient sampling Study design: case-control
Data collection: retrospective image selection/prospective interpretation
Period of data collection: NR; lesions selected in July 2005
Country: USA
Test set derived: MelaFind data randomly split into training and test sets however Melafind has
previously been evaluated, the only difference here being that only small lesions were included. Full
dataset included in review
Patient characteristics and set-
ting
Inclusion criteria: a database of images of PSLs ≤ 6 mm was used to sample images of melanoma
and non-melanoma lesions; ”approximately 80% of the lesions were biopsied to rule out melanoma,
whereas the remaining lesionswere biopsiedmostly to rule out non-melanoma skin cancer or because
of patient concern.“
Setting: mixed (private and secondary); digital dermoscopic database acquired by Electro-Optical
Sciences Inc for the development and testing of MelaFind; 26 clinical sites have contributed (der-
matologic hospital-based clinics and private practice offices)
Prior testing: selected for excision (no further detail). All lesions excised or underwent shave biopsy
Setting for prior testing: NR
Exclusion criteria: high-grade dysplastic naevi were excluded. Previously biopsied, ulcerated, or
bleeding lesions also excluded, as were those on mucosal surfaces and lesions that contained foreign
matter (e.g. tattoos)
Sample size (participants): number included: 94
Sample size (lesions): number eligible: 1977; number included: 99
Participant characteristics: none reported
Lesion characteristics: 21 invasive MM: median thickness 0.32 mm (0.10-1.40 mm). Lesion size:
range: 2 mm-22 mm
Index tests Dermoscopy: no algorithm
Method of diagnosis: dermoscopic images. Readers were provided with a CD-ROM with colour
dermoscopic images created using MelaFind multispectral image; for some cases standard dermo-
scopic images were also available. The equivalence of the 2 image types was assessed for a sample of
10 lesions by 3 readers
Prior test data: readers provided with participant gender, age, and lesion location; all evaluations
were performed independently
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Diagnostic threshold: clinical diagnosis; “Is this lesion a melanoma?” and “Would you biopsy/
excise this lesion?”. If readers indicated that they would biopsy the lesion because they were sure it
was melanoma or to rule out melanoma, then the case was considered true-positive
Diagnosis based on: average; mean and median reported (n = 10); used mean value for review
purposes
Observer qualifications: 9 dermatologists; 1 nurse practitioner specialising in dermatology
Experience in practice: high experience or ‘Expert’; ”All 10 readers were expert dermoscopists (9
dermatologists and 1 nurse practitioner specialising in dermatology)
Experience with dermoscopy: high experience /‘Expert’ users
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Details: the original histology slides were evaluated by 2 out of 4 study dermatopathologists without
knowledge of any additional clinical information; in cases of significant discordance in diagnoses,
the slide was reviewed by a third study dermatopathologist. A lesion with at least 1 diagnosis of
melanoma by the study dermatopathologists was consideredmelanoma. Dysplastic naevi with severe
cytologic atypia were considered high grade, and those withmild tomoderate atypia were considered
low grade
Disease-positive: 49; disease-negative: 50
Target condition (final diagnoses)
Melanoma (invasive): 21; melanoma (in situ): 28; BCC: 2
Mild/moderate dysplasia: 32 low-grade dysplastic; SK: 2; 14 other benign
Flow and timing Participant exclusions: none reported
Index test to reference standard interval: timing between image acquisition and original histology
NR
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
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Did the study avoid including
participants with multiple le-
sions?
Yes
High High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
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Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
Gereli 2010
Study characteristics
Patient sampling Study design: case-control
Data collection: retrospective image selection/prospective interpretation
Period of data collection: NR
Country: Turkey
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Patient characteristics and set-
ting
Inclusion criteria: images of melanoma and non-melanoma PSLs; non-melanoma lesions clinically
considered to be atypical before dermoscopic examination and excisional biopsy. Atypicality was
determined by the presence of≥ 3 of the following features: a diameter > 5 mm, ill-defined borders,
irregular margins, and the presence of papular and macular components. Melanoma and non-
melanoma lesions separately sampled
Setting: secondary (general dermatology). Authors’ institution:DeptDermatology, Istanbul, Turkey
Prior testing: clinical suspicion of malignancy
Setting for prior testing: NR
Exclusion criteria: none reported
Sample size (participants): NR
Sample size (lesions): number included: 96
Participant characteristics: none reported
Lesion characteristics: all > 5 mm diameter
Index tests Dermoscopy: 3-point rule; 7PCL
Method of diagnosis: dermoscopic images
Prior test data: no further information used
Diagnostic threshold: 3-point rule: ≥ 2 characteristics present (asymmetry, atypical pigment net-
work, blue-white structures); 7PCL: ≥ 3 characteristics present (atypical pigment network, blue-
whitish veil, atypical vascular pattern, irregular streaks, irregular dots/globules, irregular pigmenta-
tion, regression structures)
Diagnosis based on: average (n = 3)
Observer qualifications: NR; likely dermatologists (co-authors based in Dept Dermatology)
Experience in practice: mixed: “two experienced and one inexperienced observers”
Experience with dermoscopy: mixed
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone (no further details)
Disease-positive: 48; disease-negative: 48
Target condition (final diagnoses)
Melanoma (invasive): 44 (14 superficial spreading, 12 nodular, 10 acral, 4 lentiginous, 4 without
classification of tumour thickness); melanoma (in situ): 4
Sebhorrheic keratosis: 2; blue naevi 2; melanocytic naevi 44
Flow and timing Participant exclusions: none reported
Index test to reference standard interval: not described
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
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Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
High High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Unclear
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Low High
DOMAIN 3: Reference Standard
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Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
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Study characteristics
Patient sampling Study design: case series
Data collection: retrospective image selection/prospective interpretation
Period of data collection: 2003-2008
Country: Austria
Test set derived: NR. Training set: 65 melanomas and 65 dysplastic naevi, test set: 36 melanomas
and 33 dysplastic naevi (included in review)
Patient characteristics and set-
ting
Inclusion criteria: atypical melanocytic lesions with polarised dermoscopic images; describes
database as a “random, but representative, cohort” but does not describe method of selection
Setting: secondary (general dermatology)
Prior testing: unclear
Setting for prior testing: NR
Exclusion criteria: none reported
Sample size (participants): number included: NR
Sample size (lesions): number included: 199: derivation set n = 130; test set n = 69
Participant characteristics: none reported
Lesion characteristics: none reported
Index tests Dermoscopy: no algorithm
Method of diagnosis: dermoscopic images
Prior test data: no further information used; described as blinded assessment
Diagnostic threshold: NR; subjective impression; excise or not
Diagnosis based on: single observer (n = 1)
Observer qualifications: dermatologist
Experience in practice: not described
Experience with dermoscopy: not described; implies high or expert assessment. Conducted by 1
of the co-authors
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Details: “lesions were excised and examined microscopically by expert dermatopathologists using
standard: histopathologic diagnostic criteria”
Disease-positive: 36 = test set and 65 = derivation set; disease-negative: 33 = test set and 65 =
derivation set
Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 36 test set and 65 derivation set
Dysplastic naevi: 33 test set and 65 derivation set
Flow and timing Participant exclusions: none reported
Index test to reference standard interval: not described
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
252Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Gilmore 2010 (Continued)
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Unclear High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
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Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
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1 month or less?
Unclear
Glud 2009
Study characteristics
Patient sampling Study design: case series
Data collection: prospective; dermoscopic images assessed remotely from the patient
Period of data collection: January-April 2007
Country: Denmark
Patient characteristics and set-
ting
Inclusion criteria: patients referred for excision biopsy of pigmented lesions where the diagnosis of
melanoma could not be excluded on clinical investigation
Setting: secondary (other); Dept Plastic Surgery and Burn Unit
Prior testing: clinical suspicion of malignancy
Setting for prior testing: secondary (not further specified)
Exclusion criteria: none reported
Sample size (participants): number included: 65
Sample size (lesions): number included: 83
Participant characteristics: median age 47 years (18-90 years); male = 29; 45%
Lesion characteristics: melanoma thickness 0.29 mm-18 mm
Index tests Dermoscopy: no algorithm
Method of diagnosis: dermoscopic images
Prior test data: no further information used
Diagnostic threshold: NR; diagnosis of melanoma
Diagnosis based on: single observer (n = 1)
Observer qualifications: dermatologist
Experience in practice: high
Experience with dermoscopy: high experience; “dermoscopic images were examined by an expe-
rienced dermatologist”
Any other detail: the dermoscopic and SIAgraphic images were obtained by SIAscope II (Amon
Clinica, Cambridge, UK) and stored using the proprietary Dermetrics software (Astron Clinica)
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Details: following image acquisition “the excision biopsy was performed and an experienced
histopathologist examined the tissue”. Breslow thickness and Clark level were determined by stan-
dard: histopathologic examination. Tumour staging was performed as described by Balch et al ac-
cording to the 2001 melanoma staging system (Balch 2001).
Disease-positive: 12; disease-negative: 71
Target condition (final diagnoses)
Melanoma (invasive): 7; melanoma (in situ): 5; 1 melanoma metastasis (included as benign)
Sebhorrheic keratosis: 1; benign naevus: 57; ’Benign’ diagnoses: BD 1, haemangioma 1, LS 2,
epidermal naevi 2, DF 6
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Flow and timing Participant exclusions: none reported
Index test to reference standard interval: following image acquisition “the excision biopsy was
performed”
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
No
Low High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
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Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
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If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Low
Gokdemir 2011
Study characteristics
Patient sampling Study design: case series
Data collection: NR
Period of data collection: 2005-2009
Country: Turkey
Patient characteristics and set-
ting
Inclusion criteria: patients with melanocytic and non-melanocytic skin lesions excised due to
dermoscopic suspicion of malignancy or dysplasia
Setting: secondary (general dermatology)
Prior testing: NR
Setting for prior testing: unspecified
Exclusion criteria: none reported
Sample size (participants): number eligible: 1264; number included: 362
Sample size (lesions): number included: 449
Participant characteristics: mean age 40.3 years (+/- 1.08), range 1-89 years; male: 160; 44.2%
Lesion characteristics: none reported
Index tests Dermoscopy: no algorithm
Method of diagnosis: unclear; appears to be in-person diagnosis
Prior test data: clinical examination
Diagnostic threshold: NR; diagnosis of melanoma
Diagnosis based on: unclear (n = NR)
Observer qualifications: dermatologist
Experience in practice: not described
Experience with dermoscopy: high experience; at least 2 years’ experience with Molemax II
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone; not further described
Disease-positive 13; disease-negative 433
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Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 13; BCC: 45
Benign: not described
Flow and timing Participant exclusions: none reported
Index test to reference standard interval: NR
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
No
Unclear High
DOMAIN 2: Index Test Dermoscopy - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
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or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
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Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
Grimaldi 2009
Study characteristics
Patient sampling Study design: case series
Data collection: prospective
Period of data collection: October 2005-March 2006
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: cutaneous pigmented lesions with digital images forwarded by primary care
physicians to a referral centre for confirmation of diagnosis
Setting: primary; lesions selected for referral by GPs; accuracy of GP diagnosis assessed
Prior testing: NR
Setting for prior testing: NR
Exclusion criteria: lesions whose removal had been explicitly demanded by the patients for aesthetic
reasons, as well as those irritated or subjected to trauma
Sample size (participants): number included: 197
Sample size (lesions): number included: 235
Participant characteristics: none reported
Lesion characteristics: none reported
Index tests VI: no algorithm
Method of diagnosis: in-person diagnosis
Prior test data: N/A; in-person diagnosis
Other test data: “two-step judgment (before and after dermoscopy) formulated by the sending
physician, who labelled each lesion as ‘benign’ or ‘suspicious for malignancy”’
Diagnostic threshold:NR “Each physician was asked to formulate a written first judgment of every
lesion before digital acquisition and to re-evaluate it after dermoscopy”
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Diagnosis based on: single observer; (n = 13)
Observer qualifications: GP; from approximately 250 primary care clinicians attending a confer-
ence, 13 volunteered to participate
Experience in practice: not clearly described; assumed to be low experience with pigmented lesions
Experience in dermoscopy: unclear; classified as ’trained’, “simple protocols for diagnosis were
made up and given to the participants via e-learning courses, direct meetings, and involving self
assessment procedures”
Dermoscopy: ABCD
Method of diagnosis: in-person diagnosis
Prior test data: clinical examination and/or case notes
Diagnostic threshold: NR; “The evaluation method followed the ABCD rule of dermoscopy”
(Nachbar 1994); not fully clear whether this relates to GP in-person diagnosis or telediagnosis at
reference centre, “two-step judgment (before and after dermoscopy) formulated by the sending
physician, who labelled each lesion as ‘benign’ or ‘suspicious for malignancy’.”
Dermoscopy training: “During the first phase of the study, simple protocols for diagnosis were
made up and given to the participants via e-learning courses, direct meetings, and involving self-
assessment procedures (Pagnanelli 2003).”
Length of training: NR
Training format: online/in-person teaching/self-assessment procedures
Target condition and reference
standard(s)
Reference standard: histological diagnosis + follow-up (reference is expert diagnosis for telederma-
tology component of study)
Histology (not further described): n = 16; disease-positive: 5; disease-negative: 11
Clinical follow-up (6 months) + histology of suspicious lesions: n = 219; disease-positive: 0; disease-
negative: 208
Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 5
Other: 230 benign
Flow and timing Excluded participants: NR
Time interval to reference test: NR
Time interval between index test(s): NR
Comparative Blinding between tests: in-person without and with dermocopy
Time interval between index test(s): same day
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
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Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
Yes
Did the study avoid including
participants with multiple le-
sions?
No
Low High
DOMAIN 2: Index Test Visual Inspection - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
No
Unclear High
DOMAIN 2: Index Test Dermoscopy - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
Yes
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dard?
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
No
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
High Unclear
DOMAIN 4: Flow and Timing
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Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
Yes
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
DOMAIN 5: Comparative
Was each index test result in-
terpreted without knowledge of
the results of other index tests
or testing strategies?
No
Was the interval between ap-
plication of the index tests less
than one month?
Yes
Were all tests applied and inter-
preted in a clinically applicable
manner?
Yes
Low Low
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Study characteristics
Patient sampling Study design: case series
Data collection: prospective
Period of data collection: September 2004-August 2007
Country: Italy (and Australia - see Guitera 2009b (Sydney))
Patient characteristics and set-
ting
Inclusion criteria: lesions suspicious of melanoma based on dermatoscopic diagnostic criteria or
lesion change; included only a random sample of 50% of benign naevi observed during time period
Setting: secondary (general dermatology); Department of Dermatology, University of Modena,
Italy
Prior testing: clinical and/or dermatoscopic suspicion/changes on digital monitoring
Setting for prior testing: secondary (general dermatology)
Exclusion criteria: location/site of lesion lesions on soles/palms excluded; lentigomaligna excluded;
lesions used in previous assessments or RCM model development
Sample size (participants): number included: 195
Sample size (lesions): number included: 195
Participant characteristics: median age: 42 (7-88 years); IQR 32y, 59y; male: 51.3%
Lesion characteristics: pigmented: 92%; 8% amelanotic lesions or those with tan, light grey, or
pale blue pigment only). Median thickness 0.65 mm (IQR 0.23mm, 0.98mm)
Index tests Dermoscopy: pattern analysis
Method of diagnosis: in-person diagnosis; at time of first consultation and prior to RCM
Prior test data: clinical examination
Diagnostic threshold: NR
Diagnosis based on: single observer (n = 1)
Observer qualifications: dermatologist; not clearly reported, but is study co-author
Experience in practice: high experience
Experience with dermoscopy: high experience; described as Modena expert based in Dermatology
Dept
Other detail: hand-held dermoscope (Delta 10, Heine, Herrsching, Germany)
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone (not further described)
Disease-positive: 79; disease-negative: 116
Target condition (final diagnoses)
Melanoma (invasive): 61; melanoma (in situ): 18
Benign naevus: 116 (78 compound, 0 dermal, 16 junctional, and 22 Spitz)
Flow and timing Excluded participants: only 50% of imaged naevi were included (randomly selected from the image
database prior to analysis) to reduce the MM/naevus ratio
Time interval to reference test: consecutive; imaged prior to biopsy
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
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DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
High High
DOMAIN 2: Index Test Dermoscopy - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
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Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
No
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1 month or less?
High
Guitera 2009b (Sydney)
Study characteristics
Patient sampling Study design: case series
Data collection: prospective; dermoscopic images assessed remotely from the patient
Period of data collection: September 2004-August 2007
Country: Australia (and Italy - see Guitera 2009a (Modena))
Patient characteristics and set-
ting
Inclusion criteria: lesions suspicious of melanoma based on dermatoscopic diagnostic criteria or
lesion change
Setting: specialist clinic; Sydney Melanoma Diagnostic Centre, Australia
Prior testing: clinical and/or dermatoscopic suspicion/changes on digital monitoring
Setting for prior testing: specialist clinic
Exclusion criteria: location/site of lesion lesions on soles/palms excluded. Lentigomaligna excluded;
lesions used in previous assessments or RCM model development
Sample size (participants): number included: 131
Sample size (lesions): number eligible 156 number included: 131
Participant characteristics: median age: 52 (19-90years); IQR 40, 63y; male: 58.8%
Lesion characteristics: pigmented: 84%; 16% amelanotic lesions or those with tan, light grey, or
pale blue pigment only). Median thickness 0.40 mm (IQR 0, 0.84 mm)
Index tests Dermoscopy: pattern analysis
Method of diagnosis: dermoscopic images
Prior test data: lesion site and age available to observer; dermoscopy diagnosis of Sydney lesions was
made retrospectively on the images in a random order, blinded to RCM and pathological diagnosis
but not to information of site and age, by aModena expert (GP) using pattern analysis (Pehamberger
1993)
Diagnostic threshold: NR
Diagnosis based on: single observer (n = 1)
Observer qualifications: assume dermatologist; described as Modena expert based in Dermatology
Dept
Experience in practice: high experience
Experience with dermoscopy: high experience
Other detail: Sydney; high-resolution digital oil immersion dermoscopy camera (Sentry, Polartech-
nics Ltd, Sydney, NSW, Australia)
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone (no further details)
Disease-positive: 44; disease-negative: 87
Target condition (final diagnoses)
Melanoma (invasive): 26; melanoma (in situ): 16
Benign naevus: 87 (49 compound, 9 dermal, 26 junctional, and 3 Spitz)
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Flow and timing Excluded participants: 25 lesions out of 156 were rejected for poor-quality dermoscopy image,
blinded to the diagnostician
Time interval to reference test: imaged prior to biopsy
Time interval between index test(s): N/A
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
High High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
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the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
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If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
Haenssle 2010a (FV)
Study characteristics
Patient sampling Study design: case series
Data collection: prospective
Period of data collection: 1998-2008
Country: Germany
Patient characteristics and set-
ting
Inclusion criteria: participants at increased risk for melanoma: >50 common and/or ≤ 3 atypical
naevi; atypical mole syndrome; or familial atypical mole and multiple melanoma syndrome
Setting: secondary (dermatology)
Prior testing: all identified as high risk
Setting for prior testing: NR
Exclusion criteria: patients showing melanoma development on pre-existing pigmented lesions
during the following 12 months after the analysed time frame
Sample size (participants): 688
Sample size (lesions): 11,137
Participant characteristics: mean age 42 (range NR). 60% male. Group 1 (50 common and/or ≤
atypical naevi) 67%; Group 2 (atypical mole syndrome) 31.8%; Group 3 (familial atypical mole
and multiple melanoma syndrome) 1.2%. Personal history of melanoma (29.2%); family history
of melanoma (13.1%); high number (> 50) of naevi (56.4%)
Lesion characteristics: NR
Index tests Dermoscopy: 7PCL
Method of diagnosis: in person
Prior test data: also considered lesional history (e.g., increase in size, itching, scaling, change in
colour, intermittent bleeding), and the ugly duckling sign (Grob 1998) and ’moles-breed-true’
concept (Scope 2006). Lesions scoring < 3 on 7PCLwere excised if these other factors were present at
first visit. Lesions scoring < 3with defined clinical or dermatoscopic criteria of atypia (e.g. asymmetry
in shape, irregular margin, variegated colour, prominent pigment network) (Ascierto 2000) were
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marked on digital overview images and electronically stored by using two digital dermatoscopy
systems for follow-up
Diagnostic threshold: ≥ 3
Diagnosis based on: consensus of 2
Observer qualifications: dermatology residents (n = 13); supervised by experienced dermatologist
Experience in practice: NR
Experience with dermoscopy: high; formally trained in dermoscopy
Target condition and reference
standard(s)
Reference standard: histology or follow-up (every 3, 6, or 12 months)
Target condition (final diagnoses)
Invasive melanoma 77; melanoma in situ 50; BCC 2
Benign naevi 1047; SN 16; SK 12; other benign 9935 (not excised)
Flow and timing Excluded participants: none reported
Time interval to reference test: consecutive
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
No
High High
DOMAIN 2: Index Test Dermoscopy - in-person
Were the index test results in-
terpreted without knowledge of
Yes
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the results of the reference stan-
dard?
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
High Unclear
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DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
Haenssle 2010b (FU)
Study characteristics
Patient sampling Study design: case series
Data collection: prospective
Period of data collection: 1998-2008
Country: Germany
Patient characteristics and set-
ting
Inclusion criteria: participants at increased risk for melanoma: > 50 common and/or ≤ 3 atypical
naevi; atypical mole syndrome; or familial atypical mole and multiple melanoma syndrome
Setting: secondary (dermatology)
Prior testing: all identified as high risk
Setting for prior testing: NR
Exclusion criteria: patients showing melanoma development on pre-existing pigmented lesions
during the following 12 months after the analysed time frame
Sample size (participants): 688
Sample size (lesions): 11,137
Participant characteristics: mean age 42 (range NR). 60% male. Mean age 42 (range NR). 60%
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male. Group 1 (50 common and/or ≤ atypical naevi) 67%; Group 2 (atypical mole syndrome) 31.
8%; Group 3 (familial atypical mole and multiple melanoma syndrome) 1.2%. Personal history of
melanoma (29.2%); family history of melanoma (13.1%); high number (> 50) of naevi (56.4%)
Lesion characteristics: NR
Index tests Dermoscopy: 7PCL
Method of diagnosis: in person
Prior test data: also considered lesional history (e.g. increase in size, itching, scaling, change in
colour, intermittent bleeding), and the ugly duckling sign (Grob 1998) and ’moles-breed-true’
concept (Scope 2006). Lesions scoring < 3 on 7PCLwere excised if these other factors were present at
first visit. Lesions scoring < 3with defined clinical or dermatoscopic criteria of atypia (e.g. asymmetry
in shape, irregular margin, variegated colour, prominent pigment network) (Ascierto 2000) were
marked on digital overview images and electronically stored by using 2 digital dermatoscopy systems
for follow-up
Diagnostic threshold: ≥ 3
Diagnosis based on: consensus of 2
Observer qualifications: dermatology residents (n = 13); supervised by experienced dermatologist
Experience in practice: NR
Experience with dermoscopy: high; formally trained in dermoscopy
Target condition and reference
standard(s)
Reference standard: histology or follow-up (every 3, 6, or 12 months); mean follow-up 44.28
(range 2-123) months
Target condition (final diagnoses)
Invasive melanoma 77; melanoma in situ 50; BCC 2
Benign naevi 1047; SN 16; SK 12; other benign 9935 (not excised)
Flow and timing Excluded participants: none reported
Time interval to reference test: consecutive
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
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Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
No
High High
DOMAIN 2: Index Test Dermoscopy - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
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Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
High Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
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Study characteristics
Patient sampling Study design: RCT of diagnosis based on clinical/dermoscopic images versus same + MelaFind,
with observers randomised between arms. Lesions selected on a case-control type basis with cases
and controls sampled from a previous study (Monheit 2011).
Data collection: retrospective image selection/prospective interpretation
Period of data collection: NR
Country: USA
Patient characteristics and set-
ting
Inclusion criteria: subset of PSLs evaluated in Monheit 2011; melanoma and non-melanoma
randomly selected
Setting: mixed secondary/private; lesions sampled from Monheit 2011 trial: “Seven clinical sites
with 23 investigators participated in this trial. Three sites were academic institutions (University of
Pittsburgh, Duke University, and Northwestern University), and 4 sites were dermatologic practices
highly experienced in managing PLs.”
Prior testing: selected for excision (no further detail)
Setting for prior testing: NR
Exclusion criteria: ulcerated or non-pigmented lesions, or located on excluded anatomic sites.
Lesions with prebiopsy clinical diagnoses of melanoma were excluded from Monheit 2011
Sample size (participants): number included: 130
Sample size (lesions): number eligible: 1632 lesions in Monheit trial; number included: 130
Participant characteristics: none reported
Lesion characteristics: head/neck 23%; trunk 41.5%; upper limbs/shoulder 20%; lower limbs/hip
16.2%. Median thickness (melanomas) 0.39 mm (range 0.12-1.2 mm)
Index tests Dermoscopy: no algorithm
Method of diagnosis: clinical photographs and dermoscopic images (Arm 1 and Arm 3 of trial;
Arm 2 included MelaFind images)
Prior test data: clinical images (overview and close up); + 24 items regarding patient demographics
and risk factors for melanoma such as: personal or family history of melanoma, number of atypical
naevi, Fitzpatrick skin type, number of severe sunburns before and after age 20, etc
Diagnostic threshold: biopsy decision
Diagnosis based on: average. Board-certified dermatologists who were members of a public der-
matology list volunteered to participate in the trial. Selection was made on a first-come basis with
randomisation between 2 study arms until at least 65 dermatologists participated in each Arm. Of
the 227 dermatologists registered, 211 completed at least 78 cases and therefore were considered
eligible. Finally included 101/108 dermatologists in Arm 1 and 101/108 dermatologists in Arm 2
(MelaFind). A 3rd arm included 9/12 PSL experts “prospectively identified by the Principal Inves-
tigator based on field standing prior to participant recruitment”
Observer qualifications: dermatologists
Experience in practice: high; all board-certified, in Arm 1 > 90% had > 10 years’ experience in
practice; Arm 3 consisted of PSL experts
Experience with dermoscopy: high; for Arm 1 all except 6 were trained in dermoscopy use and
80/101 always or almost always used dermoscopy for PSLs; Arm 3 consisted of PSL experts
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Details: fromMonheit 2011, the electronic case record included details of the “prebiopsy diagnoses
(without dermoscopy and, if available, with dermoscopy) by the examining dermatologists”, “if the
dermatologic diagnosis was not melanoma, the reason for the biopsy was selected from the following:
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non-melanoma skin cancer, patient’s concern, patient’s discomfort, cosmetic, or, if dermoscopic
evaluation was used, clinical concern. A histologic specimen with the standard: hematoxylin-eosin
staining was provided for each lesion.” “Histologic slides for each lesion ... were evaluated by 2
independent dermatopathologists. In cases of significant discordance, histologic slideswere evaluated
independently by a third dermatopathologist. When 1 dermatopathologist diagnosed melanoma
and 2 others diagnosed a benign lesion, histologic slides were sent again to the dermatopathologist
who diagnosed melanoma for a blind re-review.”
Disease-positive: 65; disease-negative: 65
Target condition (final diagnoses)
Melanoma invasive: 36; melanoma in situ: 29
’Benign’ diagnoses: 65
Flow and timing Participant exclusions: none reported
Index test to reference standard interval: appears consecutive
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
High High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
Yes
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dard?
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Yes
Low Low
DOMAIN 4: Flow and Timing
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Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Low
Kittler 1998
Study characteristics
Patient sampling Study design: unclear
Data collection: retrospective image selection/prospective interpretation
Period of data collection: NR
Country: Austria
Patient characteristics and set-
ting
Inclusion criteria: PSL images ’selected’ by PSL experts from pigmented lesion image database
on the basis of quality of the photograph and the difficulty of diagnosis; all “melanomas selected
provided only subtle ELM features as clues to the malignancy of the lesion and were difficult to
differentiate from benign PSLs”
Setting: secondary (not further specified)
Prior testing: dermatoscopic suspicion in all cases
Setting for prior testing: secondary (general dermatology); selected from PSL database
Exclusion criteria: none reported
Sample size (participants): NR
Sample size (lesions): number included: 50
Participant characteristics: none reported
Lesion characteristics: median Breslow thickness of the MMs: 0.7 mm (IQR 0.5-0.95 mm)
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Index tests Dermoscopy: no algorithm
Method of diagnosis: dermoscopic images; both photographic slides and compressed digital images
assessed to determine whether compressed images are sufficiently informative for diagnosis; 2x2
based on digital images used for primary analysis
Prior test data: no further information used. Images viewed in 2 sessions; in each session 25 slides
and 25 digital images were viewed
Diagnostic threshold: clinical diagnosis; rated as definitely or probably melanoma; unclear whether
2x2 based on ’definite’ only as test positive or definite/probable combined
Diagnosis based on: single observer; n = 8 readers, reported separately
Observer qualifications: dermatologist
Experience in practice: not described
Experience with dermoscopy: not described; described as ’pre-trained in ELM’
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone (no further details)
Disease-positive: 23; disease-negative: 27
Target condition (final diagnoses)
Melanoma (invasive or in situ): 23
Sebhorrheic keratosis: 1; atypical naevus 17; common naevus 9
Flow and timing Participant exclusions: poor-quality images excluded; “selected’ from pigmented lesion image
database on the basis of quality of the photograph”
Index test to reference standard interval: NR
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Unclear
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
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Unclear High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
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Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
Kittler 1999
Study characteristics
Patient sampling Study design: case series
Data collection: prospective
Period of data collection: November 1996-November 1997
Country: Austria (from authors’ institution)
Patient characteristics and set-
ting
Inclusion criteria: PSLs < 1 cm in diameter, consecutively excised
Setting: secondary (general dermatology). From authors’ institution
Prior testing: selected for excision (no further detail)
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Setting for prior testing: NR
Exclusion criteria: lesion size ≥ 1 cm
Sample size (participants): number included: 352
Sample size (lesions): number included: 373
Participant characteristics: mean age 52 (SD 17 years); male: 49%
Lesion characteristics: median thickness 0.65 mm (range, 0.2-2 mm)
Index tests Dermoscopy: ABCD; ABCDE (developed in this study)
Method of diagnosis: in-person diagnosis
Prior test data: clinical examination
Diagnostic threshold: range of numerical thresholds evaluated
’Standard’ ABCD applied as previously described by Stolz 1994a and Nachbar 1994. Sensitivities
reported for a range of specificities but cut-offs NR (author communication suggested a threshold
of > 4.75 was used but not clear which sensitivity/specificity pair this relates to); randomly selected
dataset at 75% specificity for inclusion in primary analysis
’Enhanced’ ABCD-E algorithm accounts for participant report of changes in the lesion within
the previous year. The overall score was calculated by adding 1.2 to the standard ABCD score
for changing lesions and subtracting 0.8 from the standard ABCD score for non-changing lesions
according to the results of a multivariate analysis. ABCDE results reported at cut-offs ranging from
1.30-7.35
Diagnosis based on: unclear; appears to be in clinic diagnoses (n = NR)
Observer qualifications: NR; likely dermatologists
Experience in practice: not described
Experience with dermoscopy: not described
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Details: ”After excision all lesions were subjected to standard: histopathologic examination. The his-
tologic diagnosis of an atypical naevus was based on the following criteria: cellular atypia, lentiginous
hyperplasia of the epidermis, fibroplasia, bridging of rete ridges, suprabasal melanocytes, junctional
nest disarray
Disease-positive: 73; disease-negative: 283
Target condition (final diagnoses)
Melanoma (invasive): 55 (51 superficial spreading, 4 nodular, 15 lentigo maligna, 3 otherwise non-
classified melanomas); melanoma (in situ): 18
Sebhorrheic keratosis: 4; 126 (35.4%) common naevi, 113 (31.7%) atypical (dysplastic) naevi, 3
(0.8%) congenital naevi, 13 (3.7%) pigmented SN, 7 (0%) blue naevi, 2 (0.6%) combined naevi,
14 (3.9%) solar lentigines, 1 DF
Flow and timing Participant exclusions: non-melanocytic lesions (n = 17; including angiomatous tumours, pig-
mented SK, dFs, and pigmented BCCs) easily distinguished by standard ELM criteria and pattern
analysis
Index test to reference standard interval: not described
Comparative
Notes -
Methodological quality
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Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
No
High High
DOMAIN 2: Index Test Dermoscopy - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
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Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
High Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
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If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
Kittler 2001
Study characteristics
Patient sampling Study design: case-control
Data collection: retrospective image selection/prospective interpretation
Period of data collection: NR
Country: NR
Patient characteristics and set-
ting
Inclusion criteria: images of naevi frompatients withmultiple atypical naevi undergoing digital der-
moscopy follow-up. All melanomas were excised due to changes on follow-up; benign melanocytic
skin lesions included were taken at random from the participants with melanoma + other randomly
selected patients with multiple atypical naevi
Setting: secondary (assumed); states “a database” Authors’ Inst: Dept Dermatology, University of
Vienna
Prior testing: all undergoing follow-up
Setting for prior testing: NR
Exclusion criteria: none reported
Sample size (participants): number eligible: NR; number included: 20
Sample size (lesions): number eligible: NR; number included: 80
Participant characteristics: none reported
Lesion characteristics: none reported
Index tests Dermoscopy: no algorithm
Method of diagnosis: dermoscopic images
Prior test data: unclear
Diagnostic threshold: data extracted for excise decision; data also presented for 3 option response
of excise/follow-up or no intervention
Diagnosis based on: average (n = 24); 3 groups were recruited according to experience but 2x2
could be extracted only for overall average result, individual group results presented only graphically
Observer qualifications: dermatologist
Experience in practice: NR
Experience with dermoscopy: mixed; group 1 (n = 9) had basic dermoscopy experience with no
formal training, group 2 (n = 10) had dermoscopy training but only basic experience with digital
dermoscopy, and group 3 included experienced dermatologists trained in dermoscopy and using
digital dermoscopy routinely to follow-up melanocytic lesions
Target condition and reference
standard(s)
Reference standard: histological diagnosis + follow-up
Details: all lesions were excised (n = 20; including all 10 melanomas) or had at least 2 years of follow-
up with no morphologic changes during multiple examinations (n = 60; all benign)
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Target condition (final diagnoses)
Melanoma (invasive): 5, melanoma (in situ): 5
Benign melanocytic lesions: 70
Flow and timing Excluded participants: none reported
Time interval to reference test: NR for histology; clinical follow-up lasted up to 2 years
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
No
High High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
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or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
High Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
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Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
Yes
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
Krahn 1998
Study characteristics
Patient sampling Study design: case series
Data collection: prospective
Period of data collection: NR
Country: Germany
Patient characteristics and set-
ting
Inclusion criteria: excised PSLs
Setting: secondary (general dermatology)
Prior testing: NR
Setting for prior testing: NR
Exclusion criteria: none reported
Sample size (participants): number included: 80
Sample size (lesions): number included: 80
Participant characteristics: none reported
Lesion characteristics range in thickness (melanomas) 0.18-1.9 mm; 29/39 < 0.76 mm; 7/39 0.
76-1.5 mm; 3/39 > 1.5 mm
Index tests VI: no algorithm reported
Method of diagnosis: in-person diagnosis
Prior test data: unclear
Diagnostic threshold: NR; no details
Diagnosis based on: single observer (n = 1)
Observer qualifications: NR; likely dermatologist
Experience in practice: not described
Experience with dermoscopy: not described
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Dermoscopy
Method of diagnosis: in-person diagnosis
Prior test data: unclear
Diagnostic threshold: NR; no details
Test observers as described for VI (above)
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone including histometrics
Disease-positive: 39; disease-negative: 41
Target condition (final diagnoses)
Melanoma (invasive): 39 (SSM, lentigo MM, nodular M)
Benign naevus: 37 common naevus; 3 dysplastic naevus, 1 SN
Flow and timing Excluded participants: none reported
Time interval to reference test: NR
Time interval between index test(s): NR
Comparative Blinding between tests: in-person diagnosis without and then with dermoscopy
Time interval between index test(s): same day; at time of face-to-face consultation
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
Unclear High
DOMAIN 2: Index Test Visual Inspection - in-person
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Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Unclear High
DOMAIN 2: Index Test Dermoscopy - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
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Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
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of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
DOMAIN 5: Comparative
Was each index test result in-
terpreted without knowledge of
the results of other index tests
or testing strategies?
No
Was the interval between ap-
plication of the index tests less
than one month?
Yes
Were all tests applied and inter-
preted in a clinically applicable
manner?
Yes
Low Low
Kreusch 1992
Study characteristics
Patient sampling Study design: case series
Data collection: retrospective image selection/prospective interpretation
Period of data collection: NR; 1.5-year period
Country: Germany
Patient characteristics and set-
ting
Inclusion criteria: pigmented lesions suspected to be malignant melanoma with adequate photo-
documentation and histology results
Setting: secondary (dermatology)
Prior testing: NR
Setting for prior testing: NR
Exclusion criteria: non-melanocytic lesions
Sample size (participants): total 856; NR for final sample
Sample size (lesions): 265melanocytic/1506 lesions included (317 excised and 52non-melanocytic
lesions excluded)
Participant characteristics: NR
Lesion characteristics: NR
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Index tests Dermoscopy: algorithm from Kreusch 1991
Method of diagnosis: image-based
Prior test data: none; slides labelled only with patient code and lesion localisation
Diagnostic threshold:≥ 9; scored diameter > 5mm; border irregularity; loss of surface’smicrostruc-
ture; scaling/erosion/ulcer; capillaries (each 1 point); multicomponent architecture; greyish colour
(each 3 points) melanophages (6 points); pseudopods (10 points); regression (10 points)
Diagnosis based on: single observer
Observer qualifications: dermatologist (assumed) (n = 1; ‘experienced’) (also presents results for
inexperienced student - data not included)
Experience in practice: ‘experienced’
Experience with dermoscopy: ‘experienced’
Target condition and reference
standard(s)
Reference standard: histology
Target condition (final diagnoses)
Invasive melanoma 96; benign naevi 169
Flow and timing Excluded participants: 52 non-melanocytic lesions excluded from second step evaluation
Time interval to reference test: NR
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Unclear High
DOMAIN 2: Index Test Dermoscopy - image-based
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Kreusch 1992 (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
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Kreusch 1992 (Continued)
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
Langley 2007
Study characteristics
Patient sampling Study design: case series
Data collection: prospective
Period of data collection: February 2002-May 2005
Country: Canada
Patient characteristics and set-
ting
Inclusion criteria: patients with suspicious pigmented lesions scheduled for biopsy due to clinical
suspicion of malignancy determined by clinical appearance or a history of change in the lesion
Setting: specialist unit (skin cancer/PLC); division of Dermatology Pigmented Lesion Clinic and
the Plastic Surgery Clinics
Prior testing: clinical suspicion of malignancy
Setting for prior testing: specialist unit (skin cancer/PLC)
Exclusion criteria: non-pigmented; physically inaccessible lesion site; previous diagnostic biopsy
of the lesion
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Langley 2007 (Continued)
Sample size (participants): number eligible: 127; number included: 125
Sample size (lesions): number eligible: 127; number included: 125
Participant characteristics: mean age 44.2 years, range 16-84 years
Lesion characteristics: median thickness 0.62 mm, range 0.20 mm-7.92 mm
Index tests Dermoscopy: pattern analysis
Method of diagnosis: in-person diagnosis
Prior test data: clinical examination and/or case notes
Diagnostic threshold: pattern analysis; diagnosis of melanoma
Diagnosis based on: single observer (n = 1)
Observer qualifications: NR likely dermatologist; “Clinical, dermoscopic and confocal examina-
tions were conducted sequentially by a single reviewer” and a diagnosis recorded after each
Experience in practice: not described
Experience with dermoscopy: not described
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Details: “When CSLM imaging was complete, the lesions were removed by excisional biopsy. A
definitive diagnosis was made by a dermatopathologist with conventional hematoxylin-eosin stained
histopathological sections.”
Disease-positive: 37; disease-negative: 88
Target condition (final diagnoses)
Melanoma (invasive): 22; melanoma (in situ): 15
Benign naevus: 88
Flow and timing Participant exclusions: 2 participants were excluded from the database due to technical difficulties
with the imaging
Index test to reference standard interval: when CSLM imaging was complete, the lesions were
removed by excisional biopsy
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
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Langley 2007 (Continued)
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
Low High
DOMAIN 2: Index Test Dermoscopy - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
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Langley 2007 (Continued)
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
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Lorentzen 1999a
Study characteristics
Patient sampling Study design: case series
Data collection: prospective
Period of data collection: 1994-1997
Country: Denmark
Patient characteristics and set-
ting
Inclusion criteria: patients with lesions suspicious for CMM referred to outpatients clinic; only
excised included
Setting: NR
Prior testing: clinical suspicion of malignancy without dermatoscopic suspicion
Setting for prior testing: NR
Exclusion criteria: poor-quality index test image (considered under flow/timing)
Sample size (participants): number eligible: 242; number included: 232
Sample size (lesions): number eligible: 242; number included: 232*
Participant characteristics: none reported
Lesion characteristics: none reported
*NB not all cases were assessed by all observers; 2x2 are based on presented sensitivity and specificity
estimates for full dataset of lesions; ”the dermatoscopy experts assessed almost all cases (98 ± 100%)
, whereas the non-expert group completed fewer assessments, from 76%-98%
Index tests VI: no algorithm
Method of diagnosis: clinical photographs
Prior test data: no further information used; no option to change clinical diagnosis after viewing
dermoscopic image
Other test data: dermoscopic images presented to observer subsequent to diagnosis using clinical
images alone; clinical images presented before dermoscopic images
Diagnostic threshold: NR; clinical diagnosis
Diagnosis based on: average; n = 9
Observer qualifications: dermatologist
Experience in practice: high; moderate; mixed (average reported); 4 ’experienced dermatologists’
(4-5 years’ daily experience) & 5 ’non-expert dermatology residents’ (1-2 years’ interest and formal
training in dermatoscopy)
Experience with index test: high; moderate; mixed
Dermoscopy: no algorithm
Method of diagnosis: dermoscopic images
Prior test data: clinical image presented first
Diagnostic threshold: clinical diagnosis; “observers were familiar with both the ABCD-rule of
dermatoscopy proposed by Stolz et al. (Stolz 1994b) and Kenet et al’s risk-stratifying algorithm
of pigment network features of dermatoscopy (Kenet 1994). The observers were not constrained
by either of the rules. The ABCD scores were not used to obtain the diagnoses. Rather a pattern
recognition process was intended.”
Dermoscopy training: described as “formal training”
Training format: non experts had undergone prior training in dermoscopy (not documented)
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Details: a co-author from Dept of Pathology “re-evaluated all cases to confirm the pathology diag-
nosis, which was used as the gold standard in this study.”
Disease-positive: 65; disease-negative: 167
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Lorentzen 1999a (Continued)
Target condition (final diagnoses)
Melanoma (invasive): 49 ’malignant melanoma’
BCC: 16
Sebhorrheic keratosis: 12; benign naevus: 137 (pigmented naevi = 116; blue naevi = 16; atypical
naevi = 5); other: 18 (SN, BD, sarcoid, naevus spilus, hemangioma, and others)
Flow and timing Excluded participants: 10 cases were “considered unfit for evaluation” due to poor-quality image
Reference interval: “biopsy specimens...were obtained after the clinical and dermatoscopic pho-
tographs had been performed”
Comparative Blinding between tests: Each observer first recorded the clinical diagnosis and then the dermato-
scopic diagnosis on an entry form
Time interval between index test(s): same day; at time of face-to-face consultation
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Unclear High
DOMAIN 2: Index Test Visual inspection - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
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Lorentzen 1999a (Continued)
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Unclear High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
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Lorentzen 1999a (Continued)
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
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If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
DOMAIN 5: Comparative
Was each index test result in-
terpreted without knowledge of
the results of other index tests
or testing strategies?
No
Was the interval between ap-
plication of the index tests less
than one month?
Yes
Were all tests applied and inter-
preted in a clinically applicable
manner?
No
Low High
Lorentzen 2000
Study characteristics
Patient sampling Study design: case series
Data collection: retrospective image selection/prospective interpretation
Period of data collection: 1995-1999
Country: not clear; authors from Denmark and USA
Patient characteristics and set-
ting
Inclusion criteria: PSLs from patients consecutively referred to the skin cancer outpatient clinic
with available clinical photographs, dermatophotographs and a subsequent excision biopsy were
included
Setting: specialist unit (skin cancer/PLC)
Prior testing: selected for excision (no further detail)
Setting for prior testing: secondary (general dermatology)
Exclusion criteria: none reported
Sample size (participants): number included: 258
Sample size (lesions): number included: 258
Participant characteristics: none reported
Lesion characteristics: none reported
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Index tests Dermoscopy ABCD; Kenet Risk Stratification
Method of diagnosis: dermoscopic images; “Slides were projected to an 80 x 120 cm screen in
a darkened room. Based on time studies in the outpatient clinic, each patient case was shown for
approximately 3 min... additional time was allowed if any needed it.”
Prior test data: clinical photographs also projected
Diagnostic threshold: ABCD - ’possible’ MM: > 4.75; ’probable’ MM: > 5.45
Risk stratification method: ’possible’ MM: stratum 1 or 2; ’probable’ MM: stratum 1 only (1:
probable CMM: pseudopods; radial streaming; heterogeneity of pigment network with thick dark
extensions at the edge; blue-grey areas, white scar-like areas and presence of pigment network:
possible CMM: marked irregular network with irregular pigment confluence)
Diagnosis based on: single observer (n = 3; performed independently)
Observer qualifications: dermatologist
Experience in practice: high; senior dermatologists, “Three senior dermatologists with > 5 years
daily experience in clinical use of dermatoscopy and familiar with (both) dermatoscopic (algorithms)
”
Experience with dermoscopy: high; > 5 years each
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Details: lesions underwent haematoxylin and eosin staining, as well as immunohistochemical stain-
ing using HMB-45 (human melanoma black) and S100 to identify melanocytic lesions. Breslow
depth and Clark level were determined. All cases were assessed by an experienced dermatopatholo-
gist.
Disease-positive: 64; disease-negative: 194
Target condition (final diagnoses)
Melanoma (invasive): 64 CMM
BCC: 25
Sebhorrheic keratosis: 14
Benign naevus: 135; dysplastic naevus 3; other: 11 blue naevi, 1 pigmented SN, + one each of were
angioma, haemorraghia, papilloma and DF
Flow and timing Participant exclusions: none reported
Time interval to reference test: appears consecutive; “Only patients having taken clinical pho-
tographs, dermatophotographs and a subsequent excision biopsy were included”
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
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Lorentzen 2000 (Continued)
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
Unclear High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Unclear
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
DOMAIN 3: Reference Standard
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Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Yes
Low
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Lorentzen 2008
Study characteristics
Patient sampling Study design: case series
Data collection: unclear
Period of data collection: NR
Country: Denmark
Patient characteristics and set-
ting
Inclusion criteria: patients referred to the specialist naevus clinic for lesion excision
Setting: specialist unit (skin cancer/PLC)
Prior testing: NR
Setting for prior testing: NR
Exclusion criteria: not specified
Sample size (participants): number eligible: 120; number included: 119
Sample size (lesions): number included: 119
Participant characteristics: none reported
Lesion characteristics: none reported
Index tests Dermoscopy:mixed/no algorithm; describes using “the risk stratification and pattern analysis pro-
cedure” as described by Kenet 2001 and Lorentzen 2000.
Method of diagnosis: dermoscopic images; compared accuracy using standard dermoscopy images
(Dermaphot) and images obtained using a globe magnifier. Slides were randomised and evaluated
on 2 different occasions with 3-week intervals
Prior test data: no further information used
Diagnostic threshold: observer correct diagnosis of each lesion type
Diagnosis based on: unclear (assumed average) (n = NR)
Observer qualifications: dermatologist
Experience in practice: high; “dermatologists who have performed dermatoscopy for 5-10 years,
published scientific papers on dermatoscopy and carried out pre- and post-specialist training in
dermatoscopy”
Experience with dermoscopy: high
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Details: used haematoxylin-eosin staining as well as immunohistochemistry using S-100 protein
and HMB-45 (human melanoma black) on suspect melanoma lesions
Disease-positive: 24; disease-negative: 95
Target condition (final diagnoses)
Melanoma (invasive): 24
BCC: 13
Mild/moderate dysplasia: 2; SK: 9; hemangioma: 2; naevus pigmentosus: 69
Flow and timing Excluded participants: 1 DF excluded
Time interval to reference test: not described
Comparative
Notes -
Methodological quality
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Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
Unclear High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
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Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
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If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
Malvehy 2014
Study characteristics
Patient sampling Study design: case series
Data collection: prospective; dermoscopic images assessed remotely from the patient
Period of data collection: March 2010-November 2011
Country: conducted at 5 US and 17 European investigational sites (Austria, Germany, Hungary,
Spain, Sweden, and UK)
Patient characteristics and set-
ting
Inclusion criteria: all patients with skin lesions selected for total excision to rule out melanoma;
dermatologists were encouraged to enrol a mix of lesions with an even distribution of low-, medium-
and high-risk lesions
Setting: secondary; authors’ institutions primarily listed as Dept Dermatology with one, ”Derma-
tology Clinical Research Center“
Prior testing: selected for excision
Exclusion criteria: lesions < 2 mm or > 20 mm and those located: on acral skin, e.g. sole or palm;
areas of scars, crusts, psoriasis, eczema or similar skin conditions; hair-covered areas, e.g. scalp,
beards, moustaches or whiskers; genitalia; in an area that had been previously biopsied or subjected
to any kind of surgical intervention or trauma; mucosal surfaces; with foreign matter, e.g. tattoo or
splinter; acute sunburn; or skin surface not measurable, e.g. lesion on a stalk; surface not accessible,
e.g. inside ears, under nails or not intact (measurement area)
Sample size (participants): number eligible: 1951; number included: 1611 for Naevisense and NR
for VI and dermoscopy
Sample size (lesions): number eligible: 2416; number included: 1943 for Naevisense and 1701 for
VI and dermoscopy
Participant characteristics: for Naevisense sample: median age: 48 years (range 18-91); male 47.
5%; 97.5% of white ethnicity. Fitzpatrick skin types: I (7.3%); II (48.6%); III (37%); IV (9.8%);
V (1.4%); VI (0.1%)
Lesion characteristics: median Breslow thickness of 0.57 mm (153 invasive melanomas)
Index tests Dermoscopy; ABCD; 7PCL; revised 7PCL; overall diagnosis (methods describe evaluation of the
clinical ABCD rule but results not presented in Table)
Method of diagnosis: image-based; ”A photograph and dermoscopic image of each included lesion
was taken before and after Naevisense measurements“
Prior test data available: clinical and dermoscopic images presented together; observers were
blinded to Naevisense result
Diagnostic threshold: ABCD > 4.75 and > 5.45; 7PCL and revised 7PCL NR, referenced to
Argenziano 1998; overall diagnosis based on grading (0-10) on a visual classification board with a
fixed cut-off at 4
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Diagnosis based on: unclear; (n = 3)
Observer qualifications: dermatologists; ”images were reviewed by three
dermatologists with 2-5 years of experience in dermoscopy assessment. The option to reach out to
additional experienced dermoscopists in difficult cases was allowed“
Experience in practice: not described
Experience with dermoscopy: high; 2-5 years
Target condition and reference
standard(s)
Type of reference standard: histological diagnosis alone
Details: lesions were excised and underwent usual histopathology at investigational site. A fur-
ther histopathological evaluation was undertaken for study purposes by a panel of 3 experienced
histopathologists who evaluated each lesion independently; blinded from the investigational site’s
original histopathology diagnosis. If they agreed, the diagnosis was considered as the histopatho-
logical gold standard; if there was significant disagreement regarding malignancy the slides were
submitted to 2 additional experts whose diagnosis was then chosen as the histopathological gold
standard if they reached agreement. In case of disagreement by the 2 additional reviewers, the cor-
responding lesion was excluded from the efficacy analysis
Disease-positive: 238 for VI/dermoscopy; disease-negative: 1440
Target condition (final diagnoses)
For VI/dermoscopy sample, 238 melanomas including 112 in situ
Breakdon of non-diseased not provided for VI/dermoscopy sample
For Naevisense sample (includes additional 242 lesions:
153 invasive melanomas, 112 melanoma in situ,
48 BCC, 1 invasive SCC; 1 Merkel cell carcinoma
157 severely dysplastic, 988 mild-moderate dysplasia, 352 benign naevi, 5 SN, 51 SK, 6 SCC in
situ; 8 AK; 61 other
Flow and timing Participant exclusions: 473 excluded from Naevisense analysis; all reasons listed; primary reason
was investigator oversight or the inability to render a final histopathological diagnosis; 74 exclusions
were device-related (60 with inadequate reference measurement quality and 14 to device failure)
. A further 242 were excluded from VI/dermoscopy analysis due to image quality (12% of VI/
dermoscopy sample)
Index test to reference standard interval: appears consecutive; prospective recruitment with imag-
ing and then ”eligible and evaluable lesions were excised and subjected to the investigational site’s
histopathology evaluation and managed accordingly.“ ”A postprocedure follow-up either by a tele-
phone call or at a participant’s visit to the investigational site was conducted at 7 +/- 3 days after
the Naevisense evaluation, at which time the patient was evaluated for any adverse events.“
Comparative Interval between index testsConsecutive; ”A photograph and dermoscopic image of each included
lesion was taken before and after Nevisense measurements to document evaluation according to the
protocol.”
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
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Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
No
High High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
No
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
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DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Yes
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High
Menzies 1996
Study characteristics
Patient sampling Study design: unclear. Abstract describes including a random sample of excised lesions from a larger
database
Data collection: retrospective image selection/prospective interpretation
Period of data collection: NR
Country: Australia
Test set derived: NR; describes ’division’ into a training set and a test set
Patient characteristics and set-
ting
Inclusion criteria: PSLs from the SydneyMelanomaUnit with dermoscopic images and histological
diagnoses;melanomas and randomly selected clinically atypical non-melanoma lesionswere included
Setting: specialist unit (skin cancer/PLC)
Prior testing: selected for excision
Setting for prior testing: specialist unit (skin cancer/PLC)
Exclusion criteria: unequivocal non-melanoma excluded
Sample size (participants): number included: NR
Sample size (lesions): number included: 385
Participant characteristics: none reported
Lesion characteristics: none reported
Index tests Dermoscopy:Menzies criteria
Method of diagnosis: dermoscopic images
Prior test data: no further information used
Diagnostic threshold: presence of 2 negative features and at least 1 positive feature. Negative
features: point and axial symmetry of pigmentation or presence of only a single colour. Positive
features of melanoma: multiple (5-6) colours; blue-white veil; multiple brown dots; multiple blue/
grey; peripheral black dots or globules; a broadened network; pseudopods; radial streaming; scar-
like
Diagnosis based on: unclear (n = NR)
Observer qualifications: NR; likely dermatologists
Experience in practice: not described
Experience with dermoscopy: not described
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone (not further described)
Disease-positive: 107; disease-negative: 278
Target condition (final diagnoses)
Melanoma (invasive): 107; BCC: 18
Ephelis/lentigo 17; SK: 23; benign acquired naevi - 58; dysplastic naevi - 105; blue naevi 11; SN 6;
spindle cell naevus 2; DF 2; hemangioma 13; solar keratosis 9; other 14
Flow and timing Participant exclusions: none reported
Index test to reference standard interval: not described
Comparative
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Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Unclear
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Unclear High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
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Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
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of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
Menzies 2005
Study characteristics
Patient sampling Study design: case series
Data collection: retrospective image selection/prospective interpretation
Period of data collection: June 1998-September 2003
Country: multicentre (Australia, Germany, USA)
Patient characteristics and set-
ting
Inclusion criteria: all melanocytic lesions from the independent test set taken at the Sydney
Melanoma Unit that had clinical and dermoscopy photographic images; lesions imaged prior to
excision due to clinical suspicion of malignancy or because of short-term digital monitoring (study
was part of a larger multicentre study of SolarScan)
Setting: specialist unit
Prior testing: clinical suspicion of malignancy or requirement for short-term digital monitoring
Setting for prior testing: specialist unit
Exclusion criteria: awkwardly situated lesions (e.g. eyelids, some parts of the pinna, some genital
sites, and perianal and mucosal surfaces); acral lesions; non-pigmented pure amelanotic lesions
(based on dermoscopy imaging); ulcerated lesions, or diagnosed as pigmented BCC, pigmented
BD, or SCC
Sample size (participants): number included: NR
Sample size (lesions): number included for dermoscopy review: 78 (for full SolarScan study -
number eligible: 2430/number included: 1644 training; 786 test set)
Participant characteristics: none reported
Lesion characteristics: none reported
Index tests Dermoscopy: no algorithm
Method of diagnosis: dermoscopic images
Prior test data: clinical photographs and patient histories (including details of age, sex, and lesion
site; and a recorded history of whether the lesion had, within the past 2 years, bled without being
scratched, changed in colour or pattern, or increased in size)
Diagnostic threshold: data can be extracted at 2 thresholds: correct diagnosis of melanoma (in situ
or invasive) and excise decision; no details on lesion characteristics used
Diagnosis based on: average according to qualification level (n = 13)
Observer qualifications: GP 3; dermatology registrar 3; dermatologists 4; + 3 international der-
moscopy experts who headed pigmented lesion clinics
Experience in practice: not described
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Experience with dermoscopy: expert/high/moderate/low
Target condition and reference
standard(s)
Reference standard: histological diagnosis + other (full sample n = 2430)
Histology: 71% of full SolarScan study sample including training and test set (n = 1725)
Clinical follow-up + histology of suspicious lesions; length of follow-up: 3 months. 26% of full
SolarScan study sample (n = 632)
Expert opinion. 3% of full SolarScan study sample were non-melanocytic pigmented
lesions that were diagnosed clinically but not excised (n = 73)
Target condition (final diagnoses)
All numbers are for Sydney Melanoma Unit test sample lesions only (n = 78)
Melanoma (invasive): 5; melanoma (in situ): 6; lentigo maligna: 2
Benign melanocytic lesions: 65
Flow and timing Participant exclusions: poor-quality index test image as exclusion criterion; lesions outside the field
of view (24 x 18 mm), contamination of calibration surfaces, or excess artifacts (hair, air bubbles,
or movement artifacts)
Index test to reference standard interval: not described
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
High High
DOMAIN 2: Index Test Dermoscopy - image-based
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Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
No
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
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High High
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
No
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
Menzies 2008
Study characteristics
Patient sampling Study design: case series?
Data collection: retrospective image selection/prospective interpretation
Period of data collection: NR
Country: multicentre
Patient characteristics and set-
ting
Inclusion criteria: dermoscopic amelanotic (with no melanin pigmentation) or hypomelanotic (a
melanin pigmentation area of < 25% of the total surface area or slightly pigmented but with no dark
brown, deep blue, or black pigmentation) lesions. All melanomas included, and a random selection
of melanocytic and non-melanocytic lesions on a non-melanoma to melanoma ratio of 3:1
Setting: multicentre
Prior testing: NR
Setting for prior testing: NR
Exclusion criteria: lesions were excluded because of poor image quality or because they did not fit
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within any of the defined pigmentation categories
Sample size (participants): NR
Sample size (lesions): 497
Participant characteristics: NR
Lesion characteristics: NR
Index tests Dermoscopy: 7PCL; Menzies; 3PCL (new algorithm for distinguishing melanoma from non-
melanoma and any malignant from benign lesions was also developed on 80% of sample and tested
on 20% but numbers disease-positive and -negative for the test set were NR to allow 2x2 to be
estimated.)
Method of diagnosis: image-based
Prior test data: NR
Diagnostic threshold: ≥ 3; Menzies standard threshold; ≥ 2
Diagnosis based on: single observer
Observer qualifications: dermatologist (assumed) (n = 12); clinicians experienced in dermoscopic
evaluation scored 99 individual morphological features in approximately equal sample sizes
Experience in practice: NR
Experience with dermoscopy: high
Target condition and reference
standard(s)
Reference standard: histology and follow-up (numbers NR; some naevi included that showed no
changes following consecutive digital monitoring)
Target condition (final diagnoses)
Invasive melanoma 91; melanoma in situ 14; BCC 126; cSCC 4
Benign naevi 159; SN 11; SK 22; DF 17; BD 7; keratoacanthoma 1; AK 8; other 37
Flow and timing Excluded participants: none reported
Time interval to reference test: NR
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
No
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ate?
Did the study avoid including
participants with multiple le-
sions?
Unclear
High High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
No
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
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Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
Menzies 2009
Study characteristics
Patient sampling Study design: case series
Data collection: prospective
Period of data collection: December 2005-August 2006
Country: Australia
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Patient characteristics and set-
ting
Inclusion criteria: pigmented lesions which, after routine naked-eye examination by the GP, would
have been biopsied or referred, i.e. a suspicious pigmented lesion. GPs were recruited from practices
with at least 3 clinicians; excluded if they already used dermoscopy or sequential digital dermoscopy
imaging (SDDI) in their routine practice
Setting: primary
Prior testing: clinical suspicion of malignancy without dermatoscopic suspicion
Setting for prior testing: primary
Exclusion criteria: none reported
Sample size (participants): NR
Sample size (lesions): number included: 374
Participant characteristics: none reported
Lesion characteristics: none reported
Index tests VI: no algorithm
Method of diagnosis: in-person diagnosis
Prior test data: N/A; in-person diagnosis
Diagnostic threshold: NR. Initial diagnosis recorded along with confidence of diagnosis (scale 1-
10; 1 not at all confident and 10 extremely confident), certainty of melanoma (scale 0%-100%; 0
definitely not melanoma and 100 definitely melanoma) and management (biopsy, referral)
Diagnosis based on: single observer (n = 63; 102 GPs initially recruited; 74 (75%) completed the
educational intervention and online assessment; 63 GPs from 19 practices finally participated)
Observer qualifications: GP
Experience in practice: not described
Experience with dermoscopy: not fully described; classified as ’trained’. GPs must have each excised
or referred ≥ 10 PSL in previous 12-month period; excluded if dermoscopy or SDDI already used
in routine practice
Dermoscopy: no algorithm
Method of diagnosis: in-person diagnosis
Prior test data: clinical examination and/or case notes
Diagnostic threshold: NR. After clinical exam and dermoscopy GP recorded the site of the lesion
and the initial diagnosis, confidence of diagnosis, certainty of melanoma and management (as for
VI above). Approach to dermoscopy interpretation not further reported; 2x2 can be constructed
for decision to excise or to excise or monitor. Triage management options included: biopsy due to
clinician concern; biopsy due to patient concern; referral due to clinician concern; referral due to
patient concern; short-term SDDI; and patient to return if changes occur
Test observers as described for VI (above)
Dermoscopy training: online textbook in dermoscopic diagnosis and the use of SDDI, a CD-
ROM tutorial showing examples of changed and unchanged monitored lesions; a 2-h workshop on
the use of the diagnostic devices and recruitment procedures. Assessment through online pre- and
post-education intervention test of 245 lesions not seen in the textbook or the CD-ROM. Before
formal patient recruitment began, GPs assessed at least one pretrial lesion to determine the quality
of imaging with the SDDI instrument and undertake completion of trial paperwork. GPs were
allowed to practise using the dermoscopy device during this pretrial phase. The pretrial phase of
education and run-in period occurred from May 2005-January 2006
Length of training: self-learning + 2-h workshop
Post-training experience: 6-12 months
Training format: online; CD-ROM: workshop
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Target condition and reference
standard(s)
Reference standard: histological diagnosis + other (study author confirmed that all melanoma had
histological diagnosis and > 50% of benign had histology or follow-up)
Histology: described as conducted to standard practice and not necessarily blinded to the GP’s
diagnosis. Total excised or referred: 163. Immediate excision/referral: 110. Excision/referral after
SDDI: 48. Excision/examination after patient self-referral: 5
Disease-positive: 37; disease-negative: total of 126 benign or unknown were ’excised OR referred’
Clinical follow-up + histology of suspicious lesions: short-term digital monitoring (SDDI) available
as an option for lesions considered not to be melanoma but that were still considered suspicious;
follow-up imaging occurred initially at 3 months with any morphological changes to result in biopsy
or referral; some lesions continued SDDI for a further 3 months; length of follow-up: 3-6 months.
Number participants: initially recommended for SDDI 192; SDDI continued for further 3 months:
6; underwent SDDI only (no excision) 146
Disease-positive: 15 (SDDI then histologically confirmed); disease-negative: 176 benign (incl 1
missed in situ melanoma); 4 unknown
Expert opinion: GPs could refer for specialist opinion or lesions could undergo dermoscopy
telemedicine (images reviewed by an expert in dermoscopy and SDDI). Dermoscopy telemedicine
was blinded to the GP’s diagnosis.
Observe for change group, i.e. discharged after dermoscopy: 72 (plus a proportion of those in excise/
refer group will have had expert diagnosis alone but details not given)
Disease-positive: 0; disease-negative: 71 benign; 1 unknown
Target condition (final diagnoses)
Melanoma (invasive): 33; melanoma (in situ): 1
BCC: 6
2 BD; 323 benign; 9 unknown
Flow and timing Excluded participants: 9 lesions with unknown diagnoses, + BCC and BD excluded from some
analyses
Time interval to reference test: NR; histopathological and specialist examination occurred accord-
ing to standard practice
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
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Are the included patients and
chosen study setting appropri-
ate?
Yes
Did the study avoid including
participants with multiple le-
sions?
Unclear
Low Unclear
DOMAIN 2: Index Test Visual Inspection - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Unclear High
DOMAIN 2: Index Test Dermoscopy - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
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If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
No
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
No
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
No
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
High High
DOMAIN 4: Flow and Timing
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Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
No
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
Yes
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
Menzies 2013
Study characteristics
Patient sampling Study design: case series
Data collection: retrospective image selection/prospective interpretation
Period of data collection: NR
Country: multicentre (photographic libraries at various institutions; obtained frommembers of the
IDS from 5 continents)
Patient characteristics and set-
ting
Inclusion criteria: nodular malignant melanoma (an invasive melanoma without an in situ (junc-
tional) component beyond 3 rete ridges of the dermal invasive component) and a random selection
of non-nodular invasive primary melanoma, benign nodular melanocytic lesions, and nodular non-
melanocytic lesions at a ratio of NM to other subgroups of 1:2. Nodular benign melanocytic lesions
and nodular non-melanocytic lesions were identified by the clinical appearance of a solitary nodule
and confirmed using dermoscopic examination
Setting: mixed
Prior testing: NR
Setting for prior testing: NR
Exclusion criteria: excluded if the image quality was poor
Sample size (participants): NR
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Sample size (lesions): 467
Participant characteristics: excluded if the image quality was poor
Lesion characteristics: pigmented 314/467; 67%
Index tests Dermoscopy: ABCD; Menzies; CASH; 7PCL; 3PCL; Menzies algorithm for amelanotic lesions
(Menzies 2008)
Method of diagnosis: image-based
Prior test data: NR
Diagnostic threshold: > 5.45; standard Menzies; ≥ 8; standard 7PCL; standard 3PCL; ≥ 1 and≥
0
Diagnosis based on: single
Observer qualifications: dermatologist (n = 2; experience NR). 12 scorers blinded to the lesion
diagnosis scored 99 individual features in each lesion of approximately equal sample sizes, as previ-
ously described
Experience in practice: NR
Experience with dermoscopy: high
Target condition and reference
standard(s)
Reference standard: histology or follow-up (‘some’ benign melanocytic naevi showed no change
over time compared with baseline photographs)
Target condition (final diagnoses)
Invasive melanoma 217 (including 83 nodular)
Benign naevi 115
Flow and timing Excluded participants: none reported
Time interval to reference test: NR
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
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Did the study avoid including
participants with multiple le-
sions?
Unclear
High High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
No
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
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Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
Morales Callaghan 2008
Study characteristics
Patient sampling Study design: case series
Data collection: prospective
Period of data collection: 1 January 2005-31 December 2005
Country: Spain
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Patient characteristics and set-
ting
Inclusion criteria: randomly selected melanocytic lesions; melanocytic on both clinical and der-
moscopic criteria
Setting: secondary (general dermatology)
Prior testing: dermatoscopic suspicion in all cases
Setting for prior testing: NR
Exclusion criteria: palms, soles, mucous membranes of face, under nails; non-melanocytic appear-
ance
Sample size (participants): number included: 166
Sample size (lesions): number included: 200
Participant characteristics: mean age 33.7 years (SD 14.5), range 8-84 years; male: 64 (38.6%);
Fitzpatrick phototype II (44%); type III (41.5%)
Lesion characteristics: macular component = 181 (90.5%), papular component = 125 (65%) both
= 106 (53%), either one or other = 94 (47%). Asymmetrical 144 (72%). Irregular borders 154
(77%). 4 colours in 40 (20%), 3 colours in 96 (48%), 2 colours in 57 (28.5%), 1 colour in 1 (0.
5%). History of bleeding 7 (3.5%). Changes reported by participant 154 (77%). Lesion site: trunk
155 (77.5%), including the back in 106 (53%). Lesion size: mean long axis diameter 7.9 mm (SD
8.6 mm), mean short axis diameter 5.1 mm (SD 5 mm)
Index tests VI: no algorithm
Method of diagnosis: in-person diagnosis
Prior test data: clinical examination and/or case notes
Other test data: appears that dermoscopy was undertaken by same clinician(s) subsequent to clini-
cal evaluation; clinical history was constructed following a standardised protocol and a presumptive
clinical diagnosis recorded. Each lesion was then photographed and immediately afterwards exam-
ined using a manual dermatoscope
Diagnostic threshold: NR; presumptive clinical diagnosis
Diagnosis based on: consensus (n = 2)
Observer qualifications: dermatologist
Experience in practice: not clearly described; assumed to be high, “both dermatologists had expe-
rience in dermoscopy.”
Experience with dermoscopy: not clearly described; assumed to be high, “both dermatologists had
experience in dermoscopy.”
Dermoscopy: pattern analysis
Method of diagnosis: in-person diagnosis
Prior test data: clinical examination and/or case notes
Diagnostic threshold: NR; diagnosed “on the basis of predominant dermoscopic pattern(s) using
the pattern analysis algorithm”
Test observers as described for VI (above)
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Details: lesions described using terminology proposed by US National Institutes of Health
Disease-positive: 6/6 lesions; disease-negative: 194/194 lesions (assuming the 9 ’other’ diagnosis
lesions were not malignant), or 185/185 (removing the 9 ’other’ diagnosis lesions from dataset)
Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 6 (3%)
Other: atypical mole (104), common mole (70), congenital naevus (6), blue naevus (3), Spitz/Reed
naevus (1), spilus naevus (1), others (unclear whether benign or malignant) (9)
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Flow and timing Exclusions: none reported
Time interval to reference test: “Samples for histologic analysis were taken immediately after
clinical and dermoscopic examination”
Comparative Blinding between tests: in-person, without and then with dermoscopy
Time interval between index test(s): same day
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
No
Low High
DOMAIN 2: Index Test Visual Inspection - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
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the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Unclear High
DOMAIN 2: Index Test Dermoscopy - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
DOMAIN 3: Reference Standard
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Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Low
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DOMAIN 5: Comparative
Was each index test result in-
terpreted without knowledge of
the results of other index tests
or testing strategies?
No
Was the interval between ap-
plication of the index tests less
than one month?
Yes
Were all tests applied and inter-
preted in a clinically applicable
manner?
No
Low High
Nachbar 1994
Study characteristics
Patient sampling Study design: case series
Data collection: prospective
Period of data collection: November 1991-July 1992
Country: NR (authors’ institutions Germany and USA)
Patient characteristics and set-
ting
Inclusion criteria: pigmented melanocytic skin lesions consecutively excised
Setting: secondary (general dermatology)
Prior testing: selected for excision (no further detail)
Setting for prior testing: NR
Exclusion criteria: unequivocal appearance/diagnosis criteria used to exclude non-melanocytic
described in detail in Table 1
Sample size (participants): NR
Sample size (lesions): number included: 194
Participant characteristics: none reported
Lesion characteristics: thickness, 35/69 MM ≤ 0.75 mm (50.7%)
Index tests Dermoscopy: ABCD
Method of diagnosis: in-person diagnosis
Prior test data: clinical examination and/or case notes
Diagnostic threshold: > 5.45 (determined based on retrospective analysis of the data)
For the calculation of ABCD score the criteria of asymmetry (A), abrupt cutoff of the pigment
pattern at the border (B), different colours (C), and different structural components (D) were
assessed to yield a semiquantitative score (all described in detail). “The results of the retrospective
study showed that melanocytic pigmented skin lesions could be differentiated into two diagnostic
groups as follows: melanocytic naevi (MN) if the final score was less than 5.45 and MM if the score
was higher than 5.45. Retrospective analysis showed an early melanoma could not be completely
excluded in all lesions with an ABCD score between 4.75 and 5.45.Therefore these lesions were
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excised. All lesions were examined by two independent dermatopathologists.”
Diagnosis based on: unclear (n = NR)
Observer qualifications: NR; presumably dermatologists; “colleagues in our department”
Experience in practice: high experience or ‘Expert’
Experience with dermoscopy: high experience /‘Expert’ users
Study also presents 2x2 data for VI; excluded from review as clinicians ’mostly’ also used dermoscope
for diagnosis. From text: “In comparing the clinical with the dermatoscopic diagnosis with the
ABCD rule it must be noted that all our colleagues in this department referring patients for the
study were experienced and in most cases used the dermatoscope without applying the new ABCD
rule. Thus clinical diagnosis in our study was expected to be already biased by the dermatoscopic
feature and therefore to be more accurate than by the naked eye”
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone 194 (not further described)
Disease-positive: 69; disease-negative: 125
Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 69
BCC: 3
Sebhorrheic keratosis: 19
’Benign’ diagnoses: 103 melanocytic naevus
Flow and timing Time interval to reference test: NR
Time interval between index test(s): appears consecutive
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
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Low High
DOMAIN 2: Index Test Dermoscopy - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
High High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
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Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
Nilles 1994
Study characteristics
Patient sampling Study design: case series
Data collection: retrospective image selection/prospective interpretation
Period of data collection: 1989-1991
Country: Germany
Derivation of test set: images collected 1989-1990 were used to develop a new algorithm; lesions
investigated in 1991 were used for model validation (latter data included in review)
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Patient characteristics and set-
ting
Inclusion criteria: melanocytic skin lesions that underwent excision
Setting: secondary (general dermatology)
Prior testing: selected for excision (no further detail)
Setting for prior testing: NR
Exclusion criteria: non-melanocytic appearance
Sample size (participants): number included: 260 (1989-1990 group); NR for 1991 group
Sample size (lesions): number included: 260 (1989-1990 group); 209 for 1991 group
Participant characteristics: none reported
Lesion characteristics none reported
Index tests Dermoscopy: new algorithm
Method of diagnosis: for training set dermoscopic images were projected onto a screen; method
NR for test set (assumed same procedures followed)
Prior test data: no further information used
Diagnostic threshold: significance of ’8 clues of malignancy’ (Braun-Falco 1990) were investigated
in data collected 1989-1990. A subset of relevant components were identified and evaluated on the
test set of lesions (appears to be presence of any one considered test positive): asymmetrical pigment
distribution, > 3 colours, asymmetrical depigmentation, black pigment, sharp pigment border and
atypical radial streaming
Diagnosis based on: single observer (n = 1)
Observer qualifications: NR, likely dermatologist (“one of the authors”)
Experience in practice: not described
Experience with dermoscopy: not described
Derivation aspect: the 8 clues of malignancy were graded from 0 (absent) to 3 (distinct) on the test
set of lesions (including asymmetrical pigment distribution, > 3 colours, black-brown pigment, dark
brown pigment, prominent pigment network, asymmetrical depigmentation, peripheral stripes,
sharp pigment border and atypical radial streaming). Stepwise logistical regression used to select the
variables that resulted in the best model for identification of melanoma
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone (not further described)
Disease-positive: 41 in test set; disease-negative: 168 in test set
Target condition (final diagnoses)
Full breakdown reported only for training set; for test set:
Melanoma (invasive): 41
Benign naevus: 168
Flow and timing Participant exclusions: none reported
Index test to reference standard interval: not described
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
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Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Unclear High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Low High
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DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
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Unclear
Pagnanelli 2003
Study characteristics
Patient sampling Study design: unclear; likely a case-control type selection process
Data collection: retrospective image selection/prospective interpretation (dermoscopy training
study)
Period of data collection: NR
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: images of PSLs from the training set of the Consensus Net Meeting on Der-
moscopy (CNMD) (referenced to Soyer 2001), selected by 2 experts
Setting: unclear
Prior testing: NR
Setting for prior testing: NR
Exclusion criteria: none reported
Sample size (participants): NR
Sample size (lesions): number included: 20
Participant characteristics: none reported
Lesion characteristics: none reported
Index tests Dermoscopy: pattern analysis; 7PCL; ABCD; Menzies criteria
Method of diagnosis: clinical photographs and dermoscopic images. Partipants were given a CD
with lesion images and asked to evaluate the 20 cases independently over a 20-day period. This was
repeated approximately 5 weeks post-dermoscopy training
Prior test data: case notes, “Each case contained the following clinical information: age, sex, skin
phototype, total number of naevi, personal and/or family history of melanoma, location, diameter
and duration of the lesion, as well as medical history concerning morphological changes within the
year preceding excision of the lesion.” It appears as though this information was given to participants
along with lesion images
Diagnostic threshold: clinical diagnosis of melanoma; “For each case, the participants completed
an electronic data sheet that listed criteria for diagnosing PSLs by pattern analysis and by the various
algorithms. Participants offered a dermoscopic diagnosis for each case”
Diagnosis based on: average (n = 16); authors’ colleagues from Department of Dermatology were
recruited to participate
Observer qualifications: dermatology registrar 9; dermatologist 4; medical students 3
Experience in practice: not described
Experience with dermoscopy: low; dermoscopic knowledge of this group consisted only of limited
personal experience; none had formal training in this technique and or used dermoscopy in daily
professional practice
Dermoscopy training: a 1-h lecture introduced the principles of dermoscopy and the algorithms
to be evaluated. A web-based tutorial was then made available and participants were asked to spend
1 h/d for 2 weeks to learn and improve dermoscopy knowledge (dermoscopy.org)
Training format: in person and online
Post-training experience: none reported
347Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Pagnanelli 2003 (Continued)
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone (not further described)
Disease-positive: 6 (30%); disease-negative: 14 (70%)
Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 6 (30%)
BCC: 2 (10%)
Sebhorrheic keratosis: 2 (10%); Clark naevi 8 (40%); Reed/SN 2 (10%)
Flow and timing Participant exclusions: none reported
Index test to reference standard interval: not described
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Unclear
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Unclear High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
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For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
No
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
No
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
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Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
Unclear
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
Piccolo 2000
Study characteristics
Patient sampling Study design: case series
Data collection: prospective
Period of data collection: states 3 months but no specific dates given
Country: Austria (Graz)
Patient characteristics and set-
ting
Inclusion criteria: lesions included in the study were selected because of their diagnostic difficulty
and were excised for a histopathological evaluation
Setting: unspecified, described as a multicentre study
Prior testing: lesions included in the study were selected because of their diagnostic difficulty does
not specify what prior tests were done
Setting for prior testing: unspecified
Exclusion criteria: poor-quality index test image (all images scoring 4 were excluded from the
study)
Sample size (participants): number included: 40 participants
Sample size (lesions): number included: 43
Participant characteristics: median age 39.5 years, (range 3-91 years). Male: 21 (53%); female 19
(47%)
Lesion characteristics: site - face 2; head 1, neck 1, trunk 8, arms 3, legs 7, back 20, buttocks 1
Index tests Dermoscopy: no algorithm
Method of diagnosis: all lesions were examined with a dermatoscope during the face-to-face clinical
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diagnosis. Diagnosis was made by a expert dermatologist based on clinical features and dermoscopic
findings. No specific algorithm (e.g. the Stolz index) was used for dermoscopic diagnosis
Prior test data: unclear
Diagnostic threshold: NR
Diagnosis based on: single (n = 1)
Observer qualifications: dermatologist (an expert in the diagnosis of PSLs)
Experience in practice: high
Experience with index test: high
(Also evaluated teledermatology assessment of transmitted images)
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Details: all lesions were excised for a histopathological evaluation
Target condition (final diagnoses)
Melanoma (invasive): 11, BCC: 3
Sebhorrheic keratosis: 2, benign naevus: melanocytic naevus 23, ’Benign’ diagnoses: angiokeratoma
1, lentigines 3
Flow and timing Excluded participants: NR
Time interval to reference test: NR
Time interval between index test(s): NR
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
Unclear High
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DOMAIN 2: Index Test Dermoscopy - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Unclear Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
Unclear
352Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Piccolo 2000 (Continued)
matopathologist?
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Piccolo 2002a
Study characteristics
Patient sampling Study design: case series
Data collection: retrospective image selection/prospective interpretation
Period of data collection: NR; 6-month period
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: pigmented lesions excised because of equivocal dermoscopic findings or at the
patient’s request
Setting: secondary (general dermatology); from authors’ institution
Prior testing: dermatoscopic suspicion; patient request for evaluation/excision
Setting for prior testing: NR
Exclusion criteria: none reported
Sample size (participants): number included: 289
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Sample size (lesions): number included: 341
Participant characteristics: mean age 33.6 years, range 3-83 years; male: 127 (43.9%); Fitzpatrick
phototype I-II (31.4%); type III (42%); type IV-V (26.4%)
Lesion characteristics: none reported
Index tests Dermoscopy: no algorithm
Method of diagnosis: clinical photographs and dermoscopic images. Cases were clinically and
dermoscopically evaluated on a high-resolution colour monitor, in a random sequence
Prior test data: none; appears to be based on images only
Diagnostic threshold: correct diagnosis of melanoma
Diagnosis based on: single observer (n = 2)
Observer qualifications: dermatologist; (dermatology?) resident
Experience in practice: high, dermatologist had 5 years of experience; low, resident with minimal
training in PSLs
Experience with dermoscopy: high and low (resident had 6 months of experience, comprising 8
h of specialised training on 3 consecutive days and 2 h/week in routine dermoscopy)
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Details: “All excised lesions were examined histopathologically by a dermatopathologist”
Disease-positive: 13; disease-negative: 328
Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 13
Sebhorrheic keratosis: 3; benign naevus: 316; dFs 7; angiomas 2
Flow and timing Time interval to reference test: NR
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
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Did the study avoid including
participants with multiple le-
sions?
No
Unclear High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
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Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
Piccolo 2014
Study characteristics
Patient sampling Study design: case series
Data collection: retrospective image selection/prospective interpretation
Period of data collection: September 2010-October 2013
Country: Italy
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Patient characteristics and set-
ting
Inclusion criteria: dermoscopically atypical PSLs selected from the archives of the Dermatology
Department at the University of L’Aquila, Italy; described as “a panel of ... retrospectively selected
PSLs”
Setting: secondary (general dermatology)
Prior testing: NR
Setting for prior testing: NR
Exclusion criteria: location/site of lesion - acral sites and the face
Sample size (participants): number included: 165
Sample size (lesions): number included: 165
Participant characteristics: mean age 43.5 years (range 12-84 years); male: 59.4%
Lesion characteristics: lesion site; upper extremities 18 (11%); lower extremities 53 (31%); 62 (37.
5%) on the back; 32 (19.4%) on the chest. Melanoma thickness 87.9% (29/33) < 0.75 mm; 11%
(4/33) > 1.5 mm
Index tests Dermoscopy: ABCD
Method of diagnosis: dermoscopic images
Prior test data: no further information used
Diagnostic threshold: total dermoscopic score > 4.75 and > 5.45
Diagnosis based on: single observer (n = 4)
Observer qualifications: 3 dermatologists and 1 GP with different degrees of dermoscopic experi-
ence
Experience in practice: mixed
Experience with dermoscopy: high (observer 1 - dermatologist); moderate (observers 2 and 3 -
dermatologists); low (observer 4 - GP; underwent dermoscopic training by studying an interactive
atlas of dermoscopy between time periods T0 and T1)
Any other detail: experience was scored based on number of years specialising in dermoscopy;
number of PSLs assessed by dermoscopy on a daily basis; number of relevant workshops/seminars
attended; and the number of authored publications on dermoscopy
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone (not further described)
Target condition (final diagnoses)
Melanoma (invasive): 23; melanoma (in situ): 10
Benign naevus: 105 Clark naevi; 19 Spitz/Reed naevi; 5 blue naevi; 3 dermal naevi
Flow and timing Excluded participants: none reported
Time interval to reference test: not described
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
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Piccolo 2014 (Continued)
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
High High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
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DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
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Unclear
Pizzichetta 2002
Study characteristics
Patient sampling Study design: case series
Data collection: retrospective image selection/prospective interpretation
Period of data collection: April 1996-September 1998
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: small (≤ 5 mm) melanocytic skin lesions with “dermoscopic appearance not
excludingmelanona” that were surgically excised at theCentro di RiferimentoOncologico (National
Cancer Institute), Aviano
Setting: specialist unit; National Cancer Institute
Prior testing: NR
Setting for prior testing: NR
Exclusion criteria: size > 5 mm
Sample size (participants): number included: 123
Sample size (lesions): number included: 129
Participant characteristics: median age 30 years, range 13-65 years. Lesion site: trunk: 67 (52%)
; upper limbs/shoulder: 16 (14%); lower limbs/hip: 21 (16.3%); abdomen 21 (16.3%); foot 4 (3.
1%)
Lesion characteristics: median diameter 4 mm (range: 1.2-5 mm)
Index tests Dermoscopy: pattern analysis; ABCD
Method of diagnosis: dermoscopic images
Prior test data: no further information used; only images assessed for presence/absence of dermo-
scopic criteria and dermoscopic diagnosis
Diagnostic threshold: ABCD > 5.45 and ≥ 4.75; pattern analysis: “Dermoscopic criteria used for
evaluation were pigment network alterations, irregular extensions, branched streaks. grey·blue areas.
pseudopods. brown globules. black dots, whitish blue veil, hypopigmentation, white scar-like areas
and linear and dotted vascular patterns.”
Diagnosis based on: single observer (n = 2)
Observer qualifications:NR; likely oncologist/dermatologist (1 observer based in Dept of Oncol-
ogy, other in Dermatology dept)
Experience in practice: not described
Experience with dermoscopy: not described
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Details: histopathologic diagnosis of all specimens was performed by a single pathologist at the
Department of Pathology of the Centro di Riferimento Oncologico
Disease-positive: 5 lesions; disease-negative: 124 lesions
Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 5 lesions
Benign naevus: 124 lesions
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Pizzichetta 2002 (Continued)
Flow and timing Participant exclusions: none reported
Index test to reference standard interval: each lesion imaged “before surgery”
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
High High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Unclear
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Pizzichetta 2002 (Continued)
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
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Pizzichetta 2002 (Continued)
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Low
Pizzichetta 2004
Study characteristics
Patient sampling Study design: case series
Data collection: retrospective image selection/prospective interpretation
Period of data collection: January 1996 to December 2001
Country: participants recruited from 5 participating centres (4 in Italy and 1 in USA) study con-
ducted in Italy
Patient characteristics and set-
ting
Inclusion criteria: clinical and/or dermoscopic hypomelanotic (extent of pigmentation ≤ 30%)
and amelanotic skin lesions seen and excised at the 5 participating centres
Setting: secondary (general dermatology)
Prior testing: clinical and/or dermatoscopic suspicion
Setting for prior testing: NR
Exclusion criteria: poor-quality index test image (considered under Flow and timing)
Sample size (participants): number included: 151
Sample size (lesions): number eligible: 174; number included: 151
Participant characteristics: mean age 47 years (± 17.5 SD); male: 73 (48%)
Lesion characteristics: lesion site - head/neck (5.3%); trunk (20.5%); upper limbs/shoulder (11.
9%); lower limbs/hip (25.2%); back (21.2%); abdomen (11.3%); hand (3.3%); foot (1.3%).
Melanoma thickness: ≤ 1 mm 85.3% (n = 29); > 1 mm 14.7% (n = 15)
Index tests VI: no algorithm
Method of diagnosis: clinical photographs
Prior test data: only gender, age at diagnosis and the site of the skin lesion were known to the
observer
Other test data: file contained clinical and dermoscopic images; unclear whether both observed at
the same time
Diagnostic threshold: investigated clinical features such as elevation, ulceration, shape, borders,
colour
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Pizzichetta 2004 (Continued)
Diagnosis based on: single observer (n = 1)
Observer qualifications: NR; assumed dermatologist
Experience in practice: not described
Experience with index test: not described
Dermoscopy: pattern analysis
Method of diagnosis: dermoscopic images
Prior test data: clinical image also available
Diagnostic threshold: assessed the lesions using the following dermoscopic criteria associated with
melanoma and non-melanocytic skin lesions: pigment network, pigmentation, streaks, dots glob-
ules, blue-whitish veil, regression structures, hypopigmentation, leaf-like areas, multiple grey-bluish
globules, central white patch and vascular pattern
Test observers as described for VI (above)
Other detail: 122 images were taken with a digital stereomicroscope and 52 were taken with a
Dermaphot camera (Heine Optotechnik; Herrsching, Germany) (x10 magnification)and then dig-
italised with the Kodak PhotoCDsystem. Ultrasound gel was used on all the lesions (52) pho-
tographed with the Dermaphot in the Aviano centre. The other centres used the digital stereomi-
croscope consisting of a stereomicroscope and a Sony 3CCDDXC-930P colour video camera. The
digital images were taken at a magnification of x10-20
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Target condition (final diagnoses)
Melanoma (invasive): 34 (39 in full sample); melanoma (in situ): 5
Other diagnoses reported only for full sample of 151 (only 108with clinical images for VI evaluation)
: 55 (40 with clinical images) “amelanotic hypomelanotic non-melanocytic lesions” (25 BCC, 4
SCC, 10 DF, 8 BD, 8 SK)
52 (29with clinical images) “amelanotic hypomelanotic benignmelanocytic lesions” (24 compound
naevi, 17 dermal naevi, 5 SN, 4 congenital naevi and 2 combined naevi)
Flow and timing Excluded participants: 23 lesions excluded due to image quality; further 43 lesions were not
available for evaluation by clinical images (“mainly benign melanocytic lesions”)
Time interval to reference test: NR
Comparative Blinding between tests: unclear whether both clinical and dermoscopic images observed at the
same time
Time interval between index test(s): NR
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
364Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Pizzichetta 2004 (Continued)
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
High High
DOMAIN 2: Index Test Visual inspection - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Low High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
Yes
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dard?
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Low Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
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Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
DOMAIN 5: Comparative
Was each index test result in-
terpreted without knowledge of
the results of other index tests
or testing strategies?
Unclear
Was the interval between ap-
plication of the index tests less
than one month?
Unclear
Were all tests applied and inter-
preted in a clinically applicable
manner?
No
Unclear High
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Pupelli 2013
Study characteristics
Patient sampling Study design: case-control
Data collection: retrospective
Period of data collection: 2007-2011
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: consecutively excised melanomas < 5 mm diameter and 3 randomly sampled
histologically proven small-diameter naevi for each included melanoma
Setting: specialist unit (skin cancer/PLC) (from Author institution)
Prior testing: selected for excision (no further detail); all had undergone dermoscopy and RCM in
order to be included
Setting for prior testing: specialist unit (skin cancer/PLC)
Exclusion criteria: lesion size > 5 mm excluded; disagreement between evaluators on tumour
histological classification
Sample size (participants): number included: 96
Sample size (lesions): number included: 96
Participant characteristics: mean age: melanoma group 48 years (IQR 17-77 years); naevi 41 years
(IQR 6-82 years). Male: 54% of melanoma group; 58% of naevi group
Lesion characteristics: lesion site - trunk: 62% naevi; lower limbs/hip: 46%melanomas; melanoma
thickness: mean 0.37 mm (SD 0.44 mm). Lesion size (invasive melanoma): 77% (n = 10) < 1 mm,
13% (n = 3) ≥ 1 mm
Index tests Dermoscopy: 7PCL
Method of diagnosis: dermoscopic images
Prior test data: body site and age; it appears that RCM images also available at time of image
interpretation. “For each lesion a complete set of dermoscopic and confocal images (including the
whole lesion) was available”; “Dermoscopic and confocal microscopic images were evaluated - in
blind from histological diagnosis, but not from the body site or the age of the patient”
Diagnostic threshold: score ≥ 3
Diagnosis based on: unclear likely single (n = NR)
Observer qualifications: NR; no description of observers was provided
Experience in practice: not described
Experience with dermoscopy: not described
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Details: histopathology performed by 2 independent board-certified pathologists; disagreements
were reviewed by both pathologists to obtain a consensus diagnosis
Disease-positive: 24; disease-negative: 72
Target condition (final diagnoses)
Melanoma (invasive): 13; melanoma (in situ): 11
Benign naevus: 72 ( 29 junctional, 19 compound, intra-dermal, 8 blue, 4 LS and 7 Spitz)
Flow and timing Participant exclusions: none reported
Index test to reference standard interval: not described
Comparative
Notes -
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Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
High High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
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Pupelli 2013 (Continued)
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Low Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
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If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
Rao 1997
Study characteristics
Patient sampling Study design: case series
Data collection: retrospective image selection/prospective interpretation
Period of data collection: NR
Country: USA
Patient characteristics and set-
ting
Inclusion criteria: patientswith atypicalmelanocytic lesions or suspected earlymalignantmelanoma
Setting: private care
Prior testing: selected for excision (no further detail)
Setting for prior testing: private care
Exclusion criteria: lesions > 13 mm in diameter were excluded as they could not fit entirely within
the standardised photographs
Sample size (participants): number included: 63
Sample size (lesions): number included: 72
Participant characteristics: none reported
Lesion characteristics: melanoma thickness ≤ 1 mm: 100% of MM (n = 21)
Index tests VI: ABCD
Method of diagnosis: clinical photographs and dermoscopic images
Prior test data: dermoscopic images also presented to observer but unclear whether both viewed at
the same time or not, “Each color transparency was independently analyzed” by observers. The 1)
clinical, 2) ’overall’ dermoscopic, and 3) ’ABCD scored’ dermoscopic diagnoses of either MM or
atypical melanocytic naevi were recorded for each lesion by the same observers. No indication of
blinding between images
Diagnostic threshold: clinical variables were defined as follows: asymmetry (A): both silhouette
and colour distribution were considered. Border irregularity (B): this was judged by the unevenness
of the perimeter. Colour (C): colour variegation and number of colours were evaluated. Diameter
(D): the largest in situ diameter in mm of each lesion was recorded
Diagnosis based on: single observer (n = 4)
Observer qualifications: 2 experienced dermatologists, and 2 melanoma fellows
Experience in practice: mixed experience (low and high experience combined)
Experience with dermoscopy: NR
Dermoscopy: ABCD and no algorithm
Method of diagnosis: clinical photographs and dermoscopic images
Prior test data: clinical examination and/or case notes. The 1) clinical, 2) ’overall’ dermoscopic,
and 3) ’ABCD scored’ dermoscopic diagnoses of either MM or atypical melanocytic naevi were
recorded for each lesion by the same observers. No indication of blinding between images
371Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Rao 1997 (Continued)
Diagnostic threshold: ABCD-scored dermoscopic diagnosis (lesions with a score of ≤ 4.75 were
classified as benign, those with scores 4.76-5.45 as suspicious, and those with scores > 5.45 as
melanomas. Each feature was given a score of ”1”. Thus, the score ranged from 1 to 5.)
Overall dermoscopic diagnosis - no threshold reported; the overall dermoscopic impression was
recorded based on criteria in the recently published textbook (Stolz 1994b).
Test observers: as described for VI (above)
Any other detail: all photographs were taken with the Dermophot standard lens-to-lesion distance,
aperture, and flash. Fujichrome 50 colour 35 mm-transparency film was used and all exposed film
was processed in the same laboratory (Colorite, New York, NY, USA)
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Details: each of the 72 melanocytic neoplasms was histopathologically diagnosed as with atypical
melanocytic naevi or an early MM by a dermapathologist with special expertise in melanocytic
neoplasms. Each lesion was completed excised and step sectioned.
Disease-positive: 21 MMs; disease-negative: 51 atypical melanocytic naevi
Target condition (final diagnoses)
MM (invasive): 21
51 atypical melanocytic naevus
Flow and timing Excluded participants: none reported
Time interval to reference test: NR
Comparative Blinding between tests: unclear whether both images were viewed at the same time or not
Time interval between index test(s): Image-based; images likely acquired consecutively
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
No
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Rao 1997 (Continued)
Unclear High
DOMAIN 2: Index Test Visual inspection - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Unclear
373Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Rao 1997 (Continued)
Was the test applied and inter-
preted in a clinically applicable
manner?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Low Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
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If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Low
DOMAIN 5: Comparative
Was each index test result in-
terpreted without knowledge of
the results of other index tests
or testing strategies?
Unclear
Was the interval between ap-
plication of the index tests less
than one month?
Yes
Were all tests applied and inter-
preted in a clinically applicable
manner?
No
Unclear High
Rigel 2012
Study characteristics
Patient sampling Study design: unclear
Data collection: retrospective image selection/prospective interpretation
Period of data collection: NR
Country: USA
Patient characteristics and set-
ting
Inclusion criteria: PSLs that had been analysed as part of a prior study using a MSDSLA system
(Monheit 2011); melanomas and other pigmented lesions presumably selected on a case-control
type basis
Setting: unclear
Prior testing: NR
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Rigel 2012 (Continued)
Setting for prior testing: NR
Exclusion criteria: none reported
Sample size (participants): number included: NR
Sample size (lesions): number included: 24
Participant characteristics: none reported
Lesion characteristics: none reported
Index tests Dermoscopy: no algorithm
Method of diagnosis: dermoscopic images; interactive melanoma session where dermatologists
were first presented with clinical and dermoscopic images and asked to make a diagnosis; then
presented with information from MelaFind
Prior test data: patient history and clinical images were presented along with dermoscopic images
Diagnostic threshold: clinical decision to excise or not
Diagnosis based on: average (n = 179)
Observer qualifications: dermatologist; practicing dermatologists attending an educational con-
ference
Experience in practice: assumed high (median duration of practice 11-15 years)
Experience with dermoscopy: NR
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone (not further described)
Disease-positive: 5; disease-negative: 19
Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 5; ’Benign’ diagnoses: 19
Flow and timing Participant exclusions: none reported
Index test to reference standard interval: not described
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Unclear
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
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Rigel 2012 (Continued)
Did the study avoid including
participants with multiple le-
sions?
Unclear
Unclear High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
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Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
Rosendahl 2011
Study characteristics
Patient sampling Study design: case series
Data collection: retrospective image selection/prospective interpretation
Period of data collection: 30-month period; dates NR
Country: Australia
378Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Rosendahl 2011 (Continued)
Patient characteristics and set-
ting
Inclusion criteria: consecutive series of pigmented lesions submitted for histology from the primary
care skin cancer practice of 1 study author
Setting: primary/private; skin cancer practice of 1 study author
Prior testing: selected for excision (no further detail)
Setting for prior testing: primary
Exclusion criteria: poor image quality (considered under Flow and Timing)
Sample size (participants): number included: 389
Sample size (lesions): number eligible: 466 pigmented lesions out of 1959 lesions excised or
biopsied; number included: 463
Participant characteristics: mean age: 57 years (SD 17); male: 67.4%
Lesion characteristics: (53.1%) melanocytic. Lesion site: 17.7% head or face; trunk: 52.1%; 27.
6% extremities; 2.2% palms or soles. Melanoma thickness: ≤ 1 mm: 1/29 melanoma (3.4%)
Index tests VI: no algorithm
Method of diagnosis: clinical photographs; overview and close-up image presented
Prior test data: no further information used
Other test data: dermoscopic images presented to observer subsequent to diagnosis using clinical
images alone
Diagnostic threshold: clinical diagnosis/subjective impression. Observers gave a diagnosis with
level of confidence (from 0 for definitely benign to 100 for definitely malignant) after viewing
the clinical images. (NB used study authors’ threshold for detection of any skin cancer, which
includes lesions clinically considered to be MM, BCC pigmented epithelial carcinoma including
SCC, keratoacanthoma, AK andBDas test-positive; review only considered histologically confirmed
MM, BCC or invasive SCC to be disease-positive)
Diagnosis based on: single observer (n = NR)
Observer qualifications: expert dermatologist (based on author communication).
Experience in practice: expert
Experience with dermoscopy: expert
Dermoscopy: pattern analysis; new algorithm; Chaos and clues
Method of diagnosis: clinical photographs (one overview and one close-up), followed by one
dermoscopic image presented to a blinded observer on a computer screen
Prior test data: clinical image only; diagnosis made based on clinical image before presentation of
dermoscopic image
Diagnostic threshold: observers gave a diagnosis with level of confidence (from 0 for definitely
benign to 100 for definitely malignant)
Chaos and clues short algorithm; each assessed for evidence of “chaos” (asymmetry of colour or
structure); if present then “clues” searched for. Chaos: asymmetry of structure and colour defined
according to the basic principles of pattern analysis as revised by Kittler 2007. Clues included:
eccentric structureless zone (any colour except skin colour), grey or blue structures, peripheral black
dots or clods, segmental radial lines or pseudopods, polymorphous vessels, white lines, thick reticular
or branched lines, and parallel lines on ridges (acral lesions)
Observers as for VI
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Details: excise or biopsy
Disease-positive: 138; disease-negative: 325
Target condition (final diagnoses)
Melanoma (invasive): 9; melanoma (in situ): 20; BCC: 72; cSCC: 5 (including 2 keratoacanthoma)
’Benign’ diagnoses: 18 BD and 14 AK, 217 benign melanocytic + additional 140 benign non-
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melanocytic
Note: study authors considered BD, AK and keratoacanthoma as malignant; all considered benign
for review analysis
Flow and timing Excluded participants: lesions were excluded due to poor image quality (n = 3)
Time interval to reference test: unclear; lesions ’routinely photographed’ if scheduled for excision
or biopsy but not further described
Comparative Blinding between tests: clinical photographs (one overview and one close-up), followed by one
dermoscopic image presented to a blinded observer on a computer screen
Time interval between index test(s): consecutive
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
No
High High
DOMAIN 2: Index Test Visual inspection - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
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For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
No
Was the test applied and inter-
preted in a clinically applicable
manner?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
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Low Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
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1 month or less?
High
DOMAIN 5: Comparative
Was each index test result in-
terpreted without knowledge of
the results of other index tests
or testing strategies?
No
Was the interval between ap-
plication of the index tests less
than one month?
Yes
Were all tests applied and inter-
preted in a clinically applicable
manner?
No
Low High
Rubegni 2012
Study characteristics
Patient sampling Study design: case series
Data collection: retrospective image selection/prospective interpretation
Period of data collection: January2008-December 2010
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: all palmoplantar PSLs observed and removed because of the presence of clinical
and/or dermoscopic suspicious features and in the absence of any clear benignity pattern (parallel
furrow pattern, lattice-like pattern or fibrillar pattern)
Setting: secondary (general dermatology)
Prior testing: clinical and/or dermatoscopic suspicion
Setting for prior testing: secondary (general dermatology)
Exclusion criteria: non-acral lesions; site of lesion in volar skin of the folds near the toes; lesion
size > 26 mm diameter; non-melanocytic appearance; elevated or ulcerated appearance
Sample size (participants): number included: 107
Sample size (lesions): number included: 107
Participant characteristics: mean age: 49.8 years (women); 44.9 years (men); range 19-73 years;
male: 58.9%; ethnicity white: 100%
Lesion characteristics 78 on soles and 19 on palms; 9 (36%) melanomas ≤ 0.75 mm (incl 4 in
situ); 11 (44%) 0.76-1.5 mm in 11/25 lesions; 5 (20%) ≥ 1.50 mm
Index tests Dermoscopy: pattern analysis; 3-step algorithm for palmoplantar lesions (Koga 2011)
Method of diagnosis: dermoscopic images
Prior test data: no further information used
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Diagnostic threshold: clinical diagnosis (melanoma/no melanoma). For the 3-step algorithm the
conventional options are “removal, follow-up or no follow-up”; the latter 2 were combined under
the term ‘no melanoma’ for study purposes
Diagnosis based on: single observer (n = 2; one per algorithm)
Observer qualifications: dermatologist
Experience in practice: high
Experience with dermoscopy: high; 2 dermatologists with 20 years’ experience
in dermoscopy
Any other detail: ELM images achieved with the DB-Mips System; (magnification x 16)
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Details: “Histopathological diagnosis was based on the criteria of the National Institute of Health
Consensus Conference”
Disease-positive: 25; disease-negative: 82
Target condition (final diagnoses)
Melanoma (invasive): 21; melanoma (in situ): 4
’Benign’ diagnoses: 82
Flow and timing Participant exclusions: none reported
Index test to reference standard interval: not described
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
High High
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DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Yes
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
Yes
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matopathologist?
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
Rubegni 2016
Study characteristics
Patient sampling Study design: case series
Data collection: retrospective image selection/prospective interpretation
Period of data collection: 2010-2014
Country: NR. Majority of study authors based in Italy, but source of lesion images not described
Patient characteristics and set-
ting
Inclusion criteria: consecutive melanocytic skin lesions showing clear-cut dermoscopic features of
regression that were excised for suspected malignancy. Regression features included: blue-grey veil,
blue grey globules and white scar-like areas, hypopigmented areas and atypical network (all of which
may be present in benign and malignant lesions)
Setting: secondary; not clearly reported but study authors all based in dermatology units or depart-
ments
Prior testing: dermatoscopic suspicion in all cases
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Setting for prior testing: NR
Exclusion criteria: none reported
Sample size (participants): number included: 95
Sample size (lesions): number included: 95
Participant characteristics: median age: naevi group 36 years (14-59 years); melanoma group 54.
4 years (17-89 years). Male: 43; 45.2%
Lesion characteristics: lesion site: head/neck: 20 (40%) of naevi; trunk 23(46%) of naevi and 24
(55%) of melanoma group; extremities 7 (14%) of naevi group; other areas 20 (45%) of melanomas.
Lesion size: mean 7.63 mm, range 4-16 mm (naevi) and 10.33 mm 5-19 mm (melanomas)
Index tests Dermoscopy: pattern analysis using 12 dermoscopic features of regression (study also developed a
new classifier but data excluded from review, due to use of ’leave one out’ procedure for validation)
Method of diagnosis: dermoscopic images; randomly presented to observers blinded to histopatho-
logical diagnosis
Prior test data: unclear; data on morphology, site, age and gender were collected but not clear if
presented along with image
Diagnostic threshold: diagnosis of melanoma or naevus following assessment of 12 dermoscopic
structures suggestive of regression selected according to the literature (Zalaudek 2004; Seidenari
2010) including blue-grey areas, blue-whitish veil, blue globules and blue-grey peppering, white scar-
like areas, white shiny streaks, atypical network, hypopigmented areas, irregular dots and globules,
irregular streaks, irregular pigmented blotches and pink areas
Diagnosis based on: single observer and consensus of 2/3 (n = 3)
Observer qualifications: dermatologist
Experience in practice: high; expert dermatologists
Experience with dermoscopy: high; “experienced dermoscopists”
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Details: every histological diagnosis was confirmed by 2/3 expert dermopathologists
Disease-positive: 45; disease-negative: 50
Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 45
Benign naevus: 50
Flow and timing Participant exclusions: none reported
Index test to reference standard interval: not described
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
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Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
Low High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
DOMAIN 3: Reference Standard
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Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
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Study characteristics
Patient sampling Study design: case series
Data collection: retrospective image selection/prospective interpretation
Period of data collection: NR
Country: Italy (based on authors’ institution)
Patient characteristics and set-
ting
Inclusion criteria: melanocytic lesion images acquired consecutively by d-ELM at the Department
of Dermatology of Santa Chiara Hospital, Trento
Setting: secondary (general dermatology)
Prior testing: selected for excision (no further detail)
Setting for prior testing: NR
Exclusion criteria: seems that dysplastic naevi were excluded; “In this experimental setting, there
were no dysplastic naevi”
Sample size (participants): NR
Sample size (lesions): number included: 152
Participant characteristics: none reported
Lesion characteristics: mean Breslow thickness for the invasive lesions is 1.0 +/- 0.7 mm; 81% ≤
1.5 mm
Index tests Dermoscopy: no algorithm
Method of diagnosis: dermoscopic images; digitial-ELM images presented on video device
Prior test data: no further information used
Diagnostic threshold: NR; appears to be correct diagnosis of melanoma
Diagnosis based on: single observer and average (n = 8)
Observer qualifications: dermatologist
Experience in practice: not described
Experience with dermoscopy: not described
Any other detail: the d-ELM Image Acquisition consists of a LeicaWILDM-650 stereomicroscope
(Leica Microsystem, Heerbrugg, Switzerland), with a SONY 3CCD DXC-930P colour camera
(Sony Corporation,Tokyo, Japan). The software for image acquisition was DBDERMO MIPS
(Dell’Eva/Burroni Studio, Florence/Siena, Italy). The digital image size has a spatial resolution of
768 x 576 pixels and a 24-bit colour resolution
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Disease-positive: 42; disease-negative: 110
Target condition (final diagnoses)
Melanoma (invasive): 31; melanoma (in situ): 11
Benign naevus: 110
Flow and timing Participant exclusions: none reported
Index test to reference standard interval: not described
Comparative
Notes -
Methodological quality
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Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
High High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
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Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
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If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
Seidenari 1998
Study characteristics
Patient sampling Study design: case-control
Data collection: retrospective image selection/prospective interpretation
Period of data collection: NR; 4 year period
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: melanomas and benign PSLs from a larger series of PSLs used to develop a
new automated classifier; all melanomas with x20 magnification images were included + a random
sample of benign lesions with the same magnification. For the larger series, lesions were referred by
dermatologists or general physicians because of ≥ 1 PSL that were difficult to interpret on clinical
grounds alone, numerous PSLs, or because the patients were at increased risk for melanoma or had
had a malignant PSL in the past
Setting: secondary
Prior testing: clinical suspicion of malignancy
Setting for prior testing: primary; secondary (general dermatology)
Exclusion criteria: none reported
Sample size (participants): NR
Sample size (lesions): number eligible: 917; number included: 100
Participant characteristics: none reported
Lesion characteristics: melanoma thickness: ≤ 1 mm : 70.8% (n = 46), < 1 mm 58.5% (n = 38).
Mean thickness 0.73 ± 0.69 mm
Index tests Dermoscopy: no algorithm
Method of diagnosis: dermoscopic images; (obtained via videomicroscopy)
Prior test data: no further information. “Images appeared in a random sequence on the computer
screen, and no information about the patient (such as history, skin site, age of the patient, evolution
of the lesion) was given to the evaluators”
Diagnostic threshold: clinical diagnosis
Diagnosis based on: single observer (n = 2)
Observer qualifications: dermatologist
Experience in practice: not described
Experience with dermoscopy: low; 1 ’untrained’ dermatologist; high; 1 routinely used videomi-
croscopy
Any other detail: for instrumental examination a 10- (39 cases), 20- (501 cases), or 50-fold-
magnification (377 cases) was chosen according to the size of the lesion, enabling the whole lesion
to be seen on the monitor. For the study, the 31 MM with x20 magnification were selected + a
random sample of 59 benign
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Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Details: describes using “conventional histopathologic criteria”
Disease-positive: 31; disease-negative: 59
Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 31
’Benign’ diagnoses: 59 “nonmelanoma cases consisted of naevi including dysplastic naevi”
Flow and timing Participant exclusions: none reported
Index test to reference standard interval: not described
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
High High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
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For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
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Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
Seidenari 2005
Study characteristics
Patient sampling Study design: case series
Data collection: retrospective image selection/prospective interpretation
Period of data collection: NR
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: patients with melanocytic lesions referred to a pigmented lesion clinic by a
dermatologist for examination of a particular lesion or the whole skin; all lesions were excised for
clinical, dermoscopic, or cosmetic reasons
Setting: specialist unit
Prior testing: clinical and/or dermatoscopic suspicion; patient request for evaluation/excision
Setting for prior testing: NR
Exclusion criteria: none reported
Sample size (participants): NR
Sample size (lesions): number included: 603
Participant characteristics: none reported
Lesion characteristics: none reported
Index tests Dermoscopy: pattern analysis
Method of diagnosis: dermoscopic images
Prior test data: no further information used; images were retrospectively subdivided into 4 groups
according to diagnoses performed exclusively by dermoscopy by 2 dermatologists trained in der-
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moscopy
Diagnostic threshold: images grouped according to degree of atypia, with those grade 3 considered
to be melanomas dermoscopically, and those at grade 2 as dermoscopically atypical, to be excised
to rule out melanoma
Diagnosis based on: not clear but appears to be consensus (2 observers) (n = 2); “diagnoses
performed exclusively by dermoscopy by two dermatologists trained in dermoscopy and experienced
in using polarised light videomicroscopes”
Observer qualifications: dermatologist
Experience in practice: NR
Experience with dermoscopy: high
Any other detail images were captured using a digital videomicroscope (VMS-110A, Scalar Mit-
subishi, Tama-shi, Tokyo, Japan), with a 20-fold magnification
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone (no further details)
Disease-positive: 112; disease-negative: 491
Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 112
Benign naevus: 491
Flow and timing Excluded participants: NR
Time interval to reference test: NR
Time interval between index test(s): NR
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
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Unclear High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
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Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
Seidenari 2007
Study characteristics
Patient sampling Study design: case series
Data collection: retrospective image selection/prospective interpretation
Period of data collection: NR
Country: Italy
Test set derived NR; the training set consisted of 369 melanocytic lesion images (including 43
MMs); test set comprised 243 images (including 43 MMs)
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Patient characteristics and set-
ting
Inclusion criteria: dermoscopic images of melanocytic lesion that had undergone excision
Setting: unclear
Prior testing: selected for excision (no further detail)
Setting for prior testing: unspecified
Exclusion criteria: none reported
Sample size (participants): NR
Sample size (lesions): number eligible: 612; number included: 243 in test set
Participant characteristics: none reported
Lesion characteristics: MMs of the test set included 8 in situ with mean thickness 0.77 mm
Index tests Dermoscopy: no algorithm
Method of diagnosis: dermoscopic images observed on a computer screen
Prior test data: no further information used; clinicians had no access to the clinical image or to
clinical data
Diagnostic threshold: clinical diagnosis of melanoma
Diagnosis based on: single observer (n = 4; results presented per observer, but not identifiable by
experience level)
Observer qualifications: dermatology registrar (n = 3); dermatologist (n = 1)
Experience in practice: NR
Experience with dermoscopy: mixed: trained (residents had undergone 6-month daily training on
dermoscopy); high (dermatologist employed dermoscopy on a regular basis)
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone (no further details)
Disease-positive: 43; disease-negative: 200
Target condition (final diagnoses)
Melanoma (invasive): 35; melanoma (in situ): 8
Benign naevus: 200
Flow and timing Participant exclusions: none reported
Index test to reference standard interval: not described
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
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Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Unclear High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
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Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
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Study characteristics
Patient sampling Study design: case-control
Data collection: retrospective image selection/prospective interpretation
Period of data collection: July 1996-September 1996
Country: Austria
Patient characteristics and set-
ting
Inclusion criteria: consecutive lesions excised due to changes over time during digital dermoscopy
follow-up (appear to be from patients with multiple melanocytic naevi); all lesions were assessed
for presence of dermoscopic characteristics and all melanomas + random sample of same number
of benign were assessed by dermoscopic algorithms (included in review)
Setting: secondary (general dermatology)
Prior testing: NR
Setting for prior testing: unspecified
Exclusion criteria: location/site of lesion - palmar, plantar, facial lesions; lesion size lesions that
exceeded maximum field of view of the electronic camera
Sample size (participants): NR
Sample size (lesions): number included: 126
Participant characteristics: none reported
Lesion characteristics none reported
Index tests Dermoscopy 7PCL and ABCD
Method of diagnosis: dermoscopic images presented on a computer screen
Prior test data: no further information used
Diagnostic threshold: ABCD score > 4.75; 7PCL score > 2
Diagnosis based on: single observer (n = 2)
Observer qualifications: dermatologist
Experience in practice: assumed high; paper describes assessment of baseline images for dermo-
scopic criteria by ”2 experienced dermatologists“; ”additionally, the baseline images of (a subgroup
of lesions) were evaluated by 2 blinded investigators). These appear to be separate groups of observers
but have assumed similar levels of experience
Experience with dermoscopy: assumed high (as above)
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone (but all lesions followed up)
Details: “standard: histopathology” following lesion changes over time
Disease-positive: 63; disease-negative: 63
Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 63
Benign naevus: 63
Flow and timing Participant exclusions: none reported
Index test to reference standard interval: lesions suggestive of melanoma at baseline were removed
at the patient’s initial visit (immediately); the others were followed up for 3-6 months until lesion
changes initiated excision
Comparative
Notes -
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Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
High High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Unclear
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
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Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
Yes
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If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Yes
Low
Soyer 1995
Study characteristics
Patient sampling Study design: case series
Data collection: unclear
Period of data collection: NR
Country: Austria
Patient characteristics and set-
ting
Inclusion criteria: PSL, difficult to diagnose on clinical grounds alone
Setting: specialist unit (skin cancer/PLC)
Prior testing: clinical suspicion
Setting for prior testing: secondary (general dermatology); referred by dermatologists or general
physicians
Exclusion criteria: none reported
Sample size (participants): NR
Sample size (lesions): number included: 159
Participant characteristics: none reported
Lesion characteristics: “23 melanomas with a Breslow index of </= 0.75mm, 13 melanomas with
a Breslow index >/=0.76mm and </= 1.5mm, 12 melanomas with a Breslow index >/=1.51mm and
</=3.5mm, 2 melanomas with a Breslow index of >/=3.5mm.”
Index tests VI: no algorithm
Method of diagnosis: in-person diagnosis
Prior test data: N/A in-person diagnosis
Other test data: dermoscopy undertaken by same clinician(s) subsequent to clinical evaluation
Diagnostic threshold: NR
Diagnosis based on: n = 2 (1 or 2 per lesion)
Observer qualifications: dermatologist
Experience in practice: not clearly described; assumed to be high; “the examination was performed
by a dermatologist expert in dermoscopy”
Experience with dermoscopy: high; “the examination was performed by a dermatologist expert in
dermoscopy”
Other detail: “Photographic documentation was performed using an incident light stereomicro-
scope (Wild M 650) equipped with a Minolta XG-M camera”
Dermoscopy: pattern analysis
Method of diagnosis: in-person diagnosis “After application of a drop of immersion oil, each lesion
was examined with a hand-held dermatoscope”
Prior test data: clinical examination and/or case notes
Diagnostic threshold: criteria included: pigment network, irregular extensions, radial streaming,
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brown globules, black dots, whitish veil, white scar-like areas, grey-blue areas, hypopigmented areas,
reticular depigmentation, amongst others
Any other detail “After application of a drop of immersion oil, each lesion was examined with
a handheld dermatoscope (Heine, Optotechnik, Herrsching, Germany) at a magnification of x10
and with an incident light stereomicroscope (Wild M 650, Heerburg, Switzerland) with 6- to 40-
fold magnification.”
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Disease-positive: 65 (41%); disease-negative: 94 (59%)
Target condition (final diagnoses)
Melanoma (invasive): 50; melanoma (in situ): 15
BCC: pigmented BCC (3)
Sebhorrheic keratosis: 18; Clark’s naevus of dysplastic naevus (61 cases); lentigo actinica lentigo (2)
, pigmented AK (4), angioma (3), angiokeratoma (2)
Flow and timing Excluded participants: none reported
Time interval to reference test: NR
Comparative Blinding between tests: in-person diagnosis without and then with dermoscopy
Time interval between index test(s): same day; at time of face-to-face consultation
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
Unclear
Did the study avoid including
participants with multiple le-
sions?
Unclear
Unclear Unclear
DOMAIN 2: Index Test Visual Inspection - in-person
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Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
DOMAIN 2: Index Test Dermoscopy - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
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Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Unclear Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
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of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
DOMAIN 5: Comparative
Was each index test result in-
terpreted without knowledge of
the results of other index tests
or testing strategies?
No
Was the interval between ap-
plication of the index tests less
than one month?
Yes
Were all tests applied and inter-
preted in a clinically applicable
manner?
Yes
Low Low
Soyer 2004
Study characteristics
Patient sampling Study design: case series
Data collection: retrospective (for expert observer data; previously acquired images prospectively
interpreted by 6 inexperienced observers - data excluded as 3/6 medical students)
Period of data collection: January-December 2000
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: lesions at pigmented lesion clinic considered by experienced dermatologists to
merit excision on clinical grounds
Setting: specialist unit
Prior testing: clinical and/or dermatoscopic suspicion
Setting for prior testing: specialist unit
Exclusion criteria: none reported
Sample size (participants): number included: 225
Sample size (lesions): number included: 231
Participant characteristics: median age 34 years. Male: 110/225 (48.9%)
Lesion characteristics: none reported
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Index tests Dermoscopy: no algorithm (study also develops 3PCL but data ineligible due to use of medical
student observers)
Method of diagnosis: in-person
Prior test data: clinical examination
Diagnostic threshold: diagnosis of malignancy (melanoma or BCC)
Diagnosis based on: single observer (n = 1)
Observer qualifications: dermatologist
Experience in practice: high; “experienced dermatologists”
Experience with dermoscopy: high; “Each lesion was diagnosed dermoscopically by an experienced
dermoscopist”
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone (not further described)
Disease-positive: 77; disease-negative: 154
Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 68
BCC: 9
’Benign’ diagnoses: 154
Flow and timing Participant exclusions: none reported
Index test to reference standard interval: appears consecutive; “before excision, each lesion was
diagnosed dermoscopically”
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
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Low High
DOMAIN 2: Index Test Dermoscopy - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Unclear Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
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Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Low
Stanganelli 1998a
Study characteristics
Patient sampling Study design: case-control
Data collection: retrospective image selection/prospective interpretation
Period of data collection: just states 1997
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: images of PSLs selected from computerised files of the skin cancer clinic
Setting: training study; images selected from skin cancer clinic
Prior testing: NR
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Setting for prior testing: unspecified
Exclusion criteria: none reported
Sample size (participants): NR
Sample size (lesions): number included: 30 PSLs
Participant characteristics: none reported
Lesion characteristics none reported
Index tests VI: no algorithm
Method of diagnosis: clinical photographs
Prior test data: no further information used
Other test data: dermoscopic images presented to observer subsequent to diagnosis using clinical
images alone (images were randomised)
Diagnostic threshold: NR
Diagnosis based on: average; n = 20
Observer qualifications: dermatologist
Experience in practice: not described;
Experience with dermoscopy: 30 dermatologists with “experience in ELM but (with) no formal
training” attended a seminar on clinical and ELM diagnosis of PSL; 20 then participated in a test
of their diagnostic accuracy. A second session on ELM was then held
Dermoscopy: no algorithm
Method of diagnosis: dermoscopic images
Prior test data: post-training, clinical image presented alongside dermoscopic image
Diagnostic threshold: NR
Test observers as described for VI (above)
Dermoscopy training: participants undertook 75-min seminar on the overview of the principles
of ELM using digital ELM (D-ELM) images from the files at the clinic. A second session 45 min
long focused on the major aspects of the differential diagnosis of PSL as evaluated by D-ELM
Length of training 2 h
Post-training experience: < 6 months
Training format: in-person teaching
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 10
BCC: 4
Mild/moderate dysplasia: 3; SK: 3; benign naevus: melanocytic naevi-7
Other: 1 hemangioma, 1 subungunal haemorrhage, 1 plantar intraepidermal haemorrhage
Flow and timing Excluded participants: none reported
Time interval to reference test: NR
Comparative Blinding between tests: dermoscopic images presented to observer subsequent to diagnosis using
clinical images alone (images were randomised) then with dermoscopy
Time interval between index test(s): NR
Notes -
Methodological quality
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Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
High High
DOMAIN 2: Index Test Visual inspection - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
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Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Unclear High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
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Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
DOMAIN 5: Comparative
Was each index test result in-
terpreted without knowledge of
the results of other index tests
or testing strategies?
Yes
417Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Stanganelli 1998a (Continued)
Was the interval between ap-
plication of the index tests less
than one month?
Unclear
Were all tests applied and inter-
preted in a clinically applicable
manner?
No
Unclear High
Stanganelli 1999
Study characteristics
Patient sampling Study design: case-control (dermoscopy training study)
Data collection: retrospective image selection/prospective interpretation
Period of data collection: 15 November 1997-25 January 1998
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: PSL images (of melanomas, melanocytic naevi and non-melanocytic naevi)
selected from the dermoscopy files of 2 skin cancer clinics
Setting: specialist unit databases
Prior testing: NR (all lesions excised)
Setting for prior testing: NR
Exclusion criteria: none reported
Sample size (participants): NR
Sample size (lesions): number included: 30
Participant characteristics: none reported
Lesion characteristics: melanoma thickness median 0.61 mm, range 0.28-20 mm
Index tests Dermoscopy:no algorithm (training course covered principles of clinical and dermoscopic diagnosis
of PSLs and referred to a number of diagnostic algorithms, however it did not teach any one
particular method of diagnosis; same slides evaluated both pre- and post-dermoscopy training)
Method of diagnosis: clinical photographs and dermoscopic images
Prior test data: no further information used; pairs of slides were projected onto a screen without
access to patient information
Diagnostic threshold: correct diagnosis of melanoma
Diagnosis based on: average (n = 83 out of 465 professionals who participated in the meetings and
workshops over the course of a year)
Observer qualifications: dermatologists
Experience in practice: mixed; “an average of 10y of general experience in dermatology (range 1-
22years)”
Experience with dermoscopy: mixed; “A routine use of ELM was reported by 52 (63%) individ-
uals”. 35 (42%) see > 20 PSLs per week
Dermoscopy training: attendees could choose from several classes: clinical classification and diag-
nosis of PSLs; management of patients with PSLs; basic principles of ELM; ELM criteria; ELM
diagnosis; limitations of ELM
Length of training: 4 + 2 h for each session attended
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Training format: in-person teaching; delivered as 1-day workshops and meetings
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone (not further described; original histological diag-
nosis used)
Disease-positive: 11; disease-negative: 19
Target condition (final diagnoses)
Melanoma (invasive): 10; melanoma (in situ): 1
14 melanocytic naevi; 5 non-melanocytic lesions
Flow and timing Participant exclusions: none reported
Index test to reference standard interval: not described
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
High High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
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If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
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Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
Stanganelli 2000
Study characteristics
Patient sampling Study design: case series
Data collection: retrospective
Period of data collection: 1994-1996
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: patients with PSLs referred by dermatologists and GPs either for pre-surgical
assessment or consultation
Setting: specialist unit; “skin cancer clinic of Ravenna”
Prior testing: patients referred for pre-surgical assessment or consultation indicating they had had
prior tests
Setting for prior testing: primary; some patients referred for consultation only; dermoscopy findings
are reported back and management decision remains with referring clinician; secondary (general
dermatology)
Exclusion criteria: none reported
Sample size (participants): number eligible: 1556
Sample size (lesions): number eligible: 3372; number included: 3372
Participant characteristics: median age 30 years, range 10-94; male: 522 (34%)
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Lesion characteristics: none reported
Index tests VI: ABCD
Method of diagnosis: in-person diagnosis
Prior test data: N/A in-person diagnosis
Other test data: dermoscopic and clinical images subsequently presented separately to observer
subsequent to diagnosis using clinical images alone
Diagnostic threshold: NR
Diagnosis based on: single observer; n = 1
Observer qualifications: NR; described as one of the co-authors and study based in skin cancer
clinic - likely dermatologist
Experience in practice: not described
Experience with dermoscopy: not described
Other detail: a crude clinical image (magn x6 and x10) was recorded in the digital database
Dermoscopy: pattern analysis
Method of diagnosis: unclear; Patients seen in person but dermoscopic diagnosis made based on
digital ELM image (by same clinician as in-person clinical diagnosis)
Prior test data: combined clinical/dermoscopy diagnosis
Diagnostic threshold: diagnosis described as based on an integrated synopsis of the patterns most
commonly described in the literature (Steiner 1993) and generally associated with known histologic
counterparts. Features were assessed described in detail with multiple references, including: presence
of pigment network, sharpmargins, abrupt edge of pigment network, branched streaks, pseudopods,
radial streaming, brown globules, pigment dots, whitish or whitish blue veil, grey-blue areas, white
or depigmented areas, maple leaf areas, milia-cysts, horny plugs and vascular patterns
Test observers as described for VI (above)
Experience with dermoscopy:
Any other detail: the equipment consisted of a Leica Wild M-650 stereomiscroscope (Leica AG,
Heerbrugg, Switzerland), a Sony 3ccd DXC-930P colour video camera, an AT-Vista videographics
adapter, and IBM personal computer, a Sony Trinitron Analog PVM-2043MD monitor, and the
DBDERMO MIPS software
Target condition and reference
standard(s)
Reference standard: histological diagnosis + follow-up; histology report of known surgical excisions
(n = 262) + a cancer-registry-based follow-up of benign cases (n = 3110)
Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 55; BCC: 43
’Benign’ diagnoses: 3274
Flow and timing Excluded participants: none reported
Time interval to reference test: NR
Comparative Blinding between tests: unclear how dermoscopic diagnosis was made
Time interval between index test(s): not clearly reported just indicated thatD-ELMwas performed
soon after clinical examination
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
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DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
Yes
Did the study avoid including
participants with multiple le-
sions?
No
Low High
DOMAIN 2: Index Test Visual Inspection - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
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Low Unclear
DOMAIN 2: Index Test Dermoscopy - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Low Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
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Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
High Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
Yes
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
DOMAIN 5: Comparative
Was each index test result in-
terpreted without knowledge of
the results of other index tests
or testing strategies?
Unclear
Was the interval between ap-
plication of the index tests less
than one month?
Unclear
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Were all tests applied and inter-
preted in a clinically applicable
manner?
Unclear
Unclear Unclear
Stanganelli 2005
Study characteristics
Patient sampling Study design: unclear (likely case series)
Data collection: retrospective image selection/prospective interpretation
Period of data collection: NR
Country: Italy
Test set derived: a training set of 22 melanomas and 218 melanocytic naevi was randomised from
the dataset. The test set was formed by the complement (the remaining 20 melanomas and 217
naevi). A further subset of images from the original dataset, consisting of 31 melanomas and 103
naevi, was used for the comparison between observers and CAD; derivation of the subset NR
Patient characteristics and set-
ting
Inclusion criteria: melanocytic lesions from patients referred to the Skin Cancer Unit and un-
dergoing clinical and dermoscopic evaluation; images were ’selected’ from a larger image database.
Potential overlap with Stanganelli 2000 (not possible to determine)
Setting: specialist unit; Skin Cancer Unit in Ravenna
Prior testing: clinical and/or dermatoscopic suspicion
Setting for prior testing: specialist unit (skin cancer/PLC)
Exclusion criteria: none reported
Sample size (participants): number eligible: 1556 referred/number included: NR
Sample size (lesions): number eligible: 3274/number included: 477 melanocytic lesions; 237 in
test set and 134 in comparison between CAD and human operators
Participant characteristics: none reported
Lesion characteristics: melanoma thickness 61.2%, < 0.75 mm
Index tests VI: no algorithm
Method of diagnosis: clinical photographs
Prior test data: GPs evaluated only clinical images; dermatologists examined both clinical and der-
moscopic images but unclear whether clinical diagnosis was made prior to presentation of dermo-
scopic images
Diagnostic threshold: NR
Diagnosis based on: average (n = 6)
Observer qualifications: GP 3; dermatologist 3
Experience in practice: NR
Experience with dermoscopy: assumed Low for GPs; high for dermatologists - described as “der-
matologists with experience in ELM (2 years)”
Other detail: digital images included melanocytic lesions evaluated in ELM with a fixed x16 mag-
nification
Dermoscopy: no algorithm
Method of diagnosis: dermoscopic images (dermatologists only)
Prior test data: dermatologists examined both clinical and dermoscopic images
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Diagnostic threshold: NR
Test observers as described for VI (above)
Target condition and reference
standard(s)
Reference standard: histological diagnosis + cancer registry
All included lesions underwent histology but some were identified using a cancer-registry-based
follow-up of benign diagnoses
Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 42 in full sample; 31 in CAD vs human observer inter-
pretation and 20 in test set
’Benign’ diagnoses: 435 melanocytic naevi; 103 in CAD-observer complement and 217 in test set
Flow and timing Excluded participants: none reported
Time interval to reference test: NR
Comparative Blinding between tests: dermatologists examined both clinical and dermoscopic images but unclear
whether clinical diagnosis was made prior to presentation of dermoscopic images
Time interval between index test(s): obtained from patients undergoing clinical and dermoscopic
evaluation
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Unclear
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Unclear High
DOMAIN 2: Index Test Visual inspection - image-based
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Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Unclear High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
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Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Unclear
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
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of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
DOMAIN 5: Comparative
Was each index test result in-
terpreted without knowledge of
the results of other index tests
or testing strategies?
Unclear
Was the interval between ap-
plication of the index tests less
than one month?
Yes
Were all tests applied and inter-
preted in a clinically applicable
manner?
No
Low High
Stanganelli 2015
Study characteristics
Patient sampling Study design: case series
Data collection: retrospective image selection/prospective interpretation
Period of data collection: July 2010-July 2012
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: melanocytic lesions excised at the Skin Cancer Unit on the basis of clinical and/
or dermoscopic changes at follow-up suggesting a malignancy
Setting: specialist unit; “conducted at the Skin Cancer Unit at the ‘Istituto Scientifico Romagnolo
per lo Studio e la Cura dei Tumori’ (IRST IRCCS), in Ravenna/Forli and Meldola”
Prior testing: changes on digital monitoring; lesions showing clinical or dermoscopic changes on
follow-up
Setting for prior testing: specialist unit
Exclusion criteria: lack of baseline and follow-up dermoscopic images; lack of RCM images; lack
of histology
Sample size (participants): number included: 70
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Sample size (lesions): number included: 70
Participant characteristics: mean age; women 39 years; men 40 years. Male: 54%. History of
melanoma/skin cancer: 37%. Total naevus counts, 27 (39%) with > 50 melanocytic naevi, 33 (47%)
with 10-50 naevi; and 10 (14%) with < 10 naevi. Fitzpatrick phototype I-II = 19 (27%); type III
to IV = 50 (73%). Median follow-up was 25 months (range 3-134 months)
Lesion characteristics: lesion site head/neck 7.1%; trunk: 80%; upper limbs/shoulder: 1.4%; lower
limbs/hip: 11.4%. Melanoma thickness median 0.4 mm (0.2-1 mm). Lesion size: mean at baseline
8 mm (range 2-22 mm); mean at follow-up 9 mm (range 3-24 mm)
Index tests Dermoscopy: revised 7PCL (for follow-up purposes)
Method of diagnosis: dermoscopic images; baseline images assessed using standard 7PCL and
compared to follow-up images to determine criteria indicating significant change
Prior test data: baseline dermoscopic image
Diagnostic threshold: presence of “Major change” (asymmetrical structural and chromatic changes,
or the appearance of melanoma-specific criteria, i.e. major or minor criteria on original 7-point
checklist as per Argenziano 1998). Revised approach referenced to Argenziano 2010. (“Minor
change” assigned if there was only symmetrical change in structural or chromatic pattern; “moderate
change” if either structural or chromatic changes were asymmetrical, but there were no melanoma-
specific criteria; and “no change” was assigned if all variables remained constant, with a tolerance of
major axis change of 2 mm (Beer 2011; Terushkin 2012))
Diagnosis based on: unclear; n = NR for dermoscopy
Observer qualifications: NR but likely dermatologists (RCM images in same study were eval-
uated jointly by 3 expert dermatologists who had no knowledge of the clinical, dermoscopic or
histopathology information)
Experience in practice: not described
Experience with dermoscopy: not described
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Details: “histopathological diagnosis was based on the consensus of at least two out of three board-
certified pathologists”
Disease-positive: 12; disease-negative: 58
Target condition (final diagnoses)
Melanoma (invasive): 11; melanoma (in situ): 1
’Benign’ diagnoses: 55 melanocytic naevi (79%) and three non-melanocytic lesions (4%)
Flow and timing Participant exclusions: none reported
Index test to reference standard interval: appears consecutive, “Lesions showing clinical and/or
dermoscopic aspects suggesting amalignancy are excised. RCM imaging is performed before surgical
excision.”
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
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Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
Unclear High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Low High
432Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Stanganelli 2015 (Continued)
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
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Low
Stolz 1994a
Study characteristics
Patient sampling Study design: case series
Data collection: retrospective image selection/prospective interpretation
Period of data collection: from 1989-1991
Country: Germany
Test set derived: 157 cases were randomly divided into a test and training set
Patient characteristics and set-
ting
Inclusion criteria: equivocal melanocytic skin lesions < 9 x13 mm, melanoma tumour thickness of
≤ 1 mm and melanoma Clark’s ≤ level III
Setting: secondary (general dermatology); Univerisity of Munich Department of Dermatology
Prior testing: selected for excision (no further detail)
Setting for prior testing: NR
Exclusion criteria: none reported
Sample size (participants): NR
Sample size (lesions): number eligible: 650 cases/number included: 157 lesions
Participant characteristics: none reported
Lesion characteristics: melanoma thickness: 50 ≤ 0.4 mm; 30 ≤ 0.75 mm; 15 ≤ 1 mm
Index tests Dermoscopy: ABCD
Method of diagnosis: dermoscopic images; colour prints examined for 31 dermoscopic features,
most listed in the guidelines of the Consensus Conference of Surface Microscopy held in Hamburg
in 1989 (Bahmer 1990); described as a “blind study”
Prior test data: no further information used
Diagnostic threshold: > 5.45; multivariate analysis of training set data identified 8 features with
the lowest P values; the total dermoscopic score (TDS) was then developed based on: asymmetry
score x 1.3 + Border score x 0.1 + Colour score x 0.5 + Differential structure score x 0.5. New
formula then evaluated on the test set of images
Diagnosis based on: single observer (n = 1)
Observer qualifications: NR; co-author, assumed to be dermatologist
Experience in practice: not described
Experience with dermoscopy: not described
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Details: histology undertaken by 2 independent histopathologists
Disease-positive: test set = 48; disease-negative: test set = 31
Target condition (final diagnoses)
Melanoma (invasive): 85; melanoma (in situ): 10
’Benign’ diagnoses: 62 melanocytic naevi; 17 junctional; 40 compound; 5 dermal
Flow and timing Participant exclusions: none reported
Index test to reference standard interval: not described
Comparative
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Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
High High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
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Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
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of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
Tan 2009
Study characteristics
Patient sampling Study design: case-control (dermoscopy training study)
Data collection: retrospective image selection/prospective interpretation
Period of data collection: NR
Country: UK
Patient characteristics and set-
ting
Inclusion criteria: test series of images of melanomas and benign lesions; source of images NR
Setting: not described; training images
Prior testing: selected for excision (no further detail)
Setting for prior testing: unspecified
Exclusion criteria: none reported
Sample size (participants): NR
Sample size (lesions): number included: 30
Participant characteristics: none reported
Lesion characteristics: none reported
Index tests Dermoscopy: (modified) pattern analysis
Method of diagnosis: clinical photographs and dermoscopic images
Prior test data: participants presented with a test card printed on A4 laminated paper for each
lesion, each consisting of 1 macroscopic and 1 dermatoscopic image
Diagnostic threshold: excise or not (algorithm not further described)
Diagnosis based on: average (n = 6; all based at same university hospital); the study authors
presented 2x2 based on adding each 2x2 cell together for all observers; to avoid double counting of
lesions for this review, all 2x2 cells were divided by 6 to get average result
Observer qualifications: dermatology specialist registrar 3; dermatologist 3
Experience in practice: mixed
Experience with dermoscopy: low; before the study, none had routinely used a dermatoscope
Dermoscopy training: participants received an online tutorial (www.dermatoscopy.org) teaching
the Modified Pattern Analysis Diagnostic Algorithm (Steiner 1987a; Carli 2003a) and was given
a dual polarizing LED dermatoscope to use in clinical practice for 10 months. At the end of the
study, the test-card questionnaire was repeated
Length of training NR; online tutorial
Post-training experience: 10 months
Training format: online
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Target condition and reference
standard(s)
Reference standard: histological diagnosis alone (not further described)
Disease-positive: 15; disease-negative: 15
Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 15
Other: 15 (9 naevi, 1 blue naevus, 3 seborrhoeic keratoses, 1 lentigo and 1 vascular lesion)
Flow and timing Participant exclusions: none reported
Index test to reference standard interval: not described
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
High High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
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For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
No
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
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Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
Tenenhaus 2010
Study characteristics
Patient sampling Study design: case-control
Data collection: retrospective image selection/prospective interpretation
Period of data collection: not described
Country: France
Patient characteristics and set-
ting
Inclusion criteria: dermoscopic images of all melanoma lesions recorded on two PSL databases +
random sample of benign naevus
Setting: secondary (general dermatology)
Prior testing: NR
Setting for prior testing: unspecified
Exclusion criteria: none reported
Sample size (participants): NR
Sample size (lesions): number included: 227
Participant characteristics: none reported
Lesion characteristics: none reported
Index tests Dermoscopy: no algorithm
Method of diagnosis: dermoscopic images
Prior test data: clinical photographs
Diagnostic threshold: clinical diagnosis of melanoma and excise decision; presence of ABCD
and “malignancy-predictive” dermoscopic features were assessed (dichotomic answer) and diagnosis
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(melanoma, dysplastic or benign lesion) and therapeutic decision (dichotomic answer, excision/
non-excision) given
Diagnosis based on: single and average (n = 5); observers assessed lesion images independently;
sensitivity and specificity also presented for “pooled” advice
Observer qualifications: dermatologist
Experience in practice: high; “senior dermatologists”
Experience with dermoscopy: not described; assumed high
Target condition and reference
standard(s)
Reference standard: histological diagnosis + other
Histology: excision and histopathology of lesions considered to be melanomas (n = 32), dysplastic
lesions (n = 118) and some of those considered benign (n = 15)
Disease-positive: 32; disease-negative: 165
Other: “lesions considered benign were not surgically excised”; assume observer diagnosis was used
Disease-positive: 0; disease-negative: 62
Target condition (final diagnoses)
Melanoma (invasive): 28; lentigo maligna 4
Dysplastic naevus 118; blue benign naevus 2; congenital benign naevus 5; junctional and dermic
benign naevus 7; palmar-plantar benign naevus 1; ’benign naevus’ not excised: 62
Flow and timing Participant exclusions: none reported
Index test to reference standard interval: not described
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
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High High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Unclear Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
No
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Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
High High
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
Unclear
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
Unclear
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
Troyanova 2003
Study characteristics
Patient sampling Study design: case-control
Data collection: retrospective image selection/prospective interpretation
Period of data collection: NR
Country: NR
Patient characteristics and set-
ting
Inclusion criteria: images of PSLs selected for a dermoscopy training study
Setting: training study
Prior testing: NR
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Troyanova 2003 (Continued)
Setting for prior testing: NR
Exclusion criteria: lesions that were > 13 mm were not included
Sample size (participants): NR
Sample size (lesions): number included: 50 lesions
Participant characteristics: none reported
Lesion characteristics: melanoma thickness: ≤ 1 mm: 100%
Index tests VI: no algorithm
Method of diagnosis: clinical photographs and dermoscopic images
Other test data: dermoscopic images presented to observer subsequent to diagnosis using clinical
images alone
Prior test data: no further information used
Diagnostic threshold: NR
Diagnosis based on: average; n = 32
Observer qualifications: dermatologist
Experience in practice: high experience or ‘Expert’
Experience with index test: low experience/novice users; experienced in PSL field but not ELM
Dermoscopy: no algorithm; possibly pattern analysis
Method of diagnosis: dermoscopic images
Prior test data: no further information used. Previously made diagnosis based on clinical images
only; dermoscopic images presented after all clinical diagnoses had been made
Diagnostic threshold: NR
Test observers as described for VI (above)
Dermoscopy training: The group of 32 volunteer dermatologists had no formal training in the use
of ELM, but had good theoretical knowledge and personal experience; participated in a teaching
course comprised 6 h of teaching on 2 consecutive days. The training was based on the presentation
of several hundred slides with oral explanation of the ELM criteria. Tests were performed at the
beginning and end of the teaching course
Length of training 2 days (12 h in total)
Post-training experience: < 6 months
Training format: in-person teaching
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Disease-positive: 25; disease-negative: 25
Target condition (final diagnoses)
Melanoma (invasive): 25
’Benign’ diagnoses: 50 “not melanoma”
Flow and timing Excluded participants: none reported
Time interval to reference test: NR
Comparative Blinding between tests: dermoscopic images presented after all clinical diagnoses had been made
Time interval between index test(s): NR
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
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DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
High High
DOMAIN 2: Index Test Visual inspection - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
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Unclear High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
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Troyanova 2003 (Continued)
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
DOMAIN 5: Comparative
Was each index test result in-
terpreted without knowledge of
the results of other index tests
or testing strategies?
Unclear
Was the interval between ap-
plication of the index tests less
than one month?
Yes
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Were all tests applied and inter-
preted in a clinically applicable
manner?
No
Unclear High
Unlu 2014
Study characteristics
Patient sampling Study design: case series
Data collection: retrospective image selection/prospective interpretation
Period of data collection: January 2008-January 2010
Country: Turkey
Patient characteristics and set-
ting
Inclusion criteria: melanocytic lesions excised at Ankara University Department of Dermatology
Pigmented Lesion Clinic
Setting: specialist unit; Ankara University Department of Dermatology Pigmented Lesion Clinic
Prior testing: selected for excision (no further detail)
Setting for prior testing: specialist unit (skin cancer/PLC)
Exclusion criteria: location/site of lesion facial, nail and volar acral lesions were excluded; non-
melanocytic appearance
Sample size (participants): number included: 115
Sample size (lesions): number included: 115
Participant characteristics: mean age: 38.72 years (+/- 18.46 years). Male: 56 (49%)
Lesion characteristics: lesion site: 100% trunk and limbs. Melanoma thickness: 10 (41.7%) < 0.
75 mm; 14 (58.3%) ≥ 0.75 mm
Index tests VI: no algorithm; appears to be original clinical diagnosis at time of lesion presentation
Method of diagnosis: in-person diagnosis. Appears to be diagnosis on presentation
Prior test data: N/A; in-person diagnosis
Other test data: dermoscopic images presented to different observers
Diagnostic threshold: NR
Diagnosis based on: unclear; for VI appears to be single examiner at time of clinic diagnosis (n =
NR); dermoscopic images “scored by three other experienced dermatoscopists”
Observer qualifications: NR; assumed dermatologists; described as experienced dermatoscopists
Experience in practice: unclear for clinic diagnosis; dermatoscopists described as “experienced”
Experience with index test: described as “experienced”
Dermoscopy 3-point rule; 7PCL; ABCD; CASH algorithm
Method of diagnosis: dermoscopic images
Prior test data: no further information used; clinical image evaluation appears to be separate from
dermoscopy interpretation
Diagnostic threshold: ABCD score ≥ 5.45 highly suggestive for melanoma; 7-point score ≥ 3; 3-
point score 2 or 3 criteria present; CASH algorithm ≥ 8
Observers: as described for Visual Inspection above
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Unlu 2014 (Continued)
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Disease-positive: 24; disease-negative: 91
Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 24
’Benign’ diagnoses: 91 melanocytic benign lesions; 37 (32.2%) dermal naevi; 15 (13%) Clark’s
naevi; 14 (12.2%) compound naevi; 13 (11.3%) blue naevi; 6 (5.2%) SN; 4 (3.5%) congenital
melanocytic naevi; 2 (1.7%) junctional naevi
Flow and timing Excluded participants: none reported
Time interval to reference test: NR
Comparative Blinding between tests: used in-person clinical diagnosis; clinical image evaluation appears to be
separate from dermoscopy interpretation
Time interval between index test(s): appear to be consecutively applied but not described
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
Low High
DOMAIN 2: Index Test Visual Inspection - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
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Unlu 2014 (Continued)
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Unclear High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Unclear
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
450Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Unlu 2014 (Continued)
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
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If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
DOMAIN 5: Comparative
Was each index test result in-
terpreted without knowledge of
the results of other index tests
or testing strategies?
Yes
Was the interval between ap-
plication of the index tests less
than one month?
Unclear
Were all tests applied and inter-
preted in a clinically applicable
manner?
No
Unclear High
Viglizzo 2004
Study characteristics
Patient sampling Study design: case series
Data collection: NR
Period of data collection: NR
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: PSLs examined at the Dermoscopy Service and undergoing excision; a modified
version of Kenet’s risk stratification approach for dermoscopy (Ascierto 1998) was used to select
high- and very high-risk lesions for excision; medium- and low-risk lesions were excised based on
cosmetic or functional reasons. (2x2 data extracted only for melanocytic subgroup)
Setting: specialist unit (skin cancer/PLC). Dermoscopy service at a university department (Depart-
ment of Endocrinologic and Metabolic Disease)
Prior testing: clinical suspicion of malignancy without dermatoscopic suspicion
Setting for prior testing: specialist unit (skin cancer/PLC)
Exclusion criteria: none reported
Sample size (participants): number eligible: 349 participants; number included: NR
Sample size (lesions): number eligible: 520 lesions; number included: 79 lesions excised included
in the final analysis
Participant characteristics: none reported
Lesion characteristics: none reported
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Viglizzo 2004 (Continued)
Index tests VI: no algorithm
Method of diagnosis: in-person diagnosis
Prior test data: unclear
Diagnostic threshold: NR; correct diagnosis of melanoma
Diagnosis based on: single observer (n = NR; “All dermoscopic evaluations were performed by the
same operators”)
Observer qualifications: NR; “each lesion was... diagnosed clinically and dermoscopically” at the
dermoscopy service
Experience in practice: not described
Experience with dermoscopy: not described; assumed high as diagnosis at ’Dermoscopy Service’
Dermoscopy: no algorithm; appears to be based on pattern analysis
Method of diagnosis: in-person diagnosis
Prior test data: clinical examination and/or case notes
Diagnostic threshold: lesion classification based on typical dermoscopic features: lesions with a
pigment network and any of the classical dermoscopic features specific for melanoma, i.e. pseu-
dopods, radial streaming or blue-grey veil, were classified as very high-risk. Lesions with a pigment
network and dermoscopic features that might suggest melanoma but often seen in atypical naevi
were classified as high-risk
Test observers: as described above
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Target condition (final diagnoses)
Melanoma (invasive): 12
Melanocytic lesion: 67
Flow and timing Excluded participants: none reported
Time interval to reference test: NR
Comparative Blinding between tests: used in-person diagnosis without and then with dermoscopy
Time interval between index tests: not clearly reported but assumed consecutive as both recorded
at Dermoscopy Service
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
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Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Unclear High
DOMAIN 2: Index Test Visual Inspection - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Low High
DOMAIN 2: Index Test Dermoscopy - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
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If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
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Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
DOMAIN 5: Comparative
Was each index test result in-
terpreted without knowledge of
the results of other index tests
or testing strategies?
No
Was the interval between ap-
plication of the index tests less
than one month?
Yes
Were all tests applied and inter-
preted in a clinically applicable
manner?
Yes
Low Low
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Wells 2012
Study characteristics
Patient sampling Study design: case-control
Data collection: retrospective image selection/prospective interpretation
Period of data collection: NR
Country: USA
Patient characteristics and set-
ting
Inclusion criteria: pigmented lesions (melanomas and benign pigmented lesions) selected from a
repository of lesions amassed during an acquisition study conducted by MELA Sciences Inc for the
US Food and Drug Administration
Setting: company database (MELA Sciences Inc) of lesion images
Prior testing: selected for excision (no further detail)
Setting for prior testing: NR
Exclusion criteria: none reported
Sample size (participants): NR
Sample size (lesions): number included: 47
Participant characteristics: none reported
Lesion characteristics: none reported
Index tests Dermoscopy: no algorithm
Method of diagnosis: dermoscopic images
Prior test data: clinical images and detailed clinical history; observers “viewed the images and a
detailed case history for each lesion but were unaware of the MelaFind recommendations”
Diagnostic threshold: clinical diagnosis of melanoma or not; decision to biopsy the lesion
Diagnosis based on: average (n = 39)
Observer qualifications: dermatologist
Experience in practice: not described
Experience with dermoscopy: not described
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Details: “Lesions were biopsied in toto and evaluated by a panel of dermatopathologists who were
unaware of the MelaFind recommendations”
Disease-positive: 23/disease-negative: 24
Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 23
’Benign’ diagnoses: 24
Flow and timing Participant exclusions: none reported
Index test to reference standard interval: consecutive; “prior to biopsy of the lesion, photographs
of the lesion were taken”
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
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DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
High High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
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Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
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1 month or less?
Low
Westerhoff 2000
Study characteristics
Patient sampling Study design: case-control (for lesion selection; study was an RCT of dermoscopy training for
PCPs)
Data collection: retrospective
Period of data collection: NR
Country: Australia
Patient characteristics and set-
ting
Inclusion criteria: clinically atypical PSLs; 50 invasive melanomas and 50 non-melanomas ran-
domly selected from the Sydney Melanoma Unit PSLs image database
Setting: specialist unit (lesion selection)
Prior testing: selected for excision or followed up
Setting for prior testing: specialist unit (skin cancer/PLC)
Exclusion criteria: none reported
Sample size (participants): number included: NR
Sample size (lesions): number included: 100
Participant characteristics: none reported
Lesion characteristics: median Breslow thickness 0.6 mm
Index tests VI: no algorithm
Method of diagnosis: clinical photographs
Prior test data: unclear; all participants “were instructed not to look at the surface microscopic
image until they had scored the clinical image”
Diagnostic threshold: NR
Diagnosis based on: average (n = 37; 74 practising primary care practitioners randomised to
dermoscopy education intervention or not). Diagnoses were recorded for both groups of GPs at
baseline (pre-test) and after the training intervention had been administered to the intervention
group (post-test), resulting in 8 sets of 2x2 data based on interpretation of the same set of 100
lesions; post-test data for the intervention group of GPs was used for the VI analysis
Observer qualifications: GP
Experience in practice: considered to be low; only practitioners who had had no formal training
with surface microscopy and did not use a surface microscope in their clinical practice were included
Experience with dermoscopy: low experience/novice users (non-training arm); “Trained” for the
intervention arm
Other detail: camera designed for close-up clinical photography (Elicar Macrolens, Japan)
Dermoscopy: no algorithm (non-training arm); Menzies criteria (training/intervention arm)
Method of diagnosis: dermoscopic images
Prior test data: diagnosis was first based on the clinical image and then the dermoscopic image for
each lesion
Diagnostic threshold: NR; intervention arm instructed in Menzies criteria
Test observers: as above
Any other detail: dermoscopy at x10 magnification with a Dermphot camera (Heine Ltd) using
oil at the skin-lens interface
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Dermoscopy training: the education intervention included provision of the Menzies and col-
leagues pictorial atlas which reportedly describes the Menzies approach to dermoscopy diagnosis
of melanoma (Menzies 1996); they also attended a 1-h presentation on dermoscopy reviewing the
Menzies approach and including a quiz based on images of 25 different PSLs
Post-training experience: < 6 months; the median interval between pretest and education inter-
vention was 46 days (range 5-155). Median interval from education intervention to post-test was
23 days (range 2-54)
Training format: in-person teaching; written materials
Target condition and reference
standard(s)
Reference standard: histological diagnosis + follow-up
Histology: all the lesions except 2 had been excised after photography and subjected to histopatho-
logical examination
Disease-positive: 50; disease-negative: 48
Clinical follow-up + histology of suspicious lesions: the two benign PSLs that had not been excised
were monitored over a longer period of time and had shown no morphological change.
Length of follow-up: NR; disease-positive: 0/disease-negative: 2
Target condition (final diagnoses)
Melanoma (invasive): 50/’Benign’ diagnoses: 50
Flow and timing Excluded participants: none reported
Time interval to reference test: “All the lesions except two had been excised after photography”
Comparative Blinding between tests: observers were instructed not to look at the dermoscopy image until they
had scored the clinical image
Time interval between index test(s): NR; lesions described as “excised after photography” therefore
assumed consecutive
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
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Did the study avoid including
participants with multiple le-
sions?
Unclear
High High
DOMAIN 2: Index Test Visual inspection - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Unclear High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
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For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Yes
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
No
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
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Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
Unclear
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
DOMAIN 5: Comparative
Was each index test result in-
terpreted without knowledge of
the results of other index tests
or testing strategies?
No
Was the interval between ap-
plication of the index tests less
than one month?
Yes
Were all tests applied and inter-
preted in a clinically applicable
manner?
No
Low High
Winkelmann 2016
Study characteristics
Patient sampling Study design: case-control
Data collection: retrospective image selection/prospective interpretation
Period of data collection: NR
Country: NR
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Patient characteristics and set-
ting
Inclusion criteria: images of PSLs previously analysed by a digital classifier MSDSLA; method of
selection of the 12 NR
Setting: unclear; images selected for a dermoscopy conference
Prior testing: NR
Setting for prior testing: unspecified
Exclusion criteria: none reported
Sample size (participants): NR
Sample size (lesions): number included: 12
Participant characteristics: none reported
Lesion characteristics: none reported
Index tests VI: no algorithm
Method of diagnosis: clinical photographs
Prior test data: unclear
Other test data: dermoscopic images presented to observer subsequent to diagnosis using clinical
images alone
Diagnostic threshold: NR; biopsy decision
Diagnosis based on: average (n = 70)
Observer qualifications: dermatologist
Experience in practice: not described; recruited “dermatologists at a dermoscopy conference”. No
further details
Other detail: study authors report that practitioners with a particular interest in skin cancer or
technology may have chosen to attend this conference and/or self-selected to take part in the study
Dermoscopy: no algorithm
Method of diagnosis: dermoscopic images
Prior test data: clinical images provided
Diagnostic threshold: NR; biopsy decision
Test observers as described for VI (above)
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Disease-positive: 5; disease-negative: 7
Target condition (final diagnoses)
Melanoma (invasive): 3; melanoma (in situ): 2
Mild/moderate dysplasia: 7 low-grade dysplastic naevi
Flow and timing Excluded participants: none reported
Time interval to reference test: NR
Comparative Blinding between tests: dermoscopic images presented to observer subsequent to diagnosis using
clinical images alone
Time interval between index test(s): same day; at time of face-to-face consultation
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
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Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
High High
DOMAIN 2: Index Test Visual inspection - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Unclear High
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DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
Unclear
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matopathologist?
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
Yes
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
DOMAIN 5: Comparative
Was each index test result in-
terpreted without knowledge of
the results of other index tests
or testing strategies?
No
Was the interval between ap-
plication of the index tests less
than one month?
Yes
Were all tests applied and inter-
preted in a clinically applicable
manner?
No
Low High
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Zalaudek 2006
Study characteristics
Patient sampling Study design: case series
Data collection: retrospective image selection/prospective interpretation
Period of data collection: February 2003-January 2004
Country: Naples, Italy
Patient characteristics and set-
ting
Inclusion criteria: excised, equivocal and nonequivocal, pigmented and non-PSLs with good image
quality and melanin or haemoglobin pigmentation in all or part of the lesion
Setting: specialist unit; specialised PLC database
Prior testing: selected for excision (no further detail)
Setting for prior testing: specialist unit
Exclusion criteria: none reported
Sample size (participants): NR
Sample size (lesions): eligible: 2621; included 150 (+ 15 lesions used for training purposes)
Participant characteristics: none reported
Lesion characteristics 37/165 (26%) considered equivocal on clinical and dermoscopic grounds
Thickness/depth: mean Breslow 0.9 mm
Index tests Dermoscopy: 3PCL
Method of diagnosis: dermoscopic images, “optimized for colour, brightness and contrast by using
Adobe photoshop standards”
Prior test data: age, site, and gender provided
Diagnostic threshold: ≥ 1 criterion present indicates malignancy (asymmetry - in colour and/or
structure, not in shape; atypical network; pigment network with thick lines and irregular holes; and
blue white structures; presence of any blue and/or white colour within the lesion
Diagnosis based on: average (n = 150 out of 170 participating observers, who finished all 15
training cases and performed at least one evaluation of the main set of images (test set). Participation
was open to all individuals regardless of professional profile and experience in dermoscopy; study
was advertised through personal communication, e-mail correspondences, adverts during congresses
and courses, as well as via the website dermoscopy.org.
Observer qualifications: for full sample of 170: dermatologists (n = 125); GPs (n = 15); other
professionals in the field of skin lesions (n = 12); medical students (n = 7); other medical specialty
(n = 11)
Experience in practice: not described
Experience with dermoscopy: mixed; 146/170 (86%) reported some experience with dermoscopy;
24 with no dermoscopy experience, 45 (26%) with > 5 years’ experience
Dermoscopy training: a web-based tutorial was provided to describe the concept of the 3PCL of
dermoscopy including complete definitions of criteria and example images. Following web-based
tutorial, observers initially scored a random sample of 15 images, receiving real-time feedback for
that case as judged by an expert observer
Training format: online
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone (no further details)
Target condition (final diagnoses)
Melanoma (invasive): 18; melanoma (in situ): 11
BCC: 18
79 melanocytic naevi; 26 seborrhoeic keratoses; 8 vascular tumours and 3 dFs
469Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
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Flow and timing Participant exclusions: poor-quality index test image as exclusion criterion
Index test to reference standard interval: not described
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Low High
DOMAIN 2: Index Test Dermoscopy - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
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Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
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If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
3PCL: three-point checklist; 7FFM: seven features for melanoma; 7PCL: seven-point checklist; ABCD(E): asymmetry, border, colour,
differential structures (enlargement); AJCC: American Joint Committee on Cancer; AK: actinic keratosis; AMN: acral melanocytic
naevi; BCC: basal cell carcinoma; BD: Bowen’s disease; CD: compact disc; CAD: computer-assisted diagnosis; CASH: colour,
architecture, symmetry and homogeneity;CM: cutaneous melanoma;CMM: cutaneous malignant melanoma;DF: dermatofibroma;
ELM: epiluminescencemicroscopy;GP: general practitioner; IDS: InternationalDermoscopy Society; IQR: interquartile range;LK:
lichen sclerosis;LP: lichen planus;LS: lentigo simplex;MM:malignantmelanoma;MN:melanocytic naevi;MSDSLA:multispectral
digital skin lesion analysis device; N/A: not applicable; NR: not reported; PCP: primary care provider; PLC: pigmented lesion
clinic; PSL: pigmented skin lesion; RCM: reflectance confocal microscopy; RCT: randomised controlled trial; SCC: squamous cell
carcinoma; SD: standard deviation; SK: seborrhoeic keratosis; SN: Spitz naevi;SSM: superficial spreading melanoma; VI: visual
inspection.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ahnlide 2013 Ineligible index test; ’clinical diagnosis’ study
Akasu 1996 No 2x2 data only describing the dermoscopic features present in the lesions
Al Jalbout 2013 Small sample size; case study
Alendar 2009 Reference standard: only 7 reported verified histologically
Altamura 2006 Derivation study: Study was looking for characteristics associated with acral melanoma; does not give
2x2 for overall diagnosis
Altamura 2010 Wrong target condition
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Amirnia 2016 Wrong target condition
Antonio 2013 Wrong target condition; atypical naevi does not fall within our definition of disease positive
Antoszewski 2015 Sample size too small; all excised lesions were benign
No data for 2x2
Aoyagi 2010 Sample size too small
Argenziano 1997 Wrong study population; only melanoma included
Argenziano 1999 Wrong study population; only includes melanoma
Argenziano 2002 Not a primary study
Argenziano 2003 Table V gives se/sp data for 108 lesions but can’t derive the number of melanoma for this subset of the
original 128
Contacted study authors 10 May 2016 and 24 June 2016
Argenziano 2004a Only lesions with vascular structures included; presence of 10 different characteristics assessed. 2x2
would be possible
Argenziano 2004b Not a primary study; letter
Argenziano 2008 Ineligible index test; surveillance/monitoring study
Argenziano 2010 Ineligible index test and no 2x2 data. Test used for follow-up looking at dermoscopic features of
melanomas diagnosed 1 year after follow-up
Argenziano 2011a Wrong target condition and sample size too small; only 2 melanomas
Argenziano 2011b Wrong target condition; 5 melanoma metastases included as disease positive
Argenziano 2012 Ineligible reference standard; no follow-up of test-negatives
Armstrong 2011 Ineligible reference standard; no reference standard results presented for the screened lesions; just com-
pares naked-eye judgements with dermoscopy
Ascierto 1998 The data presented do not contribute to the review - no 2x2
Duplicate or related publication; data included in Ascierto 2003
Ascierto 2000 No 2x2 data. For excised lesions, study cross-tabulates ELM high/very high risk classification against
some histological classification (Table 2). Number disease positive = 580 (2x2: 504, 79, 76, 2072); 580
not mentioned anywhere else in paper
Contacted authors 10 May 2016 and 24 June 2016
Ascierto 2003 Not a primary study
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Bafounta 2001 Not a primary study; systematic review
Bajaj 2016 Unclear reference standard for benign diagnoses
Bauer 2005 Ineligible index test; follow-up/monitoring study
Bauer 2006 Ineligible index test; dermoscopy used to improve histopathology diagnosis
Benati 2015 Assesses individual lesion characteristics only
Benelli 2000b Insufficient data to populate 2x2 table; only inter-rater reliability data given (n = 25); authors have
published much larger evaluations of 7FFM and ABCD
Benvenuto-Andrade 2006 Diagnostic confidence rather than accuracy; no 2x2 data
Benvenuto-Andrade 2007 Agreement on lesion characterisation; not test accuracy; no 2x2 data
Binder 1997 Training study; only ROC curves/AUC presented pre and post-training; no 2x2 data
Contacted study authors 10 May 2016 and 24 June 2016
Blum 2003c Not a primary study
Blum 2004c Not a primary study; comment paper
Blum 2004d Letter only; limited data presented - evaluates ’3-colour’ rule as developed By MacKie 2002 (excluded
as assessment of individual lesion features only)
Blum 2004e Not a primary study; letter
Blum 2006 Wrong target condition; differentiates melanocytic from non-melanocytic lesions only
Blum 2011 Wrong study population; mucosal lesions only
Blum 2014 Sample size too small; case studies
Boespflug 2015 Wrong study population; study aim is estimate the efficacy of an online spaced educational training for
dermoscopy
Bono 2001 Aim of the study is to determine what features are present in amelanotic cutaneous melanoma; no 2x2
data
Borsari 2010 Paper focuses on diagnostic prediction of dermoscopic island for early melanoma, however the Methods
describe the calculation of the total dermoscopy score and the 7-PCL score; mean scores on each checklist
per lesion type are then presented
Contacted study authors but no reply
Bowns 2006 Ineligible index test; teledermatology study
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Braun 2000 Derivation study: this is a pilot study on the new ’wobble sign’ in ELM no training/test sets used
Braun 2007 Assesses individual lesion characteristics only
Braun-Falco 1990 Not a test accuracy study; no 2x2 data
Brown 2000 Not a primary study; systematic review
Buhl 2012 Ineligible index test; follow up/monitoring
Duplicate or related publication; same participants as Haenssle 2010 #191
Bystryn 2003 Not a primary study; letter
Cabrijan 2008 Can’t get 2x2; reports % correct diagnoses for each different lesion classification and not %misdiagnosed
as melanoma or melanomas missed
Study states, “Dermatoscopic diagnosis were conformable with pathohistological diagnosis in 75 cases
(72.82%) out of 103. The highest conformation was in diagnosing melanoma, in 5 out of 6 cases
(83.3%).”, which would give us sensitivity. Asked study authors for data on numbers mis-classified as
melanoma, i.e. false positive. Study author replied 5 July 2016 with some data but not sufficient to allow
2x2
Canpolat 2011 Derivation study: looks at dermoscopic characteristics of acral lesions; only 4 suspicious lesions excised
Cardenas 2009 Wrong study population; includes participants with palpable lesions; not all suspected of having skin
cancer
Carli 1998 Sample size too small; se/sp data are based on sample with only 4 MM
Carli 2000 Wrong target condition; only lesions histologically classified as common naevi or naevi with architectural
disorder with/without cytological atypia were considered for the study
Carli 2003c Sample size too small
Carli 2004a Sample size too small; < 5 MM per arm.
No 2x2 data
Carli 2004b Ineligible index test; can only estimate 2x2 for the full time period 1997-2001 across all observers,
however dermoscopy was only introduced routinely in 1998 so some diagnoses prior to that will have
been with VI alone, and observers were classed as dermoscopy ’users’ (those working in PLCs) and
nonusers (general dermatology)
Author passed away; unable to make contact with co-authors
Carli 2005 Study presents % MM correctly classified by naked eye +/- dermoscopy but doesn’t give any detail on
FPs. No 2x2 data
Tried to contact study authors to ask whether available anywhere and/or are these lesions included in
any subsequent publications? Author passed away; unable to make contact with co-authors
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Carlos-Ortega 2007 Gives se/sp for VI and dermoscopy in the English abstract. 68 participants/70 lesions were included
but only 36 seem to have had VI results and all underwent dermoscopy. 2 observers performed each
test blinded to each other. Table I gives 22 with BCC and 11 with melanoma overall (number disease
positive not reported for those with VI results), but using either or both of these numbers with the se/
sp provided does not give the same PPV and NPV as given by the authors
Data not clearly presented for 2x2; translator suggested alternative but still does not work out to what
is in paper; tried contacting authors twice, no reply as of 28 July 2016
Carroll 1998 Derivation study: proposes new dermoscopic criteria for diagnosis of BCC; no 2x2 data
Chen 2013 Wrong test observer
Ciudad-Blanco 2014 Wrong study population; includes melanoma only. No 2x2 data
de Giorgi 2006 Sample size insufficient; < 5 cases of participants with a final melanoma diagnosis
De Giorgi 2011 Duplicate or related publication. Assesses same lesions as in Carli 2003b but different observers
de Troya-Martin 2008 Wrong study population; only MM included
Delfino 1997 Derivation study: only reports association of each characteristics with disease positive/disease negative,
not 2x2
Di Chiacchio 2010 Wrong target condition; excluding nail bed melanoma
Insufficient data to extract for a 2x2 table
Di Stefani 2007 Sample size insufficient; < 5 malignant
Dummer 1995 Assesses individual lesion characteristics only
Elwan 2016 Derivation study: sample size insufficient for 2x2 table
Fabbrocini 2008 Insufficient data provided for each index test to populate 2x2 table
We contacted study authors to ask for a cross tabulation of each clinician’s diagnosis (e.g. at threshold
of ≥ 3 on 7PCL) against the histological diagnosis and/or a cross tabulation of the remote diagnosis
against the face-to-face diagnoses? Study author replied 30 June 2016: unable to access data needed
Ferrara 2002 Ineligible index test. This study looks at histopathological and dermoscopic disagreements not necessarily
looking at how well dermoscopy differentiates between benign and malignant diagnosis
Fidalgo 2003 Insufficient data for 2x2 table
Duplicate or related publication; appears to be superseded by Serrao 2006
Paper provides % of MM and of dysplastic naevi with algorithm scores of ≥ 5.5 and > 7
Contacted study author 10 May 2016 and 24 June 2016 to request the same information for the
remaining 127 lesions in the study and ask whether any of the 247 lesions included in this study, overlap
with the 652 reported in Serrao 2006 (#1144)
Fruhauf 2012 Ineligible reference standard; 35/219 underwent histology; 13 followed-up; 171 expert clinical diagnosis
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Fueyo-Casado 2009 Ineligible reference standard; < 50% of the study population received histology as a test. No information
given on those who were followed up
Giacomel 2005 Wrong study population; only BCC included
Giacomel 2014 Sample size insufficient
Giannotti 2004 Not a primary study; a review
Gill 2015 Derivation study
Inadequate sample size
Gilmore 2009 Derivation study: principle of lacunarity has been looked at before but not this particular application/
approach to it
Ineligible reference standard
It is possible to get 2x2 for ’standard dermoscopy criteria’ however dermoscopy-negative were not excised
and assumed benign; 201/312 underwent excision so theoretically eligible
Grichnik 2003 Sample size insufficient
Grichnik 2004 Not a primary study; editorial
Guillod 1996 Derivation study developing new algorithm
Gunduz 2003 Sample size insufficient; case study
Hacioglu 2013 Wrong target condition; does not provide sufficient data for detection of melanoma
Haenssle 2006 Ineligible index test; surveillance study estimating accuracy of different approaches to follow-up
Haenssle 2010 Insufficient data to populate 2x2 table; does not report specificity
Duplicate or related publication; same participants as Haenssle 2010 #191
Haspeslagh 2016 Assesses individual lesion characteristics only
Insufficient data to populate 2x2 table
Henning 2007 Derivation study: first application of CASH algorithm
Henning 2008 Derivation study developing new algorithm
Herschorn 2012 Not a primary study; systematic review
Hirata 2011 Wrong target condition
Ineligible index test
Hoffmann 2003 Derivation study: uses leave one out cross-validation procedure
Only giving ROC values not able to extract a 2x2 table
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Hoorens 2016 Ineligible index test
Ineligible reference standard; no info on numbers undergoing histology; and no follow-up reported for
benign-appearing lesions
Insufficient data to populate 2x2 table
Ishioka 2009 Ineligible index test
Iyatomi 2006 Derivation study: uses leave-one-out procedure and same lesions and tumour extraction method as
Iyatomi 2006
Insufficient data to populate 2x2 table
Iyatomi 2008 Derivation study: the performance was evaluated by averaging both combinations (training and test sets)
they did not present the data separately; uses leave-one-out procedure
Insufficient data to populate 2x2 table
Not test accuracy; compares automated with manual extraction of tumour area
Johr 2002 Not a primary study
Kawabata 1998 Derivation study: aim of the study was to correlate findings between dermoscopy and histology findings
of acral melanoma
Insufficient data to populate 2x2 table
Not test accuracy
Kawabata 2001 Derivation study. Aim of the study is to correlate findings between dermoscopy and histology findings
of acral melanoma. Wrong study population; MM of the nail bed
Kefel 2012 Derivation study: no test set, first use of polarised light dermoscopy, various neural networks tested
Insufficient data to populate 2x2 table
Kenet 1994 Not a primary study
Insufficient data to populate 2x2 table; not an accuracy study
Kittler 2002 Not a primary study; systematic review
Kittler 2006 Conference abstract
Koga 2011 Ineligible reference standard; ~23% of participants have their final diagnosis reached by histopathology
43/191
Korotkov 2012 Not a primary study; narrative review
Lallas 2015 Derivation study: develops new algorithm and does not use separate training/test sets of lesions
Liebman 2011 Not a primary study; comment
Liebman 2012 Not a primary study; comment
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Lipoff 2008 Wrong target condition; study does not differentiate MM from benign/other but looks to identify lesion
characteristics that might help id those at risk for MM
Liu 2012 Derivation study: asymmetry detection; 10-fold cross validation
Insufficient data to populate 2x2 table
Lorentzen 1999b Insufficient data to populate 2x2 table
Contacted study authors 10 May 2016 and 24 June 2016) to request number of melanomas that were
included in the study so that we could estimate the 2x2 contingency tables using the se/sp data provided?
Also to ask if there was overlap in the lesions included here with those included in the Lorentzen 2000
study? (see also author Qs for the 2000 study)
Luttrell 2012 Ineligible test observer; accuracy data only given for lay-persons not interested in this population of test
observers
MacKie 1971 Insufficient data to populate 2x2 table; only gives % with correct diagnosis rather than numbers mis-
classified as malignant
MacKie 2002 Presence of ≥ 3 colours on dermoscopy
Markowitz 2015 Wrong target condition; does not report sufficient data for detection of melanoma
Massi 2001 Assesses individual lesion characteristics only
Mayer 1997 Not a primary study; systematic review
Menzies 1996a Only given the se/sp of individual characteristics; lesions make up the training set for Menzies 1996 (#
1971)
Menzies 1999 Not a primary study
Menzies 2000 Wrong target condition; BCC only
Menzies 2001 Ineligible index test; monitoring purposes
Mun 2016 Ineligible reference standard; only 37% of benign group underwent adequate reference standard
Nathansohn 2007 Insufficient data to populate 2x2 table
Not test accuracy; follow-up study
Navarrete-Dechent 2016 Wrong target population; 2x2 for BCC only
Pan 2008 Derivation study: looking to ID characteristics associated with superficial BCC; 2x2 could be extracted
for combination of 3 selected characteristics. Dermoscopic features selected based on prior studies but
only patients with 3 diagnoses included: BCC, intra-epidermal carcinoma, and psoriasis
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(Continued)
Panasiti 2009 Assesses individual lesion characteristics only
Ineligible reference standard. Of the 1543 lesions analysed only 321 received histopathology diagnosis.
The accuracy data were based on this (only 20%) not sure what happened to the 80% of participants as
no mention of follow-up
Pazzini 1996 Insufficient data to populate 2x2 table
Pehamberger 1987 Insufficient data to populate 2x2 table
Not test accuracy. This is a descriptive paper defining dermoscopic criteria. It is not a study testing
accuracy of dermoscopy. From the authors’ final sign off it looks like part 2 of this paper may have details
on accuracy (Steiner 1987a).
Pellacani 2002 Not a primary study
Pellacani 2006 Derivation study: looks at detection of asymmetry between clinicians and computer
Insufficient data to populate 2x2 table; 2x2 could be derived for overall asymmetry or border cut-off but
not overall diagnosis
Pellacani 2007 Derivation study: looking at blue hue
Pellacani 2009 Wrong target condition; focus is on identifying SN from melanoma and “Clark” naevi and it is looking
to derive useful RCM characteristics. Although some data are given in the text for an RCM score of > 3
it is difficult to work out which are FP and which FN
Peris 2002a Wrong study population; only patients with BCC diagnosis included
Peris 2002b Not a primary study
Phan 2010 Insufficient data to populate 2x2 table
Not test accuracy investigating dermoscopic features of acral melanoma including of the nail apparatus;
no accuracy data given
Piccolo 2002b Not a primary study
Insufficient data to populate 2x2 table; No breakdown of index test results and ref standard
Piccolo 2004 Ineligible index test
Piccolo 2006 Sample size insufficient; 3 MMs, but also 1 lentigo and 14 dysplastic naevus; data not presented to allow
se/sp estimation
Derivation for hypoluminescence microscopy
Pizzichetta 2001a Wrong study population; population in study only those with malignant disease
Pizzichetta 2001b Insufficient data to populate 2x2 table; observer agreement only
Pizzichetta 2007 Wrong study population; only patients with melanoma included
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(Continued)
Pizzichetta 2010 Sample size insufficient; case study
Pizzichetta 2013 Presence of negative pigmented network
Pralong 2012 Wrong study population; only melanoma patients included
Provost 1998 Insufficient data to populate 2x2 table
Not test accuracy; only reports concordance
Rader 2014 Assesses individual lesion characteristics only
Insufficient data to populate 2x2 table
Rajpara 2009 Not a primary study; systematic review
Reggiani 2015 Not a primary study; systematic review keratinocyte skin cancer
Rigel 1997 Not a primary study
Ronger 2002 Assesses individual lesion characteristics only
Rosendahl 2012a Assesses individual lesion characteristics only
Rosendahl 2012b Not a primary study
Rossi 2000 Ineligible reference standard; unclear reference standard in disease-negative
Rubegni 2002 Not a primary study
Rubegni 2005a Not a primary study; editorial
Rubegni 2005b Not a primary study
Rubegni 2010 Derivation study: uses leave-one-out procedure
Insufficient data to populate 2x2 table
Sahin 2004 Derivation study: Assesses individual lesion characteristics only
Insufficient data to populate 2x2 table; no accuracy data given, study looking at dermoscopic features
of lentigo maligna
Saida 2002 Descriptive study looking at presence (%) of certain features. Not looking at accuracy. Has paragraph on
diagnostic value of this specific feature quoting se/sp but this is based upon unpublished observations
and the data are not given in this paper
Saida 2004 Assesses individual lesion characteristics only
Sakakibara 2010 Only looking at different vascular structures
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(Continued)
Salerni 2011 Sample size insufficient; < 5 cases
Salerni 2012 Ineligible index test; surveillance study
Insufficient data to populate 2x2 table
Salerni 2013 Not a primary study; systematic review of surveillance with digital dermoscopy
Salvio 2011 Not a primary study
Sample size insufficient
Sanchez-Martin 2012 Wrong study population; only BCC cases
Savk 2004 Not a primary study; letter
Sawada 2013 Not a primary study
Sboner 2003 Derivation study: describes 10-fold cross-validation process for training/testing classifier
Schulz 2001 Wrong target condition; melanoma metastases
Scope 2015 Not a primary study
Segura 2009 Ineligible index test; RCM evaluation
Seidenari 2004 No data to populate 2x2 table just ROC curve values given.
TABLE 5 provides AUC values for each diagnosis for both formats and observers. We contacted study
authors to request data in 2x2 format , e.g. for melanoma ’certain’ against final diagnosis and for
melanoma ’certain or fairly certain’ against final diagnosis but received no reply
Seidenari 2006a Wrong study population; assessing best means of follow-in up patients with previous melanoma - total
body exam versus only lesions > 2 cm. No melanoma identified
Seidenari 2006b Looks like this study is only looking at asymmetry judgement
Seidenari 2012 Looks at individual lesion characteristics to distinguish Melanoma in situ, also gives mean ABCD and
7PCL scores
Insufficient data to populate 2x2 table
Table 3 provides mean ABCD and 7PCL scores. We contacted study authors to request cross tabulation
of results with each checklist at ’standard’ thresholds against final diagnosis? e.g. ABCD > 4.75 and > 5.
45 for MIS and benign groups 7PCL: presence ≥ 2 characteristics and ≥ 3 characteristics but received
no reply
Seidenari 2013 Ineligible index test
Serrao 2006 Ineligible index test
Sgouros 2014 Ineligible index test
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(Continued)
Shakya 2012 Wrong target condition; SCC in situ is included in target condition
Shitara 2014 Assesses individual lesion characteristics only
Shitara 2015 Wrong study population; includes only melanoma
Sondak 2015 Not a primary study; comment paper
Soyer 1987 Insufficient data to populate 2x2 table; not test accuracy
Soyer 2001 Not a primary study; editorial
Stanganelli 1998b Insufficient data to populate 2x2 table; can’t derive specificity; only gives exact diagnoses for MM and 2
benign categories and not number benign misdiagnosed as MM
Steiner 1987a Insufficient data to populate 2x2 table; study only reports % correct diagnosis per lesion type for
dermoscopy and does not list incorrect diagnoses
Steiner 1987b Insufficient data to populate 2x2 table; only given the correct diagnosis for malignant
Steiner 1993 Derivation study: assesses individual lesion characteristics only
Stephens 2013 Sample size insufficient
Stoecker 2009a Derivation study: translucency
Insufficient data to populate 2x2 table; data presented only as ROC curve and AUC
Stoecker 2009b Not a primary study
Stoecker 2011 Derivation study: uses leave one out
Insufficient data to populate 2x2 table; data presented only as ROC curve and AUC
Stolz 2002 Not a primary study
Stratigos 2007 Ineligible reference standard
Insufficient data to populate 2x2 table
Stricklin 2011 Assesses individual lesion characteristics only
Strumia 2003 Conference abstract; letter only
Tasli 2012 Not a primary study; systematic review looking at frequency of publications ion dermoscopy
Teban 2003 Wrong study population; classification of Clark naevi into 12 types
Insufficient data to populate 2x2 table
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(Continued)
Terstappen 2007 Wrong study population; includes only BCC - looking for BCC characteristics on Siascope
Derivation study; first application of Siascope to pigmented BCC; 21/25 lesions were BCCs
Terushkin 2010a Sample size insufficient; only 2 invasive SCC
Insufficient data to populate 2x2 table
Terushkin 2010b Insufficient data to populate 2x2 table
Not test accuracy - reports final diagnoses of those excised over a number of time periods and benign-
malignant ratio
Tromme 2012 Inadequate reference test for disease-negatives; expert diagnosis only
Tschandl 2012 Ineligible index test; differentiating melanocytic from non-melanocytic lesions
Tschandl 2015a Ineligible test observer; medical students
Tschandl 2015b Assesses individual lesion characteristics only
Ulrich 2015 Wrong target condition; does not provide sufficient data for evaluation of melanoma
Van der Leest 2011 Inadequate reference test for test-negatives; expert diagnosis only
Van der Rhee 2010 Ineligible reference standard; < 50% of disease-negative have an adequate reference standard
Van der Rhee 2011 Sample size insufficient; < 5 cases
Vasili 2010 Conference abstract
Verduzco-Martinez 2013 Wrong study population; only BCC
Vestergaard 2008 Not a primary study; systematic review; check reference list
Wang 2008 Insufficient data to populate 2x2 table; not test accuracy; no details of misdiagnoses of benign lesions as
malignant
Warshaw 2009a Insufficient data to populate 2x2 table
Duplicate or related publication; subgroup of participants from Warshaw 2010
Study presents diagnostic accuracy of teledermatology and clinic diagnosis in comparison to histopathol-
ogy; we need the underlying 2x2 contingency tables (see Warshaw 2010 for author response)
Warshaw 2009b Insufficient data to populate 2x2 table
Duplicate or related publication; subgroup of participants from Warshaw 2010
Study presents diagnostic accuracy of teledermatology and clinic diagnosis in comparison to histopathol-
ogy; we need the underlying 2x2 contingency tables (see Warshaw 2010 for author response)
Warshaw 2010 Insufficient data to populate 2x2 table
Study presents diagnostic accuracy of teledermatology and clinic diagnosis in comparison to histopathol-
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(Continued)
ogy. Study author only able to provide numbers test-positive and -negative for melanoma and not for the
final 2 cells of the 2x2; data provided showed higher sensitivity for melanoma as the primary diagnosis
rather than as the ‘aggregate’ diagnosis and the 2x2 using the study authors’ data and the accuracy figures
from the paper showed more TP from the primary diagnosis as opposed to the aggregate
Weismann 2002 Not a primary study
Wilkes 2010 Not a primary study
Winkelmann 2015a Duplicate or related publication
Winkelmann 2015b Duplicate or related publication
Witkowski 2016 Wrong target population
Yadav 1993 Insufficient data to populate 2x2 table; not test accuracy
Yamaura 2005 Derivation study: gene amplification in acral lesions
Yelamos 2016 Not a primary study
Yoo 2015 Conference abstract
Youl 2007a Ineligible index test; evaluates ’clinical diagnosis’
Contacted study authors for more information. Replied that dermoscopy used in some but not all lesions
Youl 2007b Ineligible index test; evaluates ’clinical diagnosis’
Contacted study authors for more information. Replied that dermoscopy used in some but not all lesions
Zaballos 2013 Wrong study population; they do not have enough benign cases to include as full report
Zalaudek 2010 Not a primary study; editorial
Zell 2008 Sample size insufficient; case study
Zortea 2014 Derivation study: although data are divided into training and test sets, the test set data are used more
than once over 20 realisations of each model, especially the melanomas, for which the same 10 are used
in each realisation
Zou 2001 Not a primary study; study uses results from Stolz 1994a
Insufficient data to populate 2x2 table; just showing ROC curves
7FFM: seven features for melanoma; 7PCL: seven-point checklist; ABCD(E): asymmetry, border, colour, differential structures (en-
largement); AUC: area under the curve; BCC: basal cell carcinoma; CASH: colour, architecture, symmetry and homogeneity; ELM:
epiluminescence microscopy; FN: false negative; FP: false positive;MM:malignant melanoma; se/sp: sensitivity/specification; PLC:
pigmented lesion clinic; PPV: positive predictive values; NPV: negative predictive value; RCM: reflectance confocal microscopy;
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ROC: receiver operating characteristic; SCC: squamous cell carcinoma; SN: Spitz naevi; TN: true negative; TP: true positive; VI:
visual inspection
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D A T A
Presented below are all the data for all of the tests entered into the review.
Tests. Data tables by test
Test
No. of
studies
No. of
participants
1 Visual inspection - in-person
(invasive melanoma)
2 147
2 VI+dermoscopy - in-person
(invasive melanoma)
6 789
3 Visual inspection - image-based
(invasive melanoma)
4 454
4 Dermoscopy alone - image-based
(invasive melanoma)
13 5618
5 Visual inspection - in-person
(invasive melanoma or atypical
intraepidermal melanocytic
variants)
13 6740
6 VI+dermoscopy - in-person
(invasive melanoma or atypical
intraepidermal melanocytic
variants)
26 23169
7 Visual inspection - image-based
(invasive melanoma or atypical
intraepidermal melanocytic
variants)
11 1740
8 Dermoscopy alone - image-based
(invasive melanoma or atypical
intraepidermal melanocytic
variants)
60 13475
9 Visual inspection - in-person
(any)
2 3457
10 VI+Dermoscopy - in-person
(Any)
4 3880
11 Visual inspection - image-based
(any)
3 547
12 Dermoscopy alone -
image-based (any)
5 815
13 MM2- Dermoscopy - no
algorithm - threshold NR -
in-person
8 4707
14 MM2- Dermoscopy - pattern -
at ≥ 1 char present - in-person
1 220
15 MM2- Dermoscopy - pattern -
at ≥ 3 characteristics present -
in-person
1 68
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16 MM2- Dermoscopy - pattern -
threshold NR - in-person
6 4307
17 MM2- Dermoscopy - ABCD at
NR (likely > 5.45) - in-person
1 235
18 MM2- Dermoscopy - ABCD
at > 5.45 - in-person
4 1203
19 MM2- Dermoscopy - ABCD
at > 4.75 - in-person
1 309
20 MM2- Dermoscopy - ABCD
at 60% specificity - in-person
1 356
21 MM2- Dermoscopy - ABCD
at 80% specificity - in-person
1 356
22 MM2- Dermoscopy - ABCD
at 70% specificity - in-person
1 356
23 MM2- Dermoscopy - ABCD
at 75% specificity - in-person
1 356
24 MM2- Dermoscopy - ABCD
at 85% specificity - in-person
1 356
25 MM2- Dermoscopy - ABCD
at 90% specificity - in-person
1 356
26 MM2- Dermoscopy - ABCDE
at > 1.3 - in-person
1 356
27 MM2- Dermoscopy - ABCDE
at > 2.65 - in-person
1 356
28 MM2- Dermoscopy - ABCDE
at > 3.05 - in-person
1 356
29 MM2- Dermoscopy - ABCDE
at > 3.6 - in-person
1 356
30 MM2- Dermoscopy - ABCDE
at > 4.25 - in-person
1 356
31 MM2- Dermoscopy - ABCDE
at > 4.9 - in-person
1 356
32 MM2- Dermoscopy - 7FFM at
≥ 2 - in-person
1 401
33 MM2- Dermoscopy - 7-point
at ≥ 2 - in-person
1 638
34 MM2- Dermoscopy - 7-point
at ≥ 3 - in-person
2 11137
35 MM2- Dermoscopy - Menzies
at 2 negative and ≥ 1 positive -
in-person
1 206
36 MM2- Dermoscopy - no
algorithm - any threshold -
image-based
24 4498
37 MM2- Dermoscopy - no
algorithm - correct diagnosis -
image-based
18 4118
38 MM2- Dermoscopy - no
algorithm - excise decision -
image-based
10 831
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39 MM2- Dermoscopy - pattern -
any threshold - image-based
20 4621
40 MM2- Dermoscopy - pattern -
correct diagnosis - image-based
19 4095
41 MM2- Dermoscopy - pattern -
excise decision - image-based
3 933
42 MM2- Dermoscopy - ABCD
at > 4.75 - image-based
10 4242
43 MM2- Dermoscopy - ABCD
at > 5.45 - image-based
7 2471
44 MM2- Dermoscopy - revised
ABCD at ≥ 4 - image-based
1 269
45 MM2- Dermoscopy - ABCDE
at ≥ 4 - image-based
1 269
46 MM2- Dermoscopy - 7-point
at NR - image-based
4 1936
47 MM2- Dermoscopy - 7-point
at ≥ 3 - image-based
11 3408
48 MM2- Dermoscopy - 7-point
at ≥ 5 - image-based
1 322
49 MM2- Dermoscopy - revised
7-point at NR (likely ≥ 1) -
image-based
1 1678
50 MM2- Dermoscopy - revised
7-point at ≥ 1 - image-based
1 300
51 MM2- Dermoscopy - revised
7-point for FU - major change
- image-based
1 70
52 MM2- Dermoscopy - 7FFM at
≥ 2 - image-based
4 2200
53 MM2- Dermoscopy - Menzies
at 2 negative and ≥ 1 positive -
image-based
4 1856
54 MM2- Dermoscopy - Menzies
at NR - image-based
2 60
55 MM2- Dermoscopy - 3-point
at ≥ 2 - image-based
7 1505
56 MM2- Dermoscopy - 4-point
(scored 3-point) at > 2 -
image-based
1 75
57 MM2- Dermoscopy - Hofman
algorithm at NR - image-based
1 254
58 MM2- Dermoscopy CASH at
≥ 6 - image-based
1 477
59 MM2- Dermoscopy CASH at
≥ 8 - image-based
2 190
60 MM2- Dermoscopy
Chaos/Clues at = 2 -
image-based
2 940
61 MM2- Dermoscopy - Acral
3-step - image-based
1 107
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62 VI+dermoscopy (in-person)
- observer experience NR
(invasive melanoma or atypical
intraepidermal melanocytic
variants)
10 8390
63 VI+dermoscopy (in-person)
- high experience (invasive
melanoma or atypical
intraepidermal melanocytic
variants)
14 14213
65 VI+dermoscopy (in-person)
- trained observer (invasive
melanoma or atypical
intraepidermal melanocytic
variants)
2 566
66 Dermoscopy (image-based)
- observer experience NR
(invasive melanoma or atypical
intraepidermal melanocytic
variants)
11 2777
67 Dermoscopy (image-based)
- high experience (invasive
melanoma or atypical
intraepidermal melanocytic
variants)
34 8933
68 Dermoscopy (image-based)
- moderate experience
(invasive melanoma or atypical
intraepidermal melanocytic
variants)
5 678
69 Dermoscopy (image-based)
- low experience (invasive
melanoma or atypical
intraepidermal melanocytic
variants)
6 448
70 Dermoscopy (image-based)
- mixed experience (invasive
melanoma or atypical
intraepidermal melanocytic
variants)
5 473
71 Dermoscopy (image-based)
- trained observer (invasive
melanoma or atypical
intraepidermal melanocytic
variants)
11 1087
72 VI+dermoscopy (in-person)
- consultant expert (invasive
melanoma or atypical
intraepidermal melanocytic
variants)
11 2767
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73 VI+dermoscopy (in-person) -
consultant (invasive melanoma
or atypical intraepidermal
melanocytic variants)
10 8390
74 VI+dermoscopy (in-person)
- resident/registrar (invasive
melanoma or atypical
intraepidermal melanocytic
variants)
2 11137
75 VI+dermoscopy (in-person) -
mixed (secondary care-based)
(invasive melanoma or atypical
intraepidermal melanocytic
variants)
1 309
76 VI+dermoscopy (in-person)
- GP (invasive melanoma
or atypical intraepidermal
melanocytic variants)
2 566
77 Dermoscopy (image-based)
- consultant expert (invasive
melanoma or atypical
intraepidermal melanocytic
variants)
33 8664
78 Dermoscopy (image-based) -
consultant (invasive melanoma
or atypical intraepidermal
melanocytic variants)
24 3986
79 Dermoscopy (image-based) -
resident (invasive melanoma
or atypical intraepidermal
melanocytic variants)
5 927
80 Dermoscopy (image-based) -
mixed (secondary care based)
(invasive melanoma or atypical
intraepidermal melanocytic
variants)
4 399
81 Dermoscopy (image-based)
- mixed (other) (invasive
melanoma or atypical
intraepidermal melanocytic
variants)
4 867
82 Dermoscopy (image-based)
- GP/primary care (invasive
melanoma or atypical
intraepidermal melanocytic
variants)
3 288
83 Dermoscopy (image-based) -
physician assistant (invasive
melanoma or atypical
intraepidermal melanocytic
variants)
1 65
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84 Dermoscopy - before training
(invasive melanoma or atypical
intraepidermal melanocytic
variants)
4 245
85 Dermoscopy - after training
(invasive melanoma or atypical
intraepidermal melanocytic
variants)
4 245
86 Dermoscopy - before training
(invasive melanoma)
2 150
87 Dermoscopy - after training
(invasive melanoma)
2 150
88 MM1- Dermoscopy - no
algorithm - threshold NR -
in-person
3 190
89 MM1- Dermoscopy - pattern
analysis - threshold NR -
in-person
1 45
90 MM1- Dermoscopy - ABCD
at > 4.2 - in-person
1 495
91 MM1- Dermoscopy - ABCD
at > 5.45 - in-person
2 832
92 MM1- Dermoscopy - Kenet
(modified) at melanoma
possible - in-person
1 54
93 MM1- Dermoscopy - Kenet
(modified) at melanoma likely
- in-person
1 54
94 MM1- Dermoscopy - no
algorithm - threshold NR -
image-based
6 683
95 MM1- Dermoscopy - no
algorithm - decision to excise -
image-based (paired data only)
1 99
96 MM1- Dermoscopy - pattern
analysis - threshold NR -
image-based
1 119
97 MM1- Dermoscopy - ABCD
at > 4.75 - image-based
2 330
98 MM1- Dermoscopy - ABCD
at > 5.45 - image-based
1 258
99 MM1- Dermoscopy - 7-point
at NR - image-based
1 332
100 MM1- Dermoscopy - Menzies
at 2 negative and ≥ 1 positive -
image-based
4 4184
101 MM1- Dermoscopy - 3-point
at > NR - image-based
1 332
102MM1- Dermoscopy - Kenet at
melanoma likely - image-based
1 258
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103 MM1- Dermoscopy -
Kenet at melanoma possible -
image-based
1 258
104 MM1- Dermoscopy CASH at
≥ 8 - image-based
1 332
105 MM1- Dermoscopy - Kreusch
algorithm - image-based
1 265
106 MM1- Dermoscopy -
Menzies for amelanotic at 1 -
image-based
1 332
107 MM1- Dermoscopy -
Menzies for amelanotic at 0 -
image-based
1 332
108 MM3- Dermoscopy - no
algorithm at NR - in-person
1 231
109 MM3- Dermoscopy - pattern
analysis - threshold NR -
in-person
1 3372
110 MM3- Dermoscopy - ABCD
at > 5.45 - in-person
1 200
111 MM3- Dermoscopy - 3-point
at ≥ 2 - in-person
1 77
112 MM3- Dermoscopy - no
algorithm at NR - image-based
2 83
113 MM3- Dermoscopy - pattern
analysis - threshold NR -
image-based
1 119
114 MM3- Dermoscopy - 3-point
at ≥ 2 - image-based
1 150
115 MM2 - VI - in-person (with
image-based dermoscopy)
2 886
Test 1. Visual inspection - in-person (invasive melanoma).
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 1 Visual inspection - in-person (invasive melanoma)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Krahn 1998 31 9 8 32 0.79 [ 0.64, 0.91 ] 0.78 [ 0.62, 0.89 ]
Viglizzo 2004 8 3 4 52 0.67 [ 0.35, 0.90 ] 0.95 [ 0.85, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 2. VI+dermoscopy - in-person (invasive melanoma).
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 2 VI+dermoscopy - in-person (invasive melanoma)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ascierto 2010 12 2 0 40 1.00 [ 0.74, 1.00 ] 0.95 [ 0.84, 0.99 ]
Coras 2003 13 1 3 28 0.81 [ 0.54, 0.96 ] 0.97 [ 0.82, 1.00 ]
Feldmann 1998 16 14 9 461 0.64 [ 0.43, 0.82 ] 0.97 [ 0.95, 0.98 ]
Krahn 1998 35 3 4 38 0.90 [ 0.76, 0.97 ] 0.93 [ 0.80, 0.98 ]
Piccolo 2000 8 1 3 31 0.73 [ 0.39, 0.94 ] 0.97 [ 0.84, 1.00 ]
Viglizzo 2004 11 1 1 54 0.92 [ 0.62, 1.00 ] 0.98 [ 0.90, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 3. Visual inspection - image-based (invasive melanoma).
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 3 Visual inspection - image-based (invasive melanoma)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Lorentzen 1999a 38 20 11 163 0.78 [ 0.63, 0.88 ] 0.89 [ 0.84, 0.93 ]
Rao 1997 18 13 3 38 0.86 [ 0.64, 0.97 ] 0.75 [ 0.60, 0.86 ]
Troyanova 2003 18 5 7 20 0.72 [ 0.51, 0.88 ] 0.80 [ 0.59, 0.93 ]
Westerhoff 2000 31 23 19 27 0.62 [ 0.47, 0.75 ] 0.54 [ 0.39, 0.68 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 4. Dermoscopy alone - image-based (invasive melanoma).
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 4 Dermoscopy alone - image-based (invasive melanoma)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Arevalo 2008 315 846 26 2180 0.92 [ 0.89, 0.95 ] 0.72 [ 0.70, 0.74 ]
Friedman 2008 10 10 11 68 0.48 [ 0.26, 0.70 ] 0.87 [ 0.78, 0.94 ]
Hauschild 2014 26 48 10 46 0.72 [ 0.55, 0.86 ] 0.49 [ 0.38, 0.59 ]
Kreusch 1992 94 28 2 141 0.98 [ 0.93, 1.00 ] 0.83 [ 0.77, 0.89 ]
Lorentzen 1999a 40 11 9 172 0.82 [ 0.68, 0.91 ] 0.94 [ 0.89, 0.97 ]
Lorentzen 2000 47 23 17 171 0.73 [ 0.61, 0.84 ] 0.88 [ 0.83, 0.92 ]
Lorentzen 2008 24 3 0 92 1.00 [ 0.86, 1.00 ] 0.97 [ 0.91, 0.99 ]
Menzies 1996 98 81 9 197 0.92 [ 0.85, 0.96 ] 0.71 [ 0.65, 0.76 ]
Menzies 2013 176 35 41 80 0.81 [ 0.75, 0.86 ] 0.70 [ 0.60, 0.78 ]
Nilles 1994 37 25 4 143 0.90 [ 0.77, 0.97 ] 0.85 [ 0.79, 0.90 ]
Rao 1997 18 12 3 39 0.86 [ 0.64, 0.97 ] 0.76 [ 0.63, 0.87 ]
Troyanova 2003 23 4 2 21 0.92 [ 0.74, 0.99 ] 0.84 [ 0.64, 0.95 ]
Westerhoff 2000 38 21 12 29 0.76 [ 0.62, 0.87 ] 0.58 [ 0.43, 0.72 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 5. Visual inspection - in-person (invasive melanoma or atypical intraepidermal melanocytic variants).
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 5 Visual inspection - in-person (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Benelli 1999 51 189 9 152 0.85 [ 0.73, 0.93 ] 0.45 [ 0.39, 0.50 ]
Bono 2002a 57 56 9 191 0.86 [ 0.76, 0.94 ] 0.77 [ 0.72, 0.82 ]
Bono 2002b 10 39 3 109 0.77 [ 0.46, 0.95 ] 0.74 [ 0.66, 0.81 ]
Bono 2006 10 16 13 167 0.43 [ 0.23, 0.66 ] 0.91 [ 0.86, 0.95 ]
Carli 2002a 35 46 19 156 0.65 [ 0.51, 0.77 ] 0.77 [ 0.71, 0.83 ]
Cristofolini 1994 28 46 5 141 0.85 [ 0.68, 0.95 ] 0.75 [ 0.69, 0.81 ]
Dummer 1993 15 49 8 699 0.65 [ 0.43, 0.84 ] 0.93 [ 0.91, 0.95 ]
Grimaldi 2009 5 63 0 167 1.00 [ 0.48, 1.00 ] 0.73 [ 0.66, 0.78 ]
Menzies 2009 12 46 20 253 0.38 [ 0.21, 0.56 ] 0.85 [ 0.80, 0.89 ]
Morales Callaghan 2008 3 5 3 189 0.50 [ 0.12, 0.88 ] 0.97 [ 0.94, 0.99 ]
Soyer 1995 61 17 4 77 0.94 [ 0.85, 0.98 ] 0.82 [ 0.73, 0.89 ]
Stanganelli 2000 37 21 18 3296 0.67 [ 0.53, 0.79 ] 0.99 [ 0.99, 1.00 ]
Unlu 2014 18 39 6 52 0.75 [ 0.53, 0.90 ] 0.57 [ 0.46, 0.67 ]
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Test 6. VI+dermoscopy - in-person (invasive melanoma or atypical intraepidermal melanocytic variants).
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 6 VI+dermoscopy - in-person (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ahnlide 2016 34 23 12 240 0.74 [ 0.59, 0.86 ] 0.91 [ 0.87, 0.94 ]
Bauer 2000 33 10 9 263 0.79 [ 0.63, 0.90 ] 0.96 [ 0.93, 0.98 ]
Benelli 1999 48 37 12 304 0.80 [ 0.68, 0.89 ] 0.89 [ 0.85, 0.92 ]
Bono 2002a 60 63 6 184 0.91 [ 0.81, 0.97 ] 0.74 [ 0.69, 0.80 ]
Bono 2002b 10 42 3 106 0.77 [ 0.46, 0.95 ] 0.72 [ 0.64, 0.79 ]
Bono 2006 19 57 4 126 0.83 [ 0.61, 0.95 ] 0.69 [ 0.62, 0.75 ]
Broganelli 2005 100 10 8 520 0.93 [ 0.86, 0.97 ] 0.98 [ 0.97, 0.99 ]
Carli 1994 5 28 0 35 1.00 [ 0.48, 1.00 ] 0.56 [ 0.42, 0.68 ]
Carli 2002a 53 9 1 193 0.98 [ 0.90, 1.00 ] 0.96 [ 0.92, 0.98 ]
Cristofolini 1994 29 39 4 148 0.88 [ 0.72, 0.97 ] 0.79 [ 0.73, 0.85 ]
Dreiseitl 2009 26 121 1 310 0.96 [ 0.81, 1.00 ] 0.72 [ 0.67, 0.76 ]
Duff 2001 577 193 9 1593 0.98 [ 0.97, 0.99 ] 0.89 [ 0.88, 0.91 ]
Durdu 2011 8 5 2 185 0.80 [ 0.44, 0.97 ] 0.97 [ 0.94, 0.99 ]
Feldmann 1998 16 14 14 456 0.53 [ 0.34, 0.72 ] 0.97 [ 0.95, 0.98 ]
Gokdemir 2011 12 25 1 410 0.92 [ 0.64, 1.00 ] 0.94 [ 0.92, 0.96 ]
Grimaldi 2009 5 24 0 206 1.00 [ 0.48, 1.00 ] 0.90 [ 0.85, 0.93 ]
Guitera 2009a (Modena) 68 83 11 33 0.86 [ 0.76, 0.93 ] 0.28 [ 0.20, 0.38 ]
Haenssle 2010a (FV) 32 146 8 8263 0.80 [ 0.64, 0.91 ] 0.98 [ 0.98, 0.99 ]
Haenssle 2010b (FU) 47 228 40 2373 0.54 [ 0.43, 0.65 ] 0.91 [ 0.90, 0.92 ]
Kittler 1999 60 71 13 212 0.82 [ 0.71, 0.90 ] 0.75 [ 0.69, 0.80 ]
Langley 2007 33 14 4 74 0.89 [ 0.75, 0.97 ] 0.84 [ 0.75, 0.91 ]
Menzies 2009 17 33 15 266 0.53 [ 0.35, 0.71 ] 0.89 [ 0.85, 0.92 ]
Morales Callaghan 2008 4 6 2 188 0.67 [ 0.22, 0.96 ] 0.97 [ 0.93, 0.99 ]
Nachbar 1994 64 11 5 114 0.93 [ 0.84, 0.98 ] 0.91 [ 0.85, 0.96 ]
Soyer 1995 61 17 4 77 0.94 [ 0.85, 0.98 ] 0.82 [ 0.73, 0.89 ]
Stanganelli 2000 51 9 4 3308 0.93 [ 0.82, 0.98 ] 1.00 [ 0.99, 1.00 ]
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Test 7. Visual inspection - image-based (invasive melanoma or atypical intraepidermal melanocytic
variants).
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 7 Visual inspection - image-based (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Benelli 2000a 36 232 40 292 0.47 [ 0.36, 0.59 ] 0.56 [ 0.51, 0.60 ]
Benelli 2001 7 18 5 20 0.58 [ 0.28, 0.85 ] 0.53 [ 0.36, 0.69 ]
Bourne 2012 2 12 7 29 0.22 [ 0.03, 0.60 ] 0.71 [ 0.54, 0.84 ]
Carli 2002b 8 7 2 36 0.80 [ 0.44, 0.97 ] 0.84 [ 0.69, 0.93 ]
Carli 2003b 45 27 19 109 0.70 [ 0.58, 0.81 ] 0.80 [ 0.72, 0.86 ]
Dolianitis 2005 12 3 8 17 0.60 [ 0.36, 0.81 ] 0.85 [ 0.62, 0.97 ]
Pizzichetta 2004 25 8 14 61 0.64 [ 0.47, 0.79 ] 0.88 [ 0.78, 0.95 ]
Rosendahl 2011 6 14 23 420 0.21 [ 0.08, 0.40 ] 0.97 [ 0.95, 0.98 ]
Stanganelli 1998a 4 5 6 15 0.40 [ 0.12, 0.74 ] 0.75 [ 0.51, 0.91 ]
Stanganelli 2005 23 18 8 85 0.74 [ 0.55, 0.88 ] 0.83 [ 0.74, 0.89 ]
Winkelmann 2016 3 3 2 4 0.60 [ 0.15, 0.95 ] 0.57 [ 0.18, 0.90 ]
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Test 8. Dermoscopy alone - image-based (invasive melanoma or atypical intraepidermal melanocytic
variants).
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 8 Dermoscopy alone - image-based (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Alarcon 2014 86 128 6 123 0.93 [ 0.86, 0.98 ] 0.49 [ 0.43, 0.55 ]
Annessi 2007 82 21 14 81 0.85 [ 0.77, 0.92 ] 0.79 [ 0.70, 0.87 ]
Argenziano 1998 106 22 11 203 0.91 [ 0.84, 0.95 ] 0.90 [ 0.86, 0.94 ]
Argenziano 2011 47 23 53 177 0.47 [ 0.37, 0.57 ] 0.89 [ 0.83, 0.93 ]
Benelli 2000a 52 70 24 454 0.68 [ 0.57, 0.79 ] 0.87 [ 0.83, 0.89 ]
Benelli 2001 11 3 1 35 0.92 [ 0.62, 1.00 ] 0.92 [ 0.79, 0.98 ]
Binder 1994 38 6 2 54 0.95 [ 0.83, 0.99 ] 0.90 [ 0.79, 0.96 ]
Binder 1995 39 16 18 167 0.68 [ 0.55, 0.80 ] 0.91 [ 0.86, 0.95 ]
Binder 1999 33 45 8 164 0.80 [ 0.65, 0.91 ] 0.78 [ 0.72, 0.84 ]
Blum 2004b 76 208 8 545 0.90 [ 0.82, 0.96 ] 0.72 [ 0.69, 0.76 ]
Bourne 2012 2 12 7 24 0.22 [ 0.03, 0.60 ] 0.67 [ 0.49, 0.81 ]
Carli 2002a 44 28 10 174 0.81 [ 0.69, 0.91 ] 0.86 [ 0.81, 0.91 ]
Carli 2002b 8 6 3 36 0.73 [ 0.39, 0.94 ] 0.86 [ 0.71, 0.95 ]
Carli 2003a 37 71 7 85 0.84 [ 0.70, 0.93 ] 0.54 [ 0.46, 0.62 ]
Carli 2003b 53 27 11 109 0.83 [ 0.71, 0.91 ] 0.80 [ 0.72, 0.86 ]
Carrera 2016 89 145 30 213 0.75 [ 0.66, 0.82 ] 0.59 [ 0.54, 0.65 ]
Dal Pozzo 1999 159 79 9 466 0.95 [ 0.90, 0.98 ] 0.86 [ 0.82, 0.88 ]
di Meo 2016 19 5 13 38 0.59 [ 0.41, 0.76 ] 0.88 [ 0.75, 0.96 ]
Dolianitis 2005 16 4 4 16 0.80 [ 0.56, 0.94 ] 0.80 [ 0.56, 0.94 ]
Dummer 1993 22 10 1 738 0.96 [ 0.78, 1.00 ] 0.99 [ 0.98, 0.99 ]
Feci 2015 65 33 37 186 0.64 [ 0.54, 0.73 ] 0.85 [ 0.79, 0.89 ]
Ferrari 2015 64 124 6 128 0.91 [ 0.82, 0.97 ] 0.51 [ 0.44, 0.57 ]
Ferris 2015 16 14 9 26 0.64 [ 0.43, 0.82 ] 0.65 [ 0.48, 0.79 ]
Friedman 2008 20 10 29 40 0.41 [ 0.27, 0.56 ] 0.80 [ 0.66, 0.90 ]
Gereli 2010 43 33 5 15 0.90 [ 0.77, 0.97 ] 0.31 [ 0.19, 0.46 ]
Gilmore 2010 34 17 2 16 0.94 [ 0.81, 0.99 ] 0.48 [ 0.31, 0.66 ]
Glud 2009 11 13 1 58 0.92 [ 0.62, 1.00 ] 0.82 [ 0.71, 0.90 ]
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(. . . Continued)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Guitera 2009b (Sydney) 40 55 4 32 0.91 [ 0.78, 0.97 ] 0.37 [ 0.27, 0.48 ]
Hauschild 2014 47 30 18 35 0.72 [ 0.60, 0.83 ] 0.54 [ 0.41, 0.66 ]
Kittler 1998 20 7 3 20 0.87 [ 0.66, 0.97 ] 0.74 [ 0.54, 0.89 ]
Kittler 2001 6 27 4 43 0.60 [ 0.26, 0.88 ] 0.61 [ 0.49, 0.73 ]
Malvehy 2014 168 297 70 1143 0.71 [ 0.64, 0.76 ] 0.79 [ 0.77, 0.81 ]
Menzies 2005 12 27 1 38 0.92 [ 0.64, 1.00 ] 0.58 [ 0.46, 0.71 ]
Menzies 2008 43 67 62 325 0.41 [ 0.31, 0.51 ] 0.83 [ 0.79, 0.87 ]
Pagnanelli 2003 5 3 1 11 0.83 [ 0.36, 1.00 ] 0.79 [ 0.49, 0.95 ]
Piccolo 2002a 12 2 1 326 0.92 [ 0.64, 1.00 ] 0.99 [ 0.98, 1.00 ]
Piccolo 2014 33 69 0 63 1.00 [ 0.89, 1.00 ] 0.48 [ 0.39, 0.57 ]
Pizzichetta 2002 2 1 3 123 0.40 [ 0.05, 0.85 ] 0.99 [ 0.96, 1.00 ]
Pizzichetta 2004 35 3 4 66 0.90 [ 0.76, 0.97 ] 0.96 [ 0.88, 0.99 ]
Pupelli 2013 22 33 2 39 0.92 [ 0.73, 0.99 ] 0.54 [ 0.42, 0.66 ]
Rigel 2012 3 9 2 10 0.60 [ 0.15, 0.95 ] 0.53 [ 0.29, 0.76 ]
Rosendahl 2011 12 25 17 409 0.41 [ 0.24, 0.61 ] 0.94 [ 0.92, 0.96 ]
Rubegni 2012 24 6 1 76 0.96 [ 0.80, 1.00 ] 0.93 [ 0.85, 0.97 ]
Rubegni 2016 35 19 10 31 0.78 [ 0.63, 0.89 ] 0.62 [ 0.47, 0.75 ]
Sboner 2004 35 20 7 90 0.83 [ 0.69, 0.93 ] 0.82 [ 0.73, 0.89 ]
Seidenari 1998 25 3 6 56 0.81 [ 0.63, 0.93 ] 0.95 [ 0.86, 0.99 ]
Seidenari 2005 95 26 17 465 0.85 [ 0.77, 0.91 ] 0.95 [ 0.92, 0.97 ]
Seidenari 2007 28 30 15 170 0.65 [ 0.49, 0.79 ] 0.85 [ 0.79, 0.90 ]
Skvara 2005 20 8 43 55 0.32 [ 0.21, 0.45 ] 0.87 [ 0.77, 0.94 ]
Stanganelli 1998a 6 3 4 17 0.60 [ 0.26, 0.88 ] 0.85 [ 0.62, 0.97 ]
Stanganelli 1999 8 3 3 16 0.73 [ 0.39, 0.94 ] 0.84 [ 0.60, 0.97 ]
Stanganelli 2005 23 21 8 82 0.74 [ 0.55, 0.88 ] 0.80 [ 0.71, 0.87 ]
Stanganelli 2015 8 23 4 35 0.67 [ 0.35, 0.90 ] 0.60 [ 0.47, 0.73 ]
Stolz 1994a 47 3 1 28 0.98 [ 0.89, 1.00 ] 0.90 [ 0.74, 0.98 ]
Tan 2009 14 4 1 11 0.93 [ 0.68, 1.00 ] 0.73 [ 0.45, 0.92 ]
Tenenhaus 2010 25 29 7 166 0.78 [ 0.60, 0.91 ] 0.85 [ 0.79, 0.90 ]
Unlu 2014 22 36 2 55 0.92 [ 0.73, 0.99 ] 0.60 [ 0.50, 0.71 ]
Wells 2012 12 7 11 17 0.52 [ 0.31, 0.73 ] 0.71 [ 0.49, 0.87 ]
Winkelmann 2016 3 3 2 4 0.60 [ 0.15, 0.95 ] 0.57 [ 0.18, 0.90 ]
Zalaudek 2006 24 30 2 94 0.92 [ 0.75, 0.99 ] 0.76 [ 0.67, 0.83 ]
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(. . . Continued)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
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Test 9. Visual inspection - in-person (any).
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 9 Visual inspection - in-person (any)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Argenziano 2006 30 16 23 16 0.57 [ 0.42, 0.70 ] 0.50 [ 0.32, 0.68 ]
Stanganelli 2000 70 29 28 3245 0.71 [ 0.61, 0.80 ] 0.99 [ 0.99, 0.99 ]
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Test 10. VI+Dermoscopy - in-person (Any).
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 10 VI+Dermoscopy - in-person (Any)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Argenziano 2006 33 28 6 10 0.85 [ 0.69, 0.94 ] 0.26 [ 0.13, 0.43 ]
Durdu 2011 45 3 1 151 0.98 [ 0.88, 1.00 ] 0.98 [ 0.94, 1.00 ]
Soyer 2004 69 9 8 145 0.90 [ 0.81, 0.95 ] 0.94 [ 0.89, 0.97 ]
Stanganelli 2000 88 9 10 3265 0.90 [ 0.82, 0.95 ] 1.00 [ 0.99, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
501Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Test 11. Visual inspection - image-based (any).
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 11 Visual inspection - image-based (any)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Carli 2002b 16 9 4 25 0.80 [ 0.56, 0.94 ] 0.74 [ 0.56, 0.87 ]
Rosendahl 2011 79 54 25 305 0.76 [ 0.67, 0.84 ] 0.85 [ 0.81, 0.88 ]
Stanganelli 1998a 9 4 5 12 0.64 [ 0.35, 0.87 ] 0.75 [ 0.48, 0.93 ]
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Test 12. Dermoscopy alone - image-based (any).
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 12 Dermoscopy alone - image-based (any)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Carli 2002b 14 9 4 26 0.78 [ 0.52, 0.94 ] 0.74 [ 0.57, 0.88 ]
Lorentzen 2008 37 3 0 79 1.00 [ 0.91, 1.00 ] 0.96 [ 0.90, 0.99 ]
Rosendahl 2011 82 42 22 317 0.79 [ 0.70, 0.86 ] 0.88 [ 0.85, 0.91 ]
Stanganelli 1998a 11 4 3 12 0.79 [ 0.49, 0.95 ] 0.75 [ 0.48, 0.93 ]
Zalaudek 2006 40 30 4 76 0.91 [ 0.78, 0.97 ] 0.72 [ 0.62, 0.80 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
502Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Test 13. MM2- Dermoscopy - no algorithm - threshold NR - in-person.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 13 MM2- Dermoscopy - no algorithm - threshold NR - in-person
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ahnlide 2016 34 23 12 240 0.74 [ 0.59, 0.86 ] 0.91 [ 0.87, 0.94 ]
Bauer 2000 33 10 9 263 0.79 [ 0.63, 0.90 ] 0.96 [ 0.93, 0.98 ]
Bono 2002a 60 63 6 184 0.91 [ 0.81, 0.97 ] 0.74 [ 0.69, 0.80 ]
Bono 2002b 10 42 3 106 0.77 [ 0.46, 0.95 ] 0.72 [ 0.64, 0.79 ]
Dreiseitl 2009 26 121 1 310 0.96 [ 0.81, 1.00 ] 0.72 [ 0.67, 0.76 ]
Duff 2001 577 193 9 1593 0.98 [ 0.97, 0.99 ] 0.89 [ 0.88, 0.91 ]
Gokdemir 2011 12 25 1 410 0.92 [ 0.64, 1.00 ] 0.94 [ 0.92, 0.96 ]
Menzies 2009 17 33 15 266 0.53 [ 0.35, 0.71 ] 0.89 [ 0.85, 0.92 ]
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Test 14. MM2- Dermoscopy - pattern - at ≥ 1 char present - in-person.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 14 MM2- Dermoscopy - pattern - at≥ 1 char present - in-person
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Cristofolini 1994 29 39 4 148 0.88 [ 0.72, 0.97 ] 0.79 [ 0.73, 0.85 ]
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Test 15. MM2- Dermoscopy - pattern - at ≥ 3 characteristics present - in-person.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 15 MM2- Dermoscopy - pattern - at≥ 3 characteristics present - in-person
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Carli 1994 5 28 0 35 1.00 [ 0.48, 1.00 ] 0.56 [ 0.42, 0.68 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 16. MM2- Dermoscopy - pattern - threshold NR - in-person.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 16 MM2- Dermoscopy - pattern - threshold NR - in-person
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Carli 2002a 53 9 1 193 0.98 [ 0.90, 1.00 ] 0.96 [ 0.92, 0.98 ]
Guitera 2009a (Modena) 68 83 11 33 0.86 [ 0.76, 0.93 ] 0.28 [ 0.20, 0.38 ]
Langley 2007 33 14 4 74 0.89 [ 0.75, 0.97 ] 0.84 [ 0.75, 0.91 ]
Morales Callaghan 2008 4 6 2 188 0.67 [ 0.22, 0.96 ] 0.97 [ 0.93, 0.99 ]
Soyer 1995 61 17 4 77 0.94 [ 0.85, 0.98 ] 0.82 [ 0.73, 0.89 ]
Stanganelli 2000 51 9 4 3308 0.93 [ 0.82, 0.98 ] 1.00 [ 0.99, 1.00 ]
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Test 17. MM2- Dermoscopy - ABCD at NR (likely > 5.45) - in-person.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 17 MM2- Dermoscopy - ABCD at NR (likely > 5.45) - in-person
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Grimaldi 2009 5 24 0 206 1.00 [ 0.48, 1.00 ] 0.90 [ 0.85, 0.93 ]
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Test 18. MM2- Dermoscopy - ABCD at > 5.45 - in-person.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 18 MM2- Dermoscopy - ABCD at > 5.45 - in-person
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ahnlide 2016 34 87 12 176 0.74 [ 0.59, 0.86 ] 0.67 [ 0.61, 0.73 ]
Durdu 2011 8 5 2 185 0.80 [ 0.44, 0.97 ] 0.97 [ 0.94, 0.99 ]
Feldmann 1998 16 14 14 456 0.53 [ 0.34, 0.72 ] 0.97 [ 0.95, 0.98 ]
Nachbar 1994 64 11 5 114 0.93 [ 0.84, 0.98 ] 0.91 [ 0.85, 0.96 ]
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Test 19. MM2- Dermoscopy - ABCD at > 4.75 - in-person.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 19 MM2- Dermoscopy - ABCD at > 4.75 - in-person
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ahnlide 2016 38 145 8 118 0.83 [ 0.69, 0.92 ] 0.45 [ 0.39, 0.51 ]
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Test 20. MM2- Dermoscopy - ABCD at 60% specificity - in-person.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 20 MM2- Dermoscopy - ABCD at 60% specificity - in-person
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Kittler 1999 66 113 7 170 0.90 [ 0.81, 0.96 ] 0.60 [ 0.54, 0.66 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 21. MM2- Dermoscopy - ABCD at 80% specificity - in-person.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 21 MM2- Dermoscopy - ABCD at 80% specificity - in-person
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Kittler 1999 56 57 17 226 0.77 [ 0.65, 0.86 ] 0.80 [ 0.75, 0.84 ]
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Test 22. MM2- Dermoscopy - ABCD at 70% specificity - in-person.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 22 MM2- Dermoscopy - ABCD at 70% specificity - in-person
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Kittler 1999 62 85 11 198 0.85 [ 0.75, 0.92 ] 0.70 [ 0.64, 0.75 ]
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Test 23. MM2- Dermoscopy - ABCD at 75% specificity - in-person.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 23 MM2- Dermoscopy - ABCD at 75% specificity - in-person
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Kittler 1999 60 71 13 212 0.82 [ 0.71, 0.90 ] 0.75 [ 0.69, 0.80 ]
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Test 24. MM2- Dermoscopy - ABCD at 85% specificity - in-person.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 24 MM2- Dermoscopy - ABCD at 85% specificity - in-person
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Kittler 1999 52 42 21 241 0.71 [ 0.59, 0.81 ] 0.85 [ 0.80, 0.89 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 25. MM2- Dermoscopy - ABCD at 90% specificity - in-person.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 25 MM2- Dermoscopy - ABCD at 90% specificity - in-person
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Kittler 1999 47 28 26 255 0.64 [ 0.52, 0.75 ] 0.90 [ 0.86, 0.93 ]
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Test 26. MM2- Dermoscopy - ABCDE at > 1.3 - in-person.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 26 MM2- Dermoscopy - ABCDE at > 1.3 - in-person
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Kittler 1999 73 240 0 43 1.00 [ 0.95, 1.00 ] 0.15 [ 0.11, 0.20 ]
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Test 27. MM2- Dermoscopy - ABCDE at > 2.65 - in-person.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 27 MM2- Dermoscopy - ABCDE at > 2.65 - in-person
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Kittler 1999 71 173 2 110 0.97 [ 0.90, 1.00 ] 0.39 [ 0.33, 0.45 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 28. MM2- Dermoscopy - ABCDE at > 3.05 - in-person.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 28 MM2- Dermoscopy - ABCDE at > 3.05 - in-person
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Kittler 1999 69 123 4 160 0.95 [ 0.87, 0.98 ] 0.57 [ 0.51, 0.62 ]
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Test 29. MM2- Dermoscopy - ABCDE at > 3.6 - in-person.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 29 MM2- Dermoscopy - ABCDE at > 3.6 - in-person
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Kittler 1999 66 86 7 197 0.90 [ 0.81, 0.96 ] 0.70 [ 0.64, 0.75 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 30. MM2- Dermoscopy - ABCDE at > 4.25 - in-person.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 30 MM2- Dermoscopy - ABCDE at > 4.25 - in-person
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Kittler 1999 60 52 13 231 0.82 [ 0.71, 0.90 ] 0.82 [ 0.77, 0.86 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 31. MM2- Dermoscopy - ABCDE at > 4.9 - in-person.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 31 MM2- Dermoscopy - ABCDE at > 4.9 - in-person
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Kittler 1999 54 28 19 255 0.74 [ 0.62, 0.84 ] 0.90 [ 0.86, 0.93 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 32. MM2- Dermoscopy - 7FFM at ≥ 2 - in-person.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 32 MM2- Dermoscopy - 7FFM at≥ 2 - in-person
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Benelli 1999 48 37 12 304 0.80 [ 0.68, 0.89 ] 0.89 [ 0.85, 0.92 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 33. MM2- Dermoscopy - 7-point at ≥ 2 - in-person.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 33 MM2- Dermoscopy - 7-point at≥ 2 - in-person
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Broganelli 2005 100 10 8 520 0.93 [ 0.86, 0.97 ] 0.98 [ 0.97, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 34. MM2- Dermoscopy - 7-point at ≥ 3 - in-person.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 34 MM2- Dermoscopy - 7-point at≥ 3 - in-person
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Haenssle 2010a (FV) 32 146 8 8263 0.80 [ 0.64, 0.91 ] 0.98 [ 0.98, 0.99 ]
Haenssle 2010b (FU) 47 228 40 2373 0.54 [ 0.43, 0.65 ] 0.91 [ 0.90, 0.92 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 35. MM2- Dermoscopy - Menzies at 2 negative and ≥ 1 positive - in-person.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 35 MM2- Dermoscopy - Menzies at 2 negative and≥ 1 positive - in-person
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bono 2006 19 57 4 126 0.83 [ 0.61, 0.95 ] 0.69 [ 0.62, 0.75 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 36. MM2- Dermoscopy - no algorithm - any threshold - image-based.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 36 MM2- Dermoscopy - no algorithm - any threshold - image-based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Alarcon 2014 86 128 6 123 0.93 [ 0.86, 0.98 ] 0.49 [ 0.43, 0.55 ]
Binder 1995 39 16 18 167 0.68 [ 0.55, 0.80 ] 0.91 [ 0.86, 0.95 ]
Carli 2002b 8 6 3 36 0.73 [ 0.39, 0.94 ] 0.86 [ 0.71, 0.95 ]
Carli 2003b 53 27 11 109 0.83 [ 0.71, 0.91 ] 0.80 [ 0.72, 0.86 ]
Ferris 2015 16 14 9 26 0.64 [ 0.43, 0.82 ] 0.65 [ 0.48, 0.79 ]
Friedman 2008 20 10 29 40 0.41 [ 0.27, 0.56 ] 0.80 [ 0.66, 0.90 ]
Gilmore 2010 34 17 2 16 0.94 [ 0.81, 0.99 ] 0.48 [ 0.31, 0.66 ]
Glud 2009 11 13 1 58 0.92 [ 0.62, 1.00 ] 0.82 [ 0.71, 0.90 ]
Hauschild 2014 47 30 18 35 0.72 [ 0.60, 0.83 ] 0.54 [ 0.41, 0.66 ]
Kittler 1998 20 7 3 20 0.87 [ 0.66, 0.97 ] 0.74 [ 0.54, 0.89 ]
Kittler 2001 6 27 4 43 0.60 [ 0.26, 0.88 ] 0.61 [ 0.49, 0.73 ]
Malvehy 2014 168 297 70 1143 0.71 [ 0.64, 0.76 ] 0.79 [ 0.77, 0.81 ]
Menzies 2005 12 27 1 38 0.92 [ 0.64, 1.00 ] 0.58 [ 0.46, 0.71 ]
Piccolo 2002a 12 2 1 326 0.92 [ 0.64, 1.00 ] 0.99 [ 0.98, 1.00 ]
Rigel 2012 3 9 2 10 0.60 [ 0.15, 0.95 ] 0.53 [ 0.29, 0.76 ]
Sboner 2004 35 20 7 90 0.83 [ 0.69, 0.93 ] 0.82 [ 0.73, 0.89 ]
Seidenari 1998 25 3 6 56 0.81 [ 0.63, 0.93 ] 0.95 [ 0.86, 0.99 ]
Seidenari 2007 28 30 15 170 0.65 [ 0.49, 0.79 ] 0.85 [ 0.79, 0.90 ]
Stanganelli 1998a 6 3 4 17 0.60 [ 0.26, 0.88 ] 0.85 [ 0.62, 0.97 ]
Stanganelli 1999 8 3 3 16 0.73 [ 0.39, 0.94 ] 0.84 [ 0.60, 0.97 ]
Stanganelli 2005 23 21 8 82 0.74 [ 0.55, 0.88 ] 0.80 [ 0.71, 0.87 ]
Tenenhaus 2010 25 29 7 166 0.78 [ 0.60, 0.91 ] 0.85 [ 0.79, 0.90 ]
Wells 2012 12 7 11 17 0.52 [ 0.31, 0.73 ] 0.71 [ 0.49, 0.87 ]
Winkelmann 2016 3 3 2 4 0.60 [ 0.15, 0.95 ] 0.57 [ 0.18, 0.90 ]
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Test 37. MM2- Dermoscopy - no algorithm - correct diagnosis - image-based.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 37 MM2- Dermoscopy - no algorithm - correct diagnosis - image-based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Alarcon 2014 86 128 6 123 0.93 [ 0.86, 0.98 ] 0.49 [ 0.43, 0.55 ]
Binder 1995 39 16 18 167 0.68 [ 0.55, 0.80 ] 0.91 [ 0.86, 0.95 ]
Carli 2002b 8 6 3 36 0.73 [ 0.39, 0.94 ] 0.86 [ 0.71, 0.95 ]
Carli 2003b 53 27 11 109 0.83 [ 0.71, 0.91 ] 0.80 [ 0.72, 0.86 ]
Friedman 2008 20 10 29 40 0.41 [ 0.27, 0.56 ] 0.80 [ 0.66, 0.90 ]
Glud 2009 11 13 1 58 0.92 [ 0.62, 1.00 ] 0.82 [ 0.71, 0.90 ]
Kittler 1998 20 7 3 20 0.87 [ 0.66, 0.97 ] 0.74 [ 0.54, 0.89 ]
Malvehy 2014 168 297 70 1143 0.71 [ 0.64, 0.76 ] 0.79 [ 0.77, 0.81 ]
Menzies 2005 12 27 1 38 0.92 [ 0.64, 1.00 ] 0.58 [ 0.46, 0.71 ]
Piccolo 2002a 12 2 1 326 0.92 [ 0.64, 1.00 ] 0.99 [ 0.98, 1.00 ]
Sboner 2004 35 20 7 90 0.83 [ 0.69, 0.93 ] 0.82 [ 0.73, 0.89 ]
Seidenari 1998 25 3 6 56 0.81 [ 0.63, 0.93 ] 0.95 [ 0.86, 0.99 ]
Seidenari 2007 28 30 15 170 0.65 [ 0.49, 0.79 ] 0.85 [ 0.79, 0.90 ]
Stanganelli 1998a 6 3 4 17 0.60 [ 0.26, 0.88 ] 0.85 [ 0.62, 0.97 ]
Stanganelli 1999 8 3 3 16 0.73 [ 0.39, 0.94 ] 0.84 [ 0.60, 0.97 ]
Stanganelli 2005 23 21 8 82 0.74 [ 0.55, 0.88 ] 0.80 [ 0.71, 0.87 ]
Tenenhaus 2010 25 29 7 166 0.78 [ 0.60, 0.91 ] 0.85 [ 0.79, 0.90 ]
Wells 2012 12 7 11 17 0.52 [ 0.31, 0.73 ] 0.71 [ 0.49, 0.87 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 38. MM2- Dermoscopy - no algorithm - excise decision - image-based.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 38 MM2- Dermoscopy - no algorithm - excise decision - image-based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ferris 2015 16 14 9 26 0.64 [ 0.43, 0.82 ] 0.65 [ 0.48, 0.79 ]
Friedman 2008 35 25 14 25 0.71 [ 0.57, 0.83 ] 0.50 [ 0.36, 0.64 ]
Gilmore 2010 34 17 2 16 0.94 [ 0.81, 0.99 ] 0.48 [ 0.31, 0.66 ]
Hauschild 2014 47 30 18 35 0.72 [ 0.60, 0.83 ] 0.54 [ 0.41, 0.66 ]
Kittler 2001 6 27 4 43 0.60 [ 0.26, 0.88 ] 0.61 [ 0.49, 0.73 ]
Menzies 2005 12 36 1 29 0.92 [ 0.64, 1.00 ] 0.45 [ 0.32, 0.57 ]
Rigel 2012 3 9 2 10 0.60 [ 0.15, 0.95 ] 0.53 [ 0.29, 0.76 ]
Tenenhaus 2010 30 72 2 123 0.94 [ 0.79, 0.99 ] 0.63 [ 0.56, 0.70 ]
Wells 2012 18 14 5 10 0.78 [ 0.56, 0.93 ] 0.42 [ 0.22, 0.63 ]
Winkelmann 2016 3 3 2 4 0.60 [ 0.15, 0.95 ] 0.57 [ 0.18, 0.90 ]
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Test 39. MM2- Dermoscopy - pattern - any threshold - image-based.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 39 MM2- Dermoscopy - pattern - any threshold - image-based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Annessi 2007 82 21 14 81 0.85 [ 0.77, 0.92 ] 0.79 [ 0.70, 0.87 ]
Argenziano 1998 106 22 11 203 0.91 [ 0.84, 0.95 ] 0.90 [ 0.86, 0.94 ]
Argenziano 2011 47 23 53 177 0.47 [ 0.37, 0.57 ] 0.89 [ 0.83, 0.93 ]
Binder 1994 38 6 2 54 0.95 [ 0.83, 0.99 ] 0.90 [ 0.79, 0.96 ]
Binder 1999 33 45 8 164 0.80 [ 0.65, 0.91 ] 0.78 [ 0.72, 0.84 ]
Blum 2004a 27 15 5 110 0.84 [ 0.67, 0.95 ] 0.88 [ 0.81, 0.93 ]
Carli 2002a 44 28 10 174 0.81 [ 0.69, 0.91 ] 0.86 [ 0.81, 0.91 ]
Carli 2003a 37 71 7 85 0.84 [ 0.70, 0.93 ] 0.54 [ 0.46, 0.62 ]
Dolianitis 2005 16 4 4 16 0.80 [ 0.56, 0.94 ] 0.80 [ 0.56, 0.94 ]
Dummer 1993 22 10 1 738 0.96 [ 0.78, 1.00 ] 0.99 [ 0.98, 0.99 ]
Feci 2015 65 33 37 186 0.64 [ 0.54, 0.73 ] 0.85 [ 0.79, 0.89 ]
Guitera 2009b (Sydney) 40 55 4 32 0.91 [ 0.78, 0.97 ] 0.37 [ 0.27, 0.48 ]
Pagnanelli 2003 5 3 1 11 0.83 [ 0.36, 1.00 ] 0.79 [ 0.49, 0.95 ]
Pizzichetta 2002 2 1 3 123 0.40 [ 0.05, 0.85 ] 0.99 [ 0.96, 1.00 ]
Pizzichetta 2004 35 3 4 66 0.90 [ 0.76, 0.97 ] 0.96 [ 0.88, 0.99 ]
Rosendahl 2011 12 25 17 409 0.41 [ 0.24, 0.61 ] 0.94 [ 0.92, 0.96 ]
Rubegni 2012 24 6 1 76 0.96 [ 0.80, 1.00 ] 0.93 [ 0.85, 0.97 ]
Rubegni 2016 35 19 10 31 0.78 [ 0.63, 0.89 ] 0.62 [ 0.47, 0.75 ]
Seidenari 2005 95 26 17 465 0.85 [ 0.77, 0.91 ] 0.95 [ 0.92, 0.97 ]
Tan 2009 14 4 1 11 0.93 [ 0.68, 1.00 ] 0.73 [ 0.45, 0.92 ]
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Test 40. MM2- Dermoscopy - pattern - correct diagnosis - image-based.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 40 MM2- Dermoscopy - pattern - correct diagnosis - image-based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Annessi 2007 82 21 14 81 0.85 [ 0.77, 0.92 ] 0.79 [ 0.70, 0.87 ]
Argenziano 1998 106 22 11 203 0.91 [ 0.84, 0.95 ] 0.90 [ 0.86, 0.94 ]
Argenziano 2011 47 23 53 177 0.47 [ 0.37, 0.57 ] 0.89 [ 0.83, 0.93 ]
Binder 1994 38 6 2 54 0.95 [ 0.83, 0.99 ] 0.90 [ 0.79, 0.96 ]
Binder 1999 33 45 8 164 0.80 [ 0.65, 0.91 ] 0.78 [ 0.72, 0.84 ]
Blum 2004a 27 15 5 110 0.84 [ 0.67, 0.95 ] 0.88 [ 0.81, 0.93 ]
Carli 2002a 44 28 10 174 0.81 [ 0.69, 0.91 ] 0.86 [ 0.81, 0.91 ]
Carli 2003a 37 71 7 85 0.84 [ 0.70, 0.93 ] 0.54 [ 0.46, 0.62 ]
Dolianitis 2005 16 4 4 16 0.80 [ 0.56, 0.94 ] 0.80 [ 0.56, 0.94 ]
Dummer 1993 22 10 1 738 0.96 [ 0.78, 1.00 ] 0.99 [ 0.98, 0.99 ]
Feci 2015 65 33 37 186 0.64 [ 0.54, 0.73 ] 0.85 [ 0.79, 0.89 ]
Guitera 2009b (Sydney) 20 13 14 60 0.59 [ 0.41, 0.75 ] 0.82 [ 0.71, 0.90 ]
Pagnanelli 2003 40 55 4 32 0.91 [ 0.78, 0.97 ] 0.37 [ 0.27, 0.48 ]
Pizzichetta 2002 5 3 1 11 0.83 [ 0.36, 1.00 ] 0.79 [ 0.49, 0.95 ]
Pizzichetta 2004 2 1 3 123 0.40 [ 0.05, 0.85 ] 0.99 [ 0.96, 1.00 ]
Rosendahl 2011 35 3 4 66 0.90 [ 0.76, 0.97 ] 0.96 [ 0.88, 0.99 ]
Rubegni 2012 12 25 17 409 0.41 [ 0.24, 0.61 ] 0.94 [ 0.92, 0.96 ]
Rubegni 2016 24 6 1 76 0.96 [ 0.80, 1.00 ] 0.93 [ 0.85, 0.97 ]
Seidenari 2005 35 19 10 31 0.78 [ 0.63, 0.89 ] 0.62 [ 0.47, 0.75 ]
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Test 41. MM2- Dermoscopy - pattern - excise decision - image-based.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 41 MM2- Dermoscopy - pattern - excise decision - image-based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Argenziano 2011 82 77 18 123 0.82 [ 0.73, 0.89 ] 0.62 [ 0.54, 0.68 ]
Seidenari 2005 112 102 0 389 1.00 [ 0.97, 1.00 ] 0.79 [ 0.75, 0.83 ]
Tan 2009 14 4 1 11 0.93 [ 0.68, 1.00 ] 0.73 [ 0.45, 0.92 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 42. MM2- Dermoscopy - ABCD at > 4.75 - image-based.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 42 MM2- Dermoscopy - ABCD at > 4.75 - image-based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Annessi 2007 81 26 15 76 0.84 [ 0.76, 0.91 ] 0.75 [ 0.65, 0.83 ]
Argenziano 1998 99 77 18 148 0.85 [ 0.77, 0.91 ] 0.66 [ 0.59, 0.72 ]
Binder 1999 33 48 8 161 0.80 [ 0.65, 0.91 ] 0.77 [ 0.71, 0.83 ]
Blum 2004b 76 208 8 545 0.90 [ 0.82, 0.96 ] 0.72 [ 0.69, 0.76 ]
Carrera 2016 89 145 30 213 0.75 [ 0.66, 0.82 ] 0.59 [ 0.54, 0.65 ]
Dolianitis 2005 16 5 4 15 0.80 [ 0.56, 0.94 ] 0.75 [ 0.51, 0.91 ]
Malvehy 2014 129 159 109 1281 0.54 [ 0.48, 0.61 ] 0.89 [ 0.87, 0.91 ]
Piccolo 2014 33 69 0 63 1.00 [ 0.89, 1.00 ] 0.48 [ 0.39, 0.57 ]
Pizzichetta 2002 4 55 1 69 0.80 [ 0.28, 0.99 ] 0.56 [ 0.46, 0.65 ]
Skvara 2005 20 8 43 55 0.32 [ 0.21, 0.45 ] 0.87 [ 0.77, 0.94 ]
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Test 43. MM2- Dermoscopy - ABCD at > 5.45 - image-based.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 43 MM2- Dermoscopy - ABCD at > 5.45 - image-based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Binder 1999 30 21 11 188 0.73 [ 0.57, 0.86 ] 0.90 [ 0.85, 0.94 ]
Carli 2003a 24 36 20 120 0.55 [ 0.39, 0.70 ] 0.77 [ 0.70, 0.83 ]
Malvehy 2014 112 96 126 1344 0.47 [ 0.41, 0.54 ] 0.93 [ 0.92, 0.95 ]
Pagnanelli 2003 5 3 1 11 0.83 [ 0.36, 1.00 ] 0.79 [ 0.49, 0.95 ]
Pizzichetta 2002 4 51 1 73 0.80 [ 0.28, 0.99 ] 0.59 [ 0.50, 0.68 ]
Stolz 1994a 47 3 1 28 0.98 [ 0.89, 1.00 ] 0.90 [ 0.74, 0.98 ]
Unlu 2014 22 36 2 55 0.92 [ 0.73, 0.99 ] 0.60 [ 0.50, 0.71 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 44. MM2- Dermoscopy - revised ABCD at ≥ 4 - image-based.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 44 MM2- Dermoscopy - revised ABCD at≥ 4 - image-based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Blum 2003a 73 21 11 164 0.87 [ 0.78, 0.93 ] 0.89 [ 0.83, 0.93 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
519Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Test 45. MM2- Dermoscopy - ABCDE at ≥ 4 - image-based.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 45 MM2- Dermoscopy - ABCDE at≥ 4 - image-based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Blum 2003a 76 24 8 161 0.90 [ 0.82, 0.96 ] 0.87 [ 0.81, 0.92 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 46. MM2- Dermoscopy - 7-point at NR - image-based.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 46 MM2- Dermoscopy - 7-point at NR - image-based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Annessi 2007 75 36 21 66 0.78 [ 0.69, 0.86 ] 0.65 [ 0.55, 0.74 ]
Dolianitis 2005 17 4 3 16 0.85 [ 0.62, 0.97 ] 0.80 [ 0.56, 0.94 ]
Malvehy 2014 117 93 121 1347 0.49 [ 0.43, 0.56 ] 0.94 [ 0.92, 0.95 ]
Pagnanelli 2003 6 4 0 10 1.00 [ 0.54, 1.00 ] 0.71 [ 0.42, 0.92 ]
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Test 47. MM2- Dermoscopy - 7-point at ≥ 3 - image-based.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 47 MM2- Dermoscopy - 7-point at≥ 3 - image-based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Argenziano 1998 111 56 6 169 0.95 [ 0.89, 0.98 ] 0.75 [ 0.69, 0.81 ]
Argenziano 2011 78 74 22 126 0.78 [ 0.69, 0.86 ] 0.63 [ 0.56, 0.70 ]
Blum 2004b 76 98 8 655 0.90 [ 0.82, 0.96 ] 0.87 [ 0.84, 0.89 ]
Carli 2003a 38 76 6 80 0.86 [ 0.73, 0.95 ] 0.51 [ 0.43, 0.59 ]
Carrera 2016 84 152 35 206 0.71 [ 0.62, 0.79 ] 0.58 [ 0.52, 0.63 ]
Ferrari 2015 64 124 6 128 0.91 [ 0.82, 0.97 ] 0.51 [ 0.44, 0.57 ]
Gereli 2010 42 40 6 8 0.88 [ 0.75, 0.95 ] 0.17 [ 0.07, 0.30 ]
Menzies 2008 43 67 62 325 0.41 [ 0.31, 0.51 ] 0.83 [ 0.79, 0.87 ]
Pupelli 2013 22 33 2 39 0.92 [ 0.73, 0.99 ] 0.54 [ 0.42, 0.66 ]
Skvara 2005 7 3 56 60 0.11 [ 0.05, 0.22 ] 0.95 [ 0.87, 0.99 ]
Unlu 2014 21 31 3 60 0.88 [ 0.68, 0.97 ] 0.66 [ 0.55, 0.76 ]
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Test 48. MM2- Dermoscopy - 7-point at ≥ 5 - image-based.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 48 MM2- Dermoscopy - 7-point at≥ 5 - image-based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ferrari 2015 47 43 23 209 0.67 [ 0.55, 0.78 ] 0.83 [ 0.78, 0.87 ]
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Test 49. MM2- Dermoscopy - revised 7-point at NR (likely ≥ 1) - image-based.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 49 MM2- Dermoscopy - revised 7-point at NR (likely ≥ 1) - image-based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Malvehy 2014 145 176 93 1264 0.61 [ 0.54, 0.67 ] 0.88 [ 0.86, 0.89 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 50. MM2- Dermoscopy - revised 7-point at ≥ 1 - image-based.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 50 MM2- Dermoscopy revised 7-point at≥ 1 - image-based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Argenziano 2011 88 98 12 102 0.88 [ 0.80, 0.94 ] 0.51 [ 0.44, 0.58 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 51. MM2- Dermoscopy - revised 7-point for FU - major change - image-based.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 51 MM2- Dermoscopy - revised 7-point for FU - major change - image-based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Stanganelli 2015 8 23 4 35 0.67 [ 0.35, 0.90 ] 0.60 [ 0.47, 0.73 ]
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Test 52. MM2- Dermoscopy - 7FFM at ≥ 2 - image-based.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 52 MM2- Dermoscopy - 7FFM at≥ 2 - image-based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Benelli 2000a 52 70 24 454 0.68 [ 0.57, 0.79 ] 0.87 [ 0.83, 0.89 ]
Benelli 2001 11 3 1 35 0.92 [ 0.62, 1.00 ] 0.92 [ 0.79, 0.98 ]
Blum 2004b 79 191 5 562 0.94 [ 0.87, 0.98 ] 0.75 [ 0.71, 0.78 ]
Dal Pozzo 1999 159 79 9 466 0.95 [ 0.90, 0.98 ] 0.86 [ 0.82, 0.88 ]
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Test 53. MM2- Dermoscopy - Menzies at 2 negative and ≥ 1 positive - image-based.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 53 MM2- Dermoscopy - Menzies at 2 negative and≥ 1 positive - image-based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Blum 2004b 80 167 4 586 0.95 [ 0.88, 0.99 ] 0.78 [ 0.75, 0.81 ]
Bourne 2012 2 12 7 24 0.22 [ 0.03, 0.60 ] 0.67 [ 0.49, 0.81 ]
Carrera 2016 113 270 6 88 0.95 [ 0.89, 0.98 ] 0.25 [ 0.20, 0.29 ]
Menzies 2008 57 94 48 298 0.54 [ 0.44, 0.64 ] 0.76 [ 0.71, 0.80 ]
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Test 54. MM2- Dermoscopy - Menzies at NR - image-based.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 54 MM2- Dermoscopy - Menzies at NR - image-based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Dolianitis 2005 14 3 6 17 0.70 [ 0.46, 0.88 ] 0.85 [ 0.62, 0.97 ]
Pagnanelli 2003 6 3 0 11 1.00 [ 0.54, 1.00 ] 0.79 [ 0.49, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 55. MM2- Dermoscopy - 3-point at ≥ 2 - image-based.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 55 MM2- Dermoscopy - 3-point at≥ 2 - image-based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bourne 2012 6 28 3 8 0.67 [ 0.30, 0.93 ] 0.22 [ 0.10, 0.39 ]
Carrera 2016 82 148 37 210 0.69 [ 0.60, 0.77 ] 0.59 [ 0.53, 0.64 ]
di Meo 2016 19 10 13 83 0.59 [ 0.41, 0.76 ] 0.89 [ 0.81, 0.95 ]
Gereli 2010 43 33 5 15 0.90 [ 0.77, 0.97 ] 0.31 [ 0.19, 0.46 ]
Menzies 2008 52 114 53 278 0.50 [ 0.40, 0.59 ] 0.71 [ 0.66, 0.75 ]
Unlu 2014 19 34 5 57 0.79 [ 0.58, 0.93 ] 0.63 [ 0.52, 0.73 ]
Zalaudek 2006 24 35 2 89 0.92 [ 0.75, 0.99 ] 0.72 [ 0.63, 0.79 ]
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Test 56. MM2- Dermoscopy - 4-point (scored 3-point) at > 2 - image-based.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 56 MM2- Dermoscopy - 4-point (scored 3-point) at > 2 - image-based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
di Meo 2016 27 8 5 35 0.84 [ 0.67, 0.95 ] 0.81 [ 0.67, 0.92 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 57. MM2- Dermoscopy - Hofman algorithm at NR - image-based.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 57 MM2- Dermoscopy - Hofman algorithm at NR - image-based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Blum 2003b 65 22 10 157 0.87 [ 0.77, 0.93 ] 0.88 [ 0.82, 0.92 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 58. MM2- Dermoscopy CASH at ≥ 6 - image-based.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 58 MM2- Dermoscopy CASH at≥ 6 - image-based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Carrera 2016 93 176 26 182 0.78 [ 0.70, 0.85 ] 0.51 [ 0.46, 0.56 ]
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Test 59. MM2- Dermoscopy CASH at ≥ 8 - image-based.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 59 MM2- Dermoscopy CASH at≥ 8 - image-based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
di Meo 2016 32 10 0 33 1.00 [ 0.89, 1.00 ] 0.77 [ 0.61, 0.88 ]
Unlu 2014 22 32 2 59 0.92 [ 0.73, 0.99 ] 0.65 [ 0.54, 0.75 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 60. MM2- Dermoscopy Chaos/Clues at = 2 - image-based.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 60 MM2- Dermoscopy Chaos/Clues at = 2 - image-based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Carrera 2016 98 214 21 144 0.82 [ 0.74, 0.89 ] 0.40 [ 0.35, 0.46 ]
Rosendahl 2011 23 151 6 283 0.79 [ 0.60, 0.92 ] 0.65 [ 0.61, 0.70 ]
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Test 61. MM2- Dermoscopy - Acral 3-step - image-based.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 61 MM2- Dermoscopy - Acral 3-step - image-based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Rubegni 2012 24 7 1 75 0.96 [ 0.80, 1.00 ] 0.91 [ 0.83, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 62. VI+dermoscopy (in-person) - observer experience NR (invasive melanoma or atypical
intraepidermal melanocytic variants).
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 62 VI+dermoscopy (in-person) - observer experience NR (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Benelli 1999 48 37 12 304 0.80 [ 0.68, 0.89 ] 0.89 [ 0.85, 0.92 ]
Bono 2006 19 57 4 126 0.83 [ 0.61, 0.95 ] 0.69 [ 0.62, 0.75 ]
Broganelli 2005 100 10 8 520 0.93 [ 0.86, 0.97 ] 0.98 [ 0.97, 0.99 ]
Cristofolini 1994 29 39 4 148 0.88 [ 0.72, 0.97 ] 0.79 [ 0.73, 0.85 ]
Duff 2001 577 193 9 1593 0.98 [ 0.97, 0.99 ] 0.89 [ 0.88, 0.91 ]
Durdu 2011 8 5 2 185 0.80 [ 0.44, 0.97 ] 0.97 [ 0.94, 0.99 ]
Feldmann 1998 16 14 14 456 0.53 [ 0.34, 0.72 ] 0.97 [ 0.95, 0.98 ]
Kittler 1999 60 71 13 212 0.82 [ 0.71, 0.90 ] 0.75 [ 0.69, 0.80 ]
Langley 2007 33 14 4 74 0.89 [ 0.75, 0.97 ] 0.84 [ 0.75, 0.91 ]
Stanganelli 2000 51 9 4 3308 0.93 [ 0.82, 0.98 ] 1.00 [ 0.99, 1.00 ]
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Test 63. VI+dermoscopy (in-person) - high experience (invasive melanoma or atypical intraepidermal
melanocytic variants).
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 63 VI+dermoscopy (in-person) - high experience (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ahnlide 2016 34 23 12 240 0.74 [ 0.59, 0.86 ] 0.91 [ 0.87, 0.94 ]
Bauer 2000 33 10 9 263 0.79 [ 0.63, 0.90 ] 0.96 [ 0.93, 0.98 ]
Bono 2002a 60 63 6 184 0.91 [ 0.81, 0.97 ] 0.74 [ 0.69, 0.80 ]
Bono 2002b 10 42 3 106 0.77 [ 0.46, 0.95 ] 0.72 [ 0.64, 0.79 ]
Carli 1994 5 28 0 35 1.00 [ 0.48, 1.00 ] 0.56 [ 0.42, 0.68 ]
Carli 2002a 53 9 1 193 0.98 [ 0.90, 1.00 ] 0.96 [ 0.92, 0.98 ]
Dreiseitl 2009 26 121 1 310 0.96 [ 0.81, 1.00 ] 0.72 [ 0.67, 0.76 ]
Gokdemir 2011 12 25 1 410 0.92 [ 0.64, 1.00 ] 0.94 [ 0.92, 0.96 ]
Guitera 2009a (Modena) 68 83 11 33 0.86 [ 0.76, 0.93 ] 0.28 [ 0.20, 0.38 ]
Haenssle 2010a (FV) 32 146 8 8263 0.80 [ 0.64, 0.91 ] 0.98 [ 0.98, 0.99 ]
Haenssle 2010b (FU) 47 228 40 2373 0.54 [ 0.43, 0.65 ] 0.91 [ 0.90, 0.92 ]
Morales Callaghan 2008 4 6 2 188 0.67 [ 0.22, 0.96 ] 0.97 [ 0.93, 0.99 ]
Nachbar 1994 64 11 5 114 0.93 [ 0.84, 0.98 ] 0.91 [ 0.85, 0.96 ]
Soyer 1995 61 17 4 77 0.94 [ 0.85, 0.98 ] 0.82 [ 0.73, 0.89 ]
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Test 65. VI+dermoscopy (in-person) - trained observer (invasive melanoma or atypical intraepidermal
melanocytic variants).
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 65 VI+dermoscopy (in-person) - trained observer (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Grimaldi 2009 5 24 0 206 1.00 [ 0.48, 1.00 ] 0.90 [ 0.85, 0.93 ]
Menzies 2009 17 33 15 266 0.53 [ 0.35, 0.71 ] 0.89 [ 0.85, 0.92 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 66. Dermoscopy (image-based) - observer experience NR (invasive melanoma or atypical
intraepidermal melanocytic variants).
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 66 Dermoscopy (image-based) - observer experience NR (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Benelli 2000a 52 70 24 454 0.68 [ 0.57, 0.79 ] 0.87 [ 0.83, 0.89 ]
Dal Pozzo 1999 159 79 9 466 0.95 [ 0.90, 0.98 ] 0.86 [ 0.82, 0.88 ]
Dummer 1993 22 10 1 738 0.96 [ 0.78, 1.00 ] 0.99 [ 0.98, 0.99 ]
Pizzichetta 2002 2 1 3 123 0.40 [ 0.05, 0.85 ] 0.99 [ 0.96, 1.00 ]
Pizzichetta 2004 35 3 4 66 0.90 [ 0.76, 0.97 ] 0.96 [ 0.88, 0.99 ]
Pupelli 2013 22 33 2 39 0.92 [ 0.73, 0.99 ] 0.54 [ 0.42, 0.66 ]
Sboner 2004 35 20 7 90 0.83 [ 0.69, 0.93 ] 0.82 [ 0.73, 0.89 ]
Stanganelli 2015 8 23 4 35 0.67 [ 0.35, 0.90 ] 0.60 [ 0.47, 0.73 ]
Stolz 1994a 47 3 1 28 0.98 [ 0.89, 1.00 ] 0.90 [ 0.74, 0.98 ]
Wells 2012 12 7 11 17 0.52 [ 0.31, 0.73 ] 0.71 [ 0.49, 0.87 ]
Winkelmann 2016 3 3 2 4 0.60 [ 0.15, 0.95 ] 0.57 [ 0.18, 0.90 ]
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Test 67. Dermoscopy (image-based) - high experience (invasive melanoma or atypical intraepidermal
melanocytic variants).
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 67 Dermoscopy (image-based) - high experience (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Alarcon 2014 86 128 6 123 0.93 [ 0.86, 0.98 ] 0.49 [ 0.43, 0.55 ]
Annessi 2007 82 21 14 81 0.85 [ 0.77, 0.92 ] 0.79 [ 0.70, 0.87 ]
Argenziano 1998 99 77 18 148 0.85 [ 0.77, 0.91 ] 0.66 [ 0.59, 0.72 ]
Argenziano 2011 47 23 53 177 0.47 [ 0.37, 0.57 ] 0.89 [ 0.83, 0.93 ]
Benelli 2001 11 3 1 35 0.92 [ 0.62, 1.00 ] 0.92 [ 0.79, 0.98 ]
Binder 1994 38 6 2 54 0.95 [ 0.83, 0.99 ] 0.90 [ 0.79, 0.96 ]
Binder 1995 39 16 18 167 0.68 [ 0.55, 0.80 ] 0.91 [ 0.86, 0.95 ]
Blum 2004b 76 208 8 545 0.90 [ 0.82, 0.96 ] 0.72 [ 0.69, 0.76 ]
Carli 2002a 44 28 10 174 0.81 [ 0.69, 0.91 ] 0.86 [ 0.81, 0.91 ]
Carli 2002b 8 6 3 36 0.73 [ 0.39, 0.94 ] 0.86 [ 0.71, 0.95 ]
Carli 2003b 53 27 11 109 0.83 [ 0.71, 0.91 ] 0.80 [ 0.72, 0.86 ]
di Meo 2016 19 5 13 38 0.59 [ 0.41, 0.76 ] 0.88 [ 0.75, 0.96 ]
Feci 2015 65 33 37 186 0.64 [ 0.54, 0.73 ] 0.85 [ 0.79, 0.89 ]
Ferrari 2015 64 124 6 128 0.91 [ 0.82, 0.97 ] 0.51 [ 0.44, 0.57 ]
Ferris 2015 16 14 9 26 0.64 [ 0.43, 0.82 ] 0.65 [ 0.48, 0.79 ]
Friedman 2008 20 10 29 40 0.41 [ 0.27, 0.56 ] 0.80 [ 0.66, 0.90 ]
Gilmore 2010 34 17 2 16 0.94 [ 0.81, 0.99 ] 0.48 [ 0.31, 0.66 ]
Glud 2009 11 13 1 58 0.92 [ 0.62, 1.00 ] 0.82 [ 0.71, 0.90 ]
Guitera 2009b (Sydney) 40 55 4 32 0.91 [ 0.78, 0.97 ] 0.37 [ 0.27, 0.48 ]
Hauschild 2014 47 30 18 35 0.72 [ 0.60, 0.83 ] 0.54 [ 0.41, 0.66 ]
Malvehy 2014 168 297 70 1143 0.71 [ 0.64, 0.76 ] 0.79 [ 0.77, 0.81 ]
Menzies 2005 12 27 1 38 0.92 [ 0.64, 1.00 ] 0.58 [ 0.46, 0.71 ]
Menzies 2008 43 67 62 325 0.41 [ 0.31, 0.51 ] 0.83 [ 0.79, 0.87 ]
Piccolo 2002a 12 2 1 326 0.92 [ 0.64, 1.00 ] 0.99 [ 0.98, 1.00 ]
Piccolo 2014 33 69 0 63 1.00 [ 0.89, 1.00 ] 0.48 [ 0.39, 0.57 ]
Rosendahl 2011 12 25 17 409 0.41 [ 0.24, 0.61 ] 0.94 [ 0.92, 0.96 ]
Rubegni 2012 24 6 1 76 0.96 [ 0.80, 1.00 ] 0.93 [ 0.85, 0.97 ]
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(. . . Continued)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Rubegni 2016 35 19 10 31 0.78 [ 0.63, 0.89 ] 0.62 [ 0.47, 0.75 ]
Seidenari 1998 25 3 6 56 0.81 [ 0.63, 0.93 ] 0.95 [ 0.86, 0.99 ]
Seidenari 2005 95 26 17 465 0.85 [ 0.77, 0.91 ] 0.95 [ 0.92, 0.97 ]
Skvara 2005 20 8 43 55 0.32 [ 0.21, 0.45 ] 0.87 [ 0.77, 0.94 ]
Stanganelli 2005 23 21 8 82 0.74 [ 0.55, 0.88 ] 0.80 [ 0.71, 0.87 ]
Tenenhaus 2010 25 29 7 166 0.78 [ 0.60, 0.91 ] 0.85 [ 0.79, 0.90 ]
Unlu 2014 22 36 2 55 0.92 [ 0.73, 0.99 ] 0.60 [ 0.50, 0.71 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 68. Dermoscopy (image-based) - moderate experience (invasive melanoma or atypical intraepidermal
melanocytic variants).
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 68 Dermoscopy (image-based) - moderate experience (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Binder 1995 25 27 32 156 0.44 [ 0.31, 0.58 ] 0.85 [ 0.79, 0.90 ]
Ferris 2015 18 16 7 24 0.72 [ 0.51, 0.88 ] 0.60 [ 0.43, 0.75 ]
Hauschild 2014 45 29 20 36 0.69 [ 0.57, 0.80 ] 0.55 [ 0.43, 0.68 ]
Menzies 2005 11 26 2 39 0.85 [ 0.55, 0.98 ] 0.60 [ 0.47, 0.72 ]
Piccolo 2014 30 44 3 88 0.91 [ 0.76, 0.98 ] 0.67 [ 0.58, 0.75 ]
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Test 69. Dermoscopy (image-based) - low experience (invasive melanoma or atypical intraepidermal
melanocytic variants).
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 69 Dermoscopy (image-based) - low experience (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ferris 2015 20 21 5 19 0.80 [ 0.59, 0.93 ] 0.48 [ 0.32, 0.64 ]
Menzies 2005 8 24 5 41 0.62 [ 0.32, 0.86 ] 0.63 [ 0.50, 0.75 ]
Pagnanelli 2003 4 3 2 11 0.67 [ 0.22, 0.96 ] 0.79 [ 0.49, 0.95 ]
Piccolo 2014 24 74 9 58 0.73 [ 0.54, 0.87 ] 0.44 [ 0.35, 0.53 ]
Seidenari 1998 23 15 8 44 0.74 [ 0.55, 0.88 ] 0.75 [ 0.62, 0.85 ]
Tan 2009 12 4 3 11 0.80 [ 0.52, 0.96 ] 0.73 [ 0.45, 0.92 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 70. Dermoscopy (image-based) - mixed experience (invasive melanoma or atypical intraepidermal
melanocytic variants).
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 70 Dermoscopy (image-based) - mixed experience (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Gereli 2010 43 33 5 15 0.90 [ 0.77, 0.97 ] 0.31 [ 0.19, 0.46 ]
Kittler 2001 6 27 4 43 0.60 [ 0.26, 0.88 ] 0.61 [ 0.49, 0.73 ]
Rigel 2012 3 9 2 10 0.60 [ 0.15, 0.95 ] 0.53 [ 0.29, 0.76 ]
Seidenari 2007 28 30 15 170 0.65 [ 0.49, 0.79 ] 0.85 [ 0.79, 0.90 ]
Stanganelli 1999 6 3 5 16 0.55 [ 0.23, 0.83 ] 0.84 [ 0.60, 0.97 ]
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Test 71. Dermoscopy (image-based) - trained observer (invasive melanoma or atypical intraepidermal
melanocytic variants).
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 71 Dermoscopy (image-based) - trained observer (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Argenziano 1998 53 56 7 30 0.88 [ 0.77, 0.95 ] 0.35 [ 0.25, 0.46 ]
Benelli 2001 10 6 2 32 0.83 [ 0.52, 0.98 ] 0.84 [ 0.69, 0.94 ]
Carli 2003a 37 71 7 85 0.84 [ 0.70, 0.93 ] 0.54 [ 0.46, 0.62 ]
Dolianitis 2005 16 4 4 16 0.80 [ 0.56, 0.94 ] 0.80 [ 0.56, 0.94 ]
Kittler 1998 20 7 3 20 0.87 [ 0.66, 0.97 ] 0.74 [ 0.54, 0.89 ]
Pagnanelli 2003 5 3 1 11 0.83 [ 0.36, 1.00 ] 0.79 [ 0.49, 0.95 ]
Piccolo 2002a 9 18 4 310 0.69 [ 0.39, 0.91 ] 0.95 [ 0.91, 0.97 ]
Stanganelli 1998a 6 3 4 17 0.60 [ 0.26, 0.88 ] 0.85 [ 0.62, 0.97 ]
Stanganelli 1999 8 3 3 16 0.73 [ 0.39, 0.94 ] 0.84 [ 0.60, 0.97 ]
Tan 2009 14 4 1 11 0.93 [ 0.68, 1.00 ] 0.73 [ 0.45, 0.92 ]
Zalaudek 2006 24 30 2 94 0.92 [ 0.75, 0.99 ] 0.76 [ 0.67, 0.83 ]
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Test 72. VI+dermoscopy (in-person) - consultant expert (invasive melanoma or atypical intraepidermal
melanocytic variants).
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 72 VI+dermoscopy (in-person) - consultant expert (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bauer 2000 33 10 9 263 0.79 [ 0.63, 0.90 ] 0.96 [ 0.93, 0.98 ]
Bono 2002a 60 63 6 184 0.91 [ 0.81, 0.97 ] 0.74 [ 0.69, 0.80 ]
Bono 2002b 10 42 3 106 0.77 [ 0.46, 0.95 ] 0.72 [ 0.64, 0.79 ]
Carli 1994 5 28 0 35 1.00 [ 0.48, 1.00 ] 0.56 [ 0.42, 0.68 ]
Carli 2002a 53 9 1 193 0.98 [ 0.90, 1.00 ] 0.96 [ 0.92, 0.98 ]
Dreiseitl 2009 26 121 1 310 0.96 [ 0.81, 1.00 ] 0.72 [ 0.67, 0.76 ]
Gokdemir 2011 12 25 1 410 0.92 [ 0.64, 1.00 ] 0.94 [ 0.92, 0.96 ]
Guitera 2009a (Modena) 68 83 11 33 0.86 [ 0.76, 0.93 ] 0.28 [ 0.20, 0.38 ]
Morales Callaghan 2008 4 6 2 188 0.67 [ 0.22, 0.96 ] 0.97 [ 0.93, 0.99 ]
Nachbar 1994 64 11 5 114 0.93 [ 0.84, 0.98 ] 0.91 [ 0.85, 0.96 ]
Soyer 1995 61 17 4 77 0.94 [ 0.85, 0.98 ] 0.82 [ 0.73, 0.89 ]
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Test 73. VI+dermoscopy (in-person) - consultant (invasive melanoma or atypical intraepidermal
melanocytic variants).
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 73 VI+dermoscopy (in-person) - consultant (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Benelli 1999 48 37 12 304 0.80 [ 0.68, 0.89 ] 0.89 [ 0.85, 0.92 ]
Bono 2006 19 57 4 126 0.83 [ 0.61, 0.95 ] 0.69 [ 0.62, 0.75 ]
Broganelli 2005 100 10 8 520 0.93 [ 0.86, 0.97 ] 0.98 [ 0.97, 0.99 ]
Cristofolini 1994 29 39 4 148 0.88 [ 0.72, 0.97 ] 0.79 [ 0.73, 0.85 ]
Duff 2001 577 193 9 1593 0.98 [ 0.97, 0.99 ] 0.89 [ 0.88, 0.91 ]
Durdu 2011 8 5 2 185 0.80 [ 0.44, 0.97 ] 0.97 [ 0.94, 0.99 ]
Feldmann 1998 16 14 14 456 0.53 [ 0.34, 0.72 ] 0.97 [ 0.95, 0.98 ]
Kittler 1999 60 71 13 212 0.82 [ 0.71, 0.90 ] 0.75 [ 0.69, 0.80 ]
Langley 2007 33 14 4 74 0.89 [ 0.75, 0.97 ] 0.84 [ 0.75, 0.91 ]
Stanganelli 2000 51 9 4 3308 0.93 [ 0.82, 0.98 ] 1.00 [ 0.99, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 74. VI+dermoscopy (in-person) - resident/registrar (invasive melanoma or atypical intraepidermal
melanocytic variants).
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 74 VI+dermoscopy (in-person) - resident/registrar (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Haenssle 2010a (FV) 32 146 8 8263 0.80 [ 0.64, 0.91 ] 0.98 [ 0.98, 0.99 ]
Haenssle 2010b (FU) 47 228 40 2373 0.54 [ 0.43, 0.65 ] 0.91 [ 0.90, 0.92 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 75. VI+dermoscopy (in-person) - mixed (secondary care-based) (invasive melanoma or atypical
intraepidermal melanocytic variants).
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 75 VI+dermoscopy (in-person) - mixed (secondary care-based) (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ahnlide 2016 34 23 12 240 0.74 [ 0.59, 0.86 ] 0.91 [ 0.87, 0.94 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 76. VI+dermoscopy (in-person) - GP (invasive melanoma or atypical intraepidermal melanocytic
variants).
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 76 VI+dermoscopy (in-person) - GP (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Grimaldi 2009 5 24 0 206 1.00 [ 0.48, 1.00 ] 0.90 [ 0.85, 0.93 ]
Menzies 2009 17 33 15 266 0.53 [ 0.35, 0.71 ] 0.89 [ 0.85, 0.92 ]
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Test 77. Dermoscopy (image-based) - consultant expert (invasive melanoma or atypical intraepidermal
melanocytic variants).
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 77 Dermoscopy (image-based) - consultant expert (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Alarcon 2014 86 128 6 123 0.93 [ 0.86, 0.98 ] 0.49 [ 0.43, 0.55 ]
Annessi 2007 82 21 14 81 0.85 [ 0.77, 0.92 ] 0.79 [ 0.70, 0.87 ]
Argenziano 1998 99 77 18 148 0.85 [ 0.77, 0.91 ] 0.66 [ 0.59, 0.72 ]
Argenziano 2011 47 23 53 177 0.47 [ 0.37, 0.57 ] 0.89 [ 0.83, 0.93 ]
Benelli 2001 11 3 1 35 0.92 [ 0.62, 1.00 ] 0.92 [ 0.79, 0.98 ]
Binder 1994 38 6 2 54 0.95 [ 0.83, 0.99 ] 0.90 [ 0.79, 0.96 ]
Binder 1995 39 16 18 167 0.68 [ 0.55, 0.80 ] 0.91 [ 0.86, 0.95 ]
Blum 2004b 76 208 8 545 0.90 [ 0.82, 0.96 ] 0.72 [ 0.69, 0.76 ]
Carli 2002a 44 28 10 174 0.81 [ 0.69, 0.91 ] 0.86 [ 0.81, 0.91 ]
Carli 2002b 8 6 3 36 0.73 [ 0.39, 0.94 ] 0.86 [ 0.71, 0.95 ]
di Meo 2016 19 5 13 38 0.59 [ 0.41, 0.76 ] 0.88 [ 0.75, 0.96 ]
Feci 2015 65 33 37 186 0.64 [ 0.54, 0.73 ] 0.85 [ 0.79, 0.89 ]
Ferrari 2015 64 124 6 128 0.91 [ 0.82, 0.97 ] 0.51 [ 0.44, 0.57 ]
Ferris 2015 16 14 9 26 0.64 [ 0.43, 0.82 ] 0.65 [ 0.48, 0.79 ]
Gilmore 2010 34 17 2 16 0.94 [ 0.81, 0.99 ] 0.48 [ 0.31, 0.66 ]
Glud 2009 11 13 1 58 0.92 [ 0.62, 1.00 ] 0.82 [ 0.71, 0.90 ]
Guitera 2009b (Sydney) 40 55 4 32 0.91 [ 0.78, 0.97 ] 0.37 [ 0.27, 0.48 ]
Hauschild 2014 47 30 18 35 0.72 [ 0.60, 0.83 ] 0.54 [ 0.41, 0.66 ]
Malvehy 2014 168 297 70 1143 0.71 [ 0.64, 0.76 ] 0.79 [ 0.77, 0.81 ]
Menzies 2005 12 27 1 38 0.92 [ 0.64, 1.00 ] 0.58 [ 0.46, 0.71 ]
Menzies 2008 43 67 62 325 0.41 [ 0.31, 0.51 ] 0.83 [ 0.79, 0.87 ]
Piccolo 2002a 12 2 1 326 0.92 [ 0.64, 1.00 ] 0.99 [ 0.98, 1.00 ]
Piccolo 2014 33 69 0 63 1.00 [ 0.89, 1.00 ] 0.48 [ 0.39, 0.57 ]
Rosendahl 2011 12 25 17 409 0.41 [ 0.24, 0.61 ] 0.94 [ 0.92, 0.96 ]
Rubegni 2012 24 6 1 76 0.96 [ 0.80, 1.00 ] 0.93 [ 0.85, 0.97 ]
Rubegni 2016 35 19 10 31 0.78 [ 0.63, 0.89 ] 0.62 [ 0.47, 0.75 ]
Seidenari 1998 25 3 6 56 0.81 [ 0.63, 0.93 ] 0.95 [ 0.86, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
(Continued . . . )
537Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Seidenari 2005 95 26 17 465 0.85 [ 0.77, 0.91 ] 0.95 [ 0.92, 0.97 ]
Skvara 2005 20 8 43 55 0.32 [ 0.21, 0.45 ] 0.87 [ 0.77, 0.94 ]
Stanganelli 1999 8 3 3 16 0.73 [ 0.39, 0.94 ] 0.84 [ 0.60, 0.97 ]
Stanganelli 2005 23 21 8 82 0.74 [ 0.55, 0.88 ] 0.80 [ 0.71, 0.87 ]
Tenenhaus 2010 25 29 7 166 0.78 [ 0.60, 0.91 ] 0.85 [ 0.79, 0.90 ]
Unlu 2014 22 36 2 55 0.92 [ 0.73, 0.99 ] 0.60 [ 0.50, 0.71 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 78. Dermoscopy (image-based) - consultant (invasive melanoma or atypical intraepidermal
melanocytic variants).
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 78 Dermoscopy (image-based) - consultant (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Argenziano 1998 53 56 7 30 0.88 [ 0.77, 0.95 ] 0.35 [ 0.25, 0.46 ]
Benelli 2000a 52 70 24 454 0.68 [ 0.57, 0.79 ] 0.87 [ 0.83, 0.89 ]
Benelli 2001 10 6 2 32 0.83 [ 0.52, 0.98 ] 0.84 [ 0.69, 0.94 ]
Binder 1995 25 27 32 156 0.44 [ 0.31, 0.58 ] 0.85 [ 0.79, 0.90 ]
Dal Pozzo 1999 159 79 9 466 0.95 [ 0.90, 0.98 ] 0.86 [ 0.82, 0.88 ]
Dummer 1993 22 10 1 738 0.96 [ 0.78, 1.00 ] 0.99 [ 0.98, 0.99 ]
Gereli 2010 43 33 5 15 0.90 [ 0.77, 0.97 ] 0.31 [ 0.19, 0.46 ]
Hauschild 2014 45 29 20 36 0.69 [ 0.57, 0.80 ] 0.55 [ 0.43, 0.68 ]
Kittler 1998 20 7 3 20 0.87 [ 0.66, 0.97 ] 0.74 [ 0.54, 0.89 ]
Kittler 2001 6 27 4 43 0.60 [ 0.26, 0.88 ] 0.61 [ 0.49, 0.73 ]
Menzies 2005 11 26 2 39 0.85 [ 0.55, 0.98 ] 0.60 [ 0.47, 0.72 ]
Piccolo 2014 30 44 3 88 0.91 [ 0.76, 0.98 ] 0.67 [ 0.58, 0.75 ]
Pizzichetta 2002 2 1 3 123 0.40 [ 0.05, 0.85 ] 0.99 [ 0.96, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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(. . . Continued)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Pizzichetta 2004 35 3 4 66 0.90 [ 0.76, 0.97 ] 0.96 [ 0.88, 0.99 ]
Pupelli 2013 22 33 2 39 0.92 [ 0.73, 0.99 ] 0.54 [ 0.42, 0.66 ]
Rigel 2012 3 9 2 10 0.60 [ 0.15, 0.95 ] 0.53 [ 0.29, 0.76 ]
Sboner 2004 35 20 7 90 0.83 [ 0.69, 0.93 ] 0.82 [ 0.73, 0.89 ]
Seidenari 1998 23 15 8 44 0.74 [ 0.55, 0.88 ] 0.75 [ 0.62, 0.85 ]
Stanganelli 1998a 6 3 4 17 0.60 [ 0.26, 0.88 ] 0.85 [ 0.62, 0.97 ]
Stanganelli 1999 6 3 5 16 0.55 [ 0.23, 0.83 ] 0.84 [ 0.60, 0.97 ]
Stanganelli 2015 8 23 4 35 0.67 [ 0.35, 0.90 ] 0.60 [ 0.47, 0.73 ]
Stolz 1994a 47 3 1 28 0.98 [ 0.89, 1.00 ] 0.90 [ 0.74, 0.98 ]
Wells 2012 12 7 11 17 0.52 [ 0.31, 0.73 ] 0.71 [ 0.49, 0.87 ]
Winkelmann 2016 3 3 2 4 0.60 [ 0.15, 0.95 ] 0.57 [ 0.18, 0.90 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 79. Dermoscopy (image-based) - resident (invasive melanoma or atypical intraepidermal melanocytic
variants).
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 79 Dermoscopy (image-based) - resident (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Carli 2003a 37 71 7 85 0.84 [ 0.70, 0.93 ] 0.54 [ 0.46, 0.62 ]
Ferris 2015 18 16 7 24 0.72 [ 0.51, 0.88 ] 0.60 [ 0.43, 0.75 ]
Menzies 2005 11 42 2 23 0.85 [ 0.55, 0.98 ] 0.35 [ 0.24, 0.48 ]
Piccolo 2002a 9 18 4 310 0.69 [ 0.39, 0.91 ] 0.95 [ 0.91, 0.97 ]
Seidenari 2007 28 30 15 170 0.65 [ 0.49, 0.79 ] 0.85 [ 0.79, 0.90 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 80. Dermoscopy (image-based) - mixed (secondary care based) (invasive melanoma or atypical
intraepidermal melanocytic variants).
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 80 Dermoscopy (image-based) - mixed (secondary care based) (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Binder 1999 33 45 8 164 0.80 [ 0.65, 0.91 ] 0.78 [ 0.72, 0.84 ]
Friedman 2008 20 10 29 40 0.41 [ 0.27, 0.56 ] 0.80 [ 0.66, 0.90 ]
Pagnanelli 2003 5 3 1 11 0.83 [ 0.36, 1.00 ] 0.79 [ 0.49, 0.95 ]
Tan 2009 14 4 1 11 0.93 [ 0.68, 1.00 ] 0.73 [ 0.45, 0.92 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 81. Dermoscopy (image-based) - mixed (other) (invasive melanoma or atypical intraepidermal
melanocytic variants).
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 81 Dermoscopy (image-based) - mixed (other) (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Carli 2003b 53 27 11 109 0.83 [ 0.71, 0.91 ] 0.80 [ 0.72, 0.86 ]
Carrera 2016 89 145 30 213 0.75 [ 0.66, 0.82 ] 0.59 [ 0.54, 0.65 ]
Dolianitis 2005 16 4 4 16 0.80 [ 0.56, 0.94 ] 0.80 [ 0.56, 0.94 ]
Zalaudek 2006 24 30 2 94 0.92 [ 0.75, 0.99 ] 0.76 [ 0.67, 0.83 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 82. Dermoscopy (image-based) - GP/primary care (invasive melanoma or atypical intraepidermal
melanocytic variants).
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 82 Dermoscopy (image-based) - GP/primary care (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bourne 2012 2 12 7 24 0.22 [ 0.03, 0.60 ] 0.67 [ 0.49, 0.81 ]
Menzies 2005 8 24 5 41 0.62 [ 0.32, 0.86 ] 0.63 [ 0.50, 0.75 ]
Piccolo 2014 24 74 9 58 0.73 [ 0.54, 0.87 ] 0.44 [ 0.35, 0.53 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 83. Dermoscopy (image-based) - physician assistant (invasive melanoma or atypical intraepidermal
melanocytic variants).
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 83 Dermoscopy (image-based) - physician assistant (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ferris 2015 20 21 5 19 0.80 [ 0.59, 0.93 ] 0.48 [ 0.32, 0.64 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 84. Dermoscopy - before training (invasive melanoma or atypical intraepidermal melanocytic variants).
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 84 Dermoscopy - before training (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Pagnanelli 2003 4 3 2 11 0.67 [ 0.22, 0.96 ] 0.79 [ 0.49, 0.95 ]
Piccolo 2014 12 40 21 92 0.36 [ 0.20, 0.55 ] 0.70 [ 0.61, 0.77 ]
Stanganelli 1999 6 3 5 16 0.55 [ 0.23, 0.83 ] 0.84 [ 0.60, 0.97 ]
Tan 2009 12 4 3 11 0.80 [ 0.52, 0.96 ] 0.73 [ 0.45, 0.92 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 85. Dermoscopy - after training (invasive melanoma or atypical intraepidermal melanocytic variants).
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 85 Dermoscopy - after training (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Pagnanelli 2003 5 3 1 11 0.83 [ 0.36, 1.00 ] 0.79 [ 0.49, 0.95 ]
Piccolo 2014 24 74 9 58 0.73 [ 0.54, 0.87 ] 0.44 [ 0.35, 0.53 ]
Stanganelli 1999 8 3 3 16 0.73 [ 0.39, 0.94 ] 0.84 [ 0.60, 0.97 ]
Tan 2009 14 4 1 11 0.93 [ 0.68, 1.00 ] 0.73 [ 0.45, 0.92 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 86. Dermoscopy - before training (invasive melanoma).
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 86 Dermoscopy - before training (invasive melanoma)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Troyanova 2003 19 4 6 21 0.76 [ 0.55, 0.91 ] 0.84 [ 0.64, 0.95 ]
Westerhoff 2000 29 22 21 28 0.58 [ 0.43, 0.72 ] 0.56 [ 0.41, 0.70 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 87. Dermoscopy - after training (invasive melanoma).
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 87 Dermoscopy - after training (invasive melanoma)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Troyanova 2003 23 4 2 21 0.92 [ 0.74, 0.99 ] 0.84 [ 0.64, 0.95 ]
Westerhoff 2000 38 21 12 29 0.76 [ 0.62, 0.87 ] 0.58 [ 0.43, 0.72 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 88. MM1- Dermoscopy - no algorithm - threshold NR - in-person.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 88 MM1- Dermoscopy - no algorithm - threshold NR - in-person
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Krahn 1998 35 3 4 38 0.90 [ 0.76, 0.97 ] 0.93 [ 0.80, 0.98 ]
Piccolo 2000 8 1 3 31 0.73 [ 0.39, 0.94 ] 0.97 [ 0.84, 1.00 ]
Viglizzo 2004 11 1 1 54 0.92 [ 0.62, 1.00 ] 0.98 [ 0.90, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 89. MM1- Dermoscopy - pattern analysis - threshold NR - in-person.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 89 MM1- Dermoscopy - pattern analysis - threshold NR - in-person
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Coras 2003 13 1 3 28 0.81 [ 0.54, 0.96 ] 0.97 [ 0.82, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 90. MM1- Dermoscopy - ABCD at > 4.2 - in-person.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 90 MM1- Dermoscopy - ABCD at > 4.2 - in-person
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Feldmann 1998 22 169 3 301 0.88 [ 0.69, 0.97 ] 0.64 [ 0.60, 0.68 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 91. MM1- Dermoscopy - ABCD at > 5.45 - in-person.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 91 MM1- Dermoscopy - ABCD at > 5.45 - in-person
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Feldmann 1998 16 14 9 461 0.64 [ 0.43, 0.82 ] 0.97 [ 0.95, 0.98 ]
Menzies 2013 176 35 41 80 0.81 [ 0.75, 0.86 ] 0.70 [ 0.60, 0.78 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 92. MM1- Dermoscopy - Kenet (modified) at melanoma possible - in-person.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 92 MM1- Dermoscopy - Kenet (modified) at melanoma possible - in-person
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ascierto 2010 12 23 0 19 1.00 [ 0.74, 1.00 ] 0.45 [ 0.30, 0.61 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 93. MM1- Dermoscopy - Kenet (modified) at melanoma likely - in-person.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 93 MM1- Dermoscopy - Kenet (modified) at melanoma likely - in-person
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ascierto 2010 12 2 0 40 1.00 [ 0.74, 1.00 ] 0.95 [ 0.84, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 94. MM1- Dermoscopy - no algorithm - threshold NR - image-based.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 94 MM1- Dermoscopy - no algorithm - threshold NR - image-based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Friedman 2008 10 10 11 68 0.48 [ 0.26, 0.70 ] 0.87 [ 0.78, 0.94 ]
Hauschild 2014 26 48 10 46 0.72 [ 0.55, 0.86 ] 0.49 [ 0.38, 0.59 ]
Lorentzen 1999a 40 11 9 172 0.82 [ 0.68, 0.91 ] 0.94 [ 0.89, 0.97 ]
Rao 1997 20 10 1 41 0.95 [ 0.76, 1.00 ] 0.80 [ 0.67, 0.90 ]
Troyanova 2003 23 4 2 21 0.92 [ 0.74, 0.99 ] 0.84 [ 0.64, 0.95 ]
Westerhoff 2000 27 22 23 28 0.54 [ 0.39, 0.68 ] 0.56 [ 0.41, 0.70 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 95. MM1- Dermoscopy - no algorithm - decision to excise - image-based (paired data only).
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 95 MM1- Dermoscopy - no algorithm - decision to excise - image-based (paired data only)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Friedman 2008 17 43 4 35 0.81 [ 0.58, 0.95 ] 0.45 [ 0.34, 0.57 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 96. MM1- Dermoscopy - pattern analysis - threshold NR - image-based.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 96 MM1- Dermoscopy - pattern analysis - threshold NR - image-based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Lorentzen 2008 24 3 0 92 1.00 [ 0.86, 1.00 ] 0.97 [ 0.91, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 97. MM1- Dermoscopy - ABCD at > 4.75 - image-based.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 97 MM1- Dermoscopy - ABCD at > 4.75 - image-based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Lorentzen 2000 47 23 17 171 0.73 [ 0.61, 0.84 ] 0.88 [ 0.83, 0.92 ]
Rao 1997 18 13 3 38 0.86 [ 0.64, 0.97 ] 0.75 [ 0.60, 0.86 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 98. MM1- Dermoscopy - ABCD at > 5.45 - image-based.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 98 MM1- Dermoscopy - ABCD at > 5.45 - image-based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Lorentzen 2000 29 12 35 182 0.45 [ 0.33, 0.58 ] 0.94 [ 0.89, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 99. MM1- Dermoscopy - 7-point at NR - image-based.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 99 MM1- Dermoscopy - 7-point at NR - image-based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Menzies 2013 195 24 22 91 0.90 [ 0.85, 0.94 ] 0.79 [ 0.71, 0.86 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 100. MM1- Dermoscopy - Menzies at 2 negative and ≥ 1 positive - image-based.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 100 MM1- Dermoscopy - Menzies at 2 negative and≥ 1 positive - image-based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Arevalo 2008 315 846 26 2180 0.92 [ 0.89, 0.95 ] 0.72 [ 0.70, 0.74 ]
Menzies 1996 98 81 9 197 0.92 [ 0.85, 0.96 ] 0.71 [ 0.65, 0.76 ]
Menzies 2013 209 40 8 75 0.96 [ 0.93, 0.98 ] 0.65 [ 0.56, 0.74 ]
Westerhoff 2000 38 21 12 29 0.76 [ 0.62, 0.87 ] 0.58 [ 0.43, 0.72 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 101. MM1- Dermoscopy - 3-point at > NR - image-based.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 101 MM1- Dermoscopy - 3-point at > NR - image-based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Menzies 2013 179 69 38 46 0.82 [ 0.77, 0.87 ] 0.40 [ 0.31, 0.50 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 102. MM1- Dermoscopy - Kenet at melanoma likely - image-based.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 102 MM1- Dermoscopy - Kenet at melanoma likely - image-based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Lorentzen 2000 48 12 16 182 0.75 [ 0.63, 0.85 ] 0.94 [ 0.89, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 103. MM1- Dermoscopy - Kenet at melanoma possible - image-based.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 103 MM1- Dermoscopy - Kenet at melanoma possible - image-based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Lorentzen 2000 57 25 7 169 0.89 [ 0.79, 0.95 ] 0.87 [ 0.82, 0.91 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 104. MM1- Dermoscopy CASH at ≥ 8 - image-based.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 104 MM1- Dermoscopy CASH at≥ 8 - image-based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Menzies 2013 177 32 40 83 0.82 [ 0.76, 0.86 ] 0.72 [ 0.63, 0.80 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 105. MM1- Dermoscopy - Kreusch algorithm - image-based.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 105 MM1- Dermoscopy - Kreusch algorithm - image-based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Kreusch 1992 94 28 2 141 0.98 [ 0.93, 1.00 ] 0.83 [ 0.77, 0.89 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 106. MM1- Dermoscopy - Menzies for amelanotic at 1 - image-based.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 106 MM1- Dermoscopy - Menzies for amelanotic at 1 - image-based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Menzies 2013 198 34 19 81 0.91 [ 0.87, 0.95 ] 0.70 [ 0.61, 0.79 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 107. MM1- Dermoscopy - Menzies for amelanotic at 0 - image-based.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 107 MM1- Dermoscopy - Menzies for amelanotic at 0 - image-based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Menzies 2013 217 55 0 60 1.00 [ 0.98, 1.00 ] 0.52 [ 0.43, 0.62 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 108. MM3- Dermoscopy - no algorithm at NR - in-person.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 108 MM3- Dermoscopy no algorithm at NR - in-person
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Soyer 2004 69 9 8 145 0.90 [ 0.81, 0.95 ] 0.94 [ 0.89, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 109. MM3- Dermoscopy - pattern analysis - threshold NR - in-person.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 109 MM3- Dermoscopy - pattern analysis - threshold NR - in-person
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Stanganelli 2000 88 9 10 3265 0.90 [ 0.82, 0.95 ] 1.00 [ 0.99, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 110. MM3- Dermoscopy - ABCD at > 5.45 - in-person.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 110 MM3- Dermoscopy ABCD at > 5.45 - in-person
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Durdu 2011 45 3 1 151 0.98 [ 0.88, 1.00 ] 0.98 [ 0.94, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 111. MM3- Dermoscopy - 3-point at ≥ 2 - in-person.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 111 MM3- Dermoscopy 3-point at≥ 2 - in-person
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Argenziano 2006 33 28 6 10 0.85 [ 0.69, 0.94 ] 0.26 [ 0.13, 0.43 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 112. MM3- Dermoscopy - no algorithm at NR - image-based.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 112 MM3- Dermoscopy no algorithm at NR - image-based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Carli 2002b 14 9 4 26 0.78 [ 0.52, 0.94 ] 0.74 [ 0.57, 0.88 ]
Stanganelli 1998a 11 4 3 12 0.79 [ 0.49, 0.95 ] 0.75 [ 0.48, 0.93 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 113. MM3- Dermoscopy - pattern analysis - threshold NR - image-based.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 113 MM3- Dermoscopy - pattern analysis - threshold NR - image-based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Lorentzen 2008 37 3 0 79 1.00 [ 0.91, 1.00 ] 0.96 [ 0.90, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 114. MM3- Dermoscopy - 3-point at ≥ 2 - image-based.
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 114 MM3- Dermoscopy 3-point at≥ 2 - image-based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Zalaudek 2006 40 30 4 76 0.91 [ 0.78, 0.97 ] 0.72 [ 0.62, 0.80 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 115. MM2 - VI - in-person (with image-based dermoscopy).
Review: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults
Test: 115 MM2 - VI - in-person (with image-based dermoscopy)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Dummer 1993 15 49 8 699 0.65 [ 0.43, 0.84 ] 0.93 [ 0.91, 0.95 ]
Unlu 2014 18 39 6 52 0.75 [ 0.53, 0.90 ] 0.57 [ 0.46, 0.67 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
A D D I T I O N A L T A B L E S
Table 1. Investigation of effect of pathway positions for detection of invasive melanoma or atypical intraepidermal melanocytic
variants
Test
Position on
pathway a,
b
Studies Lesions
(cases)
DOR
(95% CI)
Specificity
at
80% sensi-
tivity
(95% CI) %
Sensitivity
at
80% speci-
ficity
(95% CI) %
RDOR
(95% CI)
P value
(LR)
a. Pathway (in-person evaluations)
Limited prior testing (all lesions included) (position 2 on clinical pathway)
Clear 2 566
(37)
15.2
(1.8 to 128)
78%
(20 to 98)
79%
(38 to 96)
0.41
(0.03 to 5.9)
0.001
Referred (all lesions included) (position 4 on clinical pathway)
Clear 2 3830
(82)
494
(58 to 4218)
100%
(94 to 100)
98%
(91 to 100)
13.4
(1.06 to 169)
Unclear 2 8764
(82)
111
(16.4 to 765)
98%
(80 to 100)
95%
(76 to 99)
3.0
(0.25 to 36.
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Table 1. Investigation of effect of pathway positions for detection of invasive melanoma or atypical intraepidermal melanocytic
variants (Continued)
0)
Referred (selected on reference standard) (position 5 on clinical pathway)
Clear 5 3247
(767)
36.9
(9.1 to 150)
91%
(64 to 98)
88%
(73 to 96)
1.0
(compara-
tor)
Unclear 12 3847
(539)
77.0
(34.0 to 174)
96%
(90 to 99)
93%
(86 to 97)
2.1
(0.41 to 10.
7)
Referred (equivocal lesions only) (position 5* on clinical pathway)
Clear 2 227
(70)
74.2
(6.4 to 859)
96%
(53 to 100)
93%
(66 to 99)
2.0
(0.14 to 29.
3)
Lesions undergoing follow-up (position 7 on clinical pathway)
Unclear 1 2688
(87)
8.3
(0.63 to 111)
63%
(6 to 98)
69%
(21 to 95)
0.23
(0.01 to 4.7)
b. Pathway (image-based evaluations)
Limited prior testing (selected on reference standard) (position 3 on clinical pathway)
Clear 1 45
(9)
0.39
(0.02 to 8.2)
5%
(0 to 68)
14%
(1 to 69)
0.02
(0.001 to 0.
43)
0.007
Unclear 1 463 (29) 7.5
(0.61 to 92.8)
61%
(8 to 97)
67%
(19 to 95)
0.33
(0.02 to 5.0)
Referred (all lesions included) (position 4 on clinical pathway)
Clear 1 134 (31) 11.6
(0.94 to 142)
73%
(13% to
98%)
75%
(25 to 96)
0.51
(0.03 to 7.7)
Unclear 4 1619
(248)
15.1
(4.2 to 54.0)
78%
(45% to
94%)
79%
(55 to 92)
0.66
(0.13 to 3.5)
Referred (selected on reference standard) (position 5 on clinical pathway)
Clear 6 1336
(304)
22.7
(8.0 to 64.6)
85%
(63% to
84%
(68 to 93)
1.0
(compara-
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Table 1. Investigation of effect of pathway positions for detection of invasive melanoma or atypical intraepidermal melanocytic
variants (Continued)
95%) tor)
Unclear 35 7436
(1680)
16.0
(10.2 to 25.0)
79%
(70 to 87)
80%
(73 to 85)
0.70
(0.23 to 2.1)
Referred (equivocal lesions only) (position 5* on clinical pathway)
Clear 3 1210
(139)
84.0
(16.2 to 436)
96%
(79 to 99)
94%
(80 to 99)
3.7
(0.52 to 26.
1)
Unclear 6 956
(326)
49.4
(16.4 to 149)
93%
(79 to 98)
91%
(80 to 96)
2.2
(0.47 to 10.
0)
Lesions undergoing follow-up (position 7 on clinical pathway)
Unclear 3 276
(85)
2.3
(0.50 to 10.4)
29%
(6 to 72)
42%
(16 to 73)
0.10
(0.02 to 0.
63)
CI: confidence interval; DOR: diagnostic odds ratio; LR: likelihood ratio test; RDOR: relative diagnostic odds ratio
apositions on the clinical pathway described in Figure 3
bclear or unclear position on the clinical pathway
Table 2. Comparison of visual inspection and dermoscopy for detection of invasive melanoma or atypical intraepidermal
melanocytic variants
Test Studies Lesions (cases) DOR
(95% CI)
Specificity at
80% sensitiv-
ity
(95% CI) %
Sensitivity at
80%
specificity
(95% CI) %
RDOR
(95% CI)
P value
(LR)
In-person evaluations
Visual inspec-
tion
13 6740 (459) 13.1
(7.0 to 24.5)
75%
(57 to 87)
76%
(66 to 85)
4.7
(3.0 to 7.5)
< 0.001
Visual inspec-
tion
+ dermoscopy
26 23,169 (1664) 61.7
(34.9 to 109)
95%
(90 to 98)
92%
(87 to 95)
Change with
adding
dermoscopy
to visual in-
- - - +20%
(+7 to +33)
+16%
(+8 to +23)
- -
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Table 2. Comparison of visual inspection and dermoscopy for detection of invasive melanoma or atypical intraepidermal
melanocytic variants (Continued)
spection (95%
CI)
In-person evaluations (direct studies)
Visual inspec-
tion
11 5854 (412) 13.7
(5.9 to 31.8)
75%
(49 to 90)
77%
(63 to 87)
4.8
(2.8 to 8.1)
< 0.001
Visual inspec-
tion
+ dermoscopy
11 5854 (412) 65.7
(27.0 to 160)
96%
(87 to 99)
92%
(84 to 96)
Change with
adding
dermoscopy
to visual in-
spection (95%
CI)
- - - +21%
(+2 to +39)
+15%
(+7 to +23)
- -
Image-based evaluations
Clinical
(macro)
images
11 1740 (305) 3.2
(1.9 to 5.4)
42%
(28 to 58)
47%
(34 to 59)
5.6
(3.7 to 8.5)
< 0.001
Dermoscopic
images
60 13,475 (2851) 17.8
(12.3 to 25.7)
82%
(75 to 87)
81%
(76 to 86)
Change
replacing
visual inspec-
tion with der-
moscopy
(95% CI)
- - - +40%
(+27 to +57)
+34%
(+24 to +46)
- -
Image-based evaluations (direct studies)
Clinical
(macro)
images
11 1740 (305) 3.6
(1.7 to 7.6)
48%
(25 to 73)
47%
(30 to 64)
5.3
(3.5 to 8.0)
< 0.001
Dermoscopic
images
11 1735 (306) 19.2
(8.7 to 42.0)
83%
(70 to 91)
83%
(68 to 92)
Change
replacing
visual inspec-
tion with der-
moscopy
- - - +34%
(+15 to +53)
+36%
(+20 to +52)
- -
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Table 2. Comparison of visual inspection and dermoscopy for detection of invasive melanoma or atypical intraepidermal
melanocytic variants (Continued)
(95% CI)
CI: confidence interval; DOR: diagnostic odds ratio; LR: likelihood ratio test; RDOR: relative diagnostic odds ratio
Table 3. Investigations of sources of heterogeneity in person studies positions for detection of invasive melanoma or atypical
intraepidermal melanocytic variants
Test Studies Lesions (cases) RDOR
(95% CI)
Specificity at
80% sensitiv-
ity
(95% CI) %
Sensitivity at
80%
specificity
(95% CI) %
RDOR
(95% CI)
P value
(LR)
Difference between in-person and image-based studies
In-person 26 23,169 (1664) 73.2
(41.2 to 130)
95%
(92 to 98)
94%
(90 to 97)
4.6
(2.4 to 9.0)
< 0.001
Image 60 13,475 (2851) 15.8
(10.7 to 23.3)
79%
(72 to 86)
80%
(73 to 85)
Difference
(95% CI)
- - - +16%
(+9 to +23)
+14%
(+8 to +21)
- -
Differences in reference standard (in-person studies)
Histology 18 5105 (767) 51.4
(24.6 to 107)
94%
(86 to 98)
91%
(84 to 95)
0.27
(0.06 to 1.22)
0.23
Histol-
ogy+FU
7 17,733 (865) 188
(50.8 to 697)
99%
(93 to 100)
97%
(90 to 99)
Difference
(95% CI)
- - - +5%
(-1 to +10)
+6%
(-0 to +12)
- -
Use of an algorithm (in-person studies)
No algorithm 16 9302 (1159) 72.6
(30.1 to 175)
96%
(88 to 99)
93%
(86 to 97)
1.4
(0.34 to 5.6)
0.17
Any algorithm 10 13,867 (505) 52.3
(18.1 to 151)
94%
(82 to 98)
91%
(80 to 96)
Difference
(95% CI)
- - - -2%
(-10 to +7)
-2%
(-11 to +7)
- -
Lesion type (in-person studies)
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Table 3. Investigations of sources of heterogeneity in person studies positions for detection of invasive melanoma or atypical
intraepidermal melanocytic variants (Continued)
Melanocytic 8 2460 (416) 38.2
(11.7 to 124)
91%
(72 to 98)
89%
(74 to 96)
0.48
(0.12 to 2.0)
0.60
Pigmented 18 20,709 (1248) 79.1
(35.7 to 175)
96%
(90 to 99)
94%
(88 to 97)
Difference
(95% CI)
- - - +5%
(-7 to +16)
+5%
(-6 to +15)
- -
Single or multiple individuals making diagnosis (in-person studies)
Single 13 8436 (1044) 60.3
(21.7 to 168)
95%
(83 to 99)
92%
(83 to 96)
1.0
(0.18 to 5.8)
0.30
Consensus 7 12,377 (294) 59.2
(14.9 to 236)
95%
(78 to 99)
92%
(76 to 98)
Difference
(95% CI)
- - - 0%
(-10 to +10)
0%
(-11 to +11)
- -
Prevalence (in-person studies)
0%-5% 6 15,392 (206) 99.1
(24.6 to 400)
97%
(87 to 99)
94%
(82 to 98)
5.4
(0.80 to 36.6)
0.008
> 5%-10% 6 1718
(117)
18.3
(4.7 to 71.9)
81%
(43 to 96)
81%
(58 to 93)
1.0
(comparator)
> 10%-20% 6 2089
(312)
49.4
(14.0 to 175)
94%
(75 to 99)
90%
(77 to 96)
2.7
(0.42 to 17.3)
> 20% 8 3970
(1029)
92.1
(27.5 to 309)
96%
(86 to 99)
93%
(86 to 97)
5.0
(0.78 to 32.4)
CI: confidence interval; DOR: diagnostic odds ratio; FU: follow-up; LR: likelihood ratio test; RDOR: relative diagnostic odds ratio
Table 4. Analysis by observer experience for detection of invasive melanoma or atypical intraepidermal melanocytic variants
Test Studies Lesions
(cases)
DOR
(95% CI)
Specificity at
80% sensitivity
(95% CI) %
Sensitivity at
80% specificity
(95% CI) %
RDOR
(95% CI)
P-value
(LR)
Experience: in-person
NR 10 8390
(1015)
97.7
(35.6 to 268)
97%
(90 to 99)
94%
(87 to 98)
1.9
(0.49 to 7.1)
0.64
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Table 4. Analysis by observer experience for detection of invasive melanoma or atypical intraepidermal melanocytic variants
(Continued)
High 14 14,213
(612)
52.4
(21.6 to 127)
94%
(84 to 98)
91%
(83 to 96)
1.00
(comparator)
Trained 2 566
(37)
19.2
(1.6 to 226)
82%
(19 to 99)
82%
(36 to 97)
0.37
(0.03 to 5.1)
Experience: image-based
NR 11 2777
(465)
35.4
(15.9 to 78.7)
90%
(80 to 96)
89%
(80 to 95)
2.0
(0.8 to 4.9)
< 0.001
High 34 8933
(1956)
17.2
(11.8 to 26.5)
82%
(74 to 87)
81%
(75 to 86)
1.00
(comparator)
Moderate 5 678
(193)
11.3
(5.9 to 21.3)
73%
(58 to 85)
74%
(61 to 84)
0.64
(0.37 to 1.1)
Low 6 448
(123)
5.3
(2.6 to 10.8)
55%
(35 to 73)
58%
(41 to 74)
0.30
(0.15 to 0.58)
Mixed 5 473
(117)
4.4
(1.4 to 13.5)
50%
(23 to 77)
54%
(29 to 78)
0.25
(0.07 to 0.81)
Trained 11 1087
(240)
9.0
(4.5 to 17.9)
68%
(51 to 81)
70%
(55 to 82)
0.15
(0.25 to 1.02)
CI: confidence interval; DOR: diagnostic odds ratio; LR: likelihood ratio test; NR: not reported; RDOR: relative diagnostic odds
ratio
Table 5. Investigations of sources of heterogeneity in image-based studies for detection of invasive melanoma or atypical
intraepidermal melanocytic variants
Test Studies Lesions (cases) DOR
(95% CI)
Specificity at
80% sensitiv-
ity
(95% CI) %
Sensitivity at
80%
specificity
(95% CI) %
RDOR
(95% CI)
P-value
(LR)
Differences in reference standard (image-based studies)
Histology 48 10,267 (2210) 20.8
(13.6 to 31.9)
84%
(77 to 89)
84%
(77 to 89)
2.8
(0.92 to 8.9)
0.19
Histol-
ogy+FU
8 2762 (549) 7.3
(2.6 to 20.9)
64%
(36 to 84)
65%
(41 to 84)
Difference
(95% CI)
- - - -20%
(-47 to +6)
-18%
(-42 to +5)
- -
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Table 5. Investigations of sources of heterogeneity in image-based studies for detection of invasive melanoma or atypical
intraepidermal melanocytic variants (Continued)
Use of an algorithm (image-based studies)
No algorithm 42 8762 (1834) 18.9
(11.8 to 30.3)
83%
(74 to 88)
82%
(75 to 88)
1.4
(0.60 to 3.3)
0.22
Any algorithm 18 4713 (1017) 13.4
(6.7 to 27.0)
77%
(62 to 87)
77%
(63 to 87)
Difference
(95% CI)
- - - -6%
(-20 to +9)
-5%
(-19 to +9)
- -
Lesion type (image-based studies)
Melanocytic 30 6980 (1710) 18.1
(9.8 to 33.4)
82%
(70 to 90)
82%
(71 to 89)
1.10
(0.49 to 2.50)
0.16
Pigmented 26 4062 (733) 16.4
(9.6 to 27.9)
80%
(70 to 88)
80%
(71 to 87)
Difference
(95% CI)
- - - -2%
(-15 to 12)
-1%
(-13 to +10)
- -
Single or multiple individuals making diagnosis (image-based studies)
Single 26 5877 (1030) 27.2
(14.5 to 51.2)
88%
(78 to 93)
87%
(78 to 92)
1.9
(0.80 to 4.4)
0.30
Consensus 28 5232 (1350) 14.4
(8.1 to 25.7)
78%
(66 to 87)
78%
(68 to 86)
Difference
(95% CI)
- - - -10%
(-23 to +4)
-8%
(-20 to +3)
- -
Prevalence (image-based studies)
0%-20% 14 4855 (519) 422
(65.2 to 2726)
99%
(94 to 100)
98%
(93 to 100)
30.7
(1.51 to 6.24)
0.12
> 20%-30% 17 3893
(901)
13.7
(1.2 to 162)
78%
(25 to 97)
77%
(20 to 98)
1.0
(comparator)
> 30%-40% 9 974
(330)
19.5
(8.8 to 42.8)
83%
(69 to 91)
83%
(68 to 92)
1.4
(0.11 to 18.8)
> 40% 14 1387
(630)
15.5
(0.2 to 23.3)
79%
(72 to 85)
79%
(71 to 86)
1.1
(0.09 to 13.9)
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Table 5. Investigations of sources of heterogeneity in image-based studies for detection of invasive melanoma or atypical
intraepidermal melanocytic variants (Continued)
CI: confidence interval; DOR: diagnostic odds ratio; FU: follow-up; LR: likelihood ratio test; RDOR: relative diagnostic odds ratio
Table 6. Algorithm and threshold analysis for each definition of the target condition
Target con-
dition
Testa
Datasets (n) Lesions
(cases)
Pooled sen-
sitivity
(95% CI)
Pooled
specificity
(95% CI)
Datasets (n) Lesions
(cases)
Pooled sen-
sitivity
(95% CI)
Pooled
specificity
(95% CI)
a. Invasive
melanoma
and atyp-
ical in-
traepi-
dermal
melanocytic
variants
In-person Image-based
No algo-
rithm: any
threshold
8 4707 (849) 0.88
(0.75 to 0.
95)
0.87
(0.80 to 0.
92)
24 4498 (941) 0.76
(0.70 to 0.
82)
0.79
(0.71 to 0.
85)
No algo-
rithm: cor-
rect diagno-
sis
- - - - 18 4118 (795) 0.77
(0.69 to 0.
83)
0.84
(0.76 to 0.
89)
No algo-
rithm: excise
decision
- - - - 10 831 (263) 0.79
(0.69 to 0.
86)
0.55
(0.50 to 0.
61)
Pattern: any
threshold or
NR
6 4307 (296) 0.92
(0.87 to 0.
95)
0.92
(0.68 to 0.
98)
20 4621 (989) 0.83
(0.76 to 0.
88)
0.87
(0.80 to 0.
92)
Pattern: at≥
1 character-
istics present
1 220 (33) 0.88
(0.72 to 0.
97)
0.79
(0.73 to 0.
85)
- - - -
Pattern: at≥
3 character-
istics present
1 68 (5) 1.00
(0.48 to 1.
00)
0.56
(0.42 to 0.
68)
- - - -
Pattern: cor-
rect diagno-
sis
- - - - 19 4095 (896) 0.81
(0.73 to 0.
87)
0.87
(0.80 to 0.
92)
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Table 6. Algorithm and threshold analysis for each definition of the target condition (Continued)
Pattern: ex-
cise decision
- - - - 3 933 (227) 0.97
(0.68 to 1.
00)
0.72
(0.60 to 0.
81)
ABCD at
NR (likely >
5.45)
1 235 (5) 1.00
(0.48 to 1.
00)
0.90
(0.85 to 0.
93)
- - - -
ABCD at >
5.45
4 1203 (155) 0.78
(0.58 to 0.
90)
0.93
(0.79 to 0.
98)
7 2471 (406) 0.81
(0.60 to 0.
92)
0.81
(0.69 to 0.
89)
ABCD at or
likely > 5.45
(2 previous
groups com-
bined)
5 1438 (160) 0.81
(0.62 to 0.
92)
0.92
(0.82 to 0.
97)
- - - -
ABCD at >
4.75
1 309 (73) 0.83
(0.69 to 0.
92)
0.45
(0.39 to 0.
51)
10 4242 (816) 0.81
(0.67 to 0.
90)
0.72
(0.93 to 0.
80)
Revised
ABCD at ≥
4
- - - - 1 269 (84) 0.87
(0.78 to 0.
93)
0.89
(0.83 to 0.
93)
ABCD at
60% speci-
ficity
1 356 (73) 0.90
(0.81 to 0.
96)
0.60
(0.54 to 0.
66)
- - - -
ABCD at
70% speci-
ficity
1 356 (73) 0.85
(0.75 to 0.
92)
0.70
(0.64 to 0.
75)
- - - -
ABCD at
75% speci-
ficity
1 356 (73) 0.85
(0.75 to 0.
92)
0.75
(0.69 to 0.
80)
- - - -
ABCD at
80% speci-
ficity
1 356 (73) 0.77
(0.65 to 0.
86)
0.80
(0.75 to 0.
84)
- - - -
ABCD at
85% speci-
ficity
1 356 (73) 0.71
(0.59 to 0.
81)
0.85
(0.80 to 0.
89)
- - - -
ABCD at
90% speci-
1 356 (73) 0.64
(0.52 to 0.
0.90
(0.86 to 0.
- - - -
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Table 6. Algorithm and threshold analysis for each definition of the target condition (Continued)
ficity 75) 93)
ABCDE at >
1.3
1 356 (73) 1.00
(0.95 to 1.
00)
0.15
(0.11 to 0.
20)
- - - -
ABCDE at >
2.65
1 356 (73) 0.97
(0.90 to 1.
00)
0.39
(0.33 to 0.
45)
- - - -
ABCDE at >
3.05
1 356 (73) 0.95
(0.87 to 0.
98)
0.57
(0.51 to 0.
62)
- - - -
ABCDE at >
3.6
1 356 (73) 0.90
(0.81 to 0.
96)
0.70
(0.64 to 0.
75)
- - - -
ABCDE at >
4.25
1 356 (73) 0.82
(0.71 to 0.
90)
0.82
(0.77 to 0.
86)
- - - -
ABCDE at >
4.9
1 356 (73) 0.74
(0.62 to 0.
84)
0.90
(0.86 to 0.
93)
- - - -
ABCDE at
≥ 4
- - - - 1 269 (84) 0.90
(0.82 to 0.
96)
0.87
(0.81 to 0.
92)
7FFM at ≥
2
1 401 (60) 0.80
(0.68 to 0.
89)
0.89
(0.85 to 0.
92)
4 2200 (340) 0.89
(0.76 to 0.
96)
0.84
(0.78 to 0.
89)
7PCL at≥ 2 1 638 (108) 0.93
(0.86 to 0.
97)
0.98
(0.97 to 0.
99)
- - - -
7PCL at≥ 3 2 11137 (127) 0.67
(0.46 to 0.
83)
0.96
(0.88 to 0.
99)
11 3408 (798) 0.80
(0.63 to 0.
91)
0.67
(0.51 to 0.
80)
7PCL at≥ 5 - - - - 1 322 (70) 0.67
(0.55 to 0.
78)
0.83
(0.78 to 0.
87)
7PCL at NR - - - - 4 1936 (360) 0.72
(0.56 to 0.
84)
0.79
(0.61 to 0.
90)
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Table 6. Algorithm and threshold analysis for each definition of the target condition (Continued)
Revised
7PCL at NR
(likely ≥ 1)
- - - - 1 1678 (238) 0.61
(0.54 to 0.
67)
0.88
(0.86 to 0.
89)
Revised
7PCL at≥ 1
- - - - 1 300 (100) 0.88
(0.80 to 0.
94)
0.51
(0.44 to 0.
58)
Re-
vised 7PCL
for FU: ma-
jor change
- - - - 1 70 (12) 0.67
(0.35 to 0.
90)
0.60
(0.47 to 0.
73)
Menzies at 2
negative and
≥ 1 positive
1 206 (23) 0.83
95)
0.69
(0.62 to 0.
75)
4 1856 (317) 0.78
(0.38 to 0.
96)
0.63
(0.39 to 0.
81)
Menzies at
NR
- - - - 2 60 (26) 0.77
(0.57 to 0.
89)
0.82
(0.66 to 0.
92)
3PCL at≥ 2 - - - - 7 1505 (363) 0.74
(0.61 to 0.
85)
0.60
(0.42 to 0.
76)
4-point
(scored
3PCL) at > 2
- - - - 1 75 (32) 0.84
(0.67 to 0.
95)
0.81
(0.67 to 0.
92)
Hofman
algorithm at
NR
- - - - 1 254 (75) 0.87
(0.77 to 0.
93)
0.88
(0.82 to 0.
92)
CASH at ≥
6
- - - - 1 477 (119) 0.78
(0.70 to 0.
85)
0.51
(0.46 to 0.
56)
CASH at ≥
8
- - - - 2 190 (56) 0.97
(0.79 to 1.
00)
0.69
(0.60 to 0.
76)
Chaos/
Clues at = 2
- - - - 2 940 (148) 0.82
(0.75 to 0.
87)
0.53
(0.36 to 0.
70)
Acral 3-step - - - - 1 107 (25) 0.96
(0.80 to 1.
00)
0.91
(0.83 to 0.
96)
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Table 6. Algorithm and threshold analysis for each definition of the target condition (Continued)
b. Invasive
melanoma
In-person Image-based
No
algorithm:
threshold
NR
3 190 (62) 0.87
(0.76 to 0.
93)
0.96
(0.91 to 0.
98)
6 683 (202) 0.77
(0.59 to 0.
88)
0.79
(0.63 to 0.
90)
Pattern anal-
ysis: thresh-
old NR
1 45 (16) 0.81 (0.54
to 0.96)
0.97
(0.82 to 1.
00)
1 119 (24) 1.00
(0.86 to 1.
00)
0.97
(0.91 to 0.
99)
ABCD at >
4.2
1 495 (23) 0.88
(0.69 to 0.
97)
0.64
(0.60 to 0.
68)
- - - -
ABCD at >
4.75
- - - - 2 330 (85) 0.76
(0.66 to 0.
84)
0.84
(0.73 to 0.
91)
ABCD at >
5.45
2 832 (242) 0.79
(0.74 to 0.
84)
0.90
(0.58 to 0.
98)
1 258 (64) 0.45
(0.33 to 0.
58)
0.94
(0.89 to 0.
97)
7PCL at NR - - - - 1 332 (217) 0.90
(0.85 to 0.
94)
0.79
(0.71 to 0.
86)
Menzies at 2
negative and
≥ 1 positive
- - - - 4 4184 (715) 0.91
(0.83 to 0.
96)
0.71
(0.68 to 0.
74)
3PCL at >
NR
- - - - 1 332 (217) 0.82
(0.77 to 0.
87)
0.40
(0.31 to 0.
50)
Kenet
(modi-
fied) at MM
likely
1 54 (12) 1.00
(0.74 to 1.
00)
0.95
(0.84 to 0.
99)
1 258 (64) 0.75
(0.63 to 0.
85)
0.94
(0.89 to 0.
97)
Kenet
(modi-
fied) at MM
possible
1 54 (12) 1.00
(0.74 to 1.
00)
0.45
(0.30 to 0.
61)
1 258 (64) 0.89
(0.79 to 0.
95)
0.87
(0.82 to 0.
91)
CASH at ≥
8
- - - - 1 332 (217) 0.82
(0.76 to 0.
86)
0.72
(0.63 to 0.
80)
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Table 6. Algorithm and threshold analysis for each definition of the target condition (Continued)
Kreusch al-
gorithm
- - - - 1 265 (96) 0.98
(0.93 to 1.
00)
0.83
(0.77 to 0.
89)
Men-
zies for ame-
lanotic at 1
- - - - 1 332 (217) 0.91 (0.87
to 0.95)
0.70
(0.61 to 0.
79)
Men-
zies for ame-
lanotic at 0
- - - - 1 332 (217) 1.00 (0.98
to 1.00)
0.52 (0.43
to 0.62)
c. Any skin
can-
cer or lesion
with high
risk of pro-
gression to
melanoma
In-person Image-based
No
algorithm at
NR
1 231 (77) 0.90
(0.81 to 0.
95)
0.94
(0.89 to 0.
97)
2 83 (32) 0.78
(0.61 to 0.
89)
0.75
(0.61 to 0.
85)
Pattern anal-
ysis: thresh-
old NR
1 3372 (98) 0.90
(0.82 to 0.
95)
1.00
(0.99 to 1.
00)
1 119 (37) 1.00
(0.91 to 1.
00)
0.96
(0.90 to 0.
99)
ABCD at >
5.45
1 200 (46) 0.98
(0.88 to 1.
00)
0.98
(0.94 to 1.
00)
- - - -
3PCL at≥ 2 1 77 (39) 0.85
(0.69 to 0.
94)
0.26
(0.13 to 0.
43)
1 150 (44) 0.91
(0.78 to 0.
97)
0.72
(0.62 to 0.
80)
3PCL: three-point checklist; 7FFM: seven features for melanoma; 7PCL: seven-point checklist; ABCD(E): asymmetry, border,
colour, differential structures (enlargement);CASH: colour, architecture, symmetry and homogeneity; CI: confidence interval; FU:
follow-up;MM: malignant melanoma; NR: not reported
aAll analyses by algorithm were undertaken using the bivariate normal model (BVN).
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Table 7. Analysis by observer qualifications for detection of invasive melanoma or atypical intraepidermal melanocytic variants
Test Studies Lesions
(cases)
DOR
(95% CI)
Specificity at
80% sensitiv-
ity
(95% CI) %
Sensitivity at
80%
specificity
(95% CI) %
RDOR
(95% CI)
P value
(LR)
Qualifications: in-person
Consultant
expert*
11 2767 (439) 52.4
(21.6 to 127)
94%
(84 to 98)
91%
(83 to 96)
1.00
(comparator)
0.33
Consultant* 10 8390
(1015)
97.7
(35.6 to 268)
97%
(90 to 99)
95%
(87 to 98)
1.86
(0.949 to 7.11)
GP 2 566
(37)
19.2
(1.6 to 226)
82%
(19 to 99)
82%
(36 to 97)
0.37
(0.03 to 5.08)
Resident/
registrara
2 11137
(127)
51.6
(2.9 to 927)
93%
(42 to 100)
93%
(42 to 100)
Not estimable
within model
-
Mixed (sec-
ondary care)a
1 309
(46)
29.6
(13.5 to 64.8)
88%
(77 to 94)
88%
(77 to 94)
Not estimable
within model
-
Qualifications: image based
Consultant
expert*
33 8664
(1854)
19.4
(13.1 to28.8)
83%
(76 to 88)
83%
(77 to 88)
1.0
(comparator)
< 0.001
Consultant* 25 4589
(955)
11.9
(7.6 to 18.6)
74%
(65 to 82)
75%
(66 to 82)
0.61
(0.40 to 0.92)
Resident* 5 927
(138)
6.0
(2.6 to 14.0)
59%
(37 to 78)
61%
(41 to 78)
0.31
(0.14 to 0.71)
Mixed (other) 4 867
(229)
15.1
(4.0 to 57.0)
79%
(48 to 94)
79%
(not estimable)
0.78
(0.20 to 3.1)
GP/Primary
care
3 288
(55)
1.9
(0.7 to 5.0)
30%
(12 to 57)
34%
(51 to 93)
0.10
(0.04 to 0.25)
Mixed (sec-
ondary care)b
4 399
(111)
10.3
(3.0 to 35.3)
72%
(43 to 90)
72%
(43 to 90)
Not estimable
within model
-
Physician as-
sistantb
1 65
(25)
3.6
(1.1 to 11.5)
47%
(22 to 74)
47%
(22 to 74)
Not estimable
within model
-
CI: confidence interval; DOR: diagnostic odds ratio; LR: likelihood ratio test; NR: not reported; RDOR: relative diagnostic odds
ratio
∗Consultants were usually dermatologists but could also be plastic surgeons or oncologists.
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aIn-person model could not be fitted including the small number of studies in these groups. Estimates for these groups are obtained
from computed the DOR for the individual study, or random effects meta-analyses of DORs where there is more than one study.
Estimates at the 80% sensitivity and specificity values are computed assuming symmetric SROC curves.
bImage-based model could not be fitted including the small number of studies in these groups. Estimates for these groups are obtained
from computed the DOR for the individual study, or random effects meta-analyses of DORs where there is more than one study.
Estimates at the 80% sensitivity and specificity values are computed assuming symmetric SROC curves.
Table 8. Sensitivity analyses for in-person visual inspection and dermoscopy added to visual inspection for the detection of
invasive melanoma or atypical intraepidermal melanocytic variants
Test Studies Lesions (cases) DOR (95% CI) Specificity
at 80% sensitivity
(95% CI) %
Sensitivity
at 80% specificity
(95% CI) %
RDOR (95% CI)
All in-person evaluations
Visual
inspection
13 6740 (459) 13.1 (7.0 to 24.5) 75% (57 to 87) 76% (66 to 85) 4.7 (3.0 to 7.5)
Vi-
sual inspection +
dermoscopy
26 23,169 (1664) 61.7 (34.9 to 109) 95% (90 to 98) 92% (87 to 95) -
Change
with adding der-
moscopy to
visual inspection
(95% CI)
- - - +20% (+7 to +33) +16% (+8 to +23) -
In-person evaluations: direct comparison
Visual
inspection
11 5854 (412) 13.7 (5.9 to 31.8) 75% (49 to 90) 77% (63 to 87) 4.8 (2.8 to 8.1)
Vi-
sual inspection +
dermoscopy
11 5854 (412) 65.7 (27.0 to 160) 95% (87 to 99) 92% (84 to 96) -
Change
with adding der-
moscopy to
visual inspection
(95% CI)
- - - +21% (+2 to +39) +15% (+7 to +23) -
In-person evaluations: with histology and follow-up for those not having surgery
Visual
inspection
2 3607 (60) 18.4 (2.63 to 128) 82% (39 to 97) 82% (40 to 97) 14.4 (4.4 to 47.6)
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Table 8. Sensitivity analyses for in-person visual inspection and dermoscopy added to visual inspection for the detection of
invasive melanoma or atypical intraepidermal melanocytic variants (Continued)
Vi-
sual inspection +
dermoscopy
6 17,574 (800) 265 (49 to 1428) 99% (91 to 100) 98% (87 to 100) -
Change
with adding der-
moscopy to
visual inspection
(95% CI)
- - - +16% (-23 to 56) +16% (-20 to 53) -
In-person evaluations with low risk of bias for the index test
Visual
inspection
4 3957 (176) 16.9 (6.1 to 46.8) 80% (52 to 94) 80% (63 to 91) 3.1 (1.3 to 7.4)
Vi-
sual inspection +
dermoscopy
20 19182 (831) 53.0 (25.8 to 109) 94% (87 to 98) 91% (84 to95) -
Change
with adding der-
moscopy to
visual inspection
(95% CI)
- - - +14% (-6 to +34) +11% (-1 to +23) -
In-person evaluations with low risk of bias for the reference test
Visual
inspection
10 2802 (367) 13.8 (7.3 to 26.3) 76% (59 to 87) 77% (67 to 85) 4.2 (2.5 to 7.1)
Vi-
sual inspection +
dermoscopy
20 7636 (1418) 57.8 (32.2 to 104) 95% (89 to 97) 92% (87 to 95) -
Change
with adding der-
moscopy to
visual inspection
(95% CI)
- - - +19% (+5 to +32) +15% (+6 to +23) -
In-person evaluations with low risk of bias for flow and timing
Visual
inspection
2 601 (66) 11.0 (2.7 to 44.4) 61% (26 to 87) 73% (55 to 85) 5.1 (1.2 to 20.9)
Vi-
sual inspection +
dermoscopy
4 984 (113) 55.7 (24.4 to 127) 95% (85 to 98) 88% (79 to 94) -
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Table 8. Sensitivity analyses for in-person visual inspection and dermoscopy added to visual inspection for the detection of
invasive melanoma or atypical intraepidermal melanocytic variants (Continued)
Change
with adding der-
moscopy to
visual inspection
(95% CI)
- - - +34% (-45 to
+100)
+16% (-28 to +60) -
In-person evaluations excluding case-control studies
Visual
inspection
13 6740 (459) 13.1 (7.0 to 24.5) 75% (57 to 87) 76% (66 to 85) 4.7 (3.0 to 7.5)
Vi-
sual inspection +
dermoscopy
26 23,169 (1664) 61.7 (34.9 to 109) 95% (90 to 98) 92% (87 to 95) -
Change
with adding der-
moscopy to
visual inspection
(95% CI)
- - - +20% (+7 to +33) +16% (+8 to +23) -
CI: confidence interval; DOR: diagnostic odds ratio; RDOR: relative diagnostic odds ratio
Table 9. Sensitivity analyses for image-based visual inspection or dermoscopy for the detection of invasive melanoma or
atypical intraepidermal melanocytic variants
Test Studies Lesions (cases) DOR
(95% CI)
Specificity at 80%
sensitivity
(95% CI) %
Sensitivity at
80% specificity
(95% CI) %
RDOR
(95% CI)
All image-based evaluations
Clinical (macro)
images
11 1740 (305) 3.2
(1.9 to 5.4)
42%
(28 to 58)
47%
(34 to 59)
5.6
(3.7 to 8.5)
Dermoscopic
images
60 13 to 475 (2851) 17.8
(12.3 to 25.7)
82%
(75 to 87)
81%
(76 to 86)
Change replac-
ing visual inspec-
tion with der-
moscopy (95%
CI)
- - - +40%
(+27 to 57)
+34%
(+24 to +46)
-
Image-based evaluations: direct studies
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Table 9. Sensitivity analyses for image-based visual inspection or dermoscopy for the detection of invasive melanoma or
atypical intraepidermal melanocytic variants (Continued)
Clinical (macro)
images
11 1740 (305) 3.6
(1.7 to 7.6)
48%
(25 to 73)
47%
(30 to 64)
5.3
(3.5 to 8.0)
Dermoscopic
images
11 1735 (306) 19.2
(8.7 to 42.0)
83%
(70 to 91)
83%
(68 to 92)
Change replac-
ing visual inspec-
tion with der-
moscopy (95%
CI)
- - - +34%
(+15 to +53)
+36%
(+20 to +52)
-
Image-based evaluations: with histology and follow-up for those not having surgery
Clinical (macro)
images
0 - - - - -
Dermoscopic
images
7 2612
(523)
7.4
(4.5 to 12.0)
67%
(58 to 75)
57%
(39 to 74)
Change replac-
ing visual inspec-
tion with der-
moscopy (95%
CI)
- - - - - -
Image-based evaluations with low risk of bias for the index test
Clinical (macro)
images
3 1113
(117)
1.9
(0.91 to 4.0)
+32%
(17 to 52)
32%
(17 to 52)
10.4
(5.7 to 19.0)
Dermoscopic
images
40 11,194
(2318)
19.8
(12.4 to 31.7)
83%
(76 to 89)
83%
(76 to 89)
Change replac-
ing visual inspec-
tion with der-
moscopy (95%
CI)
- - - +51%
(+35 to +68)
+51%
(+34 to +67)
-
Image-based evaluations with low risk of bias for the reference test
Clinical (macro)
images
9 1650
(276)
3.2
(1.9 to 5.4)
42%
(28 to 58)
47%
(34 to 59)
5.6
(3.7 to 8.5)
Dermoscopic
images
51 10,894
(2359)
17.8
(12.3 to 25.8)
82%
(75 to 87)
81%
(76 to 86)
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Table 9. Sensitivity analyses for image-based visual inspection or dermoscopy for the detection of invasive melanoma or
atypical intraepidermal melanocytic variants (Continued)
Change replac-
ing visual inspec-
tion with der-
moscopy (95%
CI)
- - - +40%
(+26 to +53)
+34%
(+24 to +46)
-
Image-based evaluations with low risk of bias for flow and timing
Clinical (macro)
images
1 53
(10)
15.9
(1.6 to 161)
79%
(21 to 98)
80%
(34 to 97)
0.54
(0.05 to 5.5)
Dermoscopic
images
11 1391
(410)
8.6
(4.4 to 16.7)
65%
(42 to 83)
69%
(56 to 80)
Change replac-
ing visual inspec-
tion with der-
moscopy (95%
CI)
- - - -14%
(-67 to +39)
-10%
(-48 to +28)
-
Image-based evaluations excluding case-control studies
Clinical (macro)
images
7 964
(183)
7.2
(3.5 to 14.8)
62%
(40 to 80)
66%
(50 to 78)
3.4
(1.8 to 6.4)
Dermoscopic
images
37 10,270
(1923)
24.3
(15.2 to 39.0)
86%
(79 to 91)
85%
(79 to 90)
Change replac-
ing visual inspec-
tion with der-
moscopy (95%
CI)
- - - +24%
(+4 to +44)
+20%
(+7 to +32)
-
CI: confidence interval; DOR: diagnostic odds ratio; RDOR: relative diagnostic odds ratio
Table 10. Comparison of visual inspection and dermoscopy for the detection of invasive melanoma
Test Studies Lesions (cases) DOR
(95% CI)
Specificity at
80% sensitiv-
ity
(95% CI) %
Sensitivity at
80%
specificity
(95% CI) %
RDOR
(95% CI)
P value
(LR)
In-person evaluations
Visual inspec-
tion
2 147
(51)
20.8
(6.0 to 72.5)
84%
(66 to 93)
84%
(57 to 95)
6.2
(1.5 to 26.6)
0.015
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Table 10. Comparison of visual inspection and dermoscopy for the detection of invasive melanoma (Continued)
Visual in-
spection+der-
moscopy
6 789
(115)
129
(19.2 to 870)
97%
(94 to 98)
97%
(46 to 100)
Difference
(95% CI)
- - - +13%
(-1 to +27)
+13%
(-0 to +27)
- -
In-person evaluations: direct studies
Visual inspec-
tion
2 147
(51)
20.1
(4.0 to 101)
75%
(23to 97)
78%
(64 to 88)
11.3
(1.4 to 689.8)
0.015
Visual inspec-
tion
+ dermoscopy
2 147
(51)
226
(21.7 to 2358)
99%
(54 to 100)
94%
(72 to 99)
Difference
(95% CI)
- - - +24%
(-21 to +69)
+15%
(+2 to +29)
- -
Image-based evaluations
Clinical
(macro)
images
4 454
(145)
11.0
(4.1 to 29.3)
74%
(52 to 88)
72%
(49 to 88)
2.5
(1.2 to 5.1)
0.032
Dermoscopic
images
13 5618
(1092)
27.5
(12.2 to 61.7)
87%
(75 to 94)
88%
(75 to 94)
Difference
(95% CI)
- - - +13%
(-1 to +28)
+15%
(-1 to +30)
- -
Image-based evaluations: direct studies
Clinical
(macro)
images
4 454
(145)
11.9
(3.4 to 40.9)
45%
(5 to 92)
72%
(59 to 82)
3.4
(1.0 to 11.1)
0.049
Dermoscopic
images
4 454
(145)
40.4
(8.2 to 198)
89%
(47 to 99)
83%
(72 to 90)
Difference
(95% CI)
- - - +44%
(-20 to +100)
+11%
(+1 to +22)
- -
CI: confidence interval; DOR: diagnostic odds ratio; LR: likelihood ratio test; RDOR: relative diagnostic odds ratio
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Table 11. Comparison of visual inspection and dermoscopy for the detection of any skin lesion requiring excision
Testa Studies Lesions
(cases)
DOR
(95% CI)
Specificity at
80% sensitivity
(95% CI) %
Sensitivity at
80% specificity
(95% CI) %
In-person evaluations
Visual inspection 2 3457 (151) 38.4
(2.5 to 582)
91%
(39 to 99)
91%
(39 to 99)
Visual inspection
+ dermoscopy
4 3880 (260) 232
(16.0 to 3354)
98%
(80 to 100)
98%
(80 to 100)
In-person evaluations: direct studies
Visual inspection 2 3457 (151) 15.0
(0.18 to 1225)
79%
(4 to 100)
79%
(4 to 100)
Visual inspection
+ dermoscopy
2 3449 (137) 88.1
(1.1 to 7338)
96%
(21 to 100)
96%
(21 to 100)
Image-based evaluations
Clinical (macro)
images
3 547
(138)
21.7
(4.8 to 98.9)
84%
(54 to 96)
84%
(54 to 96)
Dermoscopic
images
5 815
(217)
37.5
(8.8 to 161)
90%
(69 to 98)
90%
(69 to 98)
Image-based evaluations: direct studies
Clinical (macro)
images
3 547 (138) 12.1
(5.4 to 26.7)
75%
(58 to 87)
75%
(58 to 87)
Dermoscopic
images
3 546
(136)
18.4
(8.1 to 41.7)
82%
(67 to 91)
82%
(67 to 91)
CI: confidence interval; DOR: diagnostic odds ratio
aEstimates are based on fitting models with symmetric receiver operating characteristic (ROC) curves, and no formal comparisons
between tests are made due to paucity of data. It is noted that the estimates for the visual inspection studies change between the
all data and paired data analyses for both in-person and image-based analyses. This is driven by differences in the heterogeneity in
accuracy between the models, which affects all parameters in the analyses.
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Table 12. Accuracy of dermoscopy before versus after dermoscopy training (all image-based)
Test Studies Lesions
(cases)
DOR
(95% CI)
Specificity at
80% sensitiv-
ity
(95% CI) %
Sensitivity at
80%
specificity
(95% CI) %
RDOR
(95% CI)
P-value
(LR)
Detection of invasive melanoma or atypical intraepidermal melanocytic variants
Before train-
ing
4 245
(65)
6.3
(1.68 to 23.5)
62%
(27 to 88)
60%
(30 to 84)
1.4
(0.38 to 5.3)
< 0.001
After training 4 245
(65)
8.9
(2.4 to 33.3)
69%
(40 to 88)
69%
(33 to 91)
Change with
training
(95% CI)
- - - +8%
(-24 to +40)
+8%
(-19 to +36)
- -
Detection of invasive melanoma
Before train-
ing
2 150
(75)
5.2
(0.95 to 28.7)
50%
(9 to 91)
60%
(25 to 87)
3.2
(0.94 to 10.6)
0.051
After training 2 150
(75)
16.4
(2.6 to 103)
80%
(32 to 97)
80%
(47 to 95)
Change with
training
(95% CI)
- - - +29%
(-24 to +82)
+20%
(-5 to +45)
- -
CI: confidence interval; DOR: diagnostic odds ratio; LR: likelihood ratio test; RDOR: relative diagnostic odds ratio
A P P E N D I C E S
Appendix 1. Current content and structure of the Programme Grant
LIST OF REVIEWS Number of studies
Diagnosis of melanoma
1 Visual inspection 49
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(Continued)
2 Dermoscopy +/- visual inspection 104
3 Teledermatology 22
4 Smartphone applications 2
5a Computer-aided diagnosis - dermoscopy-based techniques 42
5b Computer-aided diagnosis - spectroscopy-based techniques Review amalgamated into 5a
6 Reflectance confocal microscopy 18
7 High frequency ultrasound 5
Diagnosis of keratinocyte skin cancer (BCC and cSCC)
8 Visual inspection +/- Dermoscopy 24
5c Computer-aided diagnosis - dermoscopy-based techniques Review amalgamated into 5a
5d Computer-aided diagnosis - spectroscopy-based techniques Review amalgamated into 5a
9 Optical coherence tomography 5
10 Reflectance confocal microscopy 10
11 Exfoliative cytology 9
Staging of melanoma
12 Imaging tests (ultrasound, CT, MRI, PET-CT) 38
13 Sentinel lymph node biopsy 160
Staging of cSCC
Imaging tests review Review dropped; only one study identified
13 Sentinel lymph node biopsy Review amalgamated into 13 above (n = 15 studies)
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Appendix 2. Content of algorithms used to assist melanoma diagnosis using dermoscopy
Pattern analysis
Pehamberger 1987
ABCD
Stolz 1994a
ABCD (revised)
Blum 2003a
ABCDE
Kittler 1999
Seven-point checklist
Argenziano 1998
Argenziano 2011
(revised)
• Irregular and
multicomponent
pigmentary network
pattern
• Peripheral dark
network patches
• Sharp network
margin
• Pseudopods
• Radial streaming
• Blue-grey areas
• Pigment dots
(blotches, black dots,
brown globules)
• Black dots at
periphery
• Whitish veil
• Depigmentation
and hypopigmented
areas
• Erythema
• Telangiectasia
• Comedo-like
openings, milia-like
cysts
• Red-blue areas
• Asymmetry score
x 1.3. Calculated
according to the colours
and structures present
within the lesion and
not only with respect to
the contour of the lesion
• + Border score x 0.
1. For each of 8 lesion
segments presenting
with an abrupt cut-off
of pigment pattern the
score was increased by 1
point. Maximum border
score 8
• + Colour score x
0.5. Up to 6 different
colours counted: white,
red, blue-grey light-
brown, dork-brown,
and black
• + Differential
structure score x 0.5. 5
main structural features:
homogeneous areas
network, streaks, dots,
and ’globules according
to size
Thresholds > 5.45 or > 4.
75
• Asymmetry of the
outer shape in at least 1
axis (+1); + asymmetry
of the differential
structures inside the
lesion in at least 1 axis
(+1)
• Border: abrupt
cutoff of network at the
border of the lesion in at
least 1 quarter of the
circumference (+1)
• Colour: ≥ 3
colours (+1)
• Differential
structures: ≥ 3
differential structures
(+1)
Threshold ≥ 4
As for ABCD but with
addition of ‘E’ for en-
largement or change
• Patient self-report
of change in lesion size,
colour or shape within
the last year, or whether
they experienced any
sign of ulceration or
spontaneous bleeding.
De novo appearance of
a lesion within the last
year was regarded as
change in size.
• ABCD-E score
calculated by adding 1.2
to the standard ABCD
score for changing
lesions and subtracting
0.8 from the standard
ABCD score for non-
changing lesions
• 6 thresholds tested,
no single one
recommended
Major criteria:
• atypical network
• blue-white veil
• atypical vascular
pattern
Minor criteria
• irregular dots/
globules
• irregular streaks
• irregular blotches
• regression
structures
Major criteria score 2
points each; minor cri-
teria score 1 point each.
Threshold for excision≥
3
For the revised seven-
point checklist, each
criterion is given a score
of 1 point, and the
threshold for excision is
≥ 1 point, rather than≥
3 points
Seven-point checklist
(for lesion FU)
Stanganelli 2015
Three-point checklist
Soyer 2004
Four-point checklist
di Meo 2016
Risk stratification
Kenet 1994
Risk stratification
(modified)
Ascierto 1998, Ascierto
2003, Ascierto 2010
• A score of ‘no
change’ was assigned if
all variables remained
constant, with a
tolerance of major axis
change of 2 mm (Beer
2011; Terushkin 2012);
• Asymmetry - in
colour and/or structure
in one or two axes,
• Atypical pigment
network - pigmented
network with thickened
lines and irregular
Same as three-point
checklist but asymmetry
given 2 points instead of
1
• Asymmetry of
colour and structure 1st
axis 1 point
Stratum 1 (probable
MM):
• pseudopods
• radial streaming
• heterogeneity of
pigment network with
thick dark extensions at
Very high risk
• Pigment network
and any classical ELM
features specific for
melanoma:
◦ pseudopods
◦ radial
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(Continued)
• ‘minor change’ if
there was only
symmetrical change in
structural or chromatic
pattern;
• ‘moderate change’
if either structural or
chromatic changes were
asymmetrical, but there
were no melanoma-
specific criteria; and
• ‘major change’ if
there were asymmetrical
structural and
chromatic changes, or
the appearance of
melanoma-specific
criteria (i.e. major or
minor criteria on
original 7-point
checklist: blue-white
veil, atypical or negative
pigment network,
atypical vascular
patterns, irregular dots
and globules, streaks,
irregular blotches,
peripheral pigmented
structureless areas and
regression.)
distribution
• Blue-white
structures - any blue
and/or white colour
within the lesion
The presence of two or
three criteria is sugges-
tive for melanoma
• Asymmetry of
colour and structure
2nd axis 1 point
• Irregular or thick
pigmented network 1
point
• Blue-white
structure 1 point
A total score > 2was used
as cut-off
the edge
• blue-grey areas
• white scar-like
areas and
• presence of
pigment network
Stratum 2 (possible
MM):
• marked irregular
network with irregular
pigment confluence
• eccentricity of
pigment network with
darkest regions near
edge
streaming
◦ blue-grey veil
High risk
• Pigment network
and “subtle new ELM
features that may
suggest melanoma but
often are also seen in
atypical naevi”, e.g.
◦ irregular
brown globules at
periphery
◦ irregular
black dots at periphery
◦ hypopigmentation at
lesion periphery
Menzies’ checklist
Menzies 1996
Seven features for
melanoma (7FFM)
Dal Pozzo 1999
Chaos and clues
Rosendahl 2011
CASH
Dolianitis
2005; Henning 2007;
Henning 2008
-
Negative features
• Point and axial
symmetry of
pigmentation
• Presence of only a
single colour
Positive features
• Multiple (5-6)
colours
• Blue-white veil
• Multiple brown
dots
• Multiple blue/grey
Major features
• Regression
erythema
• Radial streaming
• Grey-blue veil
• Irregularly
distributed pseudopods
Minor features score 1
each
• Unhomogeneity
• Irregular pigment
network
• Sharp margin
Chaos
• Asymmetry of
colour or structure
(defined by basic
principles of pattern
analysis as revised by
Kittler 2007.
Clues
• Eccentric
structureless zone (any
colour except skin
colour)
• Grey or blue
Colour: light brown,
dark brown, black, red,
white, blue, each receive
1 point
Architectural disorder:
non-uniformity of struc-
tures and their distribu-
tion in the lesion; benign
melanocytic lesions hav-
ing uniform structures
and distribution. Ab-
sent/mild, moderate and
marked architectural dis-
-
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• Peripheral black
dots or globules
• A broadened
network
• Pseudopods
• Radial streaming
• Scar-like
depigmentation
Threshold: both nega-
tive features absent and
≥ 1 positive features
present
Major features score 2
points each; minor fea-
tures score 1 point each
Threshold: ≥ 2
structures
• Peripheral black
dots or clods
• Segmental radial
lines or pseudopods
• Polymorphous
vessels
• White lines, thick
reticular or branched
lines, and parallel lines
on ridges (acral lesions)
Clues searched for in
presence of chaos; both
present for test-positive
order receive 0, 1, and 2
points,
respectively.
Symmetry:
• biaxial symmetry
scores 0
• monoaxial
symmetry scores 1
• biaxial asymmetry
scores 2
Homogeneity/het-
erogeneity: 7 structures
each score 1
• network
• dots/globules
• streaks/
pseudopods
• blue-whitish veil
• regression
structures (blue-grey
areas with or without
peppering; scarring)
• blotches
(structureless regions of
any colour occupying >
10% of the area of the
lesion)
• polymorphous
blood vessels (dotted
and irregular linear)
A total CASH score
(TCS) ≥ 8
is suggestive for
melanoma.
ELM: epiluminescence microscopy;MM: malignant melanoma
Appendix 3. Glossary of terms
Term Definition
Atypical intraepidermal melanocytic variant Unusual area of darker pigmentation contained within the epidermis that may
progress to an invasive melanoma; includes melanoma in situ and lentigo maligna
Atypical naevi Unusual looking but non-cancerous mole or area of darker pigmentation of the
skin
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(Continued)
BRAF V600 mutation BRAF is a human gene that makes a protein called B-Raf which is involved in the
control of cell growth. BRAF mutations (damaged DNA) occur in around 40%
of melanomas, which can then be treated with particular drugs
BRAF inhibitors Therapeutic agents that inhibit the serine-threonine protein kinase BRAFmutated
metastatic melanoma
Breslow thickness A scale for measuring the thickness of melanomas by the pathologist using a
microscope, measured in mm from the top layer of skin to the bottom of the
tumour
Congenital naevi A type of mole found on infants at birth
Dermoscopy Whereby a handheld microscope is used to allow more detailed, magnified, ex-
amination of the skin compared to examination by the naked eye alone
False-negative An individual who is truly positive for a disease, but whom a diagnostic test
classified as disease-free
False-positive An individual who is truly disease-free, but whom a diagnostic test classified as
having the disease
Histopathology/histology The study of tissue, usually obtained by biopsy or excision, for example under a
microscope
Incidence The number of new cases of a disease in a given time period
Index test A diagnostic test under evaluation in a primary study
Lentigo maligna Unusual area of darker pigmentation contained within the epidermis that includes
malignant cells butwith no invasive growth.May progress to an invasivemelanoma
Lymph node Lymph nodes filter the lymphatic fluid (clear fluid containing white blood cells)
that travels around the body to help fight disease; they are located throughout the
body often in clusters (nodal basins)
Melanocytic naevus An area of skin with darker pigmentation (or melanocytes) also referred to as
‘moles’
Meta-analysis A form of statistical analysis used to synthesise results from a collection of indi-
vidual studies
Metastases/metastatic disease Spread of cancer away from the primary site to somewhere else through the blood-
stream or the lymphatic system
Micrometastases Micrometastases are metastases so small that they can only be seen under a mi-
croscope
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(Continued)
Mitotic rate Microscopic evaluation of number of cells actively dividing in a tumour
Morbidity Detrimental effects on health
Mortality Either (1) the condition of being subject to death; or (2) the death rate, that
reflects the number of deaths per unit of population in relation to any specific
region, age group, disease, treatment or other classification, usually expressed as
deaths per 100, 1000, 10,000 or 100,000 people
Multidisciplinary team A team with members from different healthcare professions and specialties (e.g.
urology, oncology, pathology, radiology, and nursing). Cancer care in theNational
Health Service (NHS) uses this system to ensure that all relevant health profes-
sionals are engaged to discuss the best possible care for that patient
Prevalence The proportion of a population found to have a condition
Prognostic factors/indicators Specific characteristics of a cancer or the person who has it which might affect the
patient’s prognosis
Receiver operating characteristic (ROC) plot A plot of the sensitivity and 1minus the specificity of a test at the different possible
thresholds for test positivity; represents the diagnostic capability of a test with a
range of binary test results
Receiver operating characteristic (ROC) analysis The analysis of a ROCplot of a test to select an optimal threshold for test positivity
Recurrence Recurrence is when new cancer cells are detected following treatment. This can
occur either at the site of the original tumour or at other sites in the body
Reference Standard A test or combination of tests used to establish the final or ‘true’ diagnosis of a
patient in an evaluation of a diagnostic test
Reflectance confocal microscopy (RCM) A microscopic technique using infrared light (either in a handheld device or a
static unit) that can create images of the deeper layers of the skin
Sensitivity In this context the term is used to mean the proportion of individuals with a
disease who have that disease correctly identified by the study test
Specificity The proportion of individuals without the disease of interest (in this case with
benign skin lesions) who have that absence of disease correctly identified by the
study test
Staging Clinical description of the size and spread of a patient’s tumour, fitting into inter-
nationally agreed categories
Subclinical (disease) Disease that is usually asymptomatic and not easily observable, e.g. by clinical or
physical examination
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Systemic treatment Treatment, usually given by mouth or by injection, that reaches and affects cancer
cells throughout the body rather than targeting one specific area
Appendix 4. Proposed sources of heterogeneity
i. Population characteristics
• general versus higher risk populations
• patient population: Primary /secondary/specialist unit
• lesion suspicion: general suspicion/atypical/equivocal/NR
• lesion type: any pigmented; melanocytic
• inclusion of multiple lesions per participant
• ethnicity
ii. Index test characteristics
• the nature of and definition of criteria for test positivity
• observer experience with the index test
• approaches to lesion preparation (e.g., the use of oil or antiseptic gel for dermoscopy)
iii. Reference standard characteristics
• reference standard used
• whether histology-reporting meets pathology-reporting guidelines
• use of excisional versus diagnostic biopsy
• whether two independent dermatopathologists reviewed histological diagnosis
iv. Study quality
• consecutive or random sample of participants recruited
• index test interpreted blinded to the reference standard result
• index test interpreted blinded to the result of any other index test
• presence of partial or differential verification bias (whereby only a sample of those subject to the index test are verified by the
reference test or by the same reference test with selection dependent on the index test result)
• use of an adequate reference standard
• overall risk of bias
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Appendix 5. Final search strategies
Melanoma search strategies to August 2016
Database: Ovid MEDLINE(R) 1946 to August week 3 2016
Search strategy:
1 exp melanoma/
2 exp skin cancer/
3 exp basal cell carcinoma/
4 basalioma$1.ti,ab.
5 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or lesion$1 or malignan$ or nodule$1)).ti,ab.
6 (pigmented adj2 (lesion$1 or mole$ or nevus or naevi or naevus or naevi or skin)).ti,ab.
7 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or keratinocyt$).ti,ab.
8 nmsc.ti,ab.
9 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or masses or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
10 (BCC or CSCC or NMSC).ti,ab.
11 keratinocy$.ti,ab.
12 Keratinocytes/
13 or/1-12
14 dermoscop$.ti,ab.
15 dermatoscop$.ti,ab.
16 photomicrograph$.ti,ab.
17 exp epiluminescence microscopy/
18 (epiluminescence adj2 microscop$).ti,ab.
19 (confocal adj2 microscop$).ti,ab.
20 (incident light adj2 microscop$).ti,ab.
21 (surface adj2 microscop$).ti,ab.
22 (visual adj (inspect$ or examin$)).ti,ab.
23 ((clinical or physical) adj examin$).ti,ab.
24 3 point.ti,ab.
25 three point.ti,ab.
26 pattern analys$.ti,ab.
27 ABCD$.ti,ab.
28 Menzies.ti,ab.
29 7 point.ti,ab.
30 seven point.ti,ab.
31 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
32 artificial intelligence.ti,ab.
33 AI.ti,ab.
34 computer assisted.ti,ab.
35 computer aided.ti,ab.
36 neural network$.ti,ab.
37 exp diagnosis, computer-assisted/
38 MoleMax.ti,ab.
39 image process$.ti,ab.
40 automatic classif$.ti,ab.
41 image analysis.ti,ab.
42 SIAscop$.ti,ab.
43 Aura.ti,ab.
44 (optical adj2 scan$).ti,ab.
45 MelaFind.ti,ab.
46 SIMSYS.ti,ab.
585Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
47 MoleMate.ti,ab.
48 SolarScan.ti,ab.
49 VivaScope.ti,ab.
50 (high adj3 ultraso$).ti,ab.
51 (canine adj2 detect$).ti,ab.
52 ((mobile or cell or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
53 smartphone$.ti,ab.
54 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
55 Mole Detective.ti,ab.
56 Spot Check.ti,ab.
57 (mole$1 adj2 map$).ti,ab.
58 (total adj2 body).ti,ab.
59 exfoliative cytolog$.ti,ab.
60 digital analys$.ti,ab.
61 (image$1 adj3 software).ti,ab.
62 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or teledermatoscop$ or tele-
dermatoscop$).ti,ab.
63 (optical coherence adj (technolog$ or tomog$)).ti,ab.
64 (computer adj2 diagnos$).ti,ab.
65 exp sentinel lymph node biopsy/
66 (sentinel adj2 node).ti,ab.
67 naevisense.mp. or HFUS.ti,ab.
68 electrical impedance spectroscopy.ti,ab.
69 history taking.ti,ab.
70 patient history.ti,ab.
71 (naked eye adj (exam$ or assess$)).ti,ab.
72 (skin adj exam$).ti,ab.
73 physical examination/
74 ugly duckling.mp. or UD.ti,ab.
75 ((physician$ or clinical or physical) adj (exam$ or triage or recog$)).ti,ab.
76 ABCDE.mp. or VOC.ti,ab.
77 clinical accuracy.ti,ab.
78 Family Practice/or Physicians, Family/or clinical competence/
79 (confocal adj2 microscop$).ti,ab.
80 diagnostic algorithm$1.ti,ab.
81 checklist$.ti,ab.
82 virtual imag$1.ti,ab.
83 volatile organic compound$1.ti,ab.
84 dog$1.ti,ab.
85 gene expression analy$.ti,ab.
86 reflex transmission imag$.ti,ab.
87 thermal imaging.ti,ab.
88 elastography.ti,ab.
89 or/14-88
90 (CT or PET).ti,ab.
91 PET-CT.ti,ab.
92 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
93 exp Deoxyglucose/
94 deoxy-glucose.ti,ab.
95 deoxyglucose.ti,ab.
96 CATSCAN.ti,ab.
97 exp Tomography, Emission-Computed/
98 exp Tomography, X-ray computed/
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99 positron emission tomograph$.ti,ab.
100 exp magnetic resonance imaging/
101 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
102 exp echography/
103 Doppler echography.ti,ab.
104 sonograph$.ti,ab.
105 ultraso$.ti,ab.
106 doppler.ti,ab.
107 magnetic resonance imag$.ti,ab.
108 or/90-107
109 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
110 “Sensitivity and Specificity”/
111 exp cancer staging/
112 or/109-111
113 108 and 112
114 89 or 113
115 13 and 114
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations 29 August 2016
Search strategy:
1 basalioma$1.ti,ab.
2 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or lesion$1 or malignan$ or nodule$1)).ti,ab.
3 (pigmented adj2 (lesion$1 or mole$ or nevus or naevi or naevus or naevi or skin)).ti,ab.
4 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or keratinocyt$).ti,ab.
5 nmsc.ti,ab.
6 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or masses or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
7 (BCC or CSCC or NMSC).ti,ab.
8 keratinocy$.ti,ab.
9 or/1-8
10 dermoscop$.ti,ab.
11 dermatoscop$.ti,ab.
12 photomicrograph$.ti,ab.
13 (epiluminescence adj2 microscop$).ti,ab.
14 (confocal adj2 microscop$).ti,ab.
15 (incident light adj2 microscop$).ti,ab.
16 (surface adj2 microscop$).ti,ab.
17 (visual adj (inspect$ or examin$)).ti,ab.
18 ((clinical or physical) adj examin$).ti,ab.
19 3 point.ti,ab.
20 three point.ti,ab.
21 pattern analys$.ti,ab.
22 ABCD$.ti,ab.
23 Menzies.ti,ab.
24 7 point.ti,ab.
25 seven point.ti,ab.
26 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
27 artificial intelligence.ti,ab.
28 AI.ti,ab.
29 computer assisted.ti,ab.
30 computer aided.ti,ab.
31 neural network$.ti,ab.
32 MoleMax.ti,ab.
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33 image process$.ti,ab.
34 automatic classif$.ti,ab.
35 image analysis.ti,ab.
36 SIAscop$.ti,ab.
37 Aura.ti,ab.
38 (optical adj2 scan$).ti,ab.
39 MelaFind.ti,ab.
40 SIMSYS.ti,ab.
41 MoleMate.ti,ab.
42 SolarScan.ti,ab.
43 VivaScope.ti,ab.
44 (high adj3 ultraso$).ti,ab.
45 (canine adj2 detect$).ti,ab.
46 ((mobile or cell or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
47 smartphone$.ti,ab.
48 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
49 Mole Detective.ti,ab.
50 Spot Check.ti,ab.
51 (mole$1 adj2 map$).ti,ab.
52 (total adj2 body).ti,ab.
53 exfoliative cytolog$.ti,ab.
54 digital analys$.ti,ab.
55 (image$1 adj3 software).ti,ab.
56 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or teledermatoscop$ or tele-
dermatoscop$).ti,ab.
57 (optical coherence adj (technolog$ or tomog$)).ti,ab.
58 (computer adj2 diagnos$).ti,ab.
59 (sentinel adj2 node).ti,ab.
60 naevisense.mp. or HFUS.ti,ab.
61 electrical impedance spectroscopy.ti,ab.
62 history taking.ti,ab.
63 patient history.ti,ab.
64 (naked eye adj (exam$ or assess$)).ti,ab.
65 (skin adj exam$).ti,ab.
66 ugly duckling.mp. or UD.ti,ab.
67 ((physician$ or clinical or physical) adj (exam$ or triage or recog$)).ti,ab.
68 ABCDE.mp. or VOC.ti,ab.
69 clinical accuracy.ti,ab.
70 (Family adj (Practice or Physicians)).ti,ab.
71 (confocal adj2 microscop$).ti,ab.
72 clinical competence.ti,ab.
73 diagnostic algorithm$1.ti,ab.
74 checklist$.ti,ab.
75 virtual imag$1.ti,ab.
76 volatile organic compound$1.ti,ab.
77 dog$1.ti,ab.
78 gene expression analy$.ti,ab.
79 reflex transmission imag$.ti,ab.
80 thermal imaging.ti,ab.
81 elastography.ti,ab.
82 or/10-81
83 (CT or PET).ti,ab.
84 PET-CT.ti,ab.
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85 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
86 deoxy-glucose.ti,ab.
87 deoxyglucose.ti,ab.
88 CATSCAN.ti,ab.
89 positron emission tomograph$.ti,ab.
90 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
91 Doppler echography.ti,ab.
92 sonograph$.ti,ab.
93 ultraso$.ti,ab.
94 doppler.ti,ab.
95 magnetic resonance imag$.ti,ab.
96 or/83-95
97 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
98 96 and 97
99 82 or 98
100 9 and 99
Database: Embase 1974 to 29 August 2016
Search strategy:
1 *melanoma/
2 *skin cancer/
3 *basal cell carcinoma/
4 basalioma$.ti,ab.
5 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$ or adenoma$ or
epithelioma$ or lesion$ or malignan$ or nodule$)).ti,ab.
6 (pigmented adj2 (lesion$1 or mole$ or nevus or naevi or naevus or naevi or skin)).ti,ab.
7 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or keratinocyt$).ti,ab.
8 nmsc.ti,ab.
9 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1 or epithelioma$1 or
epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
10 (BCC or cscc).mp. or NMSC.ti,ab.
11 keratinocyte.ti,ab.
12 keratinocy$.ti,ab.
13 or/1-12
14 dermoscop$.ti,ab.
15 dermatoscop$.ti,ab.
16 photomicrograph$.ti,ab.
17 *epiluminescence microscopy/
18 (epiluminescence adj2 microscop$).ti,ab.
19 (confocal adj2 microscop$).ti,ab.
20 (incident light adj2 microscop$).ti,ab.
21 (surface adj2 microscop$).ti,ab.
22 (visual adj (inspect$ or examin$)).ti,ab.
23 ((clinical or physical) adj examin$).ti,ab.
24 3 point.ti,ab.
25 three point.ti,ab.
26 pattern analys$.ti,ab.
27 ABCD$.ti,ab.
28 Menzies.ti,ab.
29 7 point.ti,ab.
30 seven point.ti,ab.
31 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
32 artificial intelligence.ti,ab.
33 AI.ti,ab.
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34 computer assisted.ti,ab.
35 computer aided.ti,ab.
36 neural network$.ti,ab.
37 MoleMax.ti,ab.
38 exp diagnosis, computer-assisted/
39 image process$.ti,ab.
40 automatic classif$.ti,ab.
41 image analysis.ti,ab.
42 SIAscop$.ti,ab.
43 (optical adj2 scan$).ti,ab.
44 Aura.ti,ab.
45 MelaFind.ti,ab.
46 SIMSYS.ti,ab.
47 MoleMate.ti,ab.
48 SolarScan.ti,ab.
49 VivaScope.ti,ab.
50 confocal microscop$.ti,ab.
51 (high adj3 ultraso$).ti,ab.
52 (canine adj2 detect$).ti,ab.
53 ((mobile or cell$ or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
54 smartphone$.ti,ab.
55 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
56 Spot Check.ti,ab.
57 Mole Detective.ti,ab.
58 (mole$1 adj2 map$).ti,ab.
59 (total adj2 body).ti,ab.
60 exfoliative cytolog$.ti,ab.
61 digital analys$.ti,ab.
62 (image$1 adj3 software).ti,ab.
63 (optical coherence adj (technolog$ or tomog$)).ti,ab.
64 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or teledermatoscop$).mp. or
tele-dermatoscop$.ti,ab.
65 (computer adj2 diagnos$).ti,ab.
66 *sentinel lymph node biopsy/
67 (sentinel adj2 node).ti,ab.
68 naevisense.ti,ab.
69 HFUS.ti,ab.
70 electrical impedance spectroscopy.ti,ab.
71 history taking.ti,ab.
72 patient history.ti,ab.
73 (naked eye adj (exam$ or assess$)).ti,ab.
74 (skin adj exam$).ti,ab.
75 *physical examination/
76 ugly duckling.ti,ab.
77 UD sign$.ti,ab.
78 ((physician$ or clinical or physical) adj (exam$ or recog$ or triage)).ti,ab.
79 ABCDE.ti,ab.
80 clinical accuracy.ti,ab.
81 *general practice/
82 (confocal adj2 microscop$).ti,ab.
83 clinical competence/
84 diagnostic algorithm$.ti,ab.
85 checklist$1.ti,ab.
590Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
86 virtual image$1.ti,ab.
87 volatile organic compound$1.ti,ab.
88 VOC.ti,ab.
89 dog$1.ti,ab.
90 gene expression analys$.ti,ab.
91 reflex transmission imaging.ti,ab.
92 thermal imaging.ti,ab.
93 elastography.ti,ab.
94 dog$1.ti,ab.
95 gene expression analys$.ti,ab.
96 reflex transmission imaging.ti,ab.
97 thermal imaging.ti,ab.
98 elastography.ti,ab.
99 or/14-93
100 PET-CT.ti,ab.
101 (CT or PET).ti,ab.
102 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
103 exp Deoxyglucose/
104 CATSCAN.ti,ab.
105 deoxyglucose.ti,ab.
106 deoxy-glucose.ti,ab.
107 *positron emission tomography/
108 *computer assisted tomography/
109 positron emission tomograph$.ti,ab.
110 *nuclear magnetic resonance imaging/
111 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
112 *echography/
113 Doppler.ti,ab.
114 sonograph$.ti,ab.
115 ultraso$.ti,ab.
116 magnetic resonance imag$.ti,ab.
117 or/100-116
118 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
119 “Sensitivity and Specificity”/
120 *cancer staging/
121 or/118-120
122 117 and 121
123 99 or 122
124 13 and 123
Database: Cochrane Library (Wiley) 2016 searched 30 August 2016 CDSR Issue 8 of 12 2016 CENTRAL Issue 7 of 12 2016
HTA Issue 3 of 4 July 2016 DARE Issue 3 of 4 2015
Search strategy:
#1 melanoma* or nonmelanoma* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt* or keratinocyte*
#2 MeSH descriptor: [Melanoma] explode all trees
#3 “skin cancer*”
#4 MeSH descriptor: [Skin Neoplasms] explode all trees
#5 skin near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or lesion*
or malignan* or nodule*)
#6 nmsc
#7 “squamous cell” near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma*
or lesion* or malignan* or nodule*) near/2 (skin or epiderm* or cutaneous)
#8 “basal cell” near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or
lesion* or malignan* or nodule*)
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#9 pigmented near/2 (lesion* or nevus or mole* or naevi or naevus or naevi or skin)
#10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9
#11 dermoscop*
#12 dermatoscop*
#13 Photomicrograph*
#14 MeSH descriptor: [Dermoscopy] explode all trees
#15 confocal near/2 microscop*
#16 epiluminescence near/2 microscop*
#17 incident next light near/2 microscop*
#18 surface near/2 microscop*
#19 “visual inspect*”
#20 “visual exam*”
#21 (clinical or physical) next (exam*)
#22 “3 point”
#23 “three point”
#24 “pattern analys*”
#25 ABDC
#26 Menzies
#27 “7 point”
#28 “seven point”
#29 digital near/2 (dermoscop* or dermatoscop*)
#30 “artificial intelligence”
#31 “AI”
#32 “computer assisted”
#33 “computer aided”
#34 AI
#35 “neural network*”
#36 MoleMax
#37 “computer diagnosis”
#38 “image process*”
#39 “automatic classif*”
#40 SIAscope
#41 “image analysis”
#42 “optical near/2 scan*”
#43 Aura
#44 MelaFind
#45 SIMSYS
#46 MoleMate
#47 SolarScan
#48 Vivascope
#49 “confocal microscopy”
#50 high near/3 ultraso*
#51 canine near/2 detect*
#52 Mole* near/2 map*
#53 total near/2 body
#54 mobile* or smart near/2 phone*
#55 cell next phone*
#56 smartphone*
#57 “mitotic index”
#58 DermoScan or SkinVision or DermLink or SpotCheck
#59 “Mole Detective”
#60 “Spot Check”
#61 mole* near/2 map*
592Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
#62 total near/2 body
#63 “exfoliative cytolog*”
#64 “digital analys*”
#65 image near/3 software
#66 teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop* or tele-dermoscop* or teledermatoscop* or tele-
dermatolog*
#67 “optical coherence” next (technolog* or tomog*)
#68 computer near/2 diagnos*
#69 sentinel near/2 node*
#70 #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28
or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or #45 or #46 or
#47 or #48 or #49 or #50 or #51 or #52 or #53 or #54 or #55 or #56 or #57 or #58 or #59 or #60 or #61 or #62 or #63 or #64 or #
65 or #66 or #67 or #68 or #69
#71 ultraso*
#72 sonograph*
#73 MeSH descriptor: [Ultrasonography] explode all trees
#74 Doppler
#75 CT or PET or PET-CT
#76 “CAT SCAN” or “CATSCAN”
#77 MeSH descriptor: [Positron-Emission Tomography] explode all trees
#78 MeSH descriptor: [Tomography, X-Ray Computed] explode all trees
#79 MRI
#80 MeSH descriptor: [Magnetic Resonance Imaging] explode all trees
#81 MRI or fMRI or NMRI or scintigraph*
#82 “magnetic resonance imag*”
#83 MeSH descriptor: [Deoxyglucose] explode all trees
#84 deoxyglucose or deoxy-glucose
#85 “positron emission tomograph*”
#86 #71 or #72 or #73 or #74 or #75 or #76 or #77 or #78 or #79 or #80 or #81 or #82 or #83 or #84 or #85
#87 stage* or staging or metasta* or recurrence or sensitivity or specificity or “false negative*” or thickness*
#88 MeSH descriptor: [Neoplasm Staging] explode all trees
#89 #87 or #88
#90 #89 and #86
#91 #70 or #90
#92 #10 and #91
#93 BCC or CSCC or NMCS
#94 keratinocy*
#95 #93 or #94
#96 #10 or #95
#97 naevisense
#98 HFUS
#99 “electrical impedance spectroscopy”
#100 “history taking”
#101 “patient history”
#102 naked next eye near/1 (exam* or assess*)
#103 skin next exam*
#104 “ugly duckling” or (UD sign*)
#105 MeSH descriptor: [Physical Examination] explode all trees
#106 (physician* or clinical or physical) near/1 (exam* or recog* or triage*)
#107 ABCDE
#108 “clinical accuracy”
#109 MeSH descriptor: [General Practice] explode all trees
#110 confocal near microscop*
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#111 “diagnostic algorithm*”
#112 MeSH descriptor: [Clinical Competence] explode all trees
#113 checklist*
#114 “virtual image*”
#115 “volatile organic compound*”
#116 dog or dogs
#117 VOC
#118 “gene expression analys*”
#119 “reflex transmission imaging”
#120 “thermal imaging”
#121 elastography
#122 #97 or #98 or #99 or #100 or #101 or #102 or #103 or #104 or #105 or #106 or #107 or #108 or #109 or #110 or #111 or #
112 or #113 or #114 or #115 or #116 or #117 or #118 or #119 or #120 or #121
#123 #70 or #122
#124 #96 and #123
#125 #96 and #90
#126 #125 or #124
#127 #10 and #126
Database: CINAHL +(EBSCO) 1937 to 30 August 2016
Search strategy:
S1 (MH “Melanoma”) OR (MH “naevi and Melanomas+”)
S2 (MH “Skin Neoplasms+”)
S3 (MH “Carcinoma, Basal Cell+”)
S4 basalioma*
S5 (basal cell) N2 (cancer* or carcinoma* or mass or masses or tumor* or tumour* or neoplasm* or adenoma* or epithelioma* or
lesion* or malignan* or nodule*)
S6 (pigmented) N2 (lesion* or mole* or nevus or naevi or naevus or naevi or skin)
S7 melanom* or nonmelanoma* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt*
S8 nmsc
S9 TX BCC or cscc or NMSC
S10 (MH “Keratinocytes”)
S11 keratinocyt*
S12 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11
S13 dermoscop* or dermatoscop* or photomicrograph* or (3 point) or (three point) or ABCD* or Menzies or (7 point) or (seven
point) or AI or Molemax or SIASCOP* or Aura or MelaFind or SIMSYS or MoleMate or SolarScan or smartphone* or DermoScan
or SkinVision or DermLink or SpotCheck
S14 (epiluminescence or confocal or incident or surface) N2 (microscop*)
S15 visual N1 (inspect* or examin*)
S16 (clinical or physical) N1 (examin*)
S17 pattern analys*
S18 (digital) N2 (dermoscop* or dermatoscop*)
S19 (artificial intelligence)
S20 (computer) N2 (assisted or aided)
S21 (neural network*)
S22 (MH “Diagnosis, Computer Assisted+”)
S23 (image process*)
S24 (automatic classif*)
S25 (image analysis)
S26 SIAScop*
S27 (optical) N2 (scan*)
S28 (high) N3 (ultraso*)
S29 elastography
S30 (mobile or cell or cellular or smart) N2 (phone*) N2 (app or application*)
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S31 (mole*) N2 (map*)
S32 total N2 body
S33 exfoliative cytolog*
S34 digital analys*
S35 image N3 software
S36 teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop* or tele-dermoscop* or teledermatoscop* or tele-
dermatoscop* teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop*
S37 (optical coherence) N1 (technolog* or tomog*)
S38 computer N2 diagnos*
S39 sentinel N2 node
S40 (MH “Sentinel Lymph Node Biopsy”)
S41 naevisense or HFUS or checklist* or VOC or dog*
S42 electrical impedance spectroscopy
S43 history taking
S44 “Patient history”
S45 naked eye
S46 skin exam*
S47 physical exam*
S48 ugly duckling
S49 UD sign*
S50 (physician* or clinical or physical) N1 (exam*)
S51 clinical accuracy
S52 general practice
S53 (physician* or clinical or physical) N1 (recog* or triage)
S54 confocal microscop*
S55 clinical competence
S56 diagnostic algorithm*
S57 checklist*
S58 virtual image*
S59 volatile organic compound*
S60 gene expression analys*
S61 reflex transmission imag*
S62 thermal imaging
S63 S13 or S14 or S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR
S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR S41 OR S42 OR
S43 OR S44 OR S45 OR S46 OR S47 OR S48 OR S49 OR S50 OR S51 OR S52 OR S53 OR S54 OR S55 OR S56 OR S57 OR
S58 OR S59 OR S60 OR S61 OR S62
S64 CT or PET
S65 PET-CT
S66 FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical*
S67 (MH “Deoxyglucose+”)
S68 deoxy-glucose or deoxyglucose
S69 CATSCAN
S70 CAT-SCAN
S71 (MH “Deoxyglucose+”)
S72 (MH “Tomography, Emission-Computed+”)
S73 (MH “Tomography, X-Ray Computed”)
S74 positron emission tomograph*
S75 (MH “Magnetic Resonance Imaging+”)
S76 MRI or fMRI or NMRI or scintigraph*
S77 echography
S78 doppler
S79 sonograph*
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S80 ultraso*
S81 magnetic resonance imag*
S82 S64 OR S65 OR S66 OR S67 OR S68 OR S69 OR S70 OR S71 OR S72 OR S73 OR S74 OR S75 OR S76 OR S77 OR S78
OR S79 OR S80 OR S81
S83 stage* or staging or metasta* or recurrence or sensitivity or specificity or (false negative*) or thickness
S84 (MH “Neoplasm Staging”)
S85 S83 OR S84
S86 S82 AND S85
S87 S63 OR S86
S88 S12 AND S87
Database: Science Citation Index SCI Expanded (Web of Science) 1900 to 30 August 2016
Conference Proceedings Citation Index (Web of Science) 1900 to 1 September 2016
Search strategy:
#1 (melanom* or nonmelanom* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt* or keratinocyt*)
#2 (basalioma*)
#3 ((skin) near/2 (cancer* or carcinoma or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or lesion*
or malignan* or nodule*))
#4 ((basal) near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or
lesion* or malignan* or nodule*))
#5 ((pigmented) near/2 (lesion* or mole* or nevus or naevi or naevus or naevi or skin))
#6 (nmsc or BCC or NMSC or keratinocy*)
#7 ((squamous cell (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or
lesion* or malignan* or nodule*))
#8 (skin or epiderm* or cutaneous)
#9 #8 AND #7
#10 #9 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
#11 ((dermoscop* or dermatoscop* or photomicrograph* or epiluminescence or confocal or “incident light” or “surface microscop*”
or “visual inspect*” or “physical exam*” or 3 point or three point or pattern analy* or ABCDE or Menzies or 7 point or seven point
or dermoscop* or dermatoscop* or AI or artificial or computer aided or computer assisted or neural network* or Molemax or image
process* or automatic classif* or image analysis or siascope or optical scan* or Aura or melafind or simsys or molemate or solarscan or
vivascope or confocal microscop* or high ultraso* or canine detect* or cellphone* or mobile* or phone* or smartphone or dermoscan
or skinvision or dermlink or spotcheck or spot check or mole detective or mole map* or total body or exfoliative psychology or digital
or image software or optical coherence or teledermatology or telederm* or teledermoscop* or teledermatoscop* or computer diagnos*
or sentinel))
#12 ((naevisense or HFUS or impedance spectroscopy or history taking or patient history or naked eye or skin exam* or physical exam*
or ugly duckling or UD sign* or physician* exam* or physical exam* or ABCDE or clinical accuracy or general practice or confocal
microscop* or clinical competence or diagnostic algorithm* or checklist* or virtual image* or volatile organic or VOC or dog* or gene
expression or reflex transmission or thermal imag* or elastography))
#13 #11 or #12
#14 ((PET or CT or FDG or deoxyglucose or deoxy-glucose or fluorodeoxy* or radiopharma* or CATSCAN or positron emission or
computer assisted or nuclear magnetic or MRI or FMRI or NMRI or scintigraph* or echograph* or Doppler or sonograph* or ultraso*
or magnetic reson*))
#15 ((stage* or staging or metast* or recurrence or sensitivity or specificity or false negative* or thickness*))
#16 #14 AND #15
#17 #16 OR #13
#18 #10 AND #17
Refined by: DOCUMENT TYPES: (MEETING ABSTRACT OR PROCEEDINGS PAPER)
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Appendix 6. Full text inclusion criteria
Criterion Inclusion Exclusion
Study design For diagnostic and staging reviews
• Any study for which a 2×2 contingency table
can be extracted, e.g.
◦ diagnostic case-control studies
◦ ’cross-sectional’ test accuracy study with
retrospective or prospective data collection
◦ studies where estimation of test accuracy
was not the primary objective but test results for
both index and reference standard were available
◦ RCTs of tests or testing strategies where
participants were randomised between index tests
and all undergo a reference standard (i.e. accuracy
RCTs)
• < 5 melanoma cases (diagnosis reviews)
• < 10 participants (staging reviews)
• Studies developing new criteria for diagnosis
unless a separate ’test set’ of images were used to
evaluate the criteria (mainly digital dermoscopy)
• Studies using ’normal’ skin as controls
• Letters, editorials, comment papers, narrative
reviews
• Insufficient data to construct a 2×2 table
Target condition • Melanoma
• Keratinocyte skin cancer (or non-melanoma
skin cancer)
◦ BCC or epithelioma
◦ cSCC
• Studies exclusively conducted in children
• Studies of non-cutaneous melanoma or SCC
Population For diagnostic reviews
• Adults with a skin lesion suspicious for
melanoma, BCC, or cSCC (other terms include
PSL/naevi, melanocytic, keratinocyte, etc.)
• Adults at high risk of developing melanoma
skin cancer, BCC, or cSCC
For staging reviews
• Adults with a diagnosis of melanoma or cSCC
undergoing tests for staging of lymph nodes or
distant metastases or both
• People suspected of other forms of skin cancer
• Studies conducted exclusively in children
Index tests For diagnosis
• Visual inspection/clinical examination
• Dermoscopy/dermatoscopy
• Teledermoscpoy
• Smartphone/mobile phone applications
• Digital dermoscopy/artificial intelligence
• Confocal microscopy
• Ocular coherence tomography
• Exfoliative cytology
• High-frequency ultrasound
• Canine odour detection
• DNA expression analysis/gene chip analysis
• Other
For staging
• CT
• Sentinel lymph biopsy for therapeutic rather
than staging purposes
• Tests to determine melanoma thickness
• Tests to determine surgical margins/lesion
borders
• Tests to improve histopathology diagnose
• LND
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(Continued)
• PET
• PET-CT
• MRI
• Ultrasound +/fine needle aspiration cytology
FNAC
• SLNB +/high-frequency ultrasound
• Other
Any test combination and in any order
Any test positivity threshold
Any variation in testing procedure (e.g. radioisotope
used)
Reference standard For diagnostic studies
• Histopathology of the excised lesion
• Clinical follow-up of non-excised/benign
appearing lesions with later histopathology if
suspicious
• Expert diagnosis (studies should not be
included if expert diagnosis is the sole reference
standard)
For studies of imaging tests for staging
• Histopathology (via LND or SLMB)
• Clinical/radiological follow-up
• A combination of the above
For studies of SLNB accuracy for staging
• LND of both SLN+ and SLn participants to
identify all diseased nodes
• LND of SLN+ participants and follow-up of
SLN participants to identify a subsequent nodal
recurrence in a previously investigated nodal basin
For diagnostic studies
• Exclude if any disease positive participants have
diagnosis unconfirmed by histology
• Exclude if > 50% of disease-negative
participants have diagnosis confirmed by expert
opinion with no histology or follow-up
• Exclude studies of referral accuracy, i.e.
comparing referral decision with expert diagnosis,
unless evaluations of teledermatology or mobile
phone applications
BCC: basal cell carcinoma; cSCC: cutaneous squamous cell carcinoma; CT: computed tomography; FNAC: fine needle aspiration
cytology; lND: lymph node dissection; MRI: magnetic resonance imaging; PET: positron emission tomography; PET-CT: positron
emission tomography computed tomography; RCT: randomised controlled trial; SCC: squamous cell carcinoma; SLN+: positive
sentinel lymph node; SLn: negative sentinel lymph node; SLNB: sentinel lymph node biopsy
Appendix 7. Quality assessment (based on QUADAS-2)
Patient selection domain (1)
Selective recruitment of study participants can be a key influence on test accuracy. In general terms, all participants eligible to undergo
a test should be included in a study, allowing for the intended use of that test within the context of the study. We considered studies that
separately sampled malignant and benign lesions to have used a case-control design; and those that supplemented a series of suspicious
lesions with additional malignant or benign lesions to be at unclear risk of bias
In terms of exclusions, we considered studies that excluded particular lesion types (e.g. lentigo maligna), particular lesion sites, or
excluded lesions with lack of observer agreement (e.g. on histopathology) to be at high risk of bias. For image-based evaluations, some
studies excluded lesions on the basis of image quality as an a priori exclusion criterion while others excluded lesions with inadequate
598Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
images post hoc. In order to judge studies consistently, we considered all exclusions due to image quality in the Flow and timing domain
(Were all participants included in the analysis?).
In judging the applicability of patient populations to the review question, we considered restriction to particular lesion populations,
such as melanocytic, nodular, high risk or restrictions by size to be of high concern for applicability. Studies that included only lesions
with histopathology results were also considered of high concern for applicability on the basis that in usual practice, whether in primary,
secondary or specialist care, a greater or lesser proportion of patients will have lesions with low levels of suspicion of malignancy such
that they can be reassured and discharged, or followed up over a period of time. The restriction of a study sample to those with lesions
undergoing biopsy or excision will therefore not adequately reflect a usual-care setting. Furthermore, due to the invasive nature of
sampling lesions for histology, studies are not likely to mandate biopsy or excision as a study requirement regardless of the index of
suspicion (in which case restriction to those with histology would not be of concern in terms of having a representative population).
Given that diagnosis of skin cancer is primarily lesion-based, there is the potential for study participants with multiple lesions to
contribute disproportionately to estimates of test accuracy, especially if they are at particular risk of having skin cancer. We considered
studies that included a high number of lesions in relation to the number of study to be less representative than studies conducted in a
more general population participants (i.e. if the difference between the number of included lesions and number of included participants
was greater than 5%).
Index test domain (2)
Given the potential for subjective differences in test interpretation for melanoma, the interpretation of the index test blinded to the
result of the reference standard is a key means of reducing bias. For prospective studies and retrospective studies that used the original
index test interpretation, the diagnosis will by nature be interpreted and recorded before the result of the reference standard is known;
however, studies using previously acquired images could be particularly susceptible to information bias. For these studies to be at low
risk of bias, we required a clear indication that observers were unaware of the reference standard diagnosis at time of test interpretation.
We also added an item to assess the presence of blinding between interpretations of different algorithms, however this item was not
included in the overall assessment of risk of bias.
Pre-specification of the index test threshold was considered present if the study clearly reported that the threshold used was not data
driven, that is, was not based on study results. Studies that did not clearly describe the threshold used but that required clinicians
to record a diagnosis or management decision for a lesion were considered to be unclear on this criterion. Studies reporting accuracy
for multiple numeric thresholds, where ROC analysis was used to select the threshold, or that reported accuracy for the presence of
independently significant lesion characteristics with no separate test set of lesions were considered at high risk of bias.
In terms of applicability of the index test to the review question, we required the test to be applied and interpreted as it would be in a
clinical practice setting, that is, in person or face-to-face with the study participant, and by a single observer as opposed to a consensus
decision or average across multiple observers. Image-based studies were considered to be of high concern.
Despite the often subjective nature of test interpretation, it is also important for study authors to outline the particular lesion character-
istics that were considered to be indicative for melanoma, particularly where established algorithms or checklists were not used. Studies
were considered of low concern if the threshold used was established in a prior study or sufficient threshold details were presented to
allow replication.
The experience of the examiner will also impact on the applicability of study results. We required studies to describe the test interpreter
as ‘experienced’ or ‘expert’ to have low concern about applicability.
Reference standard domain (3)
In an ideal study, consecutively recruited participants should all undergo incisional or excisional biopsy of the skin lesion regardless of
level of clinical suspicion of melanoma. In reality, both partial and differential verification bias are likely. Partial verification bias may
occur where histology is the only reference standard used, and only those participants with a certain degree of suspicion of malignancy
based on the result of the index test undergo verification, the others either being excluded from the study or defined as being disease-
negative without further assessment or follow-up, as discussed under ‘Patient selection domain’.
Differential verification bias will be present where other reference standards are used in addition to histological verification of suspicious
lesions. A typical example of verification bias in skin cancer occurs when investigators do not biopsy people with benign-appearing
lesions but instead follow them up for a period of time to determine whether any malignancy subsequently develops (these would be
false-negatives on the index test). We defined an ’adequate’ reference standard as: all disease-positive individuals having a histological
reference standard either at the time of application of the index test or after a period of clinical follow-up; and at least 80% of disease-
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negative participants have received a histological diagnosis, with up to 20% undergoing at least three months’ follow-up of benign-
appearing lesions.
A further challenge is the potential for incorporation bias, that is, where the result of the index test is used to help determine the reference
standard diagnosis. It is normal practice for the clinical diagnosis (usually by visual inspection or dermoscopy) to be included on
pathology request forms and for the histopathologist to use this diagnosis to help with the pathology interpretation. Although inclusion
of such clinical information on the histopathology request form is theoretically a form of incorporation bias, blinded interpretation
of the histopathology reference standard is not normal practice, and enforcement of such conditions would significantly limit the
generalisability of the study results. Blinding to the index test (visual inspection or clinical diagnosis) was therefore recorded but did
not contribute to our overall assessment of risk of bias for the reference standard domain.
In judging the applicability of the reference standard to our review question, we scored studies as high concern around applicability if
they used expert diagnosis (with no follow-up) as a reference standard in any participant, or did not report histology interpretation by
a dermatopathologist.
Flow and timing domain (4)
In the ideal study, the diagnosis based on the index test and reference standard should be made consecutively or as near to each other
in time as possible to avoid changes in lesion over time. For lesions with a histological reference standard, we have defined a one-
month period as an appropriate interval between application of the index test and the reference standard. Studies reporting biopsy or
excision ‘following’, ‘after’ or ‘subsequent to’ the visual inspection diagnosis (or using similar descriptors) were considered to have met
this criterion. For studies using clinical follow-up, a minimum three-month follow-up period has been defined as at low risk of bias
for detecting false-negatives. This interval was chosen based on a study showing that most false-negative melanomas will be diagnosed
within three months of the initial negative index test although a small number will be diagnosed up to 12 months subsequently
(Altamura 2008).
In assessing whether all participants were included in the analysis, we considered studies at high risk of bias if participants were excluded
following recruitment. As discussed in the ‘Patient selection domain’, a priori exclusion of images on the basis of image quality was also
considered under this item.
Comparative domain
For studies reporting accuracy data for both visual inspection and dermoscopy, a comparative domain has been added to record blinding
between tests and the time interval between tests. Given that visual inspection is an essential component of in-person dermoscopy and
that dermoscopic image interpretation should really be done alongside a clinical image of a suspicious skin lesion, responses to this item
have been recorded but do not contribute to overall risk of bias. For the time interval between tests, in-person dermoscopy will usually
be conducted subsequent to visual inspection and clinical photographs and dermoscopic images acquired at the same consultation;
responses to this item therefore largely reflect study reporting quality rather than risk of bias.
QUADAS-2 tool
The following tables use text that was originally published in the QUADAS-2 tool by Whiting and colleagues (Whiting 2011).
Item Response (delete as required)
Participant selection (1) risk of bias
1) Was a consecutive or random sample of participants or images
enrolled?
Yes - if paper states consecutive or random
No - if paper describes other method of sampling
Unclear - if participant sampling not described
2) Was a case-control design avoided? Yes - if consecutive or random or case-control design clearly not
used
No - if study described as case-control or describes sampling spe-
cific numbers of participants with particular diagnoses
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Unclear - if not described
3) Did the study avoid inappropriate exclusions, e.g.,
• ’difficult to diagnose’ lesions not excluded
• lesions not excluded on basis of disagreement between
evaluators
Yes - if inappropriate exclusions were avoided
No - if lesions were excluded that might affect test accuracy, e.
g., ’difficult to diagnose’ lesions, or where disagreement between
evaluators was observed
Unclear - if not clearly reported but there is suspicion that difficult
to diagnose lesions may have been excluded
4) For between-person comparative studies only (i.e., allocating
different tests to different study participants):
• A) were the same participant selection criteria used for
those allocated to each test?
• B) was the potential for biased allocation between tests
avoided through adequate generation of a randomised sequence?
• C) was the potential for biased allocation between tests
avoided through concealment of allocation prior to assignment?
For A)
• Yes - if same selection criteria were used for each index test,
No - if different selection criteria were used for each index test,
Unclear - if selection criteria per test were not described, N/A -
if only 1 index test was evaluated or all participants received all
tests
For B)
• Yes - if adequate randomisation procedures are described,
No - if inadequate randomisation procedures are described,
Unclear - if the method of allocation to groups is not described
(a description of ’random’ or ’randomised’ is insufficient), N/A -
if only 1 index test was evaluated or all participants received all
tests
For C)
• Yes - if appropriate methods of allocation concealment are
described, No - if appropriate methods of allocation concealment
are not described, Unclear - if the method of allocation
concealment is not described (sufficient detail to allow a definite
judgement is required), N/A - if only 1 index test was evaluated
Could the selection of participants have introduced bias?
For non-comparative and within-person-comparative studies
1. If answers to all of questions 1), 2), and 3) ’Yes’:
2. If answers to any 1 of questions 1), 2), or 3) ’No’:
3. If answers to any 1 of questions 1), 2), or 3) ’Unclear’:
For between-person comparative studies
1. If answers to all of questions 1), 2), 3), and 4) ’Yes’:
2. If answers to any 1 of questions 1), 2), 3), or 4) ’No’:
3. If answers to any 1 of questions 1), 2), 3), or 4) ’Unclear’:
For non-comparative and within-person-comparative studies
1. Risk is low
2. Risk is high
3. Risk unclear
For between-person comparative studies
1. Risk is low
2. Risk is high
3. Risk unclear
Participant selection (1) concerns regarding applicability
1) Are the included participants and chosen study setting appro-
priate to answer the review question, i.e., are the study results gen-
eralisable?
• This item is not asking whether exclusion of certain
participant groups might bias the study’s results (as in Risk of
Bias above), but is asking whether the chosen study participants
and setting are appropriate to answer our review question.
Because we are looking to establish test accuracy in both primary
A) For studies that will contribute to the analysis of partici-
pants with a primary presentation of a skin lesion (i.e., test
naive)
Yes - if participants included in the study appear to be generally
representative of those who might present in a usual practice set-
ting
No - if study participants appear to be unrepresentative of usual
practice, e.g., in terms of severity of disease, demographic features,
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presentation and referred participants, a study could be
appropriate for 1 setting and not for the other, or it could be
unclear as to whether the study can appropriately answer either
question
• For each study assessed, please consider whether it is more
relevant for A) participants with a primary presentation of a skin
lesion or B) referred participants, and respond to the questions
in either A) or B) accordingly. If the study gives insufficient
details, please respond Unclear to both parts of the question
presence of differential diagnosis or comorbidity, setting of the
study, and previous testing protocols
Unclear - if insufficient details are provided to determine the
generalisability of study participants
B) For studies that will contribute to the analysis of referred
participants (i.e., who have already undergone some form of
testing)
Yes - if study participants appear to be representative of those who
might be referred for further investigation. If the study focuses
only on those with equivocal lesions, for example, we would sug-
gest that this is not representative of the wider referred population
No - if study participants appear to be unrepresentative of usual
practice, e.g., if a particularly high proportion of participants have
been self-referred or referred for cosmetic reasons. Other factors
to consider include severity of disease, demographic features, pres-
ence of differential diagnosis or comorbidity, setting of the study,
and previous testing protocols
Unclear - if insufficient details are provided to determine the
generalisability of study participants
2) Did the study avoid including participants with multiple le-
sions?
Yes - if the difference between the number of included lesions and
number of included participants is less than 5%
No - if the difference between the number of included lesions and
number of included participants is greater than 5%
Unclear - if it is not possible to assess
Is there concern that the included participants do not match the
review question?
1. If the answer to question 1) or 2) ’Yes’:
2. If the answer to question 1) or 2) ’No’:
3. If the answer to question 1) or 2) ’Unclear’:
1. Concern is low
2. Concern is high
3. Concern is unclear
Index test (2) risk of bias (to be completed per test evaluated)
1) Was the index test or testing strategy result interpreted without
knowledge of the results of the reference standard?
Yes - if index test described as interpreted without knowledge of
reference standard result or, for prospective studies, if index test is
always conducted and interpreted prior to the reference standard
No - if index test described as interpreted in knowledge of reference
standard result
Unclear - if index test blinding is not described
2) Was the diagnostic threshold at which the test was considered
positive (i.e., melanoma present) prespecified?
Yes - if threshold was prespecified (i.e., prior to analysing study
results)
No - if threshold was not prespecified
Unclear - if not possible to tell whether or not diagnostic threshold
was prespecified
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3) For within-person comparisons of index tests or testing strate-
gies (i.e., > 1 index test applied per participant): was each index
test result interpreted without knowledge of the results of other
index tests or testing strategies?
Yes - if all index tests were described as interpreted without knowl-
edge of the results of the others
No - if the index tests were described as interpreted in the knowl-
edge of the results of the others
Unclear - if it is not possible to tell whether knowledge of other
index tests could have influenced test interpretation
N/A - if only 1 index test was evaluated
Could the conduct or interpretation of the index test have intro-
duced bias?
For non-comparative and between-person comparison studies
1. If answers to questions 1) and 2) ’Yes’:
2. If answers to either questions 1) or 2) ’No’:
3. If answers to either questions 1) or 2) ’Unclear’:
For within-person comparative studies
1. If answers to all questions 1), 2), for any index test and 3)
’Yes’:
2. If answers to any 1 of questions 1) or 2) for any index test
or 3) ’No’:
3. If answers to any 1 of questions 1) or 2) for any index test
or 3) ’Unclear’:
For non-comparative and between-person comparison studies
1. Risk is low
2. Risk is high
3. Risk is unclear
For within-person comparative studies
1. Risk is low
2. Risk is high
3. Risk is unclear
Index test (2) concern about applicability
1) Was the diagnostic threshold to determine presence or absence
of disease established in a previously published study?
E.g., previously evaluated/established
• algorithm/checklist used
• lesion characteristics indicative of melanoma used
• objective (usually numerical) threshold used
Yes - if a previously evaluated/established tool to aid diagnosis
of melanoma was used or if the diagnostic threshold used was
established in a previously published study
No - if an unfamiliar/new tool to aid diagnosis of melanoma
was used, if no particular algorithm was used, or if the objective
threshold reportedwas chosenbased on results in the current study
Unclear - if insufficient information was reported
2) Were thresholds or criteria for diagnosis reported in sufficient
detail to allow replication?
Study results can only be reproduced if the diagnostic threshold is
described in sufficient detail. This item applies equally to studies
using pattern recognition and those using checklists or algorithms
to aid test interpretation
Yes - If the criteria for diagnosis of melanoma were reported in
sufficient detail to allow replication
No - if the criteria for diagnosis ofmelanomawereNR in sufficient
detail to allow replication
Unclear - If some but not sufficient information on criteria for
diagnosis to allow replication were provided
3) Was the test interpretation carried out by an experienced ex-
aminer?
Yes - if the test was interpreted by 1 or more speciality-accredited
dermatologists, or by examiners of any clinical background with
special interest in dermatology and with any formal training in
the use of the test
No - if the test was not interpreted by an experienced examiner
(see above)
Unclear - if the experience of the examiner(s) was NR in sufficient
detail to judge or if examiners were described as ’Expert’ with no
further detail given
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N/A - if system-based diagnosis, i.e., no observer interpretation
Is there concern that the index test, its conduct, or interpretation
differ from the review question?
1. If answers to questions 1), 2), and 3) ’Yes’:
2. If answers to questions 1), 2), or 3) ’No’:
3. If answers to questions 1), 2), or 3) ’Unclear’:
1. Concern is low
2. Concern is high
3. Concern is unclear
Reference standard (3) risk of bias
1) Is the reference standard likely to correctly classify the target
condition?
A) Disease-positive - 1 or more of the following:
• histological confirmation of melanoma following biopsy or
lesion excision
• clinical follow-up of benign-appearing lesions for at least 3
months following the application of the index test, leading to a
histological diagnosis of melanoma
B) Disease-negative - 1 or more of the following:
• histological confirmation of absence of melanoma
following biopsy or lesion excision in at least 80% of disease-
negative participants
• clinical follow-up of benign-appearing lesions for a
minimum of 3 months following the index test in up to 20% of
disease-negative participants
A) Disease-positive
Yes - if all participants with a final diagnosis of melanoma under-
went 1 of the listed reference standards
No - If a final diagnosis of melanoma for any participant was
reached without histopathology
Unclear - if the method of final diagnosis was NR for any partici-
pant with a final diagnosis of melanoma or if the length of clinical
follow-up used was not clear or if a clinical follow-up reference
standard was reported in combination with a participant-based
analysis and it was not possible to determine whether the detec-
tion of a malignant lesion during follow-up is the same lesion that
originally tested negative on the index test
B) Disease-negative
Yes - If at least 80% of benign diagnoses were reached by histology
and up to 20% were reached by clinical follow-up for a minimum
of 3 months following the index test
No - ifmore than20%of benigndiagnoseswere reachedby clinical
follow-up for a minimum of 3 months following the index test or
if clinical follow-up period was less than 3 months
Unclear - if the method of final diagnosis was NR for any partic-
ipant with benign or non-melanoma diagnosis
2) Were the reference standard results interpreted without knowl-
edge of the results of the index test?
Please score this item for all studies even though histopathology
interpretation is usually conducted with knowledge of the clinical
diagnosis (from visual inspection or dermoscopy or both).We will
deal with this by not including the response to this item in the
’Risk of bias’ assessment for these tests. For reviews of all other
tests, this item will be retained
Yes - if the reference standard diagnosis was reached blinded to
the index test result
No - if the reference standard diagnosis was reached with knowl-
edge of the index test result
Unclear - if blinded reference test interpretation was not clearly
reported
Could the reference standard, its conduct, or its interpretation
have introduced bias?
For visual inspection/dermoscopy evaluations
1. If answer to question 1) ’Yes’:
2. If answer to question 1) ’No’:
3. If answer to question 1) ’Unclear’:
For all other tests
1. If answers to questions 1) and 2) ’Yes’:
For visual inspection/dermoscopy evaluations
1. Risk is low
2. Risk is high
3. Risk is unclear
For all other tests
1. Risk is low
2. Risk is high
3. Risk is unclear
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2. If answers to questions 1) or 2) ’No’:
3. If answers to questions 1) or 2) ’Unclear’:
Reference standard (3) concern about applicability
1) Are index test results presented separately for each component
of the target condition (i.e., separate results presented for those
with invasivemelanoma,melanoma in situ, lentigomaligna, severe
dysplasia, BCC, and cSCC)?
Yes - if index test results for each component of the target condition
can be disaggregated
No - if index test results for the different components of the target
condition cannot be disaggregated
Unclear - if not clearly reported
2) Expert opinion (with no histological confirmation) was not
used as a reference standard
’Expert opinion’ means diagnosis based on the standard clinical
examination, with no histology or lesion follow-up
***do not complete this item for teledermatology studies
Yes - if expert opinion was not used as a reference standard for
any participant
No - if expert opinion was used as a reference standard for any
participant
Unclear - if not clearly reported
3) Was histology interpretation carried out by an experienced
histopathologist or by a dermatopathologist?
Yes - if histology interpretation was reported to be carried out by
an experienced histopathologist or dermatopathologist
No - if histology interpretation was reported to be carried out by
a less experienced histopathologist
Unclear - if the experience/qualifications of the pathologist were
NR
Is there concern that the target condition as defined by the refer-
ence standard does not match the review question?
1. If answers to all questions 1), 2), and 3) ’Yes’:
2. If answers to any 1 of questions 1), 2), or 3) ’No’:
3. If answers to any 1 of questions 1), 2), or 3) ’Unclear’:
***For teledermatology studies only
1. If answers to all questions 1) and 3) ’Yes’:
2. If answers to questions 1) or 3) ’No’:
3. If answers to questions 1) or 3) ’Unclear’:
1. Concern is low
2. Concern is high
3. Concern is unclear
***For teledermatology studies only
1. Concern is low
2. Concern is high
3. Concern is unclear
Flow and timing (4) risk of bias
1) Was there an appropriate interval between index test and ref-
erence standard?
A) For histopathological reference standard, was the interval be-
tween index test and reference standard ≤ 1 month?
B) If the reference standard includes clinical follow-up of border-
line/benign-appearing lesions, was there at least 3 months’ follow-
up following application of index test(s)?
A)
Yes - if study reports ≤ 1 month between index and reference
standard
No - if study reports > 1 month between index and reference
standard
Unclear - if study does not report interval between index and
reference standard
B)
Yes - if study reports ≥ 3 months’ follow-up
No - if study reports < 3 months’ follow-up
Unclear - if study does not report the length of clinical follow-up
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2) Did all participants receive the same reference standard? Yes - if all participants underwent the same reference standard
No - if more than 1 reference standard was used
Unclear - if not clearly reported
3) Were all participants included in the analysis? Yes - if all participants were included in the analysis
No - if some participants were excluded from the analysis
Unclear- if not clearly reported
4) For within-person comparisons of index tests
Was the interval between application of index tests ≤ 1 month?
Yes - if study reports ≤ 1 month between index tests
No - if study reports > 1 month between index tests
Unclear - if study does not report the interval between index tests
Could the participant flow have introduced bias?
For non-comparative and between-person comparison studies
1. If answers to questions 1), 2), and 3) ’Yes’:
2. If answers to any 1 of questions 1), 2), or 3) ’No’:
3. If answers to any 1 of questions 1), 2), or 3) ’Unclear’:
For within-person comparative studies
1. If answers to all questions 1), 2), 3), and 4) ’Yes’:
2. If answers to any 1 of questions 1), 2), 3), or 4) ’No’:
3. If answers to any 1 of questions 1), 2), 3), or 4) ’Unclear’:
For non-comparative and between-person comparison studies
1. Risk is low
2. Risk is high
3. Risk is unclear
For within-person comparative studies
1. Risk is low
2. Risk is high
3. Risk is unclear
BCC: basal cell carcinoma; cSCC: cutaneous squamous cell carcinoma
Appendix 8. Summary study details: in-person evaluations for detection of invasive melanoma and
atypical intraepidermal melanocytic variants
Study author
Pathway
(clear/
unclear)
Other target
condition as-
sessed
Study type
Setting
Country
Participants/
lesions
Inclusion cri-
teria
Index tests
(algorithm)
Diagnostic
approach
Threshold Observer
qualifications
(number)
Experience
Reference
standard
Final
diagnoses
Prevalence
Exclusions
Ahnlide 2016
Referred (se-
lected on ref-
erence) (u)
WPC-
algorithms
R-CS
Secondary
Sweden
NR/309
Excised
melanocytic
skin lesions
with recorded
dermoscopy
ABCD score
and
clinician’s pre-
liminary diag-
nosis. Prelimi-
Dermoscopy
1. no
algorithm
2. ABCD
In-person
1.
Subjective im-
pression (diag-
nosis of MM)
2. > 4.75; > 5.
45
Dermatology
registrar
or consultants
(n = 13; expe-
rienced unit;
dermoscopy
training); vis-
iting residents
data excluded
Histology
MM 23; MiS
23
BN: 263
57 lesions
with
missing scor-
ing; 5 non-
melanocytic
diagno-
sis; 5 with pre-
op di-
agnosis of LM
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nary diagnosis
of LM or SN
excluded
or SN; 1 with
ambiguous
histopatho-
logical
diagnosis
Bauer 2000
Referred (c)
WPC
NR-CS
Secondary
Italy
311/315
PSL examined
during a cam-
paign for the
early diagnosis
of cutaneous
melanoma
(CM)
Der-
moscopy (no
algorithm)
(Also evalu-
ated CAD-
Dermoscopy)
NR
Subjective im-
pression (diag-
nosis of malig-
nancy)
Dermatologist
(n = 3; trained
in recognition
of PSLs)
Consensus of
3 (expert con-
sult for dis-
agreements)
Histology
MM 30; MiS
12
’Atypical’ dys-
plastic 25; BN
212; NML 36
-
Benelli 1999
Referred (se-
lected on ref-
erence) (u)
WPC
P-CS
Secondary
Italy
NR/401
All
PSL observed
and excised at
the Dermato-
logic Surgery
Department
1. VI
(ABCDE)
2.
Dermoscopy
(7FFM)
In-person
1. ≥ 1 to all
5 characteris-
tics present
2. Score ≥ 2
Derma-
tologist (n = 2;
exp NR)
Consensus of
2
Histology
MM 54; MiS
6
BCC 1
BN 337; LS 5;
SK 1
60/401; 15%
NR
Bono 2002a
Referred (se-
lected on ref-
erence) (c)
WPC
P-CS
Specialist
clinic
Italy
298/313
PSL
with a more
or less impor-
tant suspicion
for MM on
VI and/or der-
moscopy
1 .VI (no algo-
rithm)
2. Der-
moscopy (no
algorithm)
In-person
(also evaluates
CAD-
Dermoscopy)
VI - subjective
impression
Dermosc - ≥
1 characteris-
tic present
Surgical on-
cologist (n = 4;
high)
Single
observer
Histology
MM 55; MiS
11
BCC 6; 8 SK;
3 SN; BN 230
66/313; 21%
NR
Bono 2002b
Referred (se-
lected on ref-
erence) (c)
WPC
P-CS
Specialist
clinic
Italy
157/161
PSL ≤ 6 mm
requiring sur-
gical biopsy
for diag-
nosis based on
clinical or der-
moscopic sus-
picion of MM
1. VI (no algo-
rithm)
2. Der-
moscopy (no
algorithm)
In-person
VI - subjective
impression
Dermoscopy-
≥ 1 character-
istic present
Surgical on-
cologist (n = 2;
high)
Single
observer
Histology
MM 10; MiS
3
BCC 2; SK 4;
SN 5; BN 124
13/161; 8%
NR
Bono 2006
Referred (se-
lected on ref-
erence) (c)
WPC
R-CS
Specialist
clinic
Italy
204/206
PSL ≤ 3 mm
under-
going excision
due to a more
or less impor-
tant suspicion
for MM on
1. VI (no algo-
rithm)
2.
Dermoscopy
(Menzies)
In-person
VI - subjective
impression
Dermoscopy-
NR
NR; assumed
surgical oncol-
ogist
as per Bono
2002a; Bono
2002b (n = 4;
exp NR)
Histology
MM 19; MiS
4
SN 3; BN
169; Other 11
23/206; 11%
NR
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VI and/or der-
moscopy
Single
observer
Broganelli
2005
Referred (se-
lected on ref-
erence) (u)
NC
P-CS
Secondary
Italy
NR/638
PSL undergo-
ing ex-
cision; 2x2 for
melanocytic
only included
Dermoscopy
(7PCL)
Unclear if in-
person or im-
age-based
> 1 change in
minor criteria
or ≥ 1 ma-
jor character-
istic present
Dermatologist
(assumed) (n =
NR; exp NR)
Histology
MEL 108
‘Non-
melanoma’
530
-
Carli 1994
Equivocal (se-
lected on ref-
erence) (c)
NC
NR-CS
Secondary
Italy
67/67
Clinically sus-
picious
melanocytic
lesions under-
going excision
for diagnostic
purposes (ob-
vious MM ex-
cluded)
Der-
moscopy (pat-
tern analysis)
In person
Irregu-
lar pigmented
network + ≥
1 other listed
characteristic
Derma-
tologist (n = 2;
exp High)
Consensus of
2
Histology
MM 3; MiS 2
BN 62
5/68; 7%
-
Carli 2002a
Referred (se-
lected on ref-
erence) (u)
WPC
R-CS
Secondary
Italy
NR/256
Clin-
ically equivo-
cal and suspi-
cious PSL sub-
jected to ex-
cisional biopsy
at the Institute
of Dermatol-
ogy
1. VI (no algo-
rithm)
2. Der-
moscopy (pat-
tern)
In-
person (Der-
moscopy - im-
age-based)
Subjective im-
pression
Der-
matologist (n
= 2;High exp -
“extensive ex-
perience
in both clin-
ical and der-
moscopic di-
agnosis”)
Consensus of
2
Histology
MM 40; MiS
14
BCC 5
BN 177; SN
16; SK 4
54/256; 21%
NR
Cristofolini
1994
Referred (se-
lected on ref-
erence) (u)
WPC
P-CS
Secondary
Italy
NR/220
Patients with
PSL present-
ing during a
campaign for
the early diag-
nosis of cuta-
neous
melanoma at
the Dermatol-
ogy
Department
1. VI
(ABCDE)
2. Der-
moscopy (pat-
tern)
In-person
1. ≥ 2 charac-
teristics
present
2. ≥ 1 charac-
teristic present
Dermatologist
(n = 4; High
exp - derma-
tologists
had all been
trained in the
recognition of
pigmented le-
sions)
Unclear
observer inter-
pretation
Histology
MEL 33
BCC 0
BN181; SK4;
2 other
33/220; 15%
NR
Dreiseitl 2009
Referred (c)
NC
P-CS
Specialist
clinic
Austria
Patients pre-
senting at PSL
clinic
that serves as a
secondary and
Der-
moscopy (no
algorithm)
NR
Subjective im-
pression (diag-
nosis of MM)
Derma-
tologist (n = 1;
‘expert’)
Single
observer
Histol-
ogy or FU (6
months)
MEL 31 (27
participants)
806 le-
sions (53 par-
ticipants) with
inadequate
follow-up
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458/3021 tertiary refer-
ral centre
’Benign’: 2990
(431
participants)
27/458; 6%
Duff 2001
Referred (se-
lected on ref-
erence) (c)
NC
R-CS
Specialist
clinic
UK
NR/2372
Excised le-
sions recorded
on PSL
database
Der-
moscopy (no
algorithm)
In person
Subjective as-
sessment (de-
cision to ex-
cise)
Plas-
tic surgeon (n
= 1; exp NR)
Single
observer
Histology or
FU
MM
400; MiS 186;
BCC: 316;
cSCC: 97
Dysplastic
195; “other”
14; ’Be-
nign’ (not ex-
cised): 1164
586/2372;
25%
NR
Results
for BCC; SCC
not disaggre-
gated from be-
nign lesions
Durdu 2011
Referred (se-
lected on ref-
erence) (u)
Any
WPC
P-CS
Secondary
Turkey
176/200
PSL that could
not be diag-
nosed with
only dermato-
logic physical
examina-
tion; 2x2 in-
cluded for
melanocytic
subset
Dermoscopy
(ABCD; non-
melanocytic
excluded first)
(Also eval-
uated exfolia-
tive cytology)
In person
NR Derma-
tologist (n = 1;
exp NR)
Single
observer
Histology
MEL:
10; BCC: 34;
Other malig-
nant 2
SK 24; BN
100; DF 12;
warts 16; dirt
1; other 1
10/200; 5%
-
Feldmann
1998
Referred (se-
lected on ref-
erence) (u)
Invasive
melanoma
NC
P-CS
Secondary
Austria
NR/500
Melanocytic
lesions exam-
ined by der-
matoscopy
prior to exci-
sion
Dermoscopy
(ABCD)
In person
> 5.45 NR (n = NR;
exp NR)
Unclear
observer inter-
pretation
Histology
MM 25; MiS
5
BN 272; dys-
pla-
sia 190; lentig-
ines 7; lentigo
naevi 1
30/500; 6%
NR
Gokdemir
2011
Referred (se-
lected on ref-
erence) (u)
NC
NR-CS
Secondary
Turkey
362/449
Patients with
melanocytic
and non-
melanocytic
skin le-
sions with der-
moscopic and
histologic di-
agnoses
Der-
moscopy (no
algorithm)
Unclear if in-
person or im-
age-based
Subjective as-
sess-
ment (diagno-
sis of MM)
Dermatologist
(n = NR; exp
High “at least
2 years’ ex-
perience with
Molemax II”)
Unclear
observer inter-
pretation
Histology
MEL: 13;
BCC: 45
Benign: 390
13/448; 3%
Bham team:
1 BCC moved
from FP to
TN)
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Grimaldi
2009
Limited prior
testing (c)
WPC
P-CS
Primary
Italy
197/235
Cuta-
neous PSL re-
quiring confir-
mation of di-
ag-
nosis by teled-
ermatology
1. VI (no algo-
rithm)
2. Der-
moscopy (no
algorithm)
In-person
(single)
(Also eval-
uated Teleder-
matology)
Subjective im-
pression (‘sus-
picious for
malignancy’)
GP (n = 13)
Assumed Low
(expertise NR;
simple proto-
cols for diag-
nosis provided
for study pur-
poses)
Histology/
clinical FU (6
months)
MEL: 5;
BCC
0; benign 230
(NR)
5/235; 2%
NR
Guitera 2009a
(Modena)
Referred (se-
lected on ref-
erence) (c)
WPC
P-CS
Secondary
Italy
195/195
Lesions
excised on the
basis of clin-
ical suspicion
(history, der-
moscopy
examination,
and/or digital
monitoring)
Der-
moscopy (pat-
tern analysis)
(Also evalu-
ated RCM)
In-person
Subjective as-
sess-
ment (diagno-
sis of MM)
Derma-
tologist (n = 2;
exp High)
Single
observer
Histology
MM 61; MiS
18
BN 116
(including 22
SN)
79/198; 41%
Only 50% of
imaged naevi
were included
(randomly se-
lected
from the im-
age database
prior to anal-
ysis) to reduce
the MM/nae-
vus ratio
Haenssle
2010a (FV)
Referred (u)
NC
P-CS
Secondary
Germany
688/11137
FV: 8449
Participants at
increased risk
formelanoma:
> 50 common
and/or ≤ 3
atypical naevi;
atypical mole
syndrome
(AMS); or fa-
milial atypical
mole andmul-
ti-
ple melanoma
syndrome.
(First visit data
included here)
Dermoscopy
(7PCL)
≥ 3 Dermatology
residents (n
= 13; formally
trained in der-
moscopy and
su-
pervised by ex-
perienced der-
matologist)
Consensus of
2
Histol-
ogy or FU (ev-
ery 3, 6, or 12
months)
Full sample:
MM 77; MiS
50; BCC 2
BN 1047; SN
16; SK
12; Other be-
nign 9935
40/8449; 0.
005%
-
Haenssle
2010b (FU)
Follow-up (u)
NC
P-CS
Secondary
Germany
Full sample;
688/11137
FU: 2688 le-
sions
Participants at
increased risk
formelanoma:
> 50 common
and/or ≤ 3
atypical naevi;
atypical mole
syndrome
(AMS); or fa-
Dermoscopy
(7PCL)
In person
≥ 3 Dermatology
residents (n
= 13; formally
trained in der-
moscopy and
su-
pervised by ex-
perienced der-
Histol-
ogy or FU (ev-
ery 3, 6, or 12
months)
Full sample:
MM 77; MiS
50; BCC 2
BN 1047; SN
-
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milial atypical
mole andmul-
ti-
ple melanoma
syndrome (FU
data only in-
cluded here)
matologist)
Consensus of
2
16; SK
12; Other be-
nign 9935
87/2688; 3%
Kittler 1999
Referred (se-
lected on ref-
erence) (u)
WPC-
algorithms
P-CS
Secondary
Austria
352/373
Melanocytic
PSL < 1 cm in
diameter, con-
secutively ex-
cised
Dermoscopy
1. ABCD
2. ABCDE
(developed in
this study)
In-person
1. Sensitiv-
ity at range of
specifici-
ties (randomly
sampled 75%
spec) (author
communica-
tion suggests >
4.75 used)
2. cutoffs be-
tween 1.30-7.
35
Dermatologist
(assumed) (n =
NR; exp NR)
Unclear
observer inter-
pretation
Histology
MM 55; MiS
18
SK 4; BN126;
atypical naevi
113; congen-
ital naevi 3,
SN 13; blue
naevi 7; solar
lentigines 14;
DF 1; com-
bined naevi 2
73/356; 21%
Non-
melanocytic
lesions (n =
17; including
angiomatous
tumours, pig-
mented SK,
DF, and pig-
mented BCC)
“easily dis-
tinguished by
standard ELM
crite-
ria and pattern
analysis”
Langley 2007
Referred (se-
lected on ref-
erence) (u)
WPC
P-CS
Specialist
clinic
Canada
125/125
Patients with
lesions sched-
uled for exci-
sion
at the PLC to
either remove
atypical naevi
or to rule out
melanoma or
for cos-
metic reasons;
excluded if le-
sion
not amenable
to RCM or
prior diagno-
sis biopsy
Der-
moscopy (pat-
tern analysis)
(Also evalu-
ated RCM)
In-person
Subjective as-
sess-
ment (diagno-
sis of MM)
Dermatolo-
gist (assumed)
; (n = 1; exp
NR)
Histology
MM 22; MiS
15
BN 88
37/125; 30%
Technical dif-
ficulties with
imaging (n =
2)
Menzies 2009
Limited prior
testing (c)
Any
WPC-
algorithms
P-CS
Primary
Australia
NR/374
PSL
that would be
biopsied or re-
ferred on after
rou-
tine naked-eye
examination
1 .VI (no algo-
rithm)
2. Der-
moscopy (no
algorithm)
In-person
(single)
Subjective im-
pression (“cor-
rect diagnosis
ofmelanoma”;
excise
decision)
GP (n = 62)
Assumed Low
(trained in
dermoscopy
for study; re-
quired history
of excision or
Histology/
clinical FU (3-
6 months)/ex-
pert diagnosis
MEL: 32;
BD
2; benign 323;
6 BCC
and 2 BD ex-
cluded by au-
thors, 43 ex-
cluded as both
VI + Dermo-
scopic
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referral of at
least 10 PSLs
over the previ-
ous 12-month
period but no
prior der-
moscopy use)
unknown 9
4%
diagnoses not
available
Morales
Callaghan
2008
Referred (se-
lected on ref-
erence) (u)
WPC
P-CS
Secondary
Spain
166/200
Randomly se-
lected
melanocytic
lesions;
melanocytic
on both clin-
ical and der-
moscopic cri-
teria
1. VI (no algo-
rithm)
2. Der-
moscopy (no
algorithm)
In-person
NR Der-
matologist (n
= 2; high exp -
“experience in
dermoscopy”)
Consensus of
2
Histology
MEL: 6
BN 184; SN
1; other 9
6/200; 3%
NR
Nachbar 1994
Referred (se-
lected on ref-
erence) (u)
NC
P-CS
Secondary
Germany
NR/194
Pigmented
melanocytic
skin le-
sions consecu-
tively excised
Dermoscopy
(ABCD)
In person
(excluded VI
data as der-
moscopy also
used for VI)
> 5.45 Dermatolo-
gist (assumed)
(n = NR; exp
High)
Histology
MEL: 69;
BCC 3
BN 103; SK
19
69/194; 36%
-
Soyer 1995
Equivocal (se-
lected on ref-
erence) (c)
Any
WPC
NR-CS
Austria
NR/159
PSL difficult
to diagnose on
clinical
grounds alone
1. VI (no algo-
rithm)
2. Der-
moscopy (pat-
tern)
In-person
NR Dermatolo-
gist (n = 2; exp
High; “the ex-
amination was
performed by
a dermatolo-
gist expert in
dermoscopy”)
Single
observer
Histology
MM 50; MiS
15
BCC 3; SK
18; AK 4; BN
61; other 7
65/159; 41%
NR
Stanganelli
2000
Referred (c)
Any
WPC
R-CS
Specialist
clinic
Italy
NR/3372
PSL referred
by dermatolo-
gists and
general practi-
tioners
either for pre-
surgical assess-
ment or con-
sultation
1. VI (ABCD)
2. Der-
moscopy (no
algorithm)
In-person
(single)
NR
Subjective im-
pression
NR (assumed
dermatologist
- described as
one of the co-
authors; n = 1)
Histology/
registry FU
MEL: 55
BCC 43; be-
nign 3274
55/3372; 2%
NR
BCC: 3 BCCs
considered to
be MM were
classed as TN
rather than FP
for review pur-
poses
3PCL: three-point checklist; 4PCL: four-point checklist; 7FFM: seven features for melanoma; 7PCL: seven-point checklist; ABCD
(E): asymmetry, border, colour, differential structures (enlargement); AJCC: American Joint Committee on Cancer; AK: actinic
keratosis; AMN; acral melanocytic naevi; BCC: basal cell carcinoma; BD: Bowen’s disease; Bham: Birmingham; BN: benign naevi;
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BPC: between person comparison (of tests); c: clearly positioned on clinical pathway; CCD: compact disc; CAD: computer-assisted
diagnosis; CASH: colour, architecture, symmetry and homogeneity; CCS: case-control study; CM: cutaneous melanoma; CMM:
cutaneous malignant melanoma;CS: case series; cSCC: cutaneous squamous cell carcinoma; DF: dermatofibroma; ELM: epilumi-
nescence microscopy; FP: false positive; FU: follow-up; GP: general practitioner; IDS: International Dermoscopy Society; IQR:
interquartile range; LK: lichen sclerosis; LM: lentigo maligna; LP: lichen planus; LS: lentigo simplex; MEL: invasive melanoma or
melanoma in situ;MM: malignant (invasive) melanoma;MiS: melanoma in situ;MN:melanocytic naevi; N/A: not applicable; NC:
non-comparative; NML: non melanocytic lesion; NR: not reported; P: prospective; PLC: pigmented lesion clinic; PSL: pigmented
skin lesion; R: retrospective; RCM: reflectance confocal microscopy; RCT: randomised controlled trial; SCC: squamous cell carci-
noma; SD: standard deviation; SK: seborrhoeic keratosis; SN: Spitz naevi; SSM: superficial spreading melanoma; TN: true negative;
u: unclear position on clinical pathway; VI: visual inspection; WPC: within person comparison (of tests)
Appendix 9. Summary study details: image-based evaluations for detection of invasive melanoma
and atypical intraepidermal melanocytic variants
Study
author
Pathway
(clear/
unclear)
Other
tar-
get con-
dition as-
sessed
Study
type
Country
Setting
Partici-
pants/
lesions
Inclu-
sion cri-
teria
Index
tests (al-
gorithm)
Diagnos-
tic ap-
proach
Thresh-
old
Observer qualifications (number)
Experience
Refer-
ence
standard
Final di-
agnoses
Preva-
lence
Exclu-
sions
Com-
ments
Alarcon
2014
Equiv-
ocal (se-
lected on
reference)
(c)
WPC
P-CS
Specialist
clinic
Spain
264/264
Dermo-
scopically
equivocal
pig-
mented
lesions,
assumed
to be
melanocytic
Der-
moscopy
(no algo-
rithm)
Image-
based
(RCM,
site, age)
(also eval-
uated
RCM)
NR; di-
agnosis of
MM
Dermatologist (n = 3; exp NR) described as
expert in RCM
Single observer
Histology
or FU; 79
followed-
up
MEL 92;
BCC: 12
BN 107;
53 SK
and AK
92/343;
27%
79 lesions
with-
out crite-
ria of ma-
lignancy
on RCM
were
sched-
uled
for clini-
cal or dig-
ital FU
Annessi
2007
Equiv-
ocal (se-
lected on
reference)
(u)
WPC-al-
gorithms
NR-CS
Specialist
clinic
Italy
195/198
Atypical
macular
melanocytic
lesions;
all >
5 mm
diameter,
with a flat
Der-
moscopy
(pattern
analysis;
7PCL;
ABCD)
Image-
based
NR -
likely
’stan-
dard’;
ABCD ≥
4.75
Dermatologist (n = 2; exp High) ELM-experi-
enced dermatologists” Consensus of 2
Histology
MM 72;
MiS 24
BN 102
96/198;
48%
NR
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or barely
elevated
surface
and at
least 3
of the
following
features:
(a) asym-
metry, (b)
irregular
margins,
(c) ill-
defined
borders,
and (d)
colour
variega-
tion
(blinding
NR)
Argen-
ziano
1998
Re-
ferred (se-
lected on
reference)
(u)
WPC-al-
gorithms;
observer
R-NR
Sec-
ondary
Italy
NR/342
Atypical
melanocytic
skin
lesions
with der-
moscopic
images
that had
under-
gone
biopsy
due to
clinician
suspicion
Der-
moscopy
(pattern
analysis;
ABCD;
7PCL)
Image-
based
(blinded)
Overall
diagno-
sis MM;
ABCD >
4.
75; 7PCL
≥ 3
Dermatologist (n = 3 experienced; n = 2 less
experienced who underwent training)
Consensus of 2 (expert)
Single (less experienced)
Histology
MM 99;
MiS 18
BN 225
117/342;
34%
NR
Argen-
ziano
2011
Re-
ferred (se-
lected on
reference)
(c)
WPC-al-
gorithms
CCS
Sec-
ondary
Italy
NR/300
Ran-
domly
sampled
100
melanomas;
100
excised
BN 100
BN that
showed
no rel-
evant
changes
to war-
Der-
moscopy
(pattern
analysis;
7PCL;
7PCL re-
vised)
Image-
based
(blinded)
Pattern
- diagno-
sis ofMM
and excise
decision;
7PCL ≥
3; revised
≥ 1)
Dermatologist (n = 8; exp NR) average Histology
or FU
MEL 100
57 Clark
naevi, 28
SN, 10
congen-
ital naevi,
5 blue
naevi;
100 not
excised
100/300;
NR
614Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
rant
excision
during
the FU
period;
all ≤ 15
mm
33%
Benelli
2000a
Re-
ferred (se-
lected on
reference)
(u)
WPC
CCS
Sec-
ondary
Italy
NR/600
All small
(≤ 6
mm)
melanomas
and
melanocytic
naevi
consec-
utively
excised
over 2
different
time
periods
1. VI
(ABCD)
2. Der-
moscopy
(7FFM)
Image-
based
(blinding
NR)
Both ≥ 2 Dermatologist (assumed) (n = 3; exp NR) eval-
uated by 3 different observers; in case of dis-
agreement , the majority view prevailed
Consensus of 3
Histology
alone
MEL 76
BN 524
76/600;
13%
NR
Benelli
2001
Re-
ferred (se-
lected on
reference)
(u)
WPC
R-CS
Italy
Training
images
NR/50
Slides
of PSL se-
lected
for evalu-
ationdur-
ing
a training
course on
der-
moscopy.
Le-
sions not
located
on head,
palms or
soles
1. VI
(ABCDE)
2. Der-
moscopy
(7FFM)
Image-
based
(blinded)
1. ≥ 3 &
≥ 2
2. ≥ 2
Expert author (n = 1); dermatologists (n = 65)
Single author - High exp; average result for der-
matologist group; exp NR
Histology
MM 10,
MiS 2
BCC 2
BN
25, SN 5,
SK 3,
other 2 (1
missing)
12/50;
24%
NR
Binder
1994
Re-
ferred (se-
lected on
reference)
(u)
WPC
RCS
Sec-
ondary
Austria
NR/200
Images of
PSL ran-
domly se-
lected
from a
image
database.
Der-
moscopy
(pattern
analysis)
(Also
evaluates
CADder-
moscopy)
Image-
Subjec-
tive
impres-
sion (di-
agnosis of
MM)
Dermatologist (n = 3; exp High)
Consensus of 2
Histology
MEL 40
BN 60
40/100;
40%
NR
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based
(blinded)
Binder
1995
Re-
ferred (se-
lected on
reference)
(u)
WPC-
observer
RCS
Sec-
ondary
Austria
NR/240
PSL with
avail-
able der-
moscopy
images,
both with
and with-
out oil
immer-
sion, and
histologi-
cal confir-
mation of
diagnosis
Der-
moscopy
(no algo-
rithm)
(Der-
moscopy
with/
without
oil im-
mersion)
Image-
based
(blinded)
Subjec-
tive
impres-
sion (di-
agnosis of
MM)
Dermatologist (n = 6 expert; n = 13 non-expert)
;
Average
Histology
MEL 57;
BCC: 8
Severe
dysplasia:
42; other
’Benign’ :
133
57/240;
24%
NR
Test re-
sults not
disaggre-
gated for
BCC
Binder
1999
Re-
ferred (se-
lected on
reference)
(u)
WPC-al-
gorithms
RCS
Sec-
ondary
Austria
NR/250
Ran-
domly se-
lected,
histologi-
cally
proven
PSL
with digi-
tal der-
moscopy
images
Der-
moscopy
(pattern
analysis;
ABCD)
Image-
based
(blinded)
Subjec-
tive
impres-
sion (di-
agnosis of
MM);
ABCD at
> 4.75; >
5.45
Mixed (n = 17; exp mixed) dermatology resi-
dents - 5; dermatologist (board-certified) - 12
Average result
Histology
MM 34;
MiS 7
BN 182;
13 SN;
14 lentig-
ines
41/250;
16%
NR
Blum
2003a
Re-
ferred (se-
lected on
reference)
(u)
WPC-alg
R-CS
Specialist
clinic
Germany
NR/269
Melanocytic
skin
lesions to
be excised
because
of clin-
ically
and/or
dermo-
scopically
clear or
suspi-
cious ma-
lignancy,
or by
the wish
of the
patient
ABCD
(modi-
fied)
; ABCDE
(modi-
fied)
Image-
based
(unclear)
NR Dermatologist (assumed) (n = NR; exp NR)
NR
Histology
MM 71;
MiS 9;
lM 4
’Benign’:
185
84/269;
31%
*dataset
over-
laps Blum
2004b
so not in-
cluded in
primary
analysis,
only algo-
rithm
compar-
isons (re-
cruited
Novem-
ber 1998-
March
2000)
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after clear
benign
diagno-
sis*
Blum
2003b
Re-
ferred (se-
lected on
reference)
(u)
NC
R-CS
Specialist
clinic
Germany
205/254
All
lesions of
patients
with mul-
tiple
atypical
naevi ex-
cised due
to suspi-
cious
clinical or
dermo-
scopic
features,
or both,
were in-
cluded*
New
(based on
Hof-
mann-
Wellen-
hof
2001)
Image-
based
(blinded)
Presence
of reticu-
lar, glob-
ular and
homoge-
neous
structures
Dermatologist (assumed) (n = 2; exp NR)
Consensus of 2
Histology
MM 63;
MiS 12
BN 64;
dysplastic
96; other
nevus 19
75/254;
30%
*dataset
overlaps
Blum
2004b so
not in-
cluded in
primary
analysis,
only
algorithm
com-
parisons
(recruited
Septem-
ber 1998
to De-
cember
1999)
Blum
2004a
Re-
ferred (se-
lected on
reference)
(u)
WPC-
observer
R-CS
Specialist
clinic
Germany
157/157
PSL ex-
cised due
to suspi-
cious
clin-
ical and/
or dermo-
scopic
features
Pattern
analysis
Image-
based
(blinded)
Level of
suspicion
’roughly
50% or
more’.
Dermatologist (assumed) (n = 3; with “differ-
ent experiences in dermoscopy: excellent (A),
average (B) and beginner (C).“
Single
Histology
MM
29;MiS 2
BN 53;
dys-
plastic 59
’epithelial
benign’
13
32/157;
20%
*dataset
over-
laps Blum
2004b
so not in-
cluded in
primary
anal-
ysis, only
observer
compar-
isons (re-
cruited
Septem-
ber 1998
to March
1999)
Blum
2004b
Referred
(u)
WPC-al-
gorithms
P-CS
Specialist
clinic
Germany
NR/837
Melanocytic
skin
lesions
imaged
prospec-
tively at
Der-
moscopy
(ABCD;
7PCL;
7FFM;
Menzies)
Image-
NR - au-
thor con-
firms
”pub-
lished
standards
used“
Dermatologist (assumed); n = 1
Single observer
Histol-
ogy or FU
(568 be-
nign ex-
am-
ined 2-3
times in 6
NR
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the PLC based
(blinded)
(also eval-
uated
CAD-
Der-
moscopy)
months)
MM 71;
MiS 9;
lM 4
’Benign’
766
84/837;
10%
Bourne
2012
3-Lim-
ited test-
ing (se-
lected on
reference)
(c)
WPC-al-
gorithms;
algo-
rithms
R-CS
Australia
Primary
46/50
All skin
lesions
excised to
exclude
skin can-
cer (and 3
examples
common
lesions as-
sessed
as clearly
be-
nign and
not biop-
sied)
VI (no al-
gorithm)
Der-
moscopy
(3-point;
Menzies;
BLINCK*)
Image-
based
(blinded)
NR GP (n = 3)
Clinical nurse (n = 1)
Mixed exp “varying levels of dermatoscopic ex-
perience”
Average
Histol-
ogy/clin-
ical FU/
expert di-
agnosis
MM 1;
MiS 8
BCC 6;
SK 5; BN
11; other
19
9/45;
20%
5 non-
pig-
mented
speci-
mens
(not fur-
ther iden-
tified) in
the set of
50 were
excluded
from der-
moscopic
evalua-
tions
*data for
BLINCK
excluded
as deriva-
tion
Carli
2002a
Re-
ferred (se-
lected on
reference)
(u)
WPC
NR-CS
Sec-
ondary
Italy
NR/256
Clinically
equiv-
ocal and
suspi-
cious PSL
1.
VI (no al-
gorithm)
(in-
person)
2. Der-
moscopy
(pat-
tern anal-
ysis) (in-
person
and
image-
based)
Image-
based
(age, site
provided)
Subjec-
tive
impres-
sion (di-
agnosis of
MM)
Dermatologist (n = 2; exp High; ‘extensive ex-
perience in both clinical and dermoscopic di-
agnosis of PSLs’)
Consensus of 2
Histology
alone
MM 40;
MiS 14
BCC: 5
SK 4; BN
168; 9
blue
naevi; 16
SN
54/256;
21%
None
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Carli
2002b
Re-
ferred (se-
lected on
reference)
(u)
Any
WPC
R-CS
Italy
Sec-
ondary
NR/57
Clin-
ically sus-
picious or
equiv-
ocal PSL
under-
going ex-
cision for
diagnos-
tic pur-
poses; all
≤ 14 mm
diameter
1. VI
(NR)
2. Der-
moscopy
(NR)
Image-
based
(blinded)
NR Dermatologists (n = 2)
High exp (’with experience in the field of ’);
consensus of 2
Histology
MM 6,
MiS 5
BCC 10
BN
31, SK 1;
other 4
11/57;
19%
4 ‘not
evalu-
ables’ ex-
cluded
(NB these
differ be-
tween
clinical
images
and der-
moscopic
images (1
MM ex-
cluded
from VI
analysis)
Carli
2003a
Re-
ferred (se-
lected on
reference)
(u)
WPC-al-
gorithms
RCS
Sec-
ondary
Italy
NR/200
Melanocytic
lesions <
14 mm in
diameter,
excised
because
they were
clinically
suspi-
cious or
equivocal
Der-
moscopy
(pattern
analysis;
ABCD;
7PCL)
Image-
based
(blinded)
Subjec-
tive
impres-
sion (di-
agnosis of
MM)
; ABCD>
5.
45; 7PCL
≥ 3
Dermatology registrar (n = 5; exp low)
Single observer
Histology
MM 30;
MiS 14
BN 156
44/200;
22%
NR
Carli
2003b
Equiv-
ocal (se-
lected on
reference)
(u)
WPC
R-CS
Italy
Sec-
ondary
NR/200
Clinically
difficult
to diag-
nose or
equivocal
melanocytic
lesions
randomly
selected;
all
melanomas
< 1 mm
thickness
1.
VI (no al-
gorithm)
2. Der-
moscopy
(own
choice)
Image-
based
(blinding
NR)
Subjec-
tive im-
pression
Dermatology registrar (n = 2); dermatologists
(senior experts n = 2; practicing dermatologists
n = 4)
Average result
Histology
MM 40;
MiS 24
BN 136
64/200;
32%
NR
Carrera
2016
Referred
(u)
WPC-al-
gorithms
CCS
Specialist
clinic
Images of
melanocytic
lesions
including
MM
Der-
moscopy
(ABCD;
7PCL;
CASH;
> 4.75; ≥
3; ≥
6; 2 nega-
tive and 1
pos-
GP24; dermatology registrar 25; dermatologist
73; 1 medical student and 7 ’other’;
Mean 12 years (SD 8.7) dermatology exp; 93.
8% ”comfortable“ using dermoscopy
Consensus (≥ 50%)
Histology
or FU (se-
quential
dermo-
NR
*Up to
50 lesions
per PLC
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Multi-
centre
NR/477*
with un-
equivocal
histology,
and
histo-
logically
verified
naevi
or naevi
demon-
strating
stability
under se-
quential
dermo-
scopic
imaging
over time
Menzies;
3PCL;
Chaos/
Clues)
Image-
based
(clin-
ical image
also pro-
vided)
itive char-
acteristic;
≥ 2; both
present
scopic
imaging
over time;
n = NR)
MEL 119
BN: 358
119/477;
25%
(1:3
ratio of
MEL to
BN; 1:1
polarised
or non-
polarised
images)
; ran-
domised
into 12
image
sets of 39
(n = 8) or
40 (n =
7) unique
lesions
and 5
non-
unique
lesion
images
(2 MEL,
3 BN)
repeated
in all sets
Dal Pozzo
1999
Re-
ferred (se-
lected on
reference)
(u)
NC
PCS
Sec-
ondary
Italy
NR/713
PSL ob-
served
clin-
ically and
dermo-
scopically
Der-
moscopy
(7FFM)
Image-
based
(blinded)
≥ 2 Dermatologist (assumed) (n = 3; exp NR)
Consensus of 3
Histology
MM 139;
MiS 29;
BCC: 1
SK 3; BN
536;
other 5
168/713;
24%
None
All BCC
consid-
ered TN
di Meo
2016
Re-
ferred (se-
lected on
reference)
(u)
WPC-al-
gorithms
RCS
Sec-
ondary
Italy
125/125
Melanocytic
skin
lesions
that un-
derwent
excision
(*accu-
racy data
excludes
the dys-
plastic
naevi)
Der-
moscopy
(3PCL;
CASH;
4PCL)
Image-
based
(blinded)
≥ 2 char-
acteristics
present;
≥ 8; ≥ 2
Dermatologist (n = 2; exp High) NR Histol-
ogy;
MEL 32
BN 43
32/75;
43%
50 lesions
with
mild/
mod-
erate dys-
plasia ex-
cluded
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Doliani-
tis
2005
Re-
ferred (se-
lected on
reference)
(u)
WPC-al-
gorithms
R-CS
Multi-
centre
Training
images
NR/40
Melanocytic
skin
lesions
randomly
selected
from a
collection
of der-
moscopic
images
belong-
ing to one
author
1.
VI (no al-
gorithm)
2. Der-
moscopy
(pattern
analy-
sis; Men-
zies crite-
ria; 7-
point;
ABCD)
Image-
based
(blinded)
1. subjec-
tive im-
pression
2. subjec-
tive
impres-
sion; NR;
NR; > 4.
75
Dermatologists (n = 16); dermatology trainees
(n = 16); GPs (n = 35)
Mixed exp (“range of experience levels with as-
sessment of skin lesions”);
Average result
Histology
(n = 39);
expert di-
agnosis (n
= 1)
MM 18,
MiS 2
BN
12; SN 3;
other 4
20/20;
50%
NR;
poor-
qual-
ity images
exclusion
criterion
Dummer
1993
Equiv-
ocal (se-
lected on
reference)
(c)
WPC
P-CS
Sec-
ondary
Germany
NR/771
Patients
with skin
lesions
diffi-
cult to di-
agnose
clinically
1.
VI (no al-
gorithm)
2. Der-
moscopy
(pattern
analysis)
Image-
based
(blinding
NR)
Unclear
(German
language)
; diagno-
sis ofMM
Dermatologist (assumed) (n = 2; exp unclear)
limited detail; German paper
Single
Histology
MM 23
BN 706;
SK 4;
BMN 32
23/771;
3%
Further
53 non-
melanocytic
lesions
not
included
prior to
examina-
tion (no
melanomas
present
in this
group)
Feci 2015
Re-
ferred (se-
lected on
reference)
(u)
BPC
RCS
Sec-
ondary
Italy
321/321
PSL
suspi-
cious for
melanoma
and
excised;
observers
randomly
allocated
to obser-
vation
with
different
”stres-
sors“*
Der-
moscopy
(pattern
analysis)
Image-
based
(blinded)
NR; di-
agnosis of
MM
Dermatologist (n = 3; exp High) ’expert der-
matologists’ ”with at least 10 years’ exp in der-
moscopy“ NR
Histology
MM 99;
MiS 33
BN 219
34/107;
32%
NR
*Data
pooled
across
arms for
primary
analysis
Feld-
mann
1998
NC
P-CS
Sec-
Melanocytic
lesions
Der-
moscopy
(ABCD)
> 5.45; >
4.2
NR (n = NR; exp NR)
Unclear observer interpretation
Histology
MM 25;
NR
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Re-
ferred (se-
lected on
reference)
(u)
MM
ondary
Austria
NR/500
examined
by der-
matoscopy
prior to
excision
In person MiS 5
BN 272;
mild/
moderate
dysplasia
190;
lentigines
7; lentigo
naevi 1
30/500;
6%
Ferrari
2015
Equiv-
ocal (se-
lected on
reference)
(u)
WPC
R-CS
Sec-
ondary
Italy
NR/322
Melanocytic
lesions
with
equivocal
clinical
and/or
dermo-
scopic
features
that un-
derwent
excision
Der-
moscopy
(7-point)
Image-
based
(RCM,
image)
(also eval-
uated
RCM in
sub-
group)
≥ 3; di-
agnosis of
MM
Dermatologist (n = 1; exp NR)
Single
Histology
MEL 70
’Benign’
naevi:
252 (in-
cluding
15 SN)
70/322;
22%
90 ”posi-
tive-
clear cut“
lesions
scoring
5 or more
were ex-
cluded
from
RCM
evalua-
tion
Ferris
2015
Re-
ferred (se-
lected on
reference)
(u)
WPC-
observer
R-NR
Sec-
ondary
US
NR/65
Dermo-
scopic
images
of skin le-
sions ex-
cised on
the basis
of clinical
suspicion
of malig-
nancy,
with
available
histologic
diagnoses
Der-
moscopy
(no algo-
rithm)
Image-
based
(blinded)
(Also
evaluates
CAD-
Der-
moscopy)
NR;
excise de-
cision
Dermatologist (n = 2 board certified); derma-
tology residents (n = 10); physician assistants
practicing in dermatology (n = 8)
Average per group
Histology
MM 15;
MiS 10
BN
20, blue
naevi
2, lentig-
ines 4 ,
SK 4
25/65;
38%
NR
Friedman
2008
Re-
ferred (se-
lected on
reference)
(u)
MM
WPC
CCS
Sec-
ondary/
private
USA
94/99
An in-
dustry
database
of images
of PSL
≤ 6 mm
was used
Der-
moscopy
(no algo-
rithm)
Image-
based
(site, age,
Cor-
rect diag-
nosis; ex-
cise deci-
sion
Mixed - secondary care (n = 10; exp High)
Average result (reportsmean andmedian;mean
used)
Histology
MM 21;
MiS 28;
BCC: BN
34; SK 2;
14 other
benign
NR
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to sample
images of
melanoma
and non-
melanoma
lesions;
high-
grade
dysplastic
naevi
were
excluded
gender)
(Also
evaluates
CAD-
Spec-
troscopy)
49/99;
49%
Gereli
2010
Re-
ferred (se-
lected on
reference)
(u)
WPC-al-
gorithms
CCS
Sec-
ondary
Turkey
NR/96
Lesions
consid-
ered clini-
cally
atyp-
ical *be-
fore der-
moscopic
examina-
tion and
excisional
biopsy
Der-
moscopy
(3PCL;
7PCL)
Image-
based
(blinded)
≥ 2 char-
acteristics
present;
≥ 3
Dermatologist (assumed) (n = 3; exp mixed)
”two experienced and one inexperienced ob-
servers“
Average result
Histology
MM 44
MiS 4
SK 2;
blue
naevi 2;
BN 44
48/96;
50%
NR
(*deter-
mined by
≥ 3of: di-
ameter >
5 mm, ill-
defined
borders,
irregular
margins,
presence
of papu-
lar
and mac-
ular com-
ponents)
Gilmore
2010
Re-
ferred (se-
lected on
reference)
(u)
NC
R-CS
Sec-
ondary
Austria
NR/69
Polarised
dermo-
scopic
images of
atypical
melanocytic
lesions
Der-
moscopy
(no algo-
rithm)
Image-
based
(blinded)
NR;
excise de-
cision
Dermatologist (assumed) (n = 1; exp High)
Single observer
Histology
MEL 36
BN (dys-
plastic):
33
36/69;
52%
130
in deriva-
tion set of
lesions
Glud
2009
Re-
ferred (se-
lected on
reference)
(u)
WPC
P-CS
Sec-
ondary
Denmark
65/83
Patients
referred
for ex-
cision
biopsy
of where
the diag-
nosis of
melanoma
could not
be ex-
Der-
moscopy
(no algo-
rithm)
Image-
based
(blinded)
(Also
evalu-
ates CAD
spec-
NR; di-
agnosis of
MM
Dermatologist (n = 1; exp High)
Single observer
Histology
MM 7;
MiS 5; 1
melanoma
metas-
tases
(included
as disease
negative)
SK 1; BN
NR
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cluded on
clinical
investiga-
tion
troscopy) 57; BD 1;
DF 6;
other 5
12/83;
14%
Guitera
2009b
(Sydney)
Re-
ferred (se-
lected on
reference)
(u)
WPC
P-CS
Specialist
clinic
Australia
131/131
Lesions
excised
on the ba-
sis of clin-
ical suspi-
cion (his-
tory, der-
moscopy
examina-
tion, and/
or dig-
ital moni-
toring)
Der-
moscopy
(pattern
analysis)
Image-
based
(age, site)
(Also
evaluates
RCM)
NR; di-
agnosis of
MM
Dermatologist (n = 2; exp High; ‘expert’)
Single observer
Histology
MM 28;
MiS 16
BN 87
(includ-
ing 3 SN)
44/131;
34%
(25 le-
sions out
of
156 were
rejected
for poor-
quality
der-
moscopy
image,
blinded
to the di-
agnosti-
cian)
Hauschild
2014
Re-
ferred (se-
lected on
reference)
(u)
MM
WPC-
observer
CCS*
Sec-
ondary/
private
US
130/130
Subset
of PSL
evaluated
in a
MelaFind
study
(Monheit
2011); 65
melanoma
and 65
non-
melanoma
randomly
selected.
Excluded
ulcerated,
non-pig-
mented,
or located
on ex-
cluded
anatomic
sites
Der-
moscopy
(no algo-
rithm)
(Also
evalu-
ates CAD
spec-
troscopy)
Image-
based
(clini-
cal image,
patient
history)
NR;
excise de-
cision
Dermatologists (n = 202; randomised between
2 arms); PSL experts (n = 9)
Single observer
Histology
MM 36;
MiS 29
’Benign’
diag-
noses: 65
65/130;
50%
*RCT of
diagnosis
based on
clinical/
dermo-
scopic
images
versus
same +
MelaFind,
with
observers
ran-
domised
between
arms
Kittler
1998
Equiv-
ocal (se-
lected on
NC
NR-CS
Sec-
ondary
Austria
PSL
images
selected
on image
quality
Der-
moscopy
(no al-
gorithm)
Subjec-
tive
impres-
sion; di-
Dermatologist (n = 8; exp NR) described as
“pre-trained in ELM”
Single (randomly sampled one for inclusion)
Histology
MEL: 23
SK 1; BN
26
NR
624Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
reference)
(u)
NR/50 and
difficulty
of diag-
nosis; all
melanomas
has “only
subtle
ELM
features
as clues
to the
malig-
nancy of
the lesion
.. difficult
to differ-
entiate
from
benign”
; com-
pared
photo-
graphic
slides
and com-
pressed
digital
images;
latter
used for
review
Image-
based
(blinded
agnosis of
MM
23/50;
46%
Kittler
2001
Follow-
up (u)
NC
CCS
Sec-
ondary
Austria
20/80
Images
retrieved
from
a PSL
database;
melanocytic
skin
lesions
from
patients
with
multiple
atypical
naevi
and with
digital
der-
moscopy
follow-
up*
Der-
moscopy
(no algo-
rithm)
Im-
age based
(blinded)
NR;
excise
Dermatologist (n = 24; exp mixed - includ-
ing basic dermoscopy experience (n = 9), der-
moscopy training but basic experience (n = 10)
, experienced and trained dermatologists (n =
5)
Average result reported
Histology
or FU
MM 5,
MiS 5
BN 70
10/80;
13%
NR
*10
patients
with early
melanomas
and 10
other
patients
randomly
selected;
benign
melanocytic
skin
lesions
taken at
random
from
these 20
partici-
pants
Malvehy
2014
Re-
ferred (se-
lected on
reference)
(u)
WPC
P-CS
Multi-
centre
1611/
1943
Patients
with skin
lesions
selected
for total
excision
to rule
out
Der-
moscopy
(no algo-
rithm;
ABCD;
7PCL;
7PCLrev)
Image-
Dxofma-
lig-
nancy; >
4.75; > 5.
45; 7PCL
NR
Dermatologist (n = 3; exp NR) dermatologists
with 2-5 years of experience in dermoscopy as-
sessment
Unclear
Histology
VI/der-
moscopy
only -
MM 126;
MiS 112
Break-
473
excluded
from to-
tal sample
- mainly
due to in-
vestigator
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melanoma;
derma-
tologists
were en-
couraged
to enrol
a mix of
lesions
with an
even dis-
tribution
of low-,
medium-
and
high-risk
lesions
based
(clinical
image?)
(Also
evaluates
CAD -
Nevsiense)
down of
non-dis-
eased not
pro-
vided for
VI/der-
moscopy
sample
(Full
sample of
1942:
MM 153;
MiS 112;
BCC 48,
cSCC 1;
MCC 1
BN1497;
5 SN, 51
SK,
6 SCC in
situ;
8 AK; 61
other)
238/
1678;
14%
oversight
or in-
ability to
render
a final
histopatho-
logical
diagnosis;
74 were
device-
related
(60 with
inade-
quate
reference
measure-
ment
qual-
ity and 14
to device
failure)
242
excluded
from VI/
der-
moscopy
analy-
sis due to
image
quality
Menzies
2005
Referred
(u)
WPC-
observer
R-CS
Specialist
clinic
Multi-
centre
Australia,
US, Ger-
many
NR/786*
PSL im-
aged
using So-
larScan at
9 differ-
ent clin-
ical cen-
tres
including
spe-
cialist re-
ferral cen-
tres and
private
skin can-
cer clinics
Der-
moscopy
(no algo-
rithm)
Image-
based
(clin-
ical image
and
pt history
provided)
(also eval-
uated
CAD
Der-
moscopy)
Subjec-
tive
impres-
sion (di-
agnosis of
MM)
Dermatologist; (n = 3 international experts);
dermatologists (n = 4); dermatology registrars
(n = 3); GPs (n = 3)
Average reported per group
Histol-
ogy or FU
(26% of
full sam-
ple
FU; 3%
expert di-
agnosis)
Sydney
Melanoma
Unit only
(n = 78)
MM
5;MiS 6;
lM 2
BN 65
13/78;
17%
*Only
the 78
lesions
from the
Sydney
Melanoma
Unit
included
in the
VI/Der-
moscopy
evalua-
tion
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Menzies
2008
Re-
ferred (se-
lected on
reference)
(u)
WPC-al-
gorithms
CCS
Multi-
centre
NR/497
Dermo-
scopic
ame-
lanotic
(with no
melanin
pigmen-
tation) or
hypome-
lanotic (a
melanin
pigmen-
tation
area of <
25% of
the total
surface
area or
slightly
pig-
mented
but with
no dark
brown,
deep
blue, or
black
pigmen-
tation)
lesions*
Der-
moscopy
(7PCL;
Menzies;
3PCL)
Image-
based
(blinding
NR)
(also de-
veloped
new algo-
rithm on
80%
of sample
and
tested on
20%
but num-
ber dis-
ease pos-
itive NR
for the
test set to
allow 2x2
to be esti-
mated)
≥ 3; stan-
dard
thresh-
old; ≥ 2
Dermatologist (assumed) (n = 12; exp in der-
moscopic evaluation scored 99 individual mor-
phological features in approximately equal sam-
ple sizes
Single observer
Histology
and FU
(numbers
NR;
some
naevi
included
that
showed
no
changes
following
consec-
utive
digital
monitor-
ing)
MM 91;
14
MiS; 126
BCC; 4
cSCC
BN 159;
SN 11;
SK 22;
DF 17;
BD 7; KA
1; AK 8;
other 37
105/497;
21%
NR
*All
melanomas
included,
and a
random
selec-
tion of
melanocytic
and non-
melanocytic
lesions on
a non-
melanoma
to
melanoma
ratio of 3:
1
Pag-
nanelli
2003
Re-
ferred (se-
lected on
reference)
(u)
WPC-al-
gorithms
R-NR
Setting
NR
Italy
NR/20
Images
of PSL
from the
training
set of the
Consen-
sus Net
Meeting
on Der-
moscopy
(CNMD)
, selected
by 2
experts*
Der-
moscopy
(pattern
analysis;
Menzies;
7PCL;
ABCD)
Image-
based
(clinical
image)
Subjec-
tive
impres-
sion; cor-
rect diag-
nosis; al-
gorithm
NR
Mixed - sec (n = 16; exp NR)
Average result
Histology
MEL 6;
BCC: 2
SK 2; CN
8; SN 2
6/20;
30%
NR
Data not
disaggre-
gated for
BCC
*pre- and
post- der-
moscopy
training
data pre-
sented for
each algo-
rithm
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Piccolo
2002a
Re-
ferred (se-
lected on
reference)
(u)
WPC-
observer
R-CS
Sec-
ondary
Italy
289/341
PSL ex-
cised be-
cause
of equiv-
ocal der-
moscopic
findings
or
at the pa-
tient’s re-
quest
Der-
moscopy
(no algo-
rithm)
Image-
based
(clinical
image)
(Also
evaluates
CADder-
moscopy)
NR; di-
agnosis of
MM
Dermatologist (n = 1 expert); dermatology res-
ident (n = 1)
Single observer
Histology
MEL 13
SK 3; BN
316;
DF 7; an-
giomas 2
13/341; 4
NR
Piccolo
2014
Re-
ferred (se-
lected on
reference)
(u)
WPC-
observer
R-CS
Sec-
ondary
Italy
165/165
Dermo-
scopically
atypical
PSL *
Der-
moscopy
(ABCD)
Image-
based
(blinded)
(Also
evaluates
CADder-
moscopy)
> 4.74 Dermatologists (n = 3; 1 expert, 2 non-expert)
; GP (n = 1; underwent dermoscopic training
by studying an interactive atlas of dermoscopy
between time periods T0 and T1)
Single (results per observer)
Histology
MM 23;
MiS 10
BN
105; CN;
19 SN; 5
blue
naevi;
3 dermal
naevi.
33/165;
20%
NR
*Images
as-
sessed at
T0 and at
6 months
(T1)
Pizzichetta
2002
Re-
ferred (se-
lected on
reference)
(u)
WPC-al-
gorithms
R-CS
Specialist
clinic
Italy
123/129
Small (≤
5 mm)
melanocytic
skin
lesions
surgically
excised
Der-
moscopy
(pattern
analysis;
ABCD)
Image-
based
(blinded)
Dx
of MM; >
4.75; > 5.
45
Dermatologist (assumed) (n = 2; exp NR)
Single observer
Histology
MEL5 le-
sions
BN 124
lesions
5/129;
4%
NR
Pizzichetta
2004
Re-
ferred (se-
lected on
reference)
(u)
WPC
R-CS
US/Italy
Sec-
ondary
151/151
Clin-
ical and/
or dermo-
scopic hy-
pomelan-
otic
(extent of
pigmen-
tation ≤
30%) and
amelan-
otic skin
lesions
1.
VI (no al-
gorithm)
2. Der-
moscopy
(pattern)
Image-
based
(clinical
image)
Subjec-
tive im-
pression
NR (presume dermatologist; n = 1)
Exp NR; single observer
Histology
AHM 34,
MiS 5
BCC 25,
SCC 5
BN
47, SN 5,
SK 8,
other 18
39/
108; 36%
(anal-
23 lesions
excluded
due to
image
quality;
further
43 lesions
were not
available
for evalu-
ation by
clinical
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ysed) images
(“mainly
benign
melanocytic
lesions”
Pupelli
2013
Equiv-
ocal (se-
lected on
reference)
(c)
WPC
CCS
Specialist
clinic
Italy
96/96
Melanomas
< 5 mm
consec-
utively
excised; +
3 histo-
logically
proven
small-
diameter
naevi per
included
melanoma
Der-
moscopy
(7-point)
Image-
based
(RCM,
site, age)
(also eval-
uated
RCM)
≥ 3; di-
agnosis of
MM
Dermatologist (assumed) (n = NR; exp NR) Histology
MM 13;
MiS 11
BN 72
(includ-
ing 7 SN)
24/96;
25%
NR
Rigel
2012
Re-
ferred (se-
lected on
reference)
(u)
WPC
R-NR
Unclear
US
NR/24
PSL anal-
ysed as
part
of a prior
study us-
ing a MS-
DSLA
system (
Monheit
2011)
Der-
moscopy
(no algo-
rithm)
Image-
based
(clinical
image)
(Also
evalu-
ates CAD
Spec-
troscopy)
NR;
excise de-
cision
Dermatologist (n = 179; exp mixed)
Average result
Histology
MEL 5;
’Benign’
diag-
noses: 19
5/24;
21%
-
Rosendahl
2011
3-Lim-
ited test-
ing (se-
lected on
reference)
(u)
Any
WPC-alg
R-CS
Australia
Primary
389/463
PSL sub-
mitted
for histol-
ogy from
the pri-
mary care
skin can-
cer prac-
tice
of one au-
thor
1.
VI (no al-
gorithm)
2. Der-
moscopy
(pattern;
Chaos
and
Clues)
1. subjective impres-
sion
2.NR; both character-
istics present
Dermatologist (n = 1)
High exp (confirmed by study au-
thor)
Single observer
Histology
MM 9;
MiS 20
BCC 72;
SCC 5
BN 217;
BD 18;
AK 14*;
BNM
140
29/463;
6%
3 poor-
qual-
ity images
excluded
*AK con-
sid-
ered ma-
lignant by
study au-
thors
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Rubegni
2012
Equiv-
ocal (se-
lected on
reference)
(u)
WPC-al-
gorithms
R-CS
Sec-
ondary
Italy
107/107
Palmo-
plan-
tar (acral)
PSL ex-
cised over
a
3-year pe-
riod. All
with clin-
ical/der-
moscopic
suspi-
cious fea-
tures
in the ab-
sence of
any clear
benignity
pattern
Der-
moscopy
(pattern
analysis;
3-step al-
gorithm (
Koga
2011))
Image-
based
(blinded)
diagnosis of MM; excise decision
(3-step)
Dermatologist (n =
2; exp High - 20
years’ experience in
dermoscopy)
Single observer data
Histology
MM 21;
MiS 4
’Benign’
diag-
noses: 82
25/107;
23%
NR
Rubegni
2016
Re-
ferred (se-
lected on
reference)
(u)
NR
R-CS
Sec-
ondary
NR-Italy
95/95
Melanocytic
skin
lesions
showing
clear-cut
dermo-
scopic
features
of regres-
sion and
excised
for sus-
pected
malig-
nancy
Der-
moscopy
(pattern
analysis)
Image-
based
(blinding
NR)
NR; di-
agnosis of
MM
Dermatologist (n = 3; exp High) experienced
dermoscopists
Single observer
Histology
MEL 45
BN 50
45/95;
47%
NR
Sboner
2004
Re-
ferred (se-
lected on
reference)
(u)
NC
R-CS
Sec-
ondary
NR-Italy
NR/152
Melanocytic
lesion
images
acquired
consecu-
tively
Der-
moscopy
(no algo-
rithm)
Image-
based
(blinded)
NR; diagnosis of MM Dermatologist (n = 8;
exp NR)
Single observer
Histol-
ogy;
MM 31;
MiS 11
BN 110
42/152;
28%
NR
Seidenari
1998
Re-
ferred (se-
WPC-
Obs
CCS
Sec-
Patients
referred
by der-
matolo-
Der-
moscopy
(no algo-
rithm)
Subjective impression; diagnosis of
MM
Dermatologist (n = 2;
1 expert, rou-
tinely used videomi-
Histology
MEL 31
59 “non-
-
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(Continued)
lected on
reference)
(u)
ondary
Italy
NR/90
gists or
general
physi-
cians
with ≥
1 PSL
difficult
to inter-
pret on
clinical
grounds
alone,
numer-
ous PSLs,
or be-
cause the
patients
were at
increased
risk for
melanoma
or prior
malig-
nancy
Image-
based
(blinded)
croscopy; 1 non-ex-
pert)
Single observer
melanomas”
including
dysplastic
naevi”
31/90;
34%
Seidenari
2005
Re-
ferred (se-
lected on
reference)
(u)
WPC
R-CS
Specialist
clinic
Italy
NR/603
Melanocytic
lesions,
which
had un-
dergone
surgical
exci-
sion for
clinical,
dermo-
scopic, or
cosmetic
reasons
after
referral
by a
dermatol-
ogist for
examina-
tion of a
particular
lesion or
of the
Der-
moscopy
(pattern
analysis)
Image-
based
(blinded)
Correct diagnosis of MM (atypia
grade 3); excise decision (atypia
grade 2 and above)
Dermatologist (n = 2)
Consensus of 2
Histology
MEL 112
BN 491
112/603;
19%
NR
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whole
skin
Seidenari
2007
Re-
ferred (se-
lected on
reference)
(u)
NC
R-CS
Setting
NR
Italy
NR/243
Dermo-
scopic
images of
melanocytic
lesion
that had
under-
gone
excision
Der-
moscopy
(no algo-
rithm)
Image-
based
(blinded)
NR; diagnosis of MM Mixed (n = 4; exp
mixed)
Single observer
Histology
MM 35;
MiS 8
BN 200
43/243;
18%
-
Skvara
2005
Follow-
up (u)
WPC-alg
CCS
Sec-
ondary
Austria
NR/126
Consec-
utive le-
sions
showing
changes
over
time dur-
ingdigital
der-
moscopy
follow-up
that were
excised at
2 clinics
Der-
moscopy
(ABCD;
7PCL)
Image-
based
(blinded)
> 4.75; ≥ 3 Dermatologist (n = 2;
exp High)
Histology
MEL 63
BN 63
63/126;
50%
NR
Stan-
ganelli
1998a
Re-
ferred (se-
lected on
reference)
(u)
Any
WPC
R-CS
Italy
Training
images
Italy
NR/30
PSL
images se-
lected
from
comput-
erised
files of the
skin can-
cer clinic
1.
VI (no al-
gorithm)
2. Der-
moscopy
(no algo-
rithm)
Image-
based
(clinical
image)
NR; clinical diagnosis Dermatologists (n =
20)
Exp NR (“experience
in ELM but (with) no
formal training”)
Average result
Histology
MEL 10
BCC 4
BN
10, SK 3,
other 3
10/30;
33%
NR
BCC re-
sults
not disag-
gregated
Stan-
ganelli
1999
Re-
ferred (se-
lected on
reference)
(u)
WPC-
Obs
CCS
Specialist
clinic
Italy
NR/30
PSL
images se-
lected
from
database
for train-
ing study
Der-
moscopy
(no algo-
rithm)
Image-
based
(clinical
image)
Correct diagnosis MM Dermatologist
(assumed) (n = 83; exp
mixed)
Median result pre-
and post- dermoscopy
training
Histology
MM 10;
MiS 1
14 BN; 5
BNM
11/30;
37%
NR
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Stan-
ganelli
2005
Referred
(u)
WPC
R-CS
Italy
Specialist
clinic
NR/477
Melanocytic
lesions
referred
to Skin
Cancer
Unit for
clinical
and der-
moscopic
evalua-
tion
1.
VI (no al-
gorithm)
2. Der-
moscopy
(no algo-
rithm)
Image-
based
(clin-
ical image
also pro-
vided)
(also eval-
uated
CAD
Der-
moscopy)
NR (diagnosis of
MM)
Dermatologist (n = 3); GP (n = 3)
Dermatologists -
High exp (“2 years dermoscopy ex-
perience”); exp NR for GPs, as-
sumed Low
Average reported
Histol-
ogy/reg-
istry FU
MEL 31
BN 103
31/134;
23%
NR
Stan-
ganelli
2015
Follow-
up (u)
WPC
R-CS
Specialist
clinic
Italy
70/70
Lesions
excised
on the ba-
sis of clin-
ical and/
or dermo-
scopic
changes
at follow-
up
suggest-
ing a ma-
lignancy
Der-
moscopy
(7-point
revised -
FU)
Im-
age based
(baseline
image
provided)
(also eval-
uated
RCM)
‘major change’ (diagnosis of MM) Derma-
tol-
ogist (as-
sumed)
(n = NR;
exp NR)
Histology
MM 11;
MiS 1
BN 55;
BNM 3
12/70;
17%
NR
Stolz
1994a
Equiv-
ocal (se-
lected on
reference)
(u)
NC
R-CS
Sec-
ondary
Germany
NR/157
(79
in test set
included)
Equivo-
cal PSLs
with size
< 9 x13
mm,
melanoma
tumour
thickness
of 1
mm and
melanoma
Clark’s
level ≤
III
Der-
moscopy
(ABCD)
Image-
based
(blinded)
> 5.45; diagnosis of MM NR (n =
1; exp
NR)
Single
Histology
MEL: 48
(test set
only)
BN 31
48/79;
61%
NR
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Tan 2009
Re-
ferred (se-
lected on
reference)
(u)
WPC-
Obs
CCS
Training
images
UK
NR/30
Test
series of
images of
melanomas
and
benign
lesions
Der-
moscopy
(pat-
tern anal-
ysis mod-
ified)
Image-
based
(clinical
image)
Excise decision Mixed (n
= 6; exp
mixed)
Aver-
age result;
pre- and
post- der-
moscopy
training
Histology
MEL 15
Other: 11
BN; 3
SK; 1 vas-
cular
15/30;
50%
NR
Tenen-
haus
2010
Referred
(u)
NC
CCS
Sec-
ondary
France
NR/227
Dermo-
scopic
images
of all
melanoma
lesions
recorded
on two
databases,
+ 227
randomly
selected
benign
lesions
Der-
moscopy
(no algo-
rithm;
based on
ABCD
and oth-
ers)
Image-
based
(clin-
ical image
also pro-
vided)
NR; subjective impression (diag-
nosis of MM; excise decision)
Dermatologist (n = 5;
exp High)
Single observer
Histology
+ other
(65/227
benign
not ex-
cised; as-
sume ex-
pert diag-
nosis)
MM 28;
lM 4
BN
(excised)
165; ’be-
nign’ not
excised:
62
32/27;
14%
NR
Unlu
2014
Re-
ferred (se-
lected on
reference)
(u)
WPC-al-
gorithms
R-CS
Specialist
clinic
Turkey
115/115
Melanocytic
lesions
excised at
PLC
1.
VI (no al-
gorithm)
2. Der-
moscopy
(ABCD;
7PCL;
3PCL;
CASH)
Image-
based
(blinded)
1. NR; diagnosis of MM
2. > 5.44; ≥ 3; ≥ 2; ≥ 8
Derma-
tol-
ogist (as-
sumed)
(n = 3;
expHigh)
VI
appears
to be in
clinic di-
agno-
sis (single
observer);
derm im-
ages
scored by
Histology
alone
MEL 24
BN 91
(includ-
ing 6 SN)
24/115;
21%
NR
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3
other ‘ex-
pert’ der-
mato-
scopists
Consen-
sus of 3
Wells
2012
Re-
ferred (se-
lected on
reference)
(u)
WPC
CCS
Industry
database
US
NR/47
PSL
selected
from a
reposi-
tory of
lesions
amassed
during
an ac-
quisition
study
con-
ducted by
MELA
Sciences
Inc for
the US
Food and
Drug
Adminis-
tration
Der-
moscopy
(no algo-
rithm)
Image-
based
(clinical
image,
patient
history)
(Also
evalu-
ates CAD
spec-
troscopy)
NR; MM or not Derma-
tologist
(n = 39;
exp NR).
Average
Histology
MEL 23
’Benign’
diag-
noses: 24
23/47;
49%
-
Winkel-
mann
2016
Re-
ferred (se-
lected on
reference)
(u)
WPC
CCS
Unclear
Training
images
NR/12
Se-
lected im-
ages pre-
viously
analysed
by MSD-
SLA
1.
VI (no al-
gorithm)
2. Der-
moscopy
(no algo-
rithm)
Image-
based
(clinical
image)
NR Derma-
tologists
(n = 70)
Exp NR;
average
Histology
MM 3;
MiS 2
BN 7
5/12;
42%
NR
Zalaudek
2006
Re-
ferred (se-
lected on
reference)
(u)
Any
NC
R-CS
Specialist
clinic
Italy
NR/165
Random
sample of
excised,
equivocal
and
nonequiv-
ocal, PSL
Der-
moscopy
(3PCL)
Image-
based
(age, site,
gender)
≥ 2 characteristics present Mixed
(n = 150;
exp NR)
Average
result
Histology
Full sam-
ple:
MM 18;
MiS 11
BCC: 18
79 BN;
15 used
for train-
ing pur-
poses
5 BCC
moved
from FP
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and non-
PSLs
with
melanin
or hae-
moglobin
pigmen-
tation in
all or part
of the
lesion
26 SK; 8
vascular;
3 DF
26/150;
17%
to TN
3PCL: three-point checklist; 4PCL: four-point checklist; 7FFM: seven features for melanoma; 7PCL: seven-point checklist; ABCD
(E): asymmetry, border, colour, differential structures (enlargement); AJCC: American Joint Committee on Cancer; AK: actinic
keratosis; AMN: acral melanocytic naevi; BCC: basal cell carcinoma; BD: Bowen’s disease; Bham: Birmingham; BN: benign naevi;
BPC: between person comparison (of tests); c: clearly positioned on clinical pathway; CCD: compact disc; CAD: computer-assisted
diagnosis; CASH: colour, architecture, symmetry and homogeneity; CCS: case-control study; CM: cutaneous melanoma; CMM:
cutaneous malignant melanoma;CS: case series; cSCC: cutaneous squamous cell carcinoma; DF: dermatofibroma; ELM: epilumi-
nescence microscopy; exp: experience; FP: false positive; FU: follow-up; GP: general practitioner; IDS: International Dermoscopy
Society; IQR: interquartile range; LK: lichen sclerosis; LM: lentigo maligna; LP: lichen planus; LS: lentigo simplex;MEL: invasive
melanoma or melanoma in situ;MM: malignant (invasive) melanoma; MiS: melanoma in situ;MN: melanocytic naevi; MSDSLA:
multispectral digital skin lesion analysis device; N/A: not applicable; NC: non-comparative; NML: non melanocytic lesion; NR: not
reported; P: prospective; PLC: pigmented lesion clinic; PSL: pigmented skin lesion; R: retrospective; RCM: reflectance confocal mi-
croscopy; RCT: randomised controlled trial; SCC: squamous cell carcinoma; SD: standard deviation; SK: seborrhoeic keratosis; SN:
Spitz naevi; SSM: superficial spreading melanoma; TN: true negative; u: unclear position on clinical pathway; VI: visual inspection;
WPC: within person comparison (of tests)
Appendix 10. Forest plots of sensitivity and specificity for visual inspection for the detection of
invasive melanoma and atypical intraepidermal melanocytic variants (invasive melanoma or
atypical intraepidermal melanocytic variants)
Figure 25
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Figure 25. Forest plot of tests. 5 Visual inspection - in-person (invasive melanoma or atypical
intraepidermal melanocytic variants), 7 visual inspection - image-based (invasive melanoma or atypical
intraepidermal melanocytic variants)
Appendix 11. Summary study details for detection of invasive melanoma
Study
author
Other
target con-
ditions also
assessed
Study type
Country
Setting
Partici-
pants/
lesions
Inclusion
criteria
Index tests
(algorithm)
Diagnostic
approach
Threshold Observer
qualifica-
tions (num-
ber)
Experience
Reference
standard
Final diag-
noses
Prevalence
(invasive
melanoma)
Exclusions
Comments
In-person evaluations
Ascierto
2010
WPC
P-CS
Specialist
clinic
Italy
Clinically
relevant cu-
taneous pig-
mented
lesions, un-
Der-
moscopy
(risk stratifi-
ca-
tion; modi-
Very high risk; high or very
high risk; correct diagnosis
of MM
Dermatolo-
gist (n = NR;
exp High)
Unclear ob-
Histology
MM 12
’Benign’ 42
12/42; 22%
-
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(Continued)
54/54 dergoing
dermoscopy
and excision
fied Kenet
2001)
In-person
(Also evalu-
ates
CAD Spec-
troscopy)
server inter-
pretation
Coras 2003 WPC
NR-CS
Private
Germany
NR/45
PSLs under-
going exci-
sion due to
diagnosis of
melanoma
or atypi-
cal nevus, to
rule out
melanoma
or at the pa-
tient’s
request
Der-
moscopy
(no
details; diag-
nosis based
on clinical
exam,
dermoscopy,
medical his-
tory )
In-person
(Also evalu-
ates teleder-
matology as-
sessment of
clinical/der-
moscopic
images)
NR; Correct diagnosis of
MM
Derma-
tologist (n =
3; exp High)
participating
experts with
great experi-
ence in der-
matoscopy
Single
observer
Histology
MM 16;
’Benign’: 29
16/45; 36%
10 excluded
due to poor
image qual-
ity; 45 did
not undergo
excision
Feldmann
1998
Invasive
melanoma
or atyp-
ical intraepi-
dermal
melanocytic
variants
NC
P-CS
Secondary
Austria
NR/500
Melanocytic
le-
sions exam-
ined by der-
matoscopy
prior to exci-
sion
Der-
moscopy
(ABCD)
In-person
> 5.45; > 4.2 NR (n =NR;
exp NR)
Unclear ob-
server inter-
pretation
Histology
MM 25;
MiS 5
BN
272; dyspla-
sia 190;
lentigines 7;
lentigo naevi
1
30/500; 6%
NR
Krahn 1998 WPC
P-CS Sec-
ondary Ger-
many
80/80
Excised
PSLs
1. VI (no al-
gorithm)
2. Der-
moscopy
(no
algorithm)
In-person
NR; clinical diagnosis of
MM
Derma-
tologist (as-
sumed) (n =
1; exp NR)
Single
observer
Histology
MM 39
BN 37; dys-
plastic 2; SN
1
39/80; 49%
None
Piccolo
2000
NC
NR-CS
Multicentre
PSLs
selected be-
cause
Der-
moscopy
(no
NR; correct diagnosis of
MM
Dermatol-
ogists (n = 1;
exp High)
Histology
MM 11;
BCC 3
NR; poor-
quality index
test image.
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Austria
40/43
of their di-
agnostic dif-
ficulty
algorithm)
In-person
observer
(Also evalu-
ates teleder-
matology as-
sessment of
clin/dermo-
scopic
images)
Single
observer
SK 2; BN
23; other 4
11/43; 26%
The digital
images were
assigned an
image-
quality rat-
ing (1, excel-
lent; 2, good;
3, sufficient;
4, poor). All
images scor-
ing 4 were
ex-
cluded from
the study
Viglizzo
2004
WPC
NR-CS
Specialist
clinic
Italy
NR/79
PSLs exam-
ined
at the Der-
moscopy
Ser-
vice and un-
dergoing ex-
cisions; high
andmedium
risk on der-
moscopy
were se-
lected for ex-
cision
and 2x2 can
be estimated
only for
melanocytic
subgroup
1. VI (no al-
gorithm)
2. Der-
moscopy
(no
algorithm)
In-person
NR; correct diagnosis of
MM
Dermatolo-
gist
(assumed) (n
= NR; exp
NR)
Single
observer
Histology
MM 12
MN: 67
12/67; 18%
None
Image-based
Arevalo
2008
NC
RP-CS
Specialist
clinic
Australia
NR/3367
Melanocytic
lesions im-
aged at the
Sydney
Melanoma
Unit with a
histopatho-
logic diag-
nosis or that
re-
mained un-
changed fol-
Dermoscopy (Menzies cri-
teria)
Image-based (blinded)
Ab-
sence of neg-
ative charac-
teristics +
≥ 1 positive
character-
istic present;
correct diag-
nosis of MM
Derma-
tologist (as-
sumed) (n =
2; exp NR)
Consensus
of 2; referral
to a 3rd ob-
server if dis-
agreement
Histology or
FU
MM 341
’Benign’
3026
341/3367;
10%
None
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lowing
short-term
(2.5-
4.5 months)
digital mon-
i-
toring (diag-
nosed as be-
nign)
Friedman
2008
Invasive
melanoma
or atyp-
ical intraepi-
dermal
melanocytic
variants
WPC
CCS
Secondary/
private
US
94/99
An industry
database of
im-
ages of PSL
≤ 6 mmwas
used to sam-
ple images of
melanoma
and non-
melanoma
le-
sions; high-
grade dys-
plastic naevi
were
excluded
Dermoscopy (no
algorithm)
Image-based (site, age,
gender)
(Also evaluates CAD-
Spectroscopy)
Correct di-
agnosis; ex-
cise decision
Mixed - sec-
ondary
(n = 10; exp
High)
Average re-
sult (reports
mean
and median;
mean used)
Histology
MM
21; MiS 28;
BCC: BN
34; SK 2; 14
other benign
21/99; 21%
NR
Hauschild
2014
Invasive
melanoma;
Invasive
melanoma
or atyp-
ical intraepi-
dermal
melanocytic
variants
WPC
CCS
Secondary/
private
US
130/130
Subset of
PSL eval-
uated in a
MelaFind
study
(Monheit
2011); 65
melanoma
and 65 non-
melanoma
randomly
selected.
Excluded
ulcerated,
non-pig-
mented, or
located on
excluded
anatomic
sites
Dermoscopy (no
algorithm)
(Also evaluates CAD spec-
troscopy)
Image-based (clinical im-
age, pt history)
NR; excise
decision
Dermatolo-
gist (n = 101;
exp High)
Single
observer
Histology
MM 36;
MiS 29
’Benign’ di-
agnoses: 65
36/130;
28%
-
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Kreusch
1992
NC
RP-CS Sec-
ondary Ger-
many
Full sample:
858/1506
(265
melanocytic
included)
Pigmented
lesions sus-
pected to be
malignant
melanoma
with
adequate
photo-doc-
umentation
and histol-
ogy results
Dermoscopy (from
Kreusch 1991)
Image-
based (slides labelled only
with patient code and le-
sion localisation)
≥ 9; correct
diagnosis of
MM
Dermatolo-
gist
(assumed) (n
= 1; ‘experi-
enced’)
(Also
presents re-
sults for in-
experienced
student
- data not in-
cluded)
Single
observer
Histology
MM 96;
BN 169
52 NML ex-
cluded from
second-step
evaluation
Lorentzen
1999a
WPC
P-CS Spe-
cialist clinic
Denmark
232/232
Patients
with lesions
suspicious
for CMM
referred to
outpatients
clinic
1. VI (no algorithm)
2. Dermoscopy (no algo-
rithm)
Image-based (clinical im-
age)
Subjec-
tive impres-
sion; correct
diagnosis of
MM
Dermatol-
ogist (n = 4;
exp High)
Average
Histology
MM 49;
BCC 16
SK 12; BN
137 other:
18 (SN, BD
+ others)
49/232;
21%
Poor-
quality index
test image 10
cases
excluded
Lorentzen
2000
WPC-alg
RP-CS
Specialist
clinic
Denmark
258/258
PSL from
patients
consecu-
tively re-
ferred to the
skin cancer
outpatient
clinic with
available
clinical pho-
tographs,
der-
matopho-
tographs
and a sub-
sequent
excision
biopsy were
included
Dermoscopy (ABCD;
Kenet risk stratification)
Image-based (clinical im-
age)
>
4.75; Kenet -
probable
melanoma;
possible/
probable
melanoma
Derma-
tologist (n =
3; exp High;
3 senior der-
matol-
ogists with >
5 years’ daily
expe-
rience in der-
matoscopy
Single
observer (re-
ported per
observer)
Histology
MM 64;
BCC 25
SK
14; BN 135;
dysplastic 3;
other: 16
64/258;
25%
-
Lorentzen
2008
WPC
NR-CS Spe-
cialist clinic
Denmark
Patients re-
ferred to the
specialist
naevus
Dermoscopy (Kenet risk
stratification)
Image-based (blinded)
NR Dermatolo-
gist (n =NR)
Average
Histology
MM 24;
BCC 13
BN 69;
1 DF
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119/119 clinic; com-
pared classic
der-
moscopy to
acrylic globe
magnifier
mild/mod-
erate dyspla-
sia 2; SK 9;
other 2
24/119;
20%
Menzies
1996
NC
RP-Unclear
Image li-
braries Mul-
ticentre
NR/385
PSL from
the Sydney
Melanoma
Unit
with dermo-
scopic im-
ages and his-
tological di-
agnoses;
melanomas
and ran-
domly se-
lected clini-
cally atypical
non-
melanoma
lesions were
included
Dermoscopy (Menzies cri-
teria)
Image-based (blinded)
2 character-
istics
absent and≥
1 character-
istic present;
correct diag-
nosis of MM
Dermatolo-
gist
(assumed) (n
= NR; exp
NR)
NR
Histology
MM 107;
BCC: 18
SK 23;
acquired BN
58; dysplas-
tic 105; blue
naevi
11; ephelis/
lentigo 17;
SN 6; spin-
dle cell nevus
2; DF 2; he-
mangioma
13; solar ker-
atosis 9;
other 14
107/385;
28%
-
Menzies
2013
WPC-algo-
rithms CCS
Secondary
Mixed
NR/467
Nodular
malignant
melanoma*
and a
random
selection
of non-
nodular
invasive
primary
melanoma,
benign
nodular
melanocytic
lesions,
and nodu-
lar non-
melanocytic
lesions at
a ratio of
nodular
melanoma
Der-
moscopy (ABCD; Men-
zies, CASH; 7PCL; 3PCL;
Menzies (amelanotic))
Image-based (NR)
ABCD > 5.
45; CASH >
8; Men-
zies amelan-
otic > 0 and
> 1; others
at standard
thresholds
Derma-
tologist (n =
1; exp NR)
. 12 scorers
blinded
to the lesion
diagnosis
scored 99 in-
dividual fea-
tures in each
lesion of ap-
proxi-
mately equal
sample sizes,
as previously
described.
Following
the review of
the article
for publica-
tion, an ad-
Histology or
FU (“some”
benign
melanocytic
naevi
showed no
change over
time
compared
with baseline
pho-
tographs)
NM 83; 134
MM
BN 115;
217/332;
65%
135 NML
excluded
from second
step evalua-
tion
*an invasive
melanoma
without an
in situ (junc-
tional) com-
ponent be-
yond 3 rete
ridges of the
dermal inva-
sive compo-
nent
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to other
subgroups
of 1:2.
Nodular
benign
melanocytic
lesions
and nodu-
lar non-
melanocytic
lesions were
identified by
the clinical
appearance
of a solitary
nodule and
confirmed
using der-
moscopic
examination
ditional fea-
ture (blue-
black struc-
tures) was
scored for
all lesions by
one observer
(E.C.)
Single
observer
Nilles 1994 NC
RP-CS Sec-
ondary Ger-
many
NR/209
Melanocytic
skin lesions
that un-
derwent ex-
cision
Dermoscopy (new algo-
rithm)
Image-based (blinded)
Any charac-
teris-
tic present?;
correct diag-
nosis of MM
Derma-
tologist (as-
sumed) (n =
1; exp NR) S
ingle
observer
Histology
MM 41
BN168
41/209;
20%
260 le-
sions used to
identify best
model; accu-
racy for over-
all diagnosis
reported for
209 le-
sions investi-
gated in year
1990
Rao 1997 WPC-Obs
RP-CS
Specialist
clinic
US
63/72
Patients
with atypi-
cal
melanocytic
le-
sions or sus-
pected early
malignant
melanoma
1. VI (no algorithm)
2. Dermoscopy (no algo-
rithm)
Image-based (clinical im-
age)
Subjec-
tive impres-
sion; diagno-
sis
Dermatol-
ogist (n = 2)
; melanoma
fellow (n = 2)
Single
observer
Histology
MM 21
Atypical
MN 51
21/72; 29%
None
Troyanova
2003
WPC-tests
CCS
Specialist
clinic
NR
NR/50
Im-
ages of PSLs
selected for a
dermoscopy
training
study
1. VI (no algorithm)
2. Dermoscopy (no algo-
rithm)
Image-based (blinded)
NR; correct
diagnosis of
MM
Dermatolo-
gist (n = 32;
exp High)
Average
Histology
MM 25
’Benign’ 50
25/50; 50%
NR
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(Continued)
Westerhoff
2000
WPC-Obs
CCS Spe-
cialist clinic
Australia
NR/100
Clin-
ically atypi-
cal PSLs ran-
domly se-
lected from
PSL image
database
1. VI (no algorithm)
2. Dermoscopy (no algo-
rithm; Menzies criteria)
Image-based (blinded)
NR; diagno-
sis of MM
GPs (n = 74;
no
formal train-
ing in der-
moscopy,
randomised
to der-
moscopy ed-
u-
cation inter-
vention (n =
37) or not (n
= 37)
Average re-
ported
Histology or
FU
MM 50
’Benign’ 50
50/100;
50%
*Diagnoses
recorded for
both groups
of
GPs at base-
line (pre-
test) and af-
ter training
of one arm
(post-test);
post-
test data for
the interven-
tion group of
GPs
was used for
the Vi-
sual Inspec-
tion analysis
AK: actinic keratosis; alg: algorithm; BD: Bowen’s disease; BCC: basal cell carcinoma; BN: benign naevi; BPC: between person
comparison (of tests);CAD: computer-assisted diagnosis; CCS: case-control study; CS: case series; CMM: cutaneous malignant
melanoma;cSCC: cutaneous squamous cell carcinoma; DF: dermatofibroma; FU: follow-up; LS: lentigo simplex; MiS: melanoma
in situ (or lentigo maligna); MM: malignant melanoma; NC: non-comparative; NR: not reported; Obs: observer; P: prospective;
PLC: pigmented lesion clinic; PSL: pigmented skin lesion; R: retrospective; RCM: reflectance confocal microscopy; SK: seborrhoeic
keratosis; SN: Spitz naevi; WPC: within person comparison (of tests)
Appendix 12. Forest plots of sensitivity and specificity for visual inspection and for visual inspection
plus dermoscopy for the detection of invasive melanoma
Figure 26; Figure 27
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Figure 26. Forest plot of tests. 1 Visual inspection - in-person (invasive melanoma), 2 VI+dermoscopy - in-
person (invasive melanoma)
Figure 27. Forest plot of tests. 3 Visual inspection - image-based (invasive melanoma), 4 dermoscopy alone -
image-based (invasive melanoma)
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Appendix 13. Summary study details for detection of any skin lesion requiring excision
Study author
Other target
conditions
reported
Study type
Country
Setting
Inclusion cri-
teria
Index tests
(algorithm)
Diagnostic
approach
Threshold Observer
qualifications
(number)
Experience
Reference
standard
Final
diagnoses
Prevalence
(any skin
cancer)
Exclusions
Comments
(marked *)
In-person evaluations
Argenziano
2006
RCT
Italy, Spain
Primary
NR/85
Patients ask-
ing for screen-
ing or exhibit-
ing ≥ 1 skin
tumours
as seen during
routine phys-
ical examina-
tion (patient-
finding
screening)
Participat-
ing PCPs ran-
domised to ei-
ther visual in-
spection alone
or visual in-
spection+der-
moscopy; only
excised lesions
can be
included for
each arm
VI (ABCD)
Dermoscopy
(3-point
checklist)
In-per-
son (single ob-
server)
Subjective im-
pression; diag-
nosis of malig-
nancy
GPs (n = 37)
All trained in
ABCD rule
Histology
MEL 6
BCC 37; SCC
10
Benign 32
53/85; 62%
*Only
those patients
who were con-
sidered to have
lesions sugges-
tive
of skin cancer
had histology
and could be
included; rest
had expert di-
agnosis (mak-
ing full dataset
ineligible for
this review)
Durdu 2011
Invasive
melanoma
or atypical in-
traepidermal
melanocytic
variants
WPC
P-CS
Secondary
Turkey
176/200
PSL that could
not be diag-
nosed with
only dermato-
logic physical
examina-
tion; 2x2 in-
cluded for
melanocytic
subset
Dermoscopy
(ABCD; non-
melanocytic
excluded first)
(Also eval-
uated exfolia-
tive cytology)
In-person
NR Derma-
tologist (n = 1;
exp NR)
Single
observer
Histology
MEL: 10;
BCC:
34; other ma-
lignant 2
SK 24; BN
100; DF 12;
warts 16; dirt
1; other 1
10/200; 5%
-
Soyer 2004 NC
R-CS
Specialist unit
Lesions at pig-
mented lesion
clinic consid-
Der-
moscopy (no
algorithm)
NR Derma-
tologist (n = 1;
exp High)*
Histology
MEL: 68;
BCC 9
*Also reports
data for 6 in-
ex-
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(Continued)
Italy
225/231
ered by experi-
enced derma-
tologists
to merit exci-
sion on clini-
cal grounds
In-person Single ’Benign’ 154
77/154; 33%
perienced ob-
servers inter-
pre-
tation of the
acquired der-
moscopic im-
ages; data ex-
cluded as in-
cludes 3 medi-
cal students
Stanganelli
2000
Invasive
melanoma
or atypical in-
traepidermal
melanocytic
variants
WPC
R-CS
Italy
Specialist
clinic
NR/3372
PSL referred
by dermatolo-
gists and
general practi-
tioners
either for pre-
surgical assess-
ment or con-
sultation
VI (ABCD)
Der-
moscopy (no
algorithm)
In person (sin-
gle)
NR
Subjective im-
pression
NR (assumed
dermatologist
- described as
one of the co-
authors; n = 1)
Histology/
registry FU
MEL 55
BCC 43; be-
nign 3274
98/3372; 3%
NR
Image-based evaluations
Carli 2002b
Invasive
melanoma
or atypical in-
traepidermal
melanocytic
variants
Any
WPC
R-CS
Italy
Secondary
NR/57
Clinically sus-
pi-
cious or equiv-
ocal PSL un-
dergoing exci-
sion for di-
agnostic pur-
poses; all≤ 14
mm diameter
1. VI (NR)
2.
Dermoscopy
(NR)
Image-based
(blinded)
NR Dermatolo-
gists (n = 2)
High
exp (’with ex-
perience in the
field of ’); con-
sensus of 2
Histology
MM 6, MiS 5
BCC 10
BN 31, SK 1;
other 4
11/57; 19%
4 ‘not evalu-
ables’
excluded (NB
these differ be-
tween clinical
im-
ages and der-
moscopic im-
ages (1 MM
excluded from
VI analysis)
Lorentzen
2008
Invasive
melanoma
WPC
NR-CS Spe-
cialist clinic
Denmark
119/119
Patients
referred to the
specialist nae-
vus clinic;
compared
classic der-
moscopy to
acrylic globe
magnifier
Dermoscopy
(Kenet risk
stratification)
Image-based
(blinded)
NR Dermatologist
(n = NR)
Average
Histology
MM 24; BCC
13
BN 69; mild/
moderate dys-
plasia 2; SK 9;
other 2
24/119; 20%
1 DF
Rosendahl
2011
Invasive
melanoma
WPC-
algorithms
R-CS
Australia
PSL submit-
ted for histol-
ogy from the
primary
1. VI (no algo-
rithm)
2. Der-
moscopy (pat-
1. Subjective
impression
2. NR; both
characteristics
Dermatologist
(n = 1)
High exp
(confirmed by
Histology
MM 9; MiS
20
BCC 72; SCC
3 poor-quality
images
excluded
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(Continued)
or atypical in-
traepidermal
melanocytic
variants
Primary
389/463
care skin can-
cer practice of
1 author
tern; Chaos
and Clues)
present author); single
obs
5
BN 217; BD
18; AK 14*;
BNM 140
*con-
sidered malig-
nant by study
authors
29/463; 6%
Stanganelli
1998a
Invasive
melanoma
or atypical in-
traepidermal
melanocytic
variants
Any
WPC
R-CS
Italy
Training im-
ages
Italy
NR/30
PSL images se-
lected
from comput-
erised files of
the skin cancer
clinic
1. VI (no algo-
rithm)
2. Der-
moscopy (no
algorithm)
Image-
based (clinical
image)
NR; clinical
diagnosis
Dermatolo-
gists (n = 20)
Exp NR (“ex-
perience
in ELM but
(with) no for-
mal training”)
Average result
Histology
MEL 10
BCC 4
BN 10, SK 3,
other 3
10/30; 33%
NR
BCC
results not dis-
aggregated
Zalaudek
2006
Invasive
melanoma
or atypical in-
traepidermal
melanocytic
variants
NC
R-CS
Specialist
clinic
Italy
NR/165
Random sam-
ple of excised,
equivocal
and nonequiv-
ocal, PSL
and non-PSLs
with melanin
or haemoglo-
bin pigmenta-
tion in all or
part of the le-
sion
Dermoscopy
(3PCL)
Image-based
(age, site, gen-
der)
≥ 2 character-
istics present
Mixed (n =
150; exp NR)
Average result
Histology
Full sample:
MM 18; MiS
11
BCC: 18
79 BN; 26 SK;
8 vascular; 3
DF
26/150; 17%
15 used for
training pur-
poses
5 BCC moved
from FP to
TN
3PCL: three-point checklist; AK: actinic keratosis; alg: algorithm; BD: Bowen’s disease; BCC: basal cell carcinoma; BN: benign
naevi;BPC: between person comparison (of tests);CAD: computer-assisted diagnosis; CCS: case-control study;CS: case series; cSCC:
cutaneous squamous cell carcinoma; DF: dermatofibroma; ELM: epiluminescence microscopy; exp: experience; FP: false positive;
FU: follow-up; LS: lentigo simplex;MiS:melanoma in situ (or lentigo maligna);MM:malignant melanoma; NC: non-comparative;
NR: not reported; Obs: observer; P: prospective; PCP: primary care provider; PLC: pigmented lesion clinic; PSL: pigmented skin
lesion; R: retrospective; RCM: reflectance confocal microscopy; SK: seborrhoeic keratosis; SN: Spitz naevi; TN: true negative; VI:
visual inspection; WPC: within person comparison (of tests)
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Appendix 14. Dermoscopy training interventions
Study author
Outcomes
reported
Inclusion criteria
Numberof lesions;
cases
Algorithm used
In-person/image-
based
Clin-
icians recruited for
training
Pre-training Training approach Post-training
Detection of Invasive melanoma or atypical intraepidermal melanocytic variants
Pagnanelli 2003
Pathway - unclear
Clinical and der-
moscopic images of
PSL from the train-
ing set of the Con-
sensus Net Meet-
ing on Dermoscopy
(CNMD), selected
by 2 experts
N = 20; MEL 6
Dermoscopy (pat-
tern analysis; Men-
zies; 7PCL; ABCD)
Image-based (clini-
cal image)
Recruited 16 ‘col-
leagues’, including
medical
Students (n = 3)
, dermatology resi-
dents (n = 9) and
dermatologists (n =
4)
All reported limited
personal experience
of dermoscopy, no
formal training and
did
not use dermoscopy
in daily professional
practice
After the 1-hour lec-
ture at the begin-
ning of the study,
lesion images were
provided on CD-
Rom; participants
asked to complete
electronic data sheet
listing criteria for di-
agnosing PSLs by
pattern analysis and
by the various algo-
rithms and to offer
a dermoscopic diag-
nosis for each case
within 20 days
1-hour lecture on
• basic
principles of
dermoscopy, the
dermoscopic
• features of
PSLs,
• pattern
analysis and the
diagnostic
• algorithms
(ABCD rule, seven-
point checklist,
Menzies’
• method).
+ a web-based
tutorial (http://
www.dermoscopy.org)
; participants re-
quested to devote
1 hour per day, 5
days per week for 2
consecutive weeks
Post-training evalu-
ation 5 weeks after
initial evaluation
Participants re-eval-
uated the same 20
cases, again over a
20-day period
Piccolo 2014
Pathway - unclear
Dermoscopically
atypical PSL
N = 165; MM 23;
MiS 10
Dermoscopy
(ABCD)
Image-based
(blinded)
(Also evaluates
CAD dermoscopy)
3
dermatologists and
1 GP scored accord-
ing to number of
years specializing in
dermoscopy, num-
ber of PSLs assessed
by dermoscopy on a
daily basis, number
of relevant work-
shops/sem-
inars attended, and
number of authored
publications on der-
moscopy: highly ex-
Digital
dermoscopic images
assessed by each ob-
server using ABCD
at T0
BetweenT0andT1,
Observer 4 under-
went dermoscopic
training by study-
ing an interactive at-
las of dermoscopy
(Argenziano 2003;
appears to be same
as for Pagnanelli
2003)
The same
digital dermoscopic
images were assessed
by each of the 4 ob-
servers using ABCD
after 6 months (T1)
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(Continued)
perienced (observer
1),moderately expe-
rienced, (observers 2
and 3); and mini-
mally experienced
(observer 4).
Stanganelli 1999
Pathway - unclear
PSL images selected
from database for
training study
N = 30; MM 10;
MiS 1
Dermoscopy (no al-
gorithm)
Image-based (clini-
cal image)
Of 223 dermatol-
ogists who partic-
ipated in one of
the six workshops,
83 (37%) were re-
ported on; average
of 10 years of gen-
eral
experience in der-
matology (range 1-
22) with routine use
of ELM by 52 in-
dividuals (conven-
tional dermatoscope
for 43 and digital
equipment for 9)
Pre-training
test conducted af-
ter the opening lec-
ture of each work-
shop (clinical classi-
fication of PSLs)
Images pro-
jected onto a screen
in pairs (clinical and
ELM image); clas-
sified by as CMM,
MN, NML, unclas-
sifiable or equiv-
ocal; approximately
2.5 min per lesion
Nationwide educa-
tional pro-
gramme in ELM;
one-day meet-
ings and workshops
(duration: 6 hours)
held with free reg-
istration. Topics in-
cluded:
• clinical
classification and
diagnosis of PSLs
• management
of patients with
PSLs;
• basic
principles of ELM;
• ELM criteria
• ELM
diagnosis;
• limitations of
ELM
Same set of slides re-
evaluated at the end
of the workshop.
Slides and respec-
tive correct diagno-
sis were discussed
only after the second
test
Tan 2009
Pathway - unclear
Test series of images
of melanomas and
benign lesions
N = 30; MEL 15
Dermoscopy (pat-
tern analysis modi-
fied)
Image-based (clini-
cal image)
3 consultant derma-
tolo-
gists and 3 specialist
registrars; none had
routinely used a der-
matoscope
Assessed
30 test cards con-
sisting of 1 macro-
scopic and 1 der-
matoscopic image of
each lesion; printed
on A4 laminated pa-
per
Participants classi-
fied images as ‘be-
nign’, ‘malignant’ or
‘not known’, gave a
diagnosis if known,
and indicated
whether they would
excise the lesion
Participants re-
ceived an on-
line tutorial (
www.dermatoscopy.org)
teaching the
MPADA (Modified
Pattern Analysis Di-
agnostic Algorithm)
, which could be
referred to during
the study period
Also each given a
dermatoscope to use
in clinical practice
for 10 months
10 months later, the
test-card question-
naire was
repeated (test 2)
Detection of invasive melanoma alone
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(Continued)
Troyanova 2003 Patients with atyp-
ical melanocytic le-
sions or
suspected early ma-
lignant melanoma
N = 50
1. VI (no algorithm)
2. Dermoscopy (no
algorithm)
Image-based (clini-
cal image)
Volunteer dermatol-
ogists (n = 32); ex-
perienced in clinical
di-
agnosis of PSLs, but
had no formal train-
ing in dermoscopy.
ELM qualification
based on good theo-
retical knowledge of
the literature and on
personal experience
by trial and error
50 clinical im-
ages displayed indi-
vidually using slide
projector; scored as
melanoma or “not-
melanoma”. 50 der-
moscopy slides then
presented and ELM
diagnoses recorded
Each
image shown for 30
seconds; no discus-
sion of assumed di-
agnosis was permit-
ted. None of the test
slides used for train-
ing
6 hours of teaching
daily for 2 consec-
utive days. Training
was based on pre-
sentation of several
hundred slides with
oral explanation of
the ELM criteria
Tests were
performed in the be-
ginning and in the
end of the teaching
course
Same
test performed with
slides of 50 different
PSLs
Westerhoff 2000 Images
of PSL selected for
a dermoscopy train-
ing study
N = 50; 50 MM
1. VI (no algorithm)
2. Dermoscopy (no
algorithm; Menzies
criteria)
Image-based
(blinded)
GPs
(n = 74) recruited
by telephone from a
list of current prac-
titioners. Required
to have no formal
train-
ing in dermoscopy
and did not use
dermoscopy in their
clinical practice
Participants
randomised into an
education interven-
tion group or non-
education interven-
tion
group (each n = 37)
Le-
sions presented with
the clinical photo-
graph first, followed
by dermoscopy im-
age
Participants given 4
options:
melanoma;
benign melanocytic
lesion, benign non-
melanocytic lesion,
’other’ (specify)
Clinical diag-
nosis recorded prior
to observation of
dermoscopic image.
Tests completed at
participants’ leisure
Suppliedwith picto-
rial atlas by Menzies
1996b and a 1-hour
presentation
on dermoscopy that
specifically reviewed
theMenziesmethod
and included a quiz
with images of 25
different PSL (not
used in test)
As for pre-test
ABCD: asymmetry, border, colour, dimensions;AK: actinic keratosis; alg: algorithm; BD: Bowen’s disease; BCC: basal cell carci-
noma; BN: benign naevi; BPC: between person comparison (of tests);CAD: computer-assisted diagnosis; CCS: case-control study;
CMM: cutaneous malignant melanoma; CS: case series; cSCC: cutaneous squamous cell carcinoma; DF: dermatofibroma; ELM:
epiluminescence microscopy; FU: follow-up; LS: lentigo simplex; MEL: melanoma; MiS: melanoma in situ (or lentigo maligna);
MM:malignant melanoma; NC: non-comparative; NML: non melanocytic lesion; NR: not reported;Obs: observer; P: prospective;
PLC: pigmented lesion clinic; PSL: pigmented skin lesion; R: retrospective; RCM: reflectance confocal microscopy; SK: seborrhoeic
keratosis; SN: Spitz naevi; WPC: within person comparison (of tests)
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We set out to review visual inspection and dermoscopy for the detection of melanoma in a single review, however due to the volume
of evidence identified, we prepared two separate reviews, one for visual inspection alone and one for dermoscopy. This review of
dermoscopy includes data for the accuracy of visual inspection but only where both tests were evaluated in the same study (direct
comparisons).
We changed the primary objectives and primary target condition from detection of cutaneous invasive melanoma alone, to the detection
of cutaneous invasivemelanoma and atypical intraepidermalmelanocytic variants, as the latter ismore clinically relevant to the practicing
clinician. We included the detection of the target condition of invasive melanoma alone as a secondary objective instead. We also
amended the primary objectives to conduct separate analyses by in-person/image-based diagnosis rather than to investigate the effect on
accuracy as a secondary objective, as originally proposed in the generic protocol. We took this decision very early in the review process,
based on the fact that a diagnosis based on a dermoscopic image or clinical photograph cannot approximate a face-to-face patient and
clinician consultation.
We have tailored secondary objectives to the individual test, with three objectives added: to determine the diagnostic accuracy of
individual algorithms for dermoscopy; to determine the effect of observer experience; and to determine the effect on accuracy of observer
training in dermoscopy.
Sources of heterogeneity that could be investigated (as listed in the protocol), were restricted due to lack of data.
We amended the text to clarify that studies available only as conference abstracts would be excluded from the review unless full
papers could be identified; studies available only as conference abstracts do not allow a comprehensive assessment of study methods or
methodological quality.
We excluded rather than included studies using cross-validation, such as ’leave-one-out’ cross-validation, as these methods are not
sufficiently robust and are likely to produce unrealistic estimates of test accuracy.
To improve clarity of methods, this text from the protocol, “We will include studies developing new algorithms or methods of diagnosis
(i.e., derivation studies), if they use a separate independent ’test set’ of participants or images to evaluate the new approach. We will
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also include studies using other forms of cross validation, such as ’leave-one-out’ cross-validation (Efron 1983). We will note for future
reference (but not extract), any data on the accuracy of lesion characteristics individually, e.g., the presence or absence of a pigment
network or detection of asymmetry” has been replaced with the following: “We included studies developing new algorithms or methods
of diagnosis (i.e., derivation studies), were included if they:
• used a separate independent ’test set’ of participants or images to evaluate the new approach; or
• investigated lesion characteristics that had previously been suggested as associated with melanoma and the study reported
accuracy based on the presence or absence of particular combinations of characteristics.
We excluded studies if they:
• used a statistical model to produce a data driven equation, or algorithm based on multiple diagnostic features, with no separate
test set;
• used cross-validation approaches such as ’leave-one-out’ cross-validation (Efron 1983);
• evaluated the accuracy of the presence or absence of individual lesion characteristics or morphological features, with no overall
diagnosis of malignancy;
• reported accuracy data for ‘clinical diagnosis’ with no clear description as to whether the reported data related to visual
inspection alone or included dermoscopy in all study participants;
• were based on the experience of a skin cancer-specific clinic, where dermoscopy may or may not have been used on an individual
participant basis.”
We proposed to supplement the database searches by searching the annual meetings of appropriate organisations (e.g. British Association
of Dermatologists’ Annual Meeting, American Academy of Dermatology Annual Meeting, European Academy of Dermatology and
Venereology Meeting, Society for Melanoma Research Congress, World Congress of Dermatology, European Association of Dermato
Oncology), however due to volume of evidence retrieved from database searches and time restrictions, we were unable to do this.
For quality assessment, we further tailored the QUADAS-2 tool according to the review topic. In terms of analysis, we did not restrict
analysis to per-patient data due to lack of data.
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